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Atrial fibrillation is the most commonly found and sustained arrhythmia. It affects about 1% of the 
total population and is found in more than one in ten in the elderly. The prevalence is increasing with 
the aging population. Patients with atrial fibrillation are at an increased risk of heart failure and all-
cause mortality, and have a fivefold increased risk of stroke. Atrial fibrillation is associated with 
debilitating symptoms and an impaired quality of life. The restoration and maintenance of sinus 
rhythm is favourable and the current guidelines recommend the use of both rate and rhythm control 
strategies, which involve the prescription of anti-arrhythmic drug therapy. These anti-arrhythmic 
drugs are frequently ineffective, with large studies showing that atrial fibrillation returns in as many 
as 85% of patients within one year. These drugs are also associated with adverse events, 
occasionally serious, which may lead to hospitalisation. 
Catheter ablation (a minimally invasive procedure), has over the past decade revolutionised the 
treatment of atrial fibrillation. The 2010 European Society of Cardiology guidelines recommend 
catheter ablation for paroxysmal atrial fibrillation as a class IIa recommendation with level of evidence 
“A”. Current literature indicates that patients with atrial fibrillation who undergo pulmonary vein ablation 
have a significantly lower risk of death, stroke and dementia compared to patients with atrial fibrillation 
who are not treated with ablation, while stroke and dementia is similar to that of the general population. 
This study used a decision tree analysis, a Markov model and Monte Carlo simulation to calculate the 
cost-effectiveness of catheter ablation versus commonly used anti-arrhythmic drugs for the treatment 
of paroxysmal atrial fibrillation. Input into the model was founded on an extensive literature review, 
interviews with local electrophysiologists and a sample of real patient data, which examined the costs 
associated with among others, the length of hospital stay and the cost of the procedure. 
The model simulated 1 000 patients receiving either pulmonary vein isolation through radiofrequency 
ablation or anti-arrhythmic drugs and the following variables were measured, QALYs, average cost, 
incremental costs, average effectiveness, incremental effectiveness, average length of stay in 
hospital for complications, relative risk of death for radiofrequency catheter ablation versus anti-
arrhythmic drugs and also the net monetary benefits.  
A total of fourteen variables were tested and sensitivity analyses were performed on each. It was found 
that in all but two cases, pulmonary vein isolation with radiofrequency catheter ablation dominated over 
anti-arrhythmic drug therapy as being more cost-effective for the management of paroxysmal atrial 
fibrillation. Finally, it was determined that pulmonary vein isolation with radiofrequency catheter 
ablation should be considered as a first line therapy for patients with paroxysmal atrial fibrillation in 
South Africa. 






Atriale fibrillasie is die mees algemene en volgehoue aritmie. Dit raak ongeveer 1% van die 
bevolking. Onder bejaardes is die voorkoms egter soveel as 10%, wat beteken dat die toestand 
toeneem in verhouding met die verouderende bevolking. Atriale fibrillasie verhoog ’n pasiënt se risiko 
vir beroerte vyfvoudig, tesame met hartversaking en alle-oorsake mortaliteit. Die toestand se 
uitmergelende simptome verlaag ook lewenskwaliteit. Die kanse vir die herstel en instandhouding 
van sinusritme is positief. Bestaande riglyne beveel dus die gebruik van ritme- of spoed-beheer 
medikasie aan, wat beteken dat anti-aritmie medikasie voorgeskryf word. Dit is egter dikwels 
oneffektief en verskeie omvattende studies het bewys dat tot 85% van die pasiënte binne een jaar 
weer ‘n ritmestoornis ervaar. Hierdie middels word ook dikwels verbind met newe-effekte wat ernstig 
mag wees en tot hospitalisasie mag lei. 
Kateterablasie (’n minimaal-ingrypende prosedure) het oor die afgelope dekade die behandeling van 
atriale fibrillasie onherkenbaar verander. Vir pasiënte wat hoogs simptomaties, of paroksismaal, is ten 
spyte van optimale terapie, beveel die Europese Vereniging van Kardiologie se 2010 riglyne ablasie 
aan as ‘n klas IIa aanbeveling. Huidige literatuur dui op ‘n laer koers van sterftes, beroerte en demensie 
onder atriale fibrillasie pasiënte wat atriale fibrillasie ablasie ondergaan, in vergelyking met pasiënte 
wat met medikasie behandel word. Eersgenoemde het inteendeel dieselfde risikoprofiel as die 
algemene bevolking. 
Hierdie studie gebruik ’n keuse-boom analisemodel en ’n waarskynlikheid-Markov model met Monte 
Carlo-simulasie om die koste-effektiwiteit van kateterablasie met anti-aritmiese medikasie te vergelyk 
in die behandeling van pasiënte met paroksismale atriale fibrillasie. Die data wat in die model gebruik 
word, is gebaseer op ’n uitgebreide literatuurstudie, onderhoude met elektrofisioloë, en ’n steekproef 
van pasiëntdata, en ondersoek, onder andere, die duur van hopitaalverblyf en die koste verbonde aan 
die prosedure. 
Die studie maak gebruik van ’n simulasiemodel waar 1 000 pasiënte óf ablasie óf medikasie ontvang 
het. Die volgende veranderlikes is gemeet: QALYs, gemiddelde koste, toenemende koste, gemiddelde 
doeltreffendheid, toenemende doeltreffendheid, gemiddelde hospitaalverblyf tydens komplikasies, die 
relatiewe riskio van sterfte en monetêre voordele. 
Veertien veranderlikes is getoets en aan sensitiwiteitsanalises onderwerp. In dertien uit die viertien 
analises was kateterablasie meer koste-effektief as anti-aritmiese medikasie in die behandeling en 
bestuur van anti-aritmiese medikasie. Die studie kom dus tot die gevolgtrekking dat kateterablasie 
oorweeg moet word as voorkeurterapie vir pasiënte met paroksismale atriale fibrillasie in Suid-Afrika. 
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The intention of this preface is as follows:  
1. To provide elucidatory background on the development of this dissertation; 
2. To delineate the structure of the dissertation;  
3. To provide an overview on atrial fibrillation (AF);  
4. To provide an update on changes in the literature over the past decade; and 
5. To confirm the relevance of the study area.  
 
Background to dissertation 
The first version of this dissertation was lodged for review in 2013. Two further reviews were 
undertaken in 2015 and 2019. On each occasion, I have received valuable feedback that has 
shaped the scope and structure of the finalised dissertation that is contained here. Changes made 
in response to the various reviews have been integrated into the dissertation to allow for a seamless 
review thereof.  
This document provides a summary of structural and content changes and additions that have been 
made to the dissertation to support this finalised version thereof.  
Dissertation structure 
It was agreed by the Dean’s Office in the Faculty of Economic and Management Sciences at 
Stellenbosch University in 2019 that the structure of this dissertation be as follows:  
 A preface that serves to provide an introductory statement on the dissertation topic and 
further background to locate this work within a broader context; and  
 The original dissertation, revised in accordance with examiner feedback and containing two 
major content additions:  
o Annexure A is a manuscript containing wholly new content reviewing available 
systematic reviews. Since initial completion of the dissertation in 2013, one of the 
most significant changes has been the introduction and use of Cryoballoon 
technology for atrial fibrillation ablation. At present there are some centres that only 
use Cryoablation when doing the first AF ablation on patients and reserve 
radiofrequency ablation (RFA) with 3D mapping for re-do ablations, while others 
routinely use RFA with 3D mapping for all paroxysmal atrial fibrillation (PAF) 
ablations. There is debate about which technology has better patient outcomes with 
fewer adverse events and shorter procedural and fluoroscopy time. This new 
manuscript addresses this debate. It is titled ‘Radiofrequency versus cryoablation for 




reviews’.  Eleven systematic reviews, all published between 2015 and 2018, were 
used for the overview. This manuscript has been prepared for submission to EP 
Europace. 
o Annexure B is a second manuscript in the form of a journal article based on Chapters 
6 and 7 of the dissertation, and written in response to a recommendation of the 
examiners since, in spite of the rapid growth in electrophysiology, this study remains 
unique in South Africa. This manuscript is titled ‘The Cost-Effectiveness of RF-
Ablation vs. Anti-Arrhythmic Drug Therapy for Paroxysmal Atrial Fibrillation in the 
South African Private Sector’. It has been prepared for the Cardiovascular Journal of 
Africa, which focuses on research done in Africa for Africans.  
These two annexures are positioned following all other documentation relating to the dissertation. 
As a result, they have been included on the Table of Contents for the dissertation as the final two 
items. 
Since the intention is that these manuscripts will be submitted for publication following completion of 
the dissertation examination process, the structure, style and referencing of the manuscripts follows 
the stylistic requirements of the respective journals to which they will be submitted. For ease of 
reference, a summaryof the relevant journal’s style guide outlining its requirements for journal 
submissions has been included as an appendix on each of the annexures.  
Background on atrial fibrillation 
Atrial fibrillation (AF) is the most commonly found and sustained cardiac arrhythmia of clinical 
significance and was recognised by physicians in ancient China, Egypt and Greece. In 1628 William 
Harvey (1578-1657), first described fibrillation of the auricles in animals and Jean Baptist de Sénac 
(1693-1770), a French "clinical pathologist" pondered on a possible correlation between "rebellious 
palpitation" and mitral valve stenosis (Munger, Wu & Shen, 2014). The discovery in 1785 of the 
digitalis leaf by William Withering (1741-1799) brought relief to patients with AF and congestive heart 
failure by reducing the ventricular rate. 
The first human electrocardiograph (ECG) depicting AF was published in 1906 by Willem Einthoven 
(1860-1927). Sir Thomas Lewis (1881-1945), a pioneering cardiologist and clinical scientist, was the 
first to study electrophysiological characteristics of AF. The major discoveries in the 20th century 
relating to the pathophysiology and clinical features of atrial fibrillation were led by, among others, 
Karel Frederick Wenckebach (1864-1940). But it was the Framingham Heart Study, which started in 
1948 and is now in its 72nd year, that provided substantial insight into the epidemiology of 
cardiovascular disease and its risk factors, including AF and stroke. With the data from the 
Framingham Heart Study and subsequent research into AF, physicians have sought ways to treat 




fibrillation was drugs. Anti-arrhythmic drugs are still prescribed as a first-line therapy for patients with 
AF but the awareness of transcatheter radiofrequency and cryoablation of non-valvular AF has 
increased and is now accepted in the American and European guidelines for the management of 
AF. The most recent 2019 European Society of Cardiology (ESC) guidelines for the management of 
supra-ventricular tachycardia (SVTs) now also include the use of robotic magnetic navigation to 
perform ablation. 
Estimates suggest that the prevalence of AF in patients 20 years and older is approximately 3%, 
increasing as patients age. It is expected that 25% of all middle-aged adults in Europe and the USA 
will develop AF in their lifetime. Atrial fibrillation is associated with debilitating symptoms, an impaired 
quality of life and a 1.5-fold to two-fold increase in all-cause mortality, including heart failure and 
stroke. In 2010 the worldwide estimate for AF was 33.5 million people. When applying the estimated 
incidence rates of 2010, the estimated number of new AF cases per year is 2.7 million for men and 
2.0 million for women. 
Atrial fibrillation is associated with other cardiac diseases such as coronary artery disease, valvular- 
heart disease, cardiomyopathy, hypertension, heart failure and stroke. Diabetes, chronic obstructive 
pulmonary disease, and renal failure are among the most frequent co-morbidities. Higher incidence 
and prevalence rates are found in developed countries; however, the World Health Organisation 
(WHO) data shows that, of the estimated 17.9 million deaths in 2016 as a result of cardiovascular 
disease, myocardial infarction and stroke accounted for 85% of all these deaths, and more than 
three quarters of these deaths were in low- and middle-income countries. 
The mainstay of treatment for AF has been drugs. Electrophysiology (EP), a super-specialty within 
cardiology, is a discipline that focuses on the electrical conduction in the heart, from which arrhythmia 
arises. Prior to the introduction of ablation for atrial fibrillation, only a relatively small number of 
cardiologists  pursued  the  field  of  electrophysiology  when  compared  with  their  colleagues  in 
interventional cardiology. Technology was limited and, while patients suffered from arrhythmia, only 
a limited number of patients found their way to an EP lab to have the arrhythmia ablated. 
In the late 1990s and 2000s, the number of electrophysiologists being trained globally increased to 
meet the demand for treatment, especially for atrial fibrillation.  At the same time, the number of 
electrophysiologists in South Africa declined through emigration or death. Training centres like those 
affiliated with Wits University closed; and, for many years, no new electrophysiologists were trained 
in electrophysiology in South Africa. With little or no exposure to EP during their cardiology 
fellowship, only a few cardiologists went on to further specialize in EP. (The average time to train as 
an electrophysiologist from start of undergraduate studies to completion of electrophysiology is 
around 18 years). 
When catheter-based radiofrequency ablation started to achieve international acceptance in the late 




electrophysiologists in South Africa who could perform ablation for atrial fibrillation across a 
population of close to 50 million people. 
Key stakeholders in South Africa who are in a position to help or frustrate the process for patients 
with AF to receive ablation, are the following: medical doctors (both referring and treating), funders 
(medical aids and government), and the multinational companies who developed and supplied the 
technology. When planning this research in 2010, I did so with these stakeholders in mind. At the 
time, the situation in relation to each was as follows: 
 The treating doctors in South Africa - many of them being world-renowned experts in their 
fields - were frustrated by the lack of willingness of the funders to reimburse AF ablation, 
while themselves not fully understanding (or perhaps interested in) the complexities of 
funding models, principles of rationing and cost-effectiveness. Most of them only wanted to 
be responsible for treating patients.  
 On the other hand, those responsible for funding these procedures understood the dynamics 
of our economy, healthcare structure and even health economics, but had little grasp of the 
complexities of atrial fibrillation and ablation and were often not willing to fund “expensive 
therapies”, taking a short- rather than long-term outlook on patient outcomes and often citing 
“churning” as a reason for doing so. There was simply no data to convince them that this 
treatment should be funded. Sadly, this is often still the case almost a decade later. 
 Large multi-national suppliers had little understanding of the complexities of South Africa and 
its healthcare system. To them a population of more than 50 million people meant a large 
market to tap into. They set unrealistic expectations for the growth of the market locally and 
lacked understanding that, in order to get growth, investment in training would first be 
required. 
From the outset, my aim was to conduct research that would be relevant to all these stakeholders 
and effect change for the patient in particular. With this in mind, I embarked on research that would 
address the gaps in knowledge and understanding of these stakeholders.  
Changes in literature over past decade 
 Definition of AF 
The 2001 AHA/ACC/ESC Guidelines for the management of patients with atrial fibrillation defined 
atrial fibrillation as either first detected, paroxysmal (self-terminating), persistent (not self- 
terminating) or permanent. The 2016 guidelines add an extra classification, namely long-standing 





 Guidelines for the management of AF 
The 2001 AHA/ACC/ESC Guidelines for the management of patients with atrial fibrillation 
introduced the concept of ablation for atrial fibrillation. The data showed that ablation reduced the 
frequency of recurrent AF in more than 60% of patients, with recurrent AF of 30% to 50% in the 
first year. Their recommendation was that these procedures produced promising results but were 
not widely applied. 
The 2006 AHA/ACC/ESC Guidelines updated in 2011 introduced an updated section that, for the 
first time, discussed catheter ablation for atrial fibrillation in some detail and reported that the 
available studies did not provide convincing evidence of optimum catheter positioning or absolute 
rates of treatment success, and that more evidence was needed. However, in 2012, the ESC 
published an update of the 2010 Guidelines for the management of atrial fibrillation and, for the 
first time, catheter ablation was recommended as a possible alternative to anti-arrhythmic drug 
therapy for patients with symptomatic recurrent paroxysmal AF on anti-arrhythmic drug therapy, 
provided the procedure was performed by an experienced operator. 
The European Society of Cardiology (ESC) (2016) and the American Heart Association/American 
College of Cardiology/Heart Rhythm Society Guidelines (2014) now both recommend catheter 
ablation in patients with symptomatic recurrences of atrial fibrillation on anti-arrhythmic drugs as 
a I A level of evidence for PAF and IIa level C evidence for persistent atrial fibrillation, with clinical 
data supporting catheter ablation as a first-line rhythm control strategy before the use anti-
arrhythmic drugs. 
The advent of catheter ablation in the 1990s resulted in the proliferation of ablation for atrial 
fibrillation that continues to grow, both in South African and around the world. There has also 
been another very positive spin-off related to the growth in AF ablation technologies: the 
increased number of other cardiac arrhythmia that are now treated, allowing patients to lead 
normal lives without palpitations. This has also paved the way for the more controllable and safer 
procedures for cardiac ablation, including in children with congenital heart defects. 
Since the submission of this thesis in 2019, there have not been any major changes in the way 
that paroxysmal atrial fibrillation is treated. The drugs used in the modelling in this dissertation 
therefore remain the same as recommended in the latest guidelines.  
Changes in South Africa 
Ablation for atrial fibrillation has grown significantly in numbers since the initial submission of this 
dissertation. Patients being treated in South Africa has grown from a few hundred patients a year, 
to a few thousand a year. At the time of submission there were 10 electrophysiologists practicing in 




(three electrophysiologists)  Pretoria  (one  electrophysiologist),  and  Cape  Town  (five 
electrophysiologists) and a single centre in KZN (one electrophysiologists). 
Only one academic centre (Groote Schuur Hospital) offered full time electrophysiology service with 
occasional cases being performed at Inkhosi Albert Luthuli Hospital in Durban by a visiting professor 
from Cape Town until his untimely death. 
Since 2010 there has been a 90% increase in the number of electrophysiologists in South Africa. 
The demographics of the electrophysiologists has also changed and reflects the transformation 
within South Africa. In 2010 of the 10 practicing electrophysiologists, seven were white males and 
the others males were from previously disadvantaged communities. These 10 electrophysiologists 
serviced communities by working in 10 EP labs around South Africa. In 2019 there are 34 hospitals 
where EP services are offered, with 19 electrophysiologists with new hospital starting these services 
each year. (2019 has seen three new labs being opened and two academic hospitals starting EP 
services). The demographics have changed to show further transformation in healthcare with 47% 
of electrophysiologists now coming from previously disadvantaged backgrounds and 16% of all 
electrophysiologists  are  women.  Limited  electrophysiology  services  are  now  offered  in  six 
government sector hospitals, compared with only two in 2010. These electrophysiology services 
have expanded to Namibia, with two South African doctors preforming cases in Namibia every six 
to eight weeks. There are plans to expand the electrophysiology services to Botswana and perhaps 
Angola at a later stage. There are currently two black female cardiologists undergoing 
electrophysiology training in Europe and America who are expected to return to South African in 
mid-to end 2020 and one recently qualified black male cardiologist who is working under the direction 
of a local electrophysiologist, who will, when funds are available, enter into a formal training program 
in either the northern America or Europe. Approximately 300 ablations were performed in South 
Africa in 2010 and in 2017 alone there were three EP centres who performed between 350-400 
procedures each per year, this has increased to a conservative estimate of 2500-3000 procedures 
per year and increasing year on year with some electrophysiologists reportedly performing 600 
cases a year in a single EP lab. 
Changes in patient costs 
When comparing the average cost of treating patients with atrial fibrillation with either ablation or 
anti- arrhythmic drugs in 2011 and again in 2019, it was found that outpatient costs had grown by 
127% over this period. Based on cost data over a one-year period from the same hospital where 
previous data was received, the costs associated with pulmonary vein isolation (PVI) have also 
grown by an average of 78%, with the professional fees accounting for most of this growth while the 
costs of radiofrequency ablation disposables having only grown by an average of 38% in the same 
period. The anti-arrhythmic drugs used in the 2011 model are still recommended in the 2016 




2011. The Novel Oral Anti-coagulant drugs (NOACS) are more frequently prescribed and the 
reimbursement thereof has improved, but as these would be used by both the patients treated with 
drugs and those who had ablation, this addition would not affect the outcome of the model. As the 
main cost driver in our model for the ADT group was re-hospitalisation, there is no reason to expect 
a change in the result of cost-effectiveness of RFA vs. ADT for paroxysmal atrial fibrillation as the 
cost of hospitalisation has also increased. 
The introduction of national health insurance (NHI) 
The South African government is at present pushing the NHI Bill to be passed through Parliament. 
While driven in political circles, there is still a great deal of uncertainty among the general population, 
hospitals, medical insurance and healthcare providers. Affordability will become more of a driving 
issue in decision-making for treatment options. This makes the understanding of cost-effectiveness 
of catheter ablation for atrial fibrillation important. The NHI will no doubt be an extra tax burden. 
While not a disease of only the elite, we do know that from the age of 55, the risk of developing atrial 
fibrillation increases, as does the risk of stroke. It is interesting to note that in the 2016 tax year, of 
the approximately 4.8 million tax payers, 21.8% were over 55 years of age and a further 22.3% of 
the tax payers were between 45-54 years old and fast approaching the age where they are at risk of 
developing atrial fibrillation and stroke. Having cost-effective healthcare solutions like AF ablation 
may help to reduce the already burdened healthcare sector by keeping the economically active 
population active. 
Medical aid insurance 
In spite of the volumes of literature available on ablation for atrial fibrillation, there are still a number 
of insurance companies that won’t fund AF ablation, still citing it as expensive technology.  
Arrhythmia forms part of the group of diseases known as prescribed minimum benefits (PMBs), 
meaning that treatment must be funded. However, some of the insurers continue to decline 
reimbursement of AF ablation, using the excuse that only life-threatening arrhythmia forms part of 
the PMBs. Atrial fibrillation itself does not cause patients to die but, as demonstrated in this study, it 
is associated with increased mortality and morbidity. Understanding the value and cost-effectiveness 
of ablation for atrial fibrillation would make access to this treatment available to more South Africans 
in the private sector. 
Public sector patients 
Growth in the private sector often translates into more investment being available for training in the 
public sector, which then leads to more public sector patients being treated. While AF ablation is not 
likely to be available for the general population for some time, the investment and growth in EP has 
made cardiac ablation available to public sector patients with other symptomatic or disabling cardiac 




 Relevance of study area 
Within this thesis, the chapters on atrial fibrillation are very complex, even for physicians who are 
not in the field of cardiology. Other chapters are not unique, yet were deliberately included as part 
of the study design to address the gaps in the knowledge of the various stakeholders and to answer 
my research question:  
Is radiofrequency ablation cost-effective compared to anti-arrhythmic drug therapy for 
treating atrial fibrillation in South Africa?  
With the re-submission of this dissertation, a further question is raised: 
Is this dissertation still relevant today?  
The answer is yes. In fact, with proposed changes in our healthcare system, an economy that is 
sluggish, and national health insurance looming, I believe that it is more relevant now than it was 
before. 
In summary, in spite of the many challenges in the process of completing this PhD, I have been  part  
of  a  journey  where  we  have  almost  doubled  the  number  of electrophysiologists practising in 
South Africa. Rather than training only one electrophysiologist every few years, South Africa has a 
pipeline of young cardiologists interested and being trained in electrophysiology. The demographics 
of the electrophysiologists has transformed, with more previously disadvantaged groups and women 
being trained as electrophysiologists. We have regular electrophysiology workshops being held in 
the public sector/academic hospitals with a focus on training of hospital staff at various levels. We 
now also have one paediatric cardiologist and electrophysiologist who is able to treat patients with 
congenital cardiac disorders with ablation, both in the public sector and the private sector. We have 
developed and trained people who have had opportunities to work in prestigious international 
hospitals. In answering the question as to whether this study is still relevant in South Africa, I believe 
it is more relevant than ever. Each day we move closer to achieving my end goal, to make AF ablation 




CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND 
1.1.1 The rise in cardiovascular disease 
An estimated 17.9 million people died as result of cardiovascular disease in 2016. This represented 
31% of all deaths globally (see Figure 1.1). Myocardial infarction and stroke accounted for 85% of 
all the cardiovascular deaths (WHO, 2017). More than three quarters of the cardiovascular deaths 
were in low- and middle-income countries. Of all the 17 million premature deaths in 2015 (persons 
under the age of 70 years), 82% were due to non-communicable diseases with 82% in low-and 
middle-income countries, while 37% were due to CVD.  
 
Figure 1.1: WHO reported deaths in 2016 
Source: WHO, 2017. 
These data are important for this study, as the population of patients who are being measured are 
those with atrial fibrillation (AF). People with AF have a significantly increased risk of stroke, possibly 
as much as seven times that of the general population (Dressing & Schweikert, 1985). 
A common misconception exists that cardiovascular diseases are diseases of affluent societies or 
developed nations and that developing nations are plagued with infectious diseases. However, WHO 
reports show that, in 2001, cardiovascular disease (CVD) accounted for nearly one-third of all deaths 




These statistics raise concerns as the number of deaths from CVD in low- to middle-income countries 
has doubled in recent years, and these deaths are occurring at an earlier age in these countries as 
compared to similar deaths in developed countries (The World Health Report, 2003: 85; WHO, 
2011). 
The WHO 2003 report estimated that, by 2010, death from CVD would be the leading cause of death 
in developing countries. The WHO 2011 report estimated that, by 2025, CVD disease would claim 
the lives of 25 million people globally each year. Coronary heart disease, heart failure and other 
cardiovascular diseases are chronic in nature, leading the Institute for International Health to project  
that, by 2020, 71% of deaths in the developing world would be directly related to ischaemic heart 
disease and 75% related to stroke (WHO, 2003: 86). 
People in low- and middle-income countries are also more exposed to risk factors, such as tobacco, 
which is a leading cause of CVDs, as well as other non-communicable diseases. Moreover, people 
in low- and middle-income countries often do not have the benefit of prevention programmes that 
are available to people in high-income countries. They may also have less access to effective and 
equitable health care services that respond to their needs, including prevention and early detection 
(WHO, 2012). 
Table 1.1 illustrates the cardiovascular-related deaths by cause and by region in the world for 2008 
as found in the WHO Health Report of 2011.  
Table 1.1: Cardiovascular related deaths in 2008 by cause and WHO regions (thousands) 
 
 
Note: The full description of WHO regions is given in Appendix A. 




The British Heart Foundation estimates that more than 4 million deaths occur each year in Europe 
as a result of CVD, making this the leading cause of death in Europe and accounting for 49% of all 
deaths. The WHO reported in 1990 that CVD death was the leading cause of years lost due to an 
early death. Of all the CVD-related deaths, almost 50% are from coronary disease and a further one-
third are from stroke. In a global context it should be noted that, of the estimated 32 million heart 
attacks and strokes that occur each year, about 12.5 million or 39% are fatal. Many of these CVD- 
related deaths were linked to tobacco and were preventable (Office of the Surgeon General (US) & 
Office on Smoking and Health (US), 2004). 
Reports from the World Health Organisation (WHO) in 2005 showed a global increase in the 
incidence of disease entities such as heart disease, diabetes mellitus and congestive heart failure 
(WHO, 2001). Diabetes mellitus, hypertension and cigarette smoking are known risk factors for CVD 
and strokes (Rosamond, 2007: 69), and a combination of these factors means that heart disease 
and its contributing factors are high in both developed and developing nations. In 2003 the WHO 
stated that 13% of the disease burden in adults over 15 years of age was as result of cardiovascular 
diseases and that ischaemic heart disease and stroke were the two leading causes of mortality and 
disease burden among adults over the age 60. Up to 36% of deaths in all developed countries can 
be attributed to ischaemic heart disease and stroke. These death rates are higher in men than in 
women (The World Health Report, 2003). 
The incidence of diabetes mellitus around the world has doubled in the past 30 years (Council for 
Medical Schemes Annual Report 2003-4, 2004:9). Other risk factors for heart disease, such as 
obesity, have grown by 27% in recent years. This worldwide increase in obesity, diabetes mellitus 
and cardiovascular disease (CVD) has resulted in heart disease killing more people in the world than 
any other single disease. In the United States of America (USA), 27% of the total population has one 
or more types of cardiovascular disease. Approximately 47% of these patients with CVD are over 
the age of 65 years (Rosamond, 2007: e117). 
1.1.2 The economic burden of cardiovascular disease 
Because the burden of disease is on the increase, there is also a growing economic burden. In 2006, 
the direct cost to the health care system of cardiovascular disease amounted to almost 110 billion 
Euros or 10% of the budget for healthcare in the European Union (EU). The greatest portion of this 
expenditure was allocated to hospitalisation costs for in-patient care (54%), while medication or drug 
therapy accounted for a further 28%. Of all the expenditure on CVD in 2006, 22% was related to 
ischaemic heart disease and 17% was related to stroke (24 billion Euro and 18 billion Euros 
respectively) (Allender et al., 2008: 105).  
Loss of productivity due to death or illness in people of working age adds to non-healthcare related 




due to mortality and morbidity from CVD was estimated to cost 41 billion Euros. Twenty-seven billion 
Euros or 65% was related to death and a further 35% or 14 billion Euros was due to illness. The cost 
of mortality and morbidity as the result of stroke was 26% of the total cost for CVD and accounted 
for eight billion Euros (Allender et al., 2008: 105). 
An important consideration in low- and middle-income countries affected by CVDs and other non-
communicable diseases is that the affected often die younger, which means that their most 
productive years are lost forever. This compounds the incidence and effects of poverty due to loss 
of family income, catastrophic health spending and high out-of-pocket expenditure at the household 
level. At a macro-economic level, the WHO (2012) estimates that premature death caused by non-
communicable disease, including cardiovascular disease and diabetes, reduces the GDP by up to 
6.77% in low- and middle-income countries. 
Improved methods of diagnosis have enabled physicians to diagnose these conditions far earlier, 
exposing the seriousness of these conditions. New technologies have not only afforded the medical 
fraternity the ability to make a diagnosis earlier, but they have also offered a mechanism to safely 
and effectively treat patients who, in previous years, would have been considered either ‘too old’ or 
‘too risky’ for conventional treatment. 
1.1.3 New technologies vs traditional drug options 
The costs associated with healthcare have attracted increasing attention in recent years. While some 
countries have seen a decline in general inflation during the last decade, many countries have seen 
a concomitant increase in medical inflation, at times recorded at levels double that of general 
inflation. Politicians label the increase in medical costs and medical inflation as excessive but 
continue to promise voters improved health services in a bid to gain political favour. Thus, the debate 
that has evolved around the issue of medical costs has served to unite global policy makers in their 
endeavour to reduce healthcare costs while improving the health of the world’s population 
(Drummond et al., 2006: 5). 
Life expectancy around the globe has increased and healthcare has adopted an approach not unlike 
other commodities where patients shop around on the internet for information and services. Many 
patients approach healthcare in much the same way as any other form of consumerism, demanding 
better quality of life for longer periods, thereby contributing to significantly higher costs of healthcare, 
driving medical inflation beyond general inflation and undoubtedly placing extra financial burden on 
governments and policy makers alike (Gleckman & Carey, 2002: 123; Seifan & Shemer, 2005). 
According to Gleckman and Carey (2002) the use of new health technologies may be one of the tools 
to control the acceleration in medical inflation (Gleckman & Carey, 2002: 123). Use of these new 
technologies in the United States has shown, in some instances, a reduction of overall costs as a result 




achieved through disease management programmes and the concurrent use of medical technology. 
While the initial cost of technology may be higher, there may also be significant cost savings in the 
long term. 
In 2012/2013 the size of the medical technology market was estimated at US $ 270 billion globally. 
What appears to be driving growth in this market includes the demographic trends in both developed 
countries, where ageing populations are increasing, and developing countries, where there appears 
to be a change from communicable diseases to non-communicable diseases (KPMG, 2014). Figure 
1.2 shows the growth in the global medical technology market from 2006 to 2015.  
 
Figure 1.2: Growth in the global medical technology market from 2006 to 2015 
Source: KPMG, 2014: 16. 
Not only does the United States outspend other nations in health care, but U.S. health care costs 
are growing rapidly. From 1988 to 1993, U.S. health expenditures rose by 9.7% per year. Followed 
by a slowdown from 1993 to 2000, where the costs jumped by 8.5% in 2001, 9.3% in 2002, and 
7.7% in 2003. The most rapid growth in the health care sectors were the cost of prescription drugs 
as well as administrative costs of private health insurance (each increasing at 11% to 16% in a 3 
year period). Hospital and physician expenditures grew in average by 7% to 8% year on year over 
the same 3 years period. 
High medical inflation rates are evident worldwide and the annual increase in healthcare costs have 
grown at historically high rates, with no signs of abating. Managed care has not appeared to slow 
medical inflation. From 1988 to 1993, U.S.A the health expenditure rose by 9.7% per year and 
medical insurance in the United States grew on average by 15% in 2003. This did slow down for the 
period of 2006 to 2011 when medical inflation in the USA ranged between 8.3% and 10.1% (Towers 
Watson, 2011: 3). At the time the federal government projected an average annual growth rate of 
7.2% through 2013, with health expenditures rising from $1.6 trillion in 2002 (14.9% of GDP) to 




Inflation News (2004) showed that this was particularly high when considering that medical inflation 
in February 2004 was 4.2%, an increase from November 2003 when it registered 3.5%. Both these 
rates were significantly higher than the growth in the Consumer Price Index (CPI) of 1.8% and 1.7% 
respectively. One of the biggest contributors to this was in-patient hospital care (Health Inflation 
News, 2004: 3).  
Fong (2003: 9) found that after nearly a decade of managed healthcare in the United States, which 
was meant to revolutionise the marketplace, hospital and physician expenditure showed increase of 
between 7% to 8% year in year. (Smith et al., 2005) 
Similarly, managed private healthcare costs in South Africa increased by 14.2% in 2003, totalling 
around R5.5 billion, without any apparent concomitant improvement in healthcare delivery. The USA 
is among those countries where controlling medical inflation has become of paramount importance, 
and various methods are adopted in order to achieve this. In 2003 the USA started recruiting 
medically trained doctors from developing countries as nurses. Many of these doctors were unable 
to gain a licence to practice in the USA as a medical doctor, owing to a complex registration process. 
For the USA, at least in the short term, this meant that, in addition to addressing the problem of the 
shortage of nurses, they gained the expertise of a higher level of competency and training, paying 
‘physician-nurses’ nursing salaries and wages and saving the costs involved in recruiting and training 
of nurses themselves (Clemente, 2003: 1). One may question what real long-term impact this type 
of practice will have on costs. 
Business Day (2003) refers to the fact that more and more South Africans have been funding part 
of their medical bills out-of-pocket, with this phenomenon unlikely to improve any time soon. This 
seems particularly true in the area of health technology, where the device industry has been 
increasingly expected to discount devices that offer lifesaving technologies in order to meet the 
growing out-of-pocket expenditure of patients in the private health sector. 
According to Miot (2005), there is a lack of clarity on managing costs associated with new 
technology, added to which is the lack of a legislative body to control the quality of health technology 
in South Africa. The onus rests with each individual medical scheme to assess whether new 
treatments and technology provided offer any added benefit to their patient, taking into consideration 
total cost and perceived value for money. 
With limited healthcare resources and incentives for certain insurers to save costs, policy makers for 
healthcare provision often focus only on immediate costs and prefer to spread their risk over many 
years instead of paying the sometimes-substantial upfront cost of these new technologies. One of 
the greatest challenges facing health economists is the identification and valuation of the benefits 
from healthcare interventions. This has resulted in an international trend towards evidence-based 
medicine (EBM) decision-making in healthcare which, in turn, has led to an increased demand for 




systems use economic evaluations to make system level decisions regarding which interventions 
they fund from collective resources (Drummond et al., 2006), thus using economic evidence in 
reimbursement decisions for healthcare technologies. 
1.1.4 The South African reality 
After peaking in the mid-1980s, inflation in South Africa declined to reach record low levels in the 
1990s and the first half of the 2000s. This was as a result of solid and tight monetary policies and 
the introduction in 2000 of inflation-targeting policies (Henry, 2003: 128). Yet, in spite of the fact that 
general inflation declined in the 2000s, medical inflation continued to increase at a rate consistently 
and significantly higher than the general inflation rate; at times, it was more than double that of 
general inflation (Council for Medical Schemes, 2004:9; Twine, 2008). This has resulted in medical 
insurance companies; individuals and the government being forced to find solutions to curb medical 
expenditure. 
This growing interest in and concern about healthcare costs in general has resulted in an upsurge 
in literature on the economic evaluation of healthcare by economists, medical researchers, clinicians 
and multi-disciplinary teams (Drummond et al., 2006: 1). Many of the problems associated with the 
rising costs of healthcare are not unique to South Africa, but South Africa has, in many instances, 
unique healthcare needs. The use of medical technology is often rejected in favour of traditional 
medical therapy as a means of treatment as new technologies are frequently considered too costly. 
Studies investigating the impact of cost on healthcare systems, and particularly on medical 
technology and devices, are limited in the South African environment. This study, therefore, 
examines the rising costs of healthcare expenditure in South Africa and focuses in particular on 
arrhythmia and, more specifically, on non-rheumatic atrial fibrillation in the South African population 
and the costs associated with the disease. The justification for this delimitation of the research 
domain is explained in the next section. 
Heart disease in the general South African population has also increased. This disease, identified in 
the 1970s as one that affected mainly white Afrikaans-speaking and Jewish men, is now prevalent 
in both males and females of all population groups and ages in South Africa. The epidemiological 
studies established at Chris Hani Baragwanath Hospital (Sliwa et al., 2008: 916) reveal a high 
prevalence of modifiable risk factors for atherosclerotic disease and a combination of infectious and 
non-communicable forms of heart disease. Although advances in medical care have enabled people 
to live longer, they may still have residual disease or damage to their hearts, requiring major surgery 
and lifelong drug therapy with their potentially toxic or other debilitating side effects, or both. 
The South African government remains concerned that more than 60% of the total health 
expenditure in South Africa is spent on only 15% of the population, while the remaining 85% of the 




1996 (Schellack et al., 2011; KPMG, 2014; The Economist, 2010). The public sector appears to have 
insufficient capital to access “expensive” technologies. This is as a result of insufficient resources 
and poor management of these resources. Schellack et al. (2011) state that, in spite of an enabling 
legal and fiscal environment which exists to expedite government health goals, there is 
fragmentation and a lack of co-ordination in the various policy initiatives, many of which have not 
only been poorly managed but also lack transparency and the involvement of the public.  
In a report prepared by KPMG for the South African Medical Device Association (SAMED) in 2014 
it is argued that the South African public system has typically been characterised as suffering a lack 
of resources, especially human resources, medicine and medical technology. However, it is often 
the management challenges at both a provincial and district level that are most apparent to the press 
and the public. Furthermore, the public sector’s poor service delivery is severely affected by poor 
infrastructure and backlogs in capital projects (KPMG, 2014: 12). 
The other side of the coin reflects that the medically insured population of South Africa has remained 
stagnant at around seven million lives since 1996. This industry is notorious for “churning” of 
members, i.e. members who change from one scheme to another (Council for Medical Schemes, 
2004: 15). As a direct result of this, many policy makers have adopted what some might consider a 
short-sighted attitude of not paying for what may be considered expensive technologies. The reason 
for this appears to be that the insurers consider that they may not reap the benefit of any potential 
cost-saving which these new technologies may offer. In many instances a medical device or use of 
a new technology may ameliorate the need for certain medication. However, the cost of most devices 
(or therapy) is borne upfront while the cost of medication is carried over months or even years. A 
medical scheme that pays for these new technologies or devices could potentially save on treatment 
costs over the lifetime of the device, considering that the cost of medication is unlikely to decrease 
with time. Some devices and therapies are proven to decrease hospitalisation in patients with chronic 
diseases such as congestive heart failure, again potentially saving the medical schemes a significant 
amount of money. In spite of this, however, some medical aids choose to pay for medication only. 
Should the patient move to another medical scheme (as seen in churning) the financial outlay for 
that patient is, in essence, reduced. The result of this is that the patient may not benefit from the best 
treatment modality. 
Unlike pharmaceutical agents, health technology in South Africa has no regulatory body that 
approves and monitors the introduction of new technology into the country’s healthcare system. This 
may result in not only inferior quality products entering the system but also technologies that are not 
backed up by good clinical evidence. Medical schemes are aware of the need to promote evidence-
based medicine and, at present, Discovery healthcare leads the industry by evaluating the clinical 
evidence to support their decision either to fund or not fund a specific therapy. Many of the smaller 




of Discovery Health. This has resulted in some therapies being accepted on a larger scale than might 
have been the case previously, but it does not provide an unbiased ruling as the medical scheme 
administrators are expected to conserve their financial reserves.  
According to the KPMG report of 2014, the estimated value of the South African medical devices 
industry is in excess of R10 billion. This equates to about 0.4% of the total global technology market. 
However, it should be noted that while the global compound annual growth rate in the medical 
technology market is 5.3%, the growth rate in the medical technology in South Africa has grown by 
19% since 2009 (KPMG, 2014: 18). 
This highlights the need for a Health Technology Assessment body in South Africa similar to the 
National Institute for Clinical Evidence (NICE) in the United Kingdom (UK) where unbiased evaluations 
and recommendations are made on an assessment of what the best option is for the patient. In 2005 
Brunner described how every 3.5 minutes a patient somewhere in the world who required an 
Implantable Cardiac Defibrillator died without receiving one. The value of health technology agencies 
can be seen by the change in funding policy, in particular in the UK, USA, Australia and the EU, and 
by the number of patients who now receive ICDs based on MADIT II criteria (Brunner, 2005).  
Discovery Health, the largest private health insurer in South Africa, uses a concept known as a 
financial filter in their health technology assessment. This filter enables Discovery Health to evaluate 
the contribution impact known as “premium life per month”. This premium determines the amount 
per capita needed to fund a new therapy or technology. Unfortunately, the spread of risk is skewed 
among the insured population as many young healthy employed people are not subscribing to 
medical schemes because of the costs of these schemes, and contributions are increasing at a rate 
that exceeds general inflation, despite a range of cheaper products being available from medical 
schemes. This phenomenon is not unique to South Africa. In Business Insurance (Wojcik, 2004: 6), 
Bill Sharon of Aon Consulting, as quoted by Wojcik, stated that medical insurance premiums were 
expected to increase between 15% and 25% annually. This may be the trend as described by Brady 
(2003: 101) who showed that Aetna Inc. (a medical insurance firm in the USA, with a customer base 
of 19 million members) increased their annual rates by 16% in 2003 to keep ahead of medical 
inflation.  
In South Africa some medical aid schemes have a higher percentage of pensioners who often require 
more medical treatment than the younger population, while other schemes tend to attract younger, 
healthier members. This issue has been addressed by the Council for Medical Schemes (CMS) who 
proposed the introduction of the Risk Equalisation Fund (REF) and the ruling that schemes were no 
longer permitted to turn applicants away, i.e. no “cherry picking.” The REF was to be implemented 
in 2007 but, at the time of writing this (2012), it had still not been implemented. 
This study examines rising costs in healthcare expenditure in South Africa and, in particular, costs 




population. The preceding discussion points to the need to take a closer look at the factors underlying 
the increase in the cost of medical treatments.  
1.2 RESEARCH PROBLEM AND OBJECTIVES 
Billions of USA dollars are spent annually by large corporations and governments on research and 
development of new drugs and technologies and, at some point, it becomes necessary to evaluate 
whether any of these new drugs and technologies actually improve patient outcome, what the degree 
of improvement is and, finally, at what cost. The primary objective of this study is to measure the 
cost-effectiveness of radiofrequency catheter ablation compared to anti-arrhythmic drugs for the 
treatment of paroxysmal atrial fibrillation. The secondary objectives of this study are to explore the 
various aspects of healthcare expenditure in South Africa and to understand how health technology 
is defined. Together with this the review of available literature indicates the need to analyse the rising 
costs in South African healthcare expenditure, and, in particular, costs related to the treatment of 
various cardiac and cardiovascular diseases. 
To achieve these objectives, the study will introduce the principles of health economics, evaluate the 
healthcare sector in South Africa and compare it to other developed and developing nations. The 
study will examine the concept of “willingness to pay” in the South African context and will then 
explore paroxysmal atrial fibrillation as a disease, its growing incidence, as well as the current 
treatment options available for its management, and the costs and, more importantly, the cost-
effectiveness associated with these treatment options. 
Finally, a summation will be presented of the author’s findings and recommendations offered both in 
terms of the utilisation of the various treatment options from the viewpoint of what is cost-effective in 
South Africa at a given date and also in terms of areas that would benefit from further research. 
1.3 THE VALUE OF THE STUDY 
Through the investigations proposed in this study, the author will attempt to answer important 
questions associated not only with the private health sector, but also with Government and the 
Department of Health on the behaviour of cost and trends in health technology in South Africa. There 
are various stakeholders who are affected by the apparent lack of knowledge associated with 
aspects of health technology in South Africa, namely Government, medical schemes, the Council 
for Medical Schemes, industry, physicians, potential investors and, more importantly perhaps, the 
patient, who is an unwilling or reluctant consumer.  
To attempt to establish how this type of research could improve current management practices, it 
may be argued that improvement could be introduced at various levels. It would be hoped that, as 
with the introduction of policies like prescribed minimum benefits (PMB), there would be better 




patients and ensuring that they receive not just any form of treatment but rather the appropriate 
technology based on evidence-based medicine. The information derived from such a study could 
potentially highlight, at an academic level, the critical need for an independent organisation to 
monitor health technology in South Africa.  
Unlike the pharmaceutical industry, which is regulated in South Africa, an exploration of this nature 
could help highlight one aspect within the basket of goods compounding medical inflation. The 
medical devices industry could benefit from increased exposure to and utilisation of technology 
which, in turn, could drive the provision of better expertise in the field, as well as improve potential 
investment in the country, in particular with regard to investment in the training of physicians and 
nurses. In 2012/13 it was estimated that medical technology companies in South Africa spent in the 
region of R31.7 million on the training of healthcare professionals and a further R 23.7 million on 
sponsorships to educational meetings. This is illustrated in Figure 1.3. In this regard it may be noted 
that this investment accompanies job creation and skills development, particularly in the industry 
that supports these technologies, such as hospitals. 
 
Figure 1.3: Expenditure on training on medical technology in (ZAR millions) 
Source: KPMG, 2014: 27. 
In the same period, the general contribution to the national economy by the medical technology 
industry was about R3.88 billion per year. The authors of the KPMG report suggest that when the 
associated economic multiplier is calculated at 1.25, it means that for every additional R1 spent in 
the national economy by the medical technology industry, an additional 25 cents is generated in 




The report further states that the capital and operational expenditure by the medical technology 
industry has allowed a total of 20 901 jobs to be supported, while the tax generated by the medical 
technology industry during the same period under review was estimated at R1.86 billion.  
It is important to note that there are other positive spin-offs besides the obvious economic impact, 
but also that medical technology adds value to patients, healthcare professionals and, more 
generally, the health system. 
It may be argued that incentives could be put in place by the South African government to create an 
environment in which it is more attractive for all medical technology companies, both multinationals 
and local manufacturers. These incentives could be put forward by the Department of Trade and 
Industry (DTI) who could potentially play a role in prioritising the medical technology sector as was 
done previously by this Department for the pharmaceuticals market. As such, the DTI could also 
create awareness of what the industry means for the country’s economy. 
There are at least three groups of people for whom this research may be important. The first 
comprises the medical aid societies in South Africa, who are required to make decisions about what 
new procedures they will fund. This group understands the concepts of health economics as well as 
the complexities of healthcare in South Africa. However, they are unlikely to be fully conversant in 
the topic of atrial fibrillation and all the treatment options that are available to the patients. With this 
in mind, Chapters 4-8 would be of value to the medical aid societies. 
The second group for whom this study will have value are the physicians. The physicians and, in 
particular, cardiologists and electrophysiologists have a very good understanding of atrial fibrillation, 
the diagnosis thereof and most of the treatment options that are available. They would all be 
conversant with the major drug trials relating to the treatment of atrial fibrillation. Some may not, 
however, have been exposed to the literature on the use of implantable intra-atrial cardioverters. 
While this group will have an understanding of the healthcare sector, they may not have an in-depth 
understanding of the financing of healthcare. Many would also have limited knowledge of healthcare 
economics and the criteria needed for a cost effectiveness or cost-benefit analysis. Therefore, 
Chapters 2, 3, 5, 6, 7 and 8 would be of value to this group. 
The final group who would be interested in this study are the potential investors. These are often 
large multinational companies who look for opportunities for their products and services in 
developing markets. Based on the type of products these companies have, it can be assumed that 
they would have good knowledge of health economics and atrial fibrillation. However, these investors 
often do not understand the complexities of the South African healthcare system. For this group, 




1.4 THE RESEARCH QUESTION 
As pointed out above, billions of US dollars are spent on research into and the development of new 
drugs and technologies. At some point, therefore, it becomes necessary to evaluate whether any of 
these new drugs and technologies improve the outcome for patients, what the degree of 
improvement is and finally, at what cost. The research question will focus on the domain in which 
the author is working at present, namely cardiovascular diseases. The research domain is narrowed 
down to the analysis of the question:  
Is it more cost-effective to treat South African patients suffering from paroxysmal atrial 
fibrillation with radiofrequency catheter ablation rather than the current standard of care 
which is anti-arrhythmic drugs?  
Historical records from many ancient civilizations contain accounts of various ways of treating 
patients with diseases. These have varied from bleeding patients in the Middle Ages to modern day 
surgery or pharmaceutical treatment. The latter two have proven to be the mainstay of healthcare 
for most of the last century. While drug therapy and surgery have well-defined and specific roles in 
treating patients, these two interventions are at times unable to compensate for the mechanical 
failure of the body or its organs.  
Pharmaceutical substances have been available in various forms for thousands of years and often 
evolved from herbal remedies, traditions and even folklore. Health technology and medical devices, 
on the other hand, are still relatively new and poorly defined. The terms ‘health technology’ and, 
more specifically, ‘medical devices’, refer to almost all forms of apparatus and appliances that are 
not pharmaceutical in nature, although they may include some chemical element (Medical Device 
Directive, 2007).  
1.5 HYPOTHESIS 
Treating patients in South Africa who are diagnosed with paroxysmal atrial fibrillation with radio-
frequency ablation by means of pulmonary vein isolation is more cost-effective than treating them 
with the anti-arrhythmic drugs as recommended in the current guidelines. 
1.6 RESEARCH PHILOSOPHY 
The research philosophy that underpins this study is centred in positivism, where positivism is 
believed to hold the notion that the goal of knowledge is simply to describe the phenomena and to 
evaluate what can be observed and measured (Crossan & Schindler, 2001: 48). 
The approach of this study is deductive, as the process begins with theory about healthcare costs. 
It next states a hypothesis and this is followed by a process of observation and finally a conclusion 




schematically in Figure 1.4. The end point of this research is determined by an evaluation of cost-
effectiveness between the traditional approach (ADT) and new treatment options (PVI) and is 
measured in South African Rand (ZAR). 
 
Figure 1.4: A schematic representation of deductive reasoning 
Source: Trochim, 2006. 
As clinical decisions are made based on the data available in clinical trials and may have an impact 
on millions of people’s lives, it is of utmost importance that the paradigm of this type of research be 
objective and scientific. Therefore, the nature and philosophy of clinical trials employed by healthcare 
workers around the world reflect a formal structure. Axiological assumptions are free from value and 
are unbiased, while the epistemology is determined from peer-reviewed clinical data established as 
landmark clinical trials for treatment of patients with related diseases. The ontological characteristic 
of the study is determined by the current situation in the South African healthcare environment. 
1.7 METHODOLOGY 
The methodology is triangulated, which in this study refers to the use of more than one method for 
gathering data. In this case, both qualitative and quantitative data are used (Hussein, 2009).  
Atrial fibrillation is investigated within a descriptive and interpretive philosophy, while the cost 
calculations are founded in a positivistic philosophy which takes the approach of deduction. This 
approach is followed to calculate the cost-effectiveness of treating paroxysmal atrial fibrillation with 
catheter ablation rather than anti-arrhythmic drugs. The study is structured into eight chapters with 






















Figure 1.5: The research process and progress report 
Source: Adapted from McCombes, 2019. 
As seen in Phase I on Figure 1.5, the topic is introduced and defined. An evaluation is performed on 
the existing body of knowledge about the topic. The theory that underpins the topic is explored, a 
research question is formulated, and a hypothesis is stated. Finally, the study design is described. 
Chapter 2 introduces concepts within health economics and attempts to summarise some of these 
while establishing the need for each of these evaluations. This chapter evaluates the positivistic 
nature of the study and will also defend the choice of cost-effectiveness as the method of evaluation. 
Chapter 3 is a descriptive, interpretive exploration of South Africa and investigates the demographics 
of the country as compared to other countries in order to gain a better understanding of the 
healthcare needs of the South African population. The chapter gives an overview of the healthcare 
sector in South Africa and compares it to other developing and developed nations, with regard to 
size, healthcare expenditure as a percentage of GDP and the expenditure per capita. It also 
examines some of the trends in healthcare expenditure.  
 Phase II: Execution, 
Implement Design: 
 Design Data 
 Collective Devices 
 Collect Data 
 Check for Errors 
 Code Data 








   
 
 
     
 
     
 
   
 
     
 
   
 
   
 
   
 






Phase IV: Documenting the research and 
contributing to new knowledge 
 
Existing Knowledge 
Pertaining to the problem 
 




 Research Questions 
 Hypothesis 
 Study Design 
 
Phase III Analytical 
 Analyse Data 
 Statistical Analysis 
 Interpretation 
 Draw Inferences 
 Interpret Results 




Chapter 4 is an introduction to the condition known as atrial fibrillation. This chapter is descriptive 
and defines the characteristics and nature of the disease and describes the disease in detail, from 
signs and symptoms to the diagnosis of the disease. This is of value to readers for whom the topic 
of atrial fibrillation is unfamiliar. 
Chapter 5 investigates the types of treatment currently available and employed to treat or manage 
patients with atrial fibrillation.  
Chapter 6 contains an extensive literature review of studies pertaining to the treatment of AF with 
either catheter ablation, referred to as pulmonary vein isolation (PVI) or anti-arrhythmic drugs 
therapy (ADT). It explores the concepts and data which underpin the model developed in Chapter 7 
to measure cost-effectiveness of PVI versus ADT in South Africa. It also seeks to establish the rate 
of mortality and morbidity associated with both treatment modalities as well as studies that have 
been performed to assess the impact on the quality of life (QoL) for patients with AF.  
Chapter 7 is founded in the positivistic philosophy and uses a decision tree analysis and a Markov 
model with Monte Carlo simulation as a quantitative approach to assess the relative value of different 
decision options. This conceptual model is used to perform a cost-effectiveness analysis. The 
decision analysis is an estimation of quality adjusted life years and involves a measurement in 
utilities, in this case “No AF” and “quality of life” at two years. Sensitivity analysis is used to examine 
the cost of the treatment with anti-arrhythmic drugs and compares it to the cost of treatment with 
catheter ablation therapy. This chapter includes processes from both phase II and III as illustrated 
in Figure 1.5, where devices for collection of data are designed, the data are collected and checked 
for errors (Phase II of Figure 1.5). As seen in phase III the data are then analysed statistically and 
interpreted. Inferences are drawn from the data and the results are interpreted.  
Finally, in Chapter 8, a conclusion is reached with regard to the cost-effectiveness of radiofrequency 
catheter ablation for paroxysmal AF compared to anti-arrhythmic drugs within the South African 
context; the limitations of the study are explored and discussed; and recommendations are offered for 
further research (Phase III of Figure 1.5). 
1.8 RESEARCH DESIGN 
Table 1.2 describes the method of data collection through a process of literature review, 
questionnaires and interviews with local electrophysiologists, and finally the exploration of patient 
data. The dimension is longitudinal, and the final Markov model uses statistical data and simulation 





Table 1.2: Research design 
Type of Study Formal 
Method of data collection Literature review/Interrogation 
Researches control of variables Ex Post Facto 
Purpose of the study Causal 
Time dimension Longitudinal 
The topical scope Statistical 
The research environment Simulation 
Source: Own compilation. 
1.9 PLAN OF THE STUDY 
Chapter 2 introduces relevant concepts within health economics, discusses various methods of 
evaluating cost impact and attempts to summarise some of the important concepts in health 
economics while establishing the need for each of these evaluations. This chapter introduces 
rationing in healthcare, continues to discuss the quality adjusted life years (QALY) and disability 
adjusted life years (DALY). Both the QALY and the DALY are measures of the disease burden. In 
addition, the economic measure of willingness to pay is discussed and a comparison is made within 
healthcare as opposed to consumerism. Finally, the theory of ‘cost-effectiveness analysis’ is 
introduced. This forms the basis of the analysis in Chapter 7. This chapter is of particular interest to 
physicians who may be unfamiliar with the concepts of healthcare financing and health economic 
measurement tools. 
Chapter 3 introduces South Africa from an historical, economics and demographic point of view. It 
then provides an overview of the healthcare sector in South Africa and compares it to that of other 
developing and developed nations with regard to size, healthcare expenditure as a percentage of 
GDP and expenditure per capita. It also explores trends in healthcare expenditure and examines the 
differences in the private and public healthcare sector, before discussing the proposed National 
Health Insurance model. This chapter is of particular interest to potential investors and multi-national 
companies who often have limited knowledge of the complexities of the healthcare system within 
South Africa. Often multi-national companies liken the size of the population with the opportunity 
within the country and for this reason it is important to highlight the issues such as the demographics, 
economics and healthcare structure of the country.  
Chapter 4 examines atrial fibrillation (AF) as a medical disorder. The signs and symptoms are 
explored as well as how a definitive diagnosis is made. The next stage is to identify those patients 
who are at risk of developing AF. It then defines the various characteristics of the disease from 
paroxysmal episodes to a chronic condition. The risk of stroke and congestive heart failure 




aid societies and other funding decision makers like hospital administration, who would have 
knowledge of the healthcare structure and possibly health economics but would have a limited 
understanding of the particular disease entity. 
Chapter 5 describes the many treatment modalities that are available to the patient suffering from 
AF and offers insight into the effectiveness and limitations of each. These treatment modalities 
include surgery, pacemakers, defibrillators, medical therapy and finally radiofrequency ablation. As 
with Chapter 4, this chapter is intended for medical aid societies and other policy makers. 
Chapter 6 examines the literature which underpins the basis of the cost-effectiveness model with 
regard to the efficacy of treating patients with paroxysmal AF (PAF) with anti-arrhythmic drugs and 
catheter ablation. It also reviews the literature on mortality and morbidity data associated with both 
treatment modalities as well as studies that have been performed to assess the impact on the quality 
of life (QoL) for patients with AF. Data from interviews performed with practicing South African 
electrophysiologists are reviewed to establish commonality between the studies, which have been 
completed internationally, and current clinical practice in South Africa. Chapter 6 would be of interest 
to all the stakeholders although most physicians would be familiar with this information.  
In Chapter 7 using a decision tree analysis, a Markov model and simulations is developed to 
establish the cost-effectiveness of radiofrequency catheter ablation for PAF compared with 
commonly prescribed anti-arrhythmic drugs. This chapter would be of interest to all the stakeholders 
as it presents the model and all the data collected. It also includes the results. 
Finally, in Chapter 8 a conclusion is reached with regard to the cost-effectiveness within the South 
African context. The limitations of the study are discussed, and recommendations are offered for 




CHAPTER 2: ECONOMIC EVALUATION OF HEALTHCARE COSTS 
2.1 INTRODUCTION 
Globally, an ever-increasing volume of resources is being allocated to healthcare. Moreover, in many 
developed nations where the healthcare sector is well established, a significant percentage of the 
population may live to be in their eighties. This begs the question as to whether people are living 
healthier lives. The evidence suggests not; a large proportion of the world’s population is affected 
by lifestyle diseases such as diabetes and hypertension (WHO, 2011). Health economics or medical 
economics refers to that branch of economic theory that is applied to the healthcare sector. The aim 
of this discipline is to allocate scarce medical resources to those who need them. In extended terms, 
health economics is a study of the healthcare system, its functioning and efficiency, as well as the 
private and social impact of individuals’ behaviour. This study utilises information from biostatistics 
and epidemiology and, by means of mathematical models, supports or rejects policies that may 
affect both the individual and a wider health policy (Culyer, 1989: 216). 
Sawert and the WHO Task Force on Health Economics (1996) defined the study of healthcare 
economics as follows: 
The study of how the scarce resources are allocated among alternative uses for the care 
of sickness and the promotion, maintenance and improvement of health, including the 
study of how healthcare and health related services, their costs and benefits, and health 
itself are distributed among individuals and groups in society.  
This chapter explores the nature of healthcare financing, delves into the terminology that is particular 
to healthcare expenditure and compares South Africa with both emerging and developed economies 
with regard to healthcare expenditure.  
This chapter also introduces various principles of economics that relate not only to the study of 
macro- and microeconomics but also directly to the principles related to the attainment of health. 
The emotive and financial issues related to rationing in healthcare are investigated as well as the 
various methods employed to ration healthcare. 
Finally, the various methodologies used in health economics are scrutinised in order to evaluate the 
most appropriate method of analysis for this study. These include concepts such as the QALY, 




2.2 FINANCING IN HEALTHCARE 
In many societies the effective use of scarce resources, particularly healthcare resources, is 
considered a priority (Jordan et al., 1998: 83). This section introduces important concepts related to 
financing for healthcare. It may be argued that the most critical part of any healthcare system relates 
to the structure of the financing for that system. Large databases like those of the World Health 
Organisation (WHO), the World Health Report, national health accounts (NHA) and domestic country 
specific data are examined in the hope of providing indicators based on the expenditure information 
within an internationally recognised framework. NHAs are a combination of recorded budgets and 
costs for the operation of any healthcare system and include information across geographical, 
demographic, socio-economic and epidemiological dimensions. Some important concepts in 
healthcare financing are discussed below. 
Gross domestic product (GDP) refers to the value of all goods and services produced in a country 
by both its residents and non-residents. GDP relates to the total sum of expenditure, consumption 
and investment by government and the private sector in the economy in a given year. 
A hypothetical unit of currency with the same purchasing power as the US dollar has in the United 
States at a given point in time is known as the international dollar. The international dollar utilises 
the concepts of both purchasing power parities (PPP) and international average prices of 
commodities. The PPP calculates the rate between two countries at which the currency of Country 
A is converted into that of Country B in order to guarantee that the same amount of goods and 
services can be purchased in both Country A and B (World Bank, 2010c; IMF, 2010). 
Total expenditure on health (THE) refers to the total expenditure in a given year on healthcare by 
both the government and the private sector and is computed in the national currency units in current 
prices. THE includes all costs used for the maintenance, restoration or enhancement of the health 
status of the population. As seen in Table 2.1, THE is often stated in international dollars as a 
percentage of GDP, or per capita expenditure. THE includes all social and private health insurance 
as well as the burden placed on households as result of out-of-pocket spending (OOPS) and the 
reliance on external resources in financing health. 
The sum of all the expenditure by government entities in purchasing healthcare services and goods 
is known as general government expenditure on health (GGHE). Included in this are all expenses 
on health made by all levels of government, including social security agencies, and the direct 
expenditure by parastatals and public firms. 
Social security expenditure on health (SSHE) represents expenditure for purchases of health goods 




External resources (ExtHE) incorporate all grants and loans for healthcare goods or services in cash 
or kind, regardless of whether they originate from governments or private entities. 
Private health expenditure (PvtHE) is characterised by the sum of all expenditures on health by the 
bodies listed below. 
o Prepaid plans and risk-pooling arrangements (PrepaidHE): the outlays of private 
insurance schemes and private social insurance schemes. This is typical of the medical 
aid schemes in South Africa where there is no government control over payment rates 
or participating providers. There may, however, be broad guidelines from government as 
seen in the case of the Council for Medical Schemes in South Africa. 
o The financial outlays by private enterprises for medical care or services or benefits other 
than payments to social security or other pre-paid schemes is known as firms’ 
expenditure on health. These would include clinics at the workplace. 
o Non-profit institutions or non-government organisations (NGOs) are entities whose 
status does not permit them to be a source of financial gain for the units that establish, 
control or finance them. These NGOs may be either internally or externally funded. 
o Household out-of-pocket spending (OOPS) refers to all direct expenditure incurred by 
households, including, but not limited to, gratuities and in-kind payments made to health 
practitioners, suppliers of pharmaceuticals, therapeutic appliances and other goods and 
services, direct payments to public and private providers of healthcare services, non-
profit institutions, and non-reimbursable cost sharing, such as deductibles, co-payments 
and fees for services. 
Table 2.1 illustrates the total health expenditure in a selection of countries as a percentage of the 
GDP in 2000 and in 2005, as well as the change in total healthcare expenditure over this period. 
This offers insight into the expenditure of South Africa, its neighbours, and various developing 
countries and developed countries such as the UK, USA and Canada, which have well developed 
medical systems. With an expenditure of GDP on health of more than 8%, South Africa’s expenditure 
is the highest of all cited African countries, except Malawi, which experienced a growth in healthcare 
expenditure of 100% between 2000 and 2005. The expenditure of 8.8% is also in line with that of 
many developed countries like Australia (8.8%), Italy (8.9%) Netherlands (9.2%) but is lower than 





Table 2.1: Total healthcare expenditure (THE) as a percentage of GDP 
Year 2000 2005 Percentage change 
2000–2005 
Angola 2.4 1.8 (25) 
Australia 8.3 8.8 6.0 
Botswana 4.8 8.3 72.9 
Canada 8.8 9.7 10.2 
Egypt 5.6 6.1 8.9 
France 9.6 11.2 16.6 
Germany 10.3 10.7 3.8 
Ireland 6.3 8.2 30.1 
Israel 8.0 7.8 (2.5) 
Italy 8.1 8.9 9.8 
Lesotho 6.2 5.5 (11.2) 
Malawi 6.1 12.2 100 
Namibia 7.0 5.3 (24.2) 
Netherlands 8.0 9.2 15 
Portugal 8.8 10.2 15.9 
South Africa 8.1 8.8 8.6 
Switzerland 10.3 11.4 10.6 
United Kingdom 7.2 8.2 13.8 
United States of America 13.2 15.2 15.1 
Note: Figures in parenthesis () indicate reduction in expenditure. 
Source: WHO, 2005. 
Table 2.2 highlights the fact that the South African healthcare system is mainly funded privately, with 
58.3% of expenditure coming from fully private investment. This is second only to Egypt with 62% of 
their expenditure coming from private healthcare, and more than the USA, which also has a highly 





Table 2.2: General government expenditure and private expenditure on health 
as a percentage of THE 
  GGE PvtHE 
Year 2000 2005 2000 2005 
Angola 79.9 81.5 20.1 18.5 
Australia 67.0 67.0 33 33 
Botswana 63.7 78.4 36.3 21.6 
Canada 70.4 70.3 29.6 29.7 
Egypt 40.1 38 59.9 62 
France 78.3 79.9 21.7 20.1 
Germany 79.7 76.9 20.3 23.1 
Ireland 73.5 79.5 26.5 20.5 
Israel 69.5 66.5 30.6 33.5 
Italy 72.5 76.6 27.5 23.4 
Lesotho 51.0 56.1 49 43.9 
Malawi 43.8 71.3 47.6 28.7 
Namibia 68.9 65.2 31.1 34.8 
Netherlands 63.1 64.9 36.9 35.1 
Portugal 72.5 72.3 27.5 27.7 
South Africa 42.4 41.7 57.6 58.3 
Switzerland 55.6 59.7 44.4 40.3 
United Kingdom 80.9 87.1 19.1 12.9 
United States of 
America 
43.7 45.1 56.3 54.9 
Source: WHO, 2005. 
2.3 HEALTH ECONOMICS 
The discipline of health economics has grown significantly over the past 30 to 40 years, mainly as a 
result of the explosive growth in available medical treatment options. The field of health economics 
was born out of two main foundations or theories which date back to the 1960s / early-1970s and 
include applied economics. On the one hand, there are theories of human capital where the 
investment in health is one of the forms of human capital. The second foundation acknowledges the 
unique nature of the health care market. Grossman, in his pivotal work, On the Concept of Health 
Capital and the Demand for Health, published in 1972, developed the concept of health as an 
important element of human capital. Grossman (1972) suggested that the demand for healthcare is 
unlike most other markets or goods as each individual is simultaneously a producer and consumer 
of health. In this 1972 model, Grossman viewed health as a stock. Thus, if there is insufficient 
investment to replenish the stock, it would degrade over time. The model compared health at a basic 




The Grossman model remains one of the most original and fruitful contributions to health economics, 
particularly because it has proved to be a highly useful tool for analysis and explanation of 
differences in levels of health and the demand for health services by individuals.  
However, the birth of health economics is often associated with the seminal paper by K.J. Arrow 
(1963), Uncertainty and the Welfare Economics of Medical Care. This is due in part to the fact that 
it deals with a more profound set of problems more directly rooted in neo-classical economic theory, 
and in part to the fact that there are a greater number of subsequent applications and ramifications. 
Arrow examined the differences between health and mainstream economic goals and found that, in 
principle, the dilemma in healthcare was subject to the fact of relative scarcity of resources and his 
work defends the thesis that the functioning of the medical services market is affected by special 
economic problems that can keep that market from attaining efficiency. These problems are caused 
basically by the existence of uncertainty, which concerns both the incidence of illnesses, giving rise 
to, among other factors, worries about financial risk and the efficacy of the treatment option. There 
is also the non-commercial nature of many of the risks arising from that uncertainty, for which there 
is no insurance. The lack of markets for those risks implies loss of well-being, since there are 
individuals who would be willing to transfer their risk (at a cost) and individuals for whom it would be 
profitable to acquire those risks at that cost. It is forbidden, or at least frowned upon, for a person 
who requires a kidney transplant to trade a kidney and agree to a price with a donor. On the other 
hand, one cannot insure oneself against the risk of falling ill as, even where insurance is available, 
it is, as a rule, incomplete and does not operate under the ideal conditions for competitive markets. 
No one can insure oneself against the risk of an incomplete cure. It is in the presence of uncertainty 
that information and knowledge become goods, which are not distributed symmetrically among 
doctors and patients. Since an individual cannot try out the product before consuming it, the 
exchange of health services is based mainly on trust. Given these circumstances, it is difficult to 
conceptualise the demand for health services as one might under the conditions of perfect 
information in a competitive market. On the supply side, Arrow points out other specificities, such as 
restrictions on entry into the medical profession and the lack of diversity in the quality and prices of 
medical services.  
In the 40 years that have passed since then, the study of health economics has undergone extensive 
development. According to two highly respected authors, T. Culyer and J. Newhouse, editors of The 
Journal of Health Economics and The Handbook of Health Economics, the study of health economics 
has flourished because it has shown that it can provide practical answers to practical problems and 
has been able to develop its own theoretical models which contribute to the main current of 
economics. The fields where those contributions (or “mutual inspirations”) have been made include, 
as mentioned above, human capital theory, but also product measurement and assessment in the 
case of services such as health service, which are traditionally difficult to quantify and measure. 




methodology, the fundamentals of the economics of well-being, the economics of insurance, 
principal-agent models, economics of information, the theory of incomplete markets, and the theory 
of regulation. 
Health economists may argue that healthcare financing is different as a result of the intrinsic 
uncertainties in health, but this argument is often refuted by mainstream economists who point out 
that life is full of uncertainties and countries may be affected by natural disasters that can also have 
an impact on budgeting for government (Suvanto & Vartianen, 2007: 112).  
The importance of this discipline lies in the fact that the growth in healthcare development is almost 
unprecedented. The continued innovation in healthcare can be seen by the fact that that it was only 
around the turn of the 20th century that the impact of hygiene and clean running water was realised, 
and the importance of sterilisation or at least surgically clean instruments was accepted. By 1930, 
further improvements in sanitation and hygiene in the West saw the life expectancy at birth reach 
59.7. As recently as during World War II, the use of penicillin on a wide scale significantly reduced 
the number of lives lost due to infection (Faria, 2002: 122).  
Treatment options for diseases such tuberculosis, pneumonia, syphilis, typhoid fever, and diphtheria 
were hailed as major breakthroughs and spurred the pharmaceutical industry to invest large amounts 
of money into research and development. Today, an internet search on any medical topic reveals a 
myriad of treatment options. The availability of information in the public domain has stimulated a 
demand for healthcare options from patients driving the healthcare industry towards what may now 
be regarded as consumerism. 
Burden of disease studies highlight the rapid increase in lifestyle-related diseases such as obesity, 
diabetes mellitus, and cardiac diseases, while at the same time there is a drive to increase longevity 
and decrease morbidity. This all comes at a cost and as healthcare in many countries is the 
responsibility of governments, the control of this cost is also the responsibility of the government. It 
may be stated that the responsibility to provide healthcare services, stimulate health and support 
and promote improved productivity of its members, lies with government. As with all other 
government departments the annual healthcare budget is set and is measured as a percentage of 
GDP. To set these budgets, a good understanding of the demand for healthcare is required and this 
must be matched by the ability to supply these services. 
It is important to acknowledge that, with the ever-increasing costs of healthcare interventions, it is 
the responsibility of the payer to ensure that the limited resources available are utilised in an 
appropriate manner. To ensure that there are sufficient resources available to cover medical costs, 
many insurers create what are known as risk pools. The concept of risk pooling is that young, healthy 
members subsidise the health of the aged and infirm. It is impossible to predict fully the potential 
medical expenses of members and adverse selection can have a very negative impact on the risk 




not yet implemented (at the time of writing), is one method which is employed to ensure that such 
adverse selection does not destroy any particular fund. Another method employed in South Africa is 
to ensure that insurers do not only accept young, healthy members. This is referred to by medical 
insurers in South African as “cherry picking”. One way to protect insurers from the effects of adverse 
selection is to make use of exclusions for pre-existing conditions. 
While healthcare funding entails a component of consumerism, the reality is that the competition 
which defines a free market system is not available in most healthcare systems. This is because 
healthcare in most countries is often heavily regulated by the government, which is often the largest 
purchaser of healthcare services. In addition, other factors that distinguish healthcare economics 
from mainstream areas of economic interest include the asymmetry of information, and intractable 
uncertainties. The consumer or patient in this context experiences an unbalanced relationship with 
the real demand for medical care and the real cost. This is typically the case because most medical 
services are not purchased directly by the consumer, but are acquired through insurance, either 
social or private, and therefore any out-of-pocket expense is typically at a value much lower than the 
real market value. As a result, the effective demand differs in price and quantity from the real demand 
or marginal benefit curve (Grossman, 1972: 240). 
Uncertainty in terms of patient outcomes and financial obligation is intrinsic to healthcare. The 
principle of asymmetrical information refers to the knowledge gap created between the treating 
physician and the patient, who may be at a distinct disadvantage. 
These concepts are important within the South African context to expose the reader to concepts 
such as scarcity of resources, financing of healthcare, considering the patient as a consumer and, 
finally, to expose the reader to concepts such as cost-effectiveness analysis. 
However, in spite of these arguments many people have difficulty in making the connection between 
health and economics, as most would argue that health is a “priceless” commodity. But does 
“priceless” refer to something that is invaluable in an ethical sense or does it refer to something that 
is very costly in an economic sense? Either way, expenditure on healthcare since the 1960s and 
1970s in many Western countries, measured as a percentage of GDP, has more than doubled, as 
seen in Table 2.3. This has resulted in many countries implementing legislative measures to curb 





Table 2.3: Healthcare expenditure as a percentage of the GDP from 1960 to 2008 in selected 
countries  
 
Sources: Adapted from Zweifel & Breyer, 1997; OECD, 2010. 
Figure 2.1, which illustrates the growth in expenditure in healthcare as a percentage of GDP between 
1960 and 2008, shows the share in the USA trebling between 1960 and 2010 (Zweifel & Breyer, 
1997; OECD, 2010). 
 
Figure 2.1: Growth in healthcare expenditure as a percentage of GDP  
1960-2008 
Sources: Adapted from Zweifel & Breyer, 1997; OECD, 2010.  
While it is accepted that healthcare costs are not the only costs that have experienced this 
“explosion”, healthcare has perhaps eluded stringent evaluation for much longer, as certain 
idiosyncrasies exist in healthcare that may have prevented such comparisons being made. What 
remains important is that there is a high degree of similarity between the principles of economics 
and health economics. In health economics, as in mainstream economics, the same features exist, 
that is, wants, needs and demands (Zweifel & Breyer, 1997: 382). 
Year 1960 1970 1980 1990 2000 2008 
Canada 5.5 7.1 7.4 9.0 8.8 10.1 
Germany 4.7 5.9 8.4 8.1 10.3 10.5 
France 4.2 5.8 7.6 8.9 10.1 11.2 
Italy 3.3 5.2 6.8 7.6 8.1 9.1 
Japan 2.9 4.4 6.4 6.5 7.7 8.1 
Netherlands 3.9 6.0 8.0 8.1 8.0 9.0 
Sweden 4.7 7.2 9.4 8.7 8.2 9.4 
Switzerland 3.3 5.2 7.3 7.4 10.2 10.7 
United Kingdom 3.9 4.5 5.6 6.1 7.0 8.7 





It is not unusual for societies to experience unlimited wants and desire for goods and services where 
each individual is prone to want better goods or improved services. The concept of “wants” differs 
vastly from “needs,” where needs may be thought of as necessities, or things that are essential for 
survival. Wants or desires on the other hand may be limitless and, as such, difficult to measure. The 
concept of demand differs from both needs and wants by virtue of the fact that demands for goods 
or services are usually made by those who are able to pay for them (Mohr & Fourie, 2000). 
The same situation arises in healthcare. Health may be considered a want for certain individuals who, 
for example, “want” cosmetic surgery. But health can also be defined as a need where certain aspects 
are considered necessities, for example fresh air, sanitation and clean drinking water. Finally, as 
healthcare is funded globally by contributions of individuals either through a system of taxation or 
through health insurance, these same individuals may demand both goods and services. 
Thus, it is of great importance that the question is again posed: “Is health a priceless commodity?” 
As previously stated, there are two possible interpretations of this. One, the ethical stance, is that 
health is priceless as it is invaluable; no price can be placed on health or life. The second, a pure 
economics interpretation, is that health may be expensive. 
Society can determine the basic needs for survival. An example of this is represented by research 
conducted by the Bureau for Market Research (UNISA, 2007) of the University of South Africa, which 
evaluated the basic goods and services required by a household to sustain a minimum standard of 
living. What are the minimum requirements to sustain health? Should this measure be on pure 
economic levels or based on ethical values, or perhaps both? A second and perhaps more pertinent 
question is who makes the decision?  
A well-known way of calculating poverty lines as a statistical measure is to estimate the cost of a 
minimum basket of goods that would offer the daily energy requirement per person needed over a 
period of one month. This was defined by the South African Medical Research Council (MRC), as 
2 261 kilocalories per person. Based on data from the 2000 Income and Expenditure Survey from 
Statistics South Africa and evaluating the type of food sources generally available to low-income 
South Africans, the cost was determined at R211 per person every month at 2000 prices. However, 
it needs to be considered that households require other goods and services, beyond food, to meet 
basic needs. These include housing, electricity, clothing, schooling, transport and medical services. 
The cost of these essential non-food items was calculated at R111 per person each month. This 
means that, in 2000 prices, the minimum cost of essential food and non-food consumption per 
person per month is R322. Based on 2006 prices, the per capita poverty line was R431 (Woolard & 
Leibbrand, 2006: 8). 
Economic principles generally require that a level of satisfaction is achieved while consuming the 
minimum amount of a scarce resource. Each country, province, hospital, family and individual will, 




required in some way to evaluate a budget available for these needs. This means that each such 
entity, at some stage, will be required to make certain choices with regard to allocating resources to 
health. 
Other factors of importance when discussing healthcare delivery and health economics include, but 
are not limited to, the following: 
 Public regulation of the health services 
Government involvement in healthcare costs is found in all nations, with the result that, in many 
instances, the more involved the government is in healthcare, the more regulated the healthcare 
system is. Examples of these healthcare systems are the National Health System in the UK and 
Italy, where, as noted in Table 2.2, in 2005 the government contribution to healthcare was 87% and 
77% respectively. In these systems, most of the services are carried out by civil servants. South 
Africa and the USA, on the other hand, have most healthcare dependent on health insurance 
policies, with 58% and 54% respectively of total health expenditure being private. These insurance 
policies or medical aids typically result in a fixing of fee schedules for medical services rendered. 
What is important to note is that both of these models deviate from true market forces and elicit the 
question as to whether it is possible to achieve an optimal allocation of scarce resources in such 
circumstances. 
 Emotional significance 
The subject of health, or lack thereof, is an emotional one. It is not unusual for politicians 
campaigning for leadership to use promises of healthcare policies to attract votes. Often these 
promises cannot be fulfilled as governments and insurance agencies are forced to evaluate the 
resource available and develop policies to ensure the best use of these scarce resources. All too 
often conflict surfaces between the economic allocation of these resources on the one hand and 
the ethical allocation on the other, and, if left unchecked, emotive choices are made as life is 
deemed to be invaluable. The study of health economics is aimed at developing methods to 
structure the expenditure on a group of goods that change over time, in an appropriate way, 
avoiding many of the emotive issues through the analysis of statistical lives as opposed to real 
ones (Zweifel & Breyer, 1997: 2). 
 The size of the healthcare sector 
As illustrated in Table 2.3, most western, industrialised countries spend close to 10% of their GDP 
on health. This ratio has grown significantly over the past three decades and has also had an 
impact on the number of people who are employed in the healthcare sector. 
Table 2.4 illustrates the percentage of the population who were employed in the healthcare sector 




number of healthcare workers of up to 168% with an average change in healthcare employment 
of 92% or 3.1% per annum.  
Table 2.4: Employment in healthcare as a share of total employment (in percentages) 
 
Note: ** Percentage change from 1970 to 1980. 
Source: Huber and Orosz, 2003. 
In 2011 Miliard stated that, in the USA, the proportion of those employed only in the private sector 
of healthcare had grown to 10.7%. Considering that only 60% of healthcare expenditure in the USA 
is in the private sector, it infers that considerably more than 10.7% of people in the USA are employed 
in the healthcare sector (Miliard, 2011). This is an interesting phenomenon, as it appears that 
employment growth in healthcare is dissimilar to the economy at large. Miliard (2011) reports that 
between December 2007 and January 2011 employment in the healthcare sector grew by 6.3%, 
while non-healthcare employment fell by 6.8%.  
As discussed above, there has also been a substantial increase across the globe in the total 
healthcare expenditure as a percentage of GDP. The average increase in total healthcare 
expenditure (THE) for the period 2000 to 2005 was roughly 2.1% per annum. 
These measures may give some perspective to the allocation of total resources within a specific 
country. This may also help to evaluate the similarities or difference between various countries by 
measuring the percentage of GDP that is spent on total healthcare, but it does not offer sufficient 
information to form a true perspective of the impact of this percentage on the country. Other 
important factors to be considered include the size of the GDP, as a high percentage of a low GDP 
may look impressive but does not offer the individual much in the form of resources. It is also 
important to examine factors such as GDP per capita, how far the resource must stretch, and the 
healthy life expectancy of the country, as well as child mortality rates. 
2.3.1 The macro- and micro-economic view of healthcare 
All individuals seek to be healthy, in the sense that they do not desire the opposite, which is to be 
unhealthy or diseased. However, to be always totally free of disease is unlikely. Simple lifestyle 
choices like diet, exercise or stress introduce elements of life that are contradictory to health. Thus, 
Year 1970 1980 1989 Change 1970-1989 
Germany 2.9 4.5 5.5 90 
United Kingdom 3.1 4.6 4.7 52 
Italy 1.6 3.9 4.3 168 
Netherlands 4.0 6.4 7.1 78 
Switzerland 2.8 4.6 n.a 64** 





in real terms ‘health’ may be traded off against all other targets (Zweifel & Breyer, 1997). In economic 
terms, ‘health’ is traded off against any other aim.  
Two important factors to consider with regard to health are that: 
1. The consumptive benefit that a person can gain from his/her income is dependent on 
his/her state of health.  
2. There is an assumption that only a person in good health can earn an income in the labour 
market. Thus Zweifel and Breyer (1997) state that disposable income is dependent on the 
state of health. They further argue that, if income were not dependent on health, then 
budget constraints would be linear. 
Therefore, it may be hypothesised that, as health improves, one is able to consume more.  
2.4 MEASURING UNCERTAINTY IN COST AND EFFECTIVENESS 
2.4.1 Uncertainty in measuring costs 
Where there is uncertainty in the estimations of cost-effectiveness, this could lead to a situation 
where an incorrect set of interventions is financed. It is therefore vital to understand that the manner 
in which the available evidence is interpreted and then applied when calculating the costs and 
outcomes are dependent on uncertainty. The impact of this could be that the target population’s 
healthcare is not maximised, resulting in an opportunity cost to uncertainty in terms of health.  
Most economic evaluation studies tackle the issue of uncertainty surrounding the estimates 
associated with the measuring costs and effectiveness. Within economic evaluations, uncertainty is 
likely to occur in three situations, namely, uncertainty in measuring costs, uncertainty in measuring 
effectiveness, and uncertainty in the choice of the discount rate. 
Uncertainty in measuring costs may occur in the following: 
 The identification of the range and resources to be included. 
 The valuation of the unit costs.  
 The measurement of the volume of the resource used. 
Uncertainty in measuring effectiveness is often associated with imprecision in the process used and 
may be associated with the following: 
 The choice of the outcome being measured. 
 Where and how the required effectiveness data was acquired. 




 In general, a baseline discount rate should be used. In this study, a discount rate of 3.5% per 
annum was applied for both costs and outcome, which is consistent with the lower range of 
the inflation target set for South Africa. However, economic evaluation studies may use 
discount rates with a range which could, for example, be between 0% and 15% 
It should also be noted that uncertainty regarding the true value of an estimate could occur for a 
number of reasons, which may include the following: 
 Inadequate data sources. 
 Situations where an investigator uses the results of a specific region and generalises them. 
 Situations where the estimates are specific to a precise time. 
 Analytical techniques used in the study that are open to debate. 
Sensitivity analysis is the traditional method used in economic evaluation studies to test for 
uncertainty.  
2.4.2 Sensitivity analysis  
Sensitivity analysis is a useful method of exploring how sensitive the results of an economic 
evaluation are when the cost and effectiveness values are changed. To do so the investigator may 
vary these values of the cost parameter by halving, doubling or even trebling the values. This allows 
the investigator to assess the significance of this factor in reaching the final result. Sensitivity analysis 
can be useful for a range of reasons, which include, but are not limited to, the following: 
 To test the robustness of the results in a model where uncertainty exists. 
 To increase the understanding of the relationships between input variables and the output 
variables in a model. 
 To recognise inputs in the model which may result in considerable uncertainty in the output 
of the model. 
 To explore possible errors in the model. 
2.5 RATIONING IN HEALTHCARE 
The healthcare market does not behave the same way as traditional demand-supply markets. The 
demand is ever increasing, creating a disparity between the demand and the ability to supply. Unlike 
traditional markets where the consumers’ understanding of their purchase precipitates the correct 





It has been noted that the two most important factors to the individual are the state of health (H) and 
consumption (C). Attempts to direct healthcare start with these two concepts. The subject of 
healthcare provision remains an emotive one, and one that brings in votes for political figures, but 
the fact remains that each country has a limited amount of available resources for healthcare and 
there is a continual drive to stabilise the extent of healthcare expenditure as a percentage of GDP 
as well as limiting the increase of contribution to healthcare expenditure as a portion of wages. This 
has resulted in increased amounts of out-of-pocket expenditure in many societies (Zweifel & Breyer, 
1997: 7, 8, 64, 151). 
Rationing in healthcare is difficult as it may, in effect, divert resources from one area of healthcare 
expenditure to another and thereby possibly prevent some individuals from receiving therapies which 
may be deemed beneficial or necessary. In reality, the increased demand for healthcare services 
and the cost associated with providing them indicates that rationing manifests itself in all medical 
systems. Rationing has traditionally occurred through location, the availability of practitioners and 
services, as well as the ability of the population to pay (Mechanic, 1995: 1665). 
Interest in the subject of healthcare rationing has intensified over the past few years. This has been 
a focus not only of governments but also of academia, industry, the media and, through them, the 
public at large. Globally, the life expectancy of the population is increasing and, as new technologies 
burgeon, the topic of healthcare rationing ascends on the political arena (Jagsi et al., 2004: 2249). 
Rationing occurs at many levels. The first level may be at the level of government, the local 
authorities, and insurance plans. Another level of rationing is seen at hospital level, where long 
waiting lists are a crude but real form of rationing. Rationing at a clinical level occurs when the 
clinician makes decisions about certain treatment schedules (Mechanic, 1997: 83). An unpopular 
form of rationing occurs when centres of excellence are set up for the performance of certain 
procedures. This principle tries to ensure that services will only be reimbursed if specific centres or 
physicians are used. While this opens itself up to political bargaining, there may be merit in it. Data 
from the 1999 Dartmouth Atlas showed that there was a relationship between the volume of 
procedures at centres and outcome for most surgical procedures.  
Figures 2.2 and 2.3 indicate the 30-day mortality rate in low volume centres compared with high 
volume centres for four different procedures, namely coronary artery bypass grafting, mitral valve 
replacement, oesophagectomy and pancreatic resection, as documented in a study by Birkmeyer et 
al. (2002). The results from this study revealed significantly lower mortality rates in the high volume 
centres. This fact has been disputed in other studies, but it remains a consideration among payers 












Note: Values above bars in each graph are the percentage of mortality (P<0.001 for all procedures). 
Figure 2.2: Adjusted in-hospital or 30-day mortality among Medicare patients (1994-1999) 
according to quintile of total hospital for cardiac procedures 











Values above bars are the percentage of mortality (P<0.001 for all procedures). 
Figure 2.3: Adjusted in hospital or 30-day mortality among Medicare patients (1994-1999) 
according to quintile of total hospital for resections for gastrointestinal cancer 
Source: Adapted from Birkmeyer et al., 2002: 1136. 
Rationing may be classified as either explicit or implicit. Explicit rationing refers to an open process 
which is codified and written down or expressed. It is transparent, and the outcome is stated 
(Mechanic, 1997: 84). On the other hand, implicit rationing refers to the discretionary decisions made 
at a clinical level or by managers within a fixed budgetary allowance. Examples of these different 
approaches may be seen in the public sector in South Africa where a combination of both implicit 
and explicit rationing occurs. Services might be said to be implicitly rationed if a patient with 
HIV/AIDS is not admitted to an ICU, or where a 93-year old patient may not get an aortic valve 
replacement.  
An example of explicit rationing in the public sector is the medicine formularies that are available. 
The private healthcare sector in South Africa typically exercises explicit rationing where defined 





2.5.1 Explicit rationing 
The benefits of explicit decisions in healthcare are that they establish the framework for medical 
practice. Governments can ascertain the level of expenditure and the type of resources that are 
available to the population. Explicit rationing occurs in both public and private healthcare and is 
impacted on by the facilities and types of technologies that are available. Explicit rationing is under 
question in the UK. Brown and Calnan (2010) describe the rationing of healthcare in the UK as 
having transformed from a system where healthcare budgets were rationed through the discretionary 
decisions and where general practitioners and specialists effectively were the gatekeepers, to a 
modern, world-renowned body using evidence-based medicine. This new body, the National Institute 
for Clinical Excellence (NICE), espoused a framework of systematic decisions which were made in 
a transparent way, offering polices based on meticulous reviews of scientific evidence for treatments 
that are both cost-effective and affordable (Brown & Calnan, 2010: 65). 
Some of the problems inherent in explicit rationing include the fact that these types of policies are 
laborious to develop, which means there may be a degree of resistance to change once established. 
It takes NICE, on average, fourteen months to perform a full appraisal of a new therapy (although 
there are some therapies which may be fast-tracked over a six-month period). This results in lags 
between policy approval and changing realities and NICE, in particular, is trying to compensate for 
this by scanning the horizon of new technologies and therapies. These long processes can be 
problematic, particularly in the case of medical devices where technology evolves at a fast rate and 
the product life cycle is very short and product changes are made continuously to improve 
efficiencies of the procedure. 
Mechanic (1997) describes medical care as a process of discovery and negotiation between 
physician and patient, where the relationship between patient and physician is iterative and the 
course of action for each patient is not commonly known beforehand. 
A third important factor is the difference between patients’ needs and values. Patients, given a 
choice, may have varying views about treatment options as well as the trade-off between longevity 
and quality of life. 
A further consideration for explicit rationing is the potential for political or emotional manipulation. An 
example of this is cited by Brown and Calnan (2010: 66), who question the public legitimacy of NICE 
in the UK. Brown and Calnan (2010) describe NICE as “engaged in ongoing, complex and 
interdependent relationships with interested parties”. Mechanic (1997: 86), in his debate about the 
balance between explicit and implicit rationing, states that explicit rationing may result in medical 
decisions being debated in public forums with conflicting needs, preferences and political 
mobilisation and even political manipulation. He asserts that once the decision is taken out of the 




social, moral and political battles are waged. Brown and Calnan (2010) define how these battles may 
be waged and use six examples of how the pharmaceutical industry is potentially able to influence 
NICE in its policy making process, namely: 
 the development and presentation of its own evidence; 
 lobbying NICE and the media; 
 through funding of patient advocacy groups to lobby NICE; 
 through government and the media; 
 by liaising with government directly through cost sharing schemes; and 
 by legally contesting decisions made by NICE. 
2.5.2 Implicit rationing 
Lauridsen et al. (2007) describe implicit rationing as a system where the range of choices available 
to the patients of potentially beneficial treatment options is limited. The only aim of setting these 
limits is to reduce costs and contain expenses. The limits which have been set are hidden from the 
patient, as is the rationale for setting the limits. 
Mechanic (1997) argues that the strengths of implicit rationing include its discretion, flexibility and 
ability to take account of emotions, aspirations and preferences. Implicit rationing relies on the 
discretionary judgment of healthcare professionals and managers. A variety of strategies can be 
used. These include queuing, reducing the intensity of services, and substituting expensive services 
for less expensive ones. One of the values of implicit rationing is the fact that it can respond to 
complexities, diversity and any changes in information. This response is likely to be sensitive and 
timely. Implicit rationing should be underpinned by the understanding that there is a place for open 
public discussion and fair allocation of resources, and that rationing should never be done in secrecy. 
While implicit rationing builds on the strength of the doctor-patient relationship and addresses the 
needs and preferences of the patient, the characteristics of implicit rationing may have a 
contradictory role for potential violation of trust and abuse of discretion (Mechanic, 1997: 84). 
Rationing in healthcare is inevitable and the literature supports arguments for both implicit and 
explicit rationing. Both these systems have positive and negative arguments. It is perhaps a 
combination of these two policies that best serves the needs of all the stakeholders, where guidelines 
are set through the interaction of professional bodies and the payers. The use of evidence-based 
medicine should not be overlooked, nor should the discretionary judgment of the clinician on a case-
by-case level be ignored. All stakeholders need to understand that they share the same goal, which 




2.6 HEALTH ASSESSMENT 
Some questions that remain unanswered in most countries are “How much healthcare do we need?” 
and “How many doctors should we train?” and “Is there a relationship between volume and outcome 
of procedures?” In the past two decades the number of cardiologists in the USA has doubled, while 
the number of radiologists has increased fivefold. In spite of managed care programmes, the costs 
in healthcare in the USA has shown the highest growth as a percentage of GDP from 1960 to 2008 
(see Table 2.3). However, the healthcare status of Americans has shown no evidence of greater 
improvement than that of any other G7 country (Chapman, 2006). Data however show that the 
demand for physicians is driven by demographic changes. The U.S. Census Bureau projects that by 
2030, 20% of the USA’s population will be over 65 years of age. An example of this is that during 
2003 alone, an estimated 906 million visits were made in the USA to physician offices (Hing et al., 
2005), as shown on Table 2.5.  
Table 2.5: Annual physician visits by patient age group in USA 
Age group <1 yr. 1-12 yrs. 13-21 yrs. 22-49 yrs. 50-65 yrs. >65 yrs. 
No. of annual visits 6.5 2 1.5 3 4 6.6 
Source: Hing et al., 2005. 
There were approximately 3.2 visits per person overall with infants aged <1 year and adults aged 
>65 years accounting for most of these visits, with approximately 6.6 visits per person in each of 
those age groups as seen in Table 2.5.  
Chapman (2006) also claims that the diagnosis rate varies despite the constant prevalence of 
disease. Chapman cites Gan et al. (2000) and refers to studies that show gender bias in treatment 
between men and women. One study examined information from the charts of 138 956 Medicare 
beneficiaries (49% of them women) who, between 1994 and 1995, suffered acute myocardial 
infarction. Multivariate analysis was performed to measure differences between women and men 
with regard to the medications that were prescribed, the procedures performed, the assignment of 
“do-not-resuscitate” status and, finally, 30-day mortality. The results indicated that women in all age 
groups were less likely than men to undergo diagnostic cardiac catheterisation. The difference was 
more apparent among older women and, in particular, women over 85 years of age. The adjusted 
relative risk in this group was 0.75 (95% confidence interval, 0.68 to 0.83). The study found that 
women were less likely than their male counterparts to receive thrombolytic therapy within 60 
minutes (adjusted relative risk, 0.93; 95 % confidence interval, 0.90 to 0.96) or to receive aspirin 
within 24 hours after hospital admission (adjusted relative risk, 0.96; 95% confidence interval, 0.95 
to 0.97). Both men and women were equally likely to receive beta-blockers (adjusted relative risk, 
0.99; 95% confidence interval, 0.95 to 1.03). Women were more likely than men to receive 




particular note was the fact that women were more likely to have a “do-not-resuscitate” order in their 
records (adjusted relative risk, 1.26; 95% confidence interval, 1.22 to 1.29). This was in spite of the 
fact that, after adjustment, women and men had similar 30-day mortality rates (hazard ratio, 1.02; 
95% confidence interval, 0.99 to 1.04). The reason for highlighting these differences is to point out 
that the provision of healthcare services is dependent on good assessment, good clinical judgment 
and evidence-based medicine and, in spite of policies that may be in place, healthcare services are 
not necessarily equitable among all recipients. 
Assessment of health needs is the systematic method of identifying the unmet health needs within a 
given population. This assessment must address economic, clinical and ethical issues and should 
include perspectives from patients (Jordan et al., 1998: 84). Both quantitative epidemiological data as 
well as qualitative data may be used to determine the priorities in the specific society being studied. 
The assessment of needs is fundamental to the success of any healthcare programme even as far as 
it addresses the needs of different geographical areas. Data are not easily transferable. For example, 
the unmet needs of the population in Bournemouth with an aged population, in the case of the care of 
those with dementia, differ significantly from those in Soweto, which has a relatively young population 
and a high incidence of HIV/AIDS and tuberculosis (TB). 
2.7 HEALTH ECONOMIC EVALUATION 
Economic evaluation in healthcare is important as there is a myriad of treatment options available, 
each with different features, benefits and medical claims. There is inequality in information and the end 
user or patient is an unwilling consumer, having choices made on their behalf. This inequality creates 
a possibility for exploitation by various parties in the medical profession. As illustrated in Figure 2.4, in 
most systems the need for economic evaluation at both a national and local level is to maximise scarce 
available resources and to provide a set of research methods and tools to support decision making 
(Chapman, 2006). 
       
 
Figure 2.4: Economic evaluation as part of the healthcare system 
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Economic evaluation is particularly useful when new technologies or treatment options, which are in 
competition with established treatment options, are introduced into the market. As such, economic 
evaluation focuses on the incremental or marginal cost of implementing a new therapy and the 
marginal outcomes suggested by the therapy (Seifan & Shemer, 2005: 68). 
The economic evaluation of health may provide vital information for the decision makers and payers 
and it must be noted that it often only addresses one dimension of a healthcare programme. To ensure 
that the analysis is valuable to all stakeholders the following questions should be answered: 
 Is the programme efficacious? To understand this, a simple question may be asked: Can 
the programme work? The answer needs to reflect that, by implementing the 
programme, procedure or service, it will ensure that more good is done than harm to 
those who are affected by such a programme or service. Efficaciousness is usually 
determined in a clinical study based on empirical data, produced under contro lled 
conditions where the population is both limited and known. In many cases these 
studies are clinical trials designed for registration or licensing of products.  
 What is the availability of the programme? To ensure that a programme has value it must 
be available to all those who need it and not restricted to only a few. This principle 
refers to equity, as priority may be given to certain groups, for example, patients with 
breast cancer. Other simple questions to be answered are: “Should this therapy be 
used and what will the cost or economic implications of this programme be or is there 
economic efficiency?” An example is developing a vaccine for a broad range of viral 
pneumonias that may be considered to be much more effective than a vaccine against 
a Hantavirus infection (Lopez et al., 2001: 5). 
 Is the programme effective? To evaluate effectiveness, the question to be asked is: “Does 
it work?” Effectiveness differs from efficacy in that it should be applied to the real world. 
While a treatment may prove to be efficacious in empirical data, one needs to question 
its application in the real world. Does it offer clinical value? (Chapman, 2006; 
Drummond et al., 2006: 8). 
Drummond et al. (2006) describe the process of economic evaluation as a comparison of two or 
more possible treatment options in terms of both cost and consequences. The different types of 
evaluation are defined by the approach used to measure the outcome of a particular therapy. The 





There are several different methods of doing health economic evaluation and the process usually 
involves one or more of the following: 
 QALYs 
 DALYs 
 Cost-utility analysis 
 Cost-benefit analysis 
 Willingness to pay 
 Cost minimisation 
 Cost-effectiveness analysis 
 Discounting 
 Sensitivity analysis 
 Programme budgeting and marginal analysis. 
2.7.1 Quality adjusted life years (QALY) 
Both quantity and quality of life are measures used when weighing the outcomes of healthcare 
provision. A quality adjusted life year (QALY) is a measure of both of these, combining morbidity and 
mortality into a single index (Chapman, 2006). A QALY is simply an arithmetic product of both life 
expectancy and the quality of the remaining life-years and is defined as a year of life free of all 
disabilities and symptoms (Chapman, 2006). NICE defines a QALY as a ‘measure of a person’s 
length of life weighted by a valuation of their health-related quality of life’ (NICE, 2010). The QALY 
is used to assess the value for money of a medical intervention and requires independent utilities 
which are risk neutral and constant proportional trade-off behaviour (NICE, 2010). Therefore, the 
QALY may be thought of as providing a common currency for measuring the extent of health gain 
that results from healthcare interventions and, when combined with the costs associated with the 
interventions, can be used to assess their relative worth from an economic perspective. 
Weinstein et al. (2009) agree that both the USA Panel on Cost-Effectiveness in Health and Medicine 
and the National Institute of Health and Clinical Excellence (NICE) in the UK endorse the 
conventional QALY as a standardised methodological approach to promote comparability in cost-
effectiveness analyses of different healthcare interventions. 
Life expectancy refers only to the quantity of life and, in these terms, it is accepted that a person is 
either dead or alive. When evaluating the quality of life, several factors need to be taken into 
consideration. Quality of life may include both physical and psychological attributes. 
Health utilities are used to evaluate quality of life and these may include, among others, standard 





Each health state is represented by a value on a continuum between 0 and 1, where 0 is equivalent 
to death and 1 to the best possible state in health. These measurements of health-related quality of 
life allow for states of health that are considered worse than death and these may be allocated a 
negative valuation, as seen in Figure 2.5 (Phillips, 2009: 2). Some people may, for example, consider 
being in a permanent vegetative state worse than death and so would give such a health state a 
negative utility (Garner, 2010). 
 
Figure 2.5: Valuation of health state where 1 is perfect health, 0 is death 
Source: Phillips, 2009: 2. 
Various rating scales are used to evaluate the preference for a treatment option. The preference 
should be representative of the patient, the practitioner or the public at large. There are a number of 
rating methods which can be used: 
 Time-trade-off (TTO). As suggested by the name, this requires respondents to make a 
choice between remaining in a state of ill health for longer, and being restored to perfect 
health, but with a shorter life expectancy. 
 Visual analogue scale (VAS). This is a method which is open to subjectivity, whereby 
respondents are asked to rate a state of ill health. The scale ranges from 0 to 100, where 0 
represents death and 100 represents perfect health. 
 Standard gamble (SG). This involves a choice between remaining in a state of ill health for 
a period of time or choosing a medical intervention which has a chance of either restoring 
them to perfect health or resulting in their death. 
 Willingness to pay (WTP). This is a measure of what the individual is willing to pay to be 
cured or to prevent an incident.  
Another instrument for the measurement and valuation of health-related quality of life appraisals is 
the EQ-5D. As seen in Table 2.6, the EQ-5D scoring system used to measure quality of health 





Table 2.6: The EQ-5D scores as a measure of the individual’s ability to function in five 
dimensions 
Description Scoring 
Mobility 1. No problem walking around 
2. Some problems walking around 
3. Confined to bed 
Pain or discomfort 1. No pain or discomfort 
2. Moderate pain or discomfort 
3. Extreme pain or discomfort 
Self- care 1. No problem with self-care 
2. Some problems washing or dressing 
3. Unable to wash or dress oneself 
Anxiety/ depression 1. Not anxious or depressed 
2. Moderately anxious or depressed 
3. Extremely anxious or depressed 
Usual activities (work, study, 
housework, leisure activities) 
1. No problems in performing usual activities 
2. Some problems in performing usual activities 
3. Unable to perform activities 
Source: Phillips, 2009: 2. 
Together with the states “unconscious” and “dead,” there are 245 different possible health states. 
Table 2.7 provides some examples of selected possible EQ-5D health state valuations. 
Table 2.7: Examples of selected possible EQ-5D health state valuations 
 





1,1,1,1,1 No problems 1.0 
1,1,2,2,1 
No problem walking about, no problem with self-care, some problem 
performing activities, some pain/discomfort, not anxious or depressed 
0.760 
2,2,2,2,2 
Some problem walking about, some problem with self-care, some problem 
with activities, moderate pain/discomfort, moderately anxious or depressed 
0.516 
1,2,3,2,1 
No problem walking around, some problem with self-care, unable to perform 
activities, moderate pain/discomfort, not anxious or depressed 
0.329 
2,1,1,2,3 
Some problem walking around, no problem with self-care, no problem with 
activities, moderate pain/discomfort, extremely depressed 
0.222 
2,3,3,2,2 
Some problem walking around, unable to care for self, unable to perform 
activities, moderate pain/discomfort, moderately anxious/ depressed 
0.079 
3,3,3,3,2 
Confined to bed, unable to wash or dress self, unable to perform activities, 






A QALY simply refers to the amount of time spent in a health state which is then weighted by using 
a utility score given to that health state. One year of perfect health equals one QALY (utility score of 
1). On the other hand, one year in a health state valued at 0.5 is regarded as being equivalent to 
half a QALY. Therefore, when evaluating any medical intervention that produces four additional 
years in a health state valued at 0.5, two extra QALYs are generated. Similarly, an intervention that 
generates four additional years in a health state valued at 0.25, generates one extra QALY. It may 
be noted that when the QALY is combined with the cost associated with the medical intervention, it 
results in a cost-utility ratio. The cost-utility ratio denotes the cost required to produce a year of 
perfect health or one QALY. On this basis different therapy options can be compared and the best 
cost per QALY can be determined. An example of an application of a cost-utility ratio is given in 
Figure 2.6. 
 
Figure 2.6: An example of the calculation of cost-utility ratios 
Source: Phillips, 2009. 
QALYs may be calculated as follows: Therapy A offers the individual four years in the health state 
of 0.75, therefore they have 3 QALYs, while Therapy B results in four years in the health state of 
0.5, or 2 QALYs. Note that Therapy A generates one additional QALY. 
The measure of cost-effectiveness in relation to healthcare remains controversial. Agencies like 
NICE use incremental cost-effectiveness ratios or cost per quality life year, or cost per QALY as a 
means to shed light on the cost-effectiveness of a treatment option. There is much debate waged 
about the validity of this measure and despite its shortcomings the use of cost per QALY remains, 
in many instances the best measure available. The method of measuring cost per QALY is a complex 
measure that determines the cost for a group of people and not for individuals. The question is how, 
even by using the QALY, does one ascertain whether a therapy is cost-effective or not. Traditionally 
in the USA the threshold limit of US$50 000 is used for a QALY. The origin of this frequently cited 
benchmark seems to date back to at least 1992. There has been much speculation about the value 
and concept of the QALY in the US. Kaplan and Bush (1982) refer to renal dialysis as the standard 
for the acceptance of US$50 000 for a QALY but fail to comment on the empiricism of arriving at this 
value. 
The theory connecting the QALY to renal dialysis is common among those in the field of health 
economics. The fact is that the value has remained in use with no adjustment for inflation for almost 
20 years. Bridges et al. (2010) argue that the creation of the US$50 000 threshold is neither linked 




suggest that no single threshold should be set but rather that a range of between US$20 000 to 
US$100 000 be used. The concept of a single threshold appeals to policy makers and is seen as 
being open and transparent. The application of a set threshold may be of value in societies like the 
UK, where the majority of the population access the NHS, and the single value threshold offers the 
opportunity to provide new technologies in a uniform fashion. This type of explicit threshold also 
gives manufacturers insight into what is required should they apply for their technology to be 
reimbursed. The downside of a single threshold it that it does not allow for shifts caused by normal 
supply and demands variations. 
The cost per QALY in Canada is set at $40 000 while in the UK, NICE has accepted an incremental 
cost-effectiveness ratio of £20 000, but NICE generally accepts values that range from £20 000 to 
£30 000. The highest incremental cost per QALY that has been accepted by NICE was £49 000; the 
indication was for the blast phase of chronic myeloid leukaemia (Steinbrook, 2008: 1980). Whether 
one agrees or disagrees with the concept of a single fixed threshold for the QALY, most academics 
agree that at this stage it is still the most effective measure available. 
2.7.2 Disability adjusted life year (DALY) 
In 1992, the WHO worked together with Harvard University to start a study known as the Global 
Burden of Disease study. This was a systematic measure of more than 100 diseases over eight 
regions and 20 countries in the world. The result was a comprehensive and internally consistent 
estimate by age, sex and region of mortality and morbidity data (WHO, 2010: 1; Lopez et al., 2001: 
2). 
An important outcome from the study was the introduction of a new metric known as the DALY. The 
DALY is a single measure of burden of disease, risk factors and injury. The premise underpinning 
the DALY is based on years of life lost from premature death and years of life lived in less than 
perfect health (WHO, 2011). The use of mortality data alone skews the picture of the burden of 
disease borne by individuals in different communities. When using DALY, for example in the case of 
death by drowning or measles, the burden of disease results only in early death but no disability, 
however, when compared to brain damage as result of near drowning or blindness as a complication 
of measles, where early death was averted, severe disability may remain. 
One DALY therefore represents the loss of the one year of full health. In 2004, in all regions of the 
world, the global average burden of disease was 237 DALYs per 1 000 of the population. Close to 
60% of these DALYs were due to premature death while the other 40% was due to non-fatal health 
outcomes. This report highlighted the usefulness of the DALY and showed that in 2004, 36% of the 
total disease and injury burden for the world involved children under the age of 15 years. Another 
50% of total disease and injury burden involved adults between the age of 15 and 59 years (Mathers, 




One DALY is the sum of the years of life lost (YLL) due to premature mortality and years of life lost 
due to disability (YLD) or put more simply one lost year of "healthy" life. Currently life expectancy is 
measured at the most extreme, that of Japanese women at around 86 years of age. 
Therefore, it can be stated that 
DALY= YLL+YLD 
YLL=N x L where  
N = number of deaths and L = standard life expectancy at age of death in years 
YLD = I x DW x L where  
I = number of incident cases, DW = disability weight and L = average duration of the case until 
remission or death (measured in years) (Lopez et al., 2001: 3). 
The major findings of the 2001 Global Burden of Disease were as follows: Of the 56 million deaths 
globally in 2001, 20% or 10.5 million were children under the age of five. Thirty three percent or 3.3 
million stillbirths were recorded and almost 40% or 4 million children died before reaching the age of 
one month. Over 10.3 million of the 10.5 million deaths occurred in low to middle income countries. 
In the age group 15 to 59, those who were deemed to be part of the productive society, only 15% of 
deaths were in high income countries, while twice as many (30%) of the deaths in the low to middle 
income countries were in this age group. 
In 1990 and again in 2001 the number of deaths attributed to communicable diseases, maternal or 
peri-natal conditions or nutritional deficiencies remained almost unchanged at one out every three 
deaths. One major difference however was that in 1990 HIV/AIDS accounted for only 2% of all 
deaths, whereas in 2001, 14% of all deaths were attributed to HIV/AIDS. 
An unexpected result of both the 1990 and 2001 global burden of disease report was that previously 
the burden of non-fatal illnesses and in particular neuropsychiatric disorders were not recognised. 
Neuropsychiatric disorders accounted for more than 37% of YLD among adults over the age of 15 
in all regions of the world. Depression was the leading cause of disability for men and women with 
women having a 50% greater burden of depression than men. Disorders like migraine, senile 
dementia and anxiety disorders were more common in women than in men, but men were shown to 
have a six times higher predisposition for alcohol and drug disorders (Lopez et al., 2001: 7). 
The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria 
through the formulation of Millennium Development Goals. The high priority status of these three 
diseases was confirmed through the creation of the Global Fund to Fight AIDS, Tuberculosis and 
Malaria in 2002. The 2013 Global burden of disease found that the incidence of HIV was 1.8 million 









Figure 2.7: Global age-sex distribution of new HIV infections in 2013 
Source: Murray et al., 2014: 9. 
Figure 2.8 shows the age standardised incidence of HIV in 2013 for both sexes by region, with the 
highest prevalence per 100 000 of the population being in Southern sub-Saharan Africa. The 2013 
prevalence of HIV was estimated at 29.2 million.  
 
  
Figure 2.8: Age standardised incidence of HIV in 2013 for both sexes by region 
Source: Murray et al., 2014: 9. 
As illustrated in Figure 2.9 there were 1.3 million deaths attributed to HIV. This had declined from 
1.7 million deaths in 2005 when the HIV epidemic was at its peak. Murray et al. (2014: 2) estimated 





Figure 2.9: Global age-sex distribution of deaths related to HIV infections in 2013 
Source: Murray et al., 2014: 9. 
The 2013 incidence of all forms of tuberculosis was estimated at 7.5 million. These included HIV-
positive people. The prevalence of TB was 11.9 million and 1.4 million deaths were attributed to TB 
in 2013. Figure 2.10 shows the global age-sex distribution of the incidence of tuberculosis for 2013 
in HIV-negative individuals, while Figure 2.11 shows the global age-sex distribution of deaths 
accredited to tuberculosis for 2013 in HIV-negative individuals. 
 
 
Figure 2.10: Global incidence of TB, by age/sex (2013). (HIV-negative individuals) 






Figure 2.11: Global deaths accredited to TB by sex/age in HIV-negative individuals (2013) 
Source: Murray et al., 2014: 28. 
Finally, the global number of malaria cases increased rapidly from 1990 reaching a peak in 2003 
with an estimated 232 million cases (Figure 2.12). It should be noted that the highest incidence is in 
Africa, in particular Central and Western sub-Saharan Africa.  
 
 
Figure 2.12: Age-standardised incidence of malaria for both sexes in 2013 









Figure 2.13: Age-standardised deaths as result of malaria for both sexes in 2013 
Source: Murray et al., 2014: 28. 
The highest incidence occurs in the age groups below the age of 15 years (Figure 2.14) and the 




Figure 2.14: Global age-sex adjusted distribution of incidence of malaria in 2013 






Figure 2.15: Global age-sex adjusted distribution of deaths from malaria in 2013 
Source: Murray et al., 2014: 28. 
The use of the QALY may be advantageous in the short to medium term but the use of the DALY 
should force policy makers to consider the long-term implications for priority setting in health to 
ensure that sufficient funds are allocated for specific interventions to reduce the loss of health and 
to promote productivity. 
2.7.3 Cost-utility analysis (CUA) 
The use of cost-utility studies dates back to the early 1980s when this type of analysis was called 
this by the York group of health economists. Prior to 1980s this type of analysis was called 
generalised cost-effectiveness analysis (1971) and later utility maximisation (1972). In 1982 Kaplan 
and Bush described the use of CUA in their work. The concept of CUA has, however, not been 
adopted in all health economic centres and the USA does not use CUA but rather utilises cost-
effectiveness analysis (CEA). CUA is used as an estimate of the ratio between the cost of a health-
related intervention and the benefit it produces in terms of the number of years lived in full health by 
the beneficiaries. Hence it can be considered a special case of cost-effectiveness-analysis. In reality 
the two concepts are closely related. One of the main similarities between these two measures is 
the fact that the results are usually expressed in cost per unit effect, for example a QALY. The 
measure on the cost side is almost identical in both cost-effectiveness analysis and cost-utility 




2.7.3.1 What are utilities? 
As discussed in section 2.6.1 above, rating scales such as time trade-off and standard gamble are 
used as methods of asking individuals to trade off health status against life expectancy. The results 
of these exercises are known as utilities.  
Utilities of a health state have been demonstrated to vary based on how the health state was 
described, who asked the question, and how the question was posed. This exposes the subjectivity 
of this type of measure. 
Costs are measured in monetary units while benefits are expressed in a way that takes into account 
health states that are considered less preferable to full health. These are given quantitative values, in 
this case QALY. However, unlike  cost-benefit analysis, the benefits are not necessarily stated in 
monetary terms. 
The use of cost-effectiveness analysis is as a measure of a specific, single outcome while cost-utility 
analysis may have multiple, generic measures. An example of where cost-utility analysis could be 
used is a pancreatic resection colon procedure vs coronary artery bypass surgery. Cost-utility 
analysis has a major advantage in that it can be used to make comparisons across a broad spectrum 
of possible interventions. The York economists argue that cost-utility analysis was developed for this 
very reason (Drummond et al., 2006: 138). 
2.7.3.2 When should cost-utility analysis be used? 
Cost-utility analysis was developed as a tool to enable decision makers to be able to compare the 
value of alternative interventions that have different benefits or outcomes. Cost-utility specifies a 
value assigned to a specific health state. This allows transparency in the process of allocating 
resources. 
The primary outcome of the cost-utility analysis is the measure of cost per QALY. This is also referred 
to as the incremental cost-effectiveness ratio (ICER). The measurement of ICER is the calculated 
difference between the costs of two interventions divided by the difference in QALYs produced by 
such interventions. The ICER can be thought of as the ratio between the difference in costs and the 
difference between the benefits of two interventions. 
An example of this is where intervention “A” enables a patient to live for three years longer than if no 
intervention had taken place, but with a quality of life weight of only 0.6, then the intervention 
presents 3 * 0.6 = 1.8 QALYs to the patient. If intervention “B” grants the patient two extra years of 
life at a quality of life weight of 0.75, then it presents an additional 1.5 QALYs to the patient. The net 




McCabe (2009) alludes to the fact that the early literature made the assumption that the results from 
cost-utility studies could be used to construct a cost-utility table, i.e. a ranking of ICERs, with the most 
efficient being noted at the top of the table and least efficient at the bottom. Such a league table would 
be most useful in determining which treatment options to choose as decision makers could, in theory, 
move down the league table until such time as resources had been exhausted. Sadly, the reality is far 
more complex than that and, in order to implement such a system, it would be necessary to have 
ICERs for all possible interventions, both old and new, at current prices. 
The best way to utilise the ICER is by means of an ICER threshold. In most instances, ICERs below 
the ICER threshold are funded, while those above the threshold frequently are not. This, however, 
does not mean that an ICER with a high value will automatically be declined for funding, but it does 
mean that it might be under consideration for funding based on the severity of the condition, the 
availability of treatment and the burden of disease. The ICER may be thought of as the willingness 
to pay (McCabe, 2009: 3). 
Since January 2005, the National Institute of Clinical Excellence (NICE) is thought to have applied 
a value of £30 000 for a QALY, although this has not been made public (Devlin & Parkin, 2004). 
Should this be true, it can be stated that any treatment that has an ICER of less than £30 000 per 
QALY gained will be funded. The USA uses an ICER of US$ 50 000 as its threshold (NICE, 2010). 
Although this has been debated in South Africa, the Council of Medical Schemes has not agreed to 
a set value in South Africa but has argued that different levels should be set for different conditions 
(Personal meeting with CMS, December 2010). 
The advantages of cost-utility analysis are that unlike cost-effectiveness analysis it allows 
comparisons to be made using different conditions and, unlike cost-benefit analysis, CUA enables 
the comparisons to be made without placing a monetary value on life. CUA utilises both mortality 
and morbidity data and, with the use of established rating scales like EQ-5D scores as illustrated in 
Table 2.6, the data are relatively easy and inexpensive to capture and assess. 
The main disadvantage of the CUA is that there is concern among healthcare workers that the 
instruments used to measure the utilities may not be sufficiently sensitive to account for subtle 
differences in treatment options. With regard to chronic conditions, the assumption is that the utility 
is independent of the time spent in that particular health state. Also, health gains for critically ill 
patients may be valued more than moderate gains in less severe conditions.  
McCabe (2009) suggests that CUA is not an appropriate foundation to allocate resources as it fails 




2.7.4 Cost-benefit analysis (CBA) 
Drummond et al. (2006:11) state that the main criterion that differentiates practices of economic 
evaluation resides in the way that the outcomes or consequences of the healthcare programmes are 
valued. In this regard, cost-benefit analysis (CBA) differs from other health economic methods in 
that the consequences of the programme are expressed in the same units, which are frequently 
monetary. CBA is used to determine the efficiency of the allocation of resources, for example, by 
comparing the costs and benefits relating to programmes serving different patient groups. It is 
important to note that although it may not always be possible to measure some of the items of 
resource or benefit in the same common unit of account (for example, monetary) these should not 
be excluded from the analysis. Drummond et al. (2006) usually define cost-benefit analysis in health 
economics as a technique in which all costs and benefits are measured in terms of monetary units. 
These costs may be either actual costs or opportunity costs. 
Grosse et al. (2008) explain that the clearest difference between CBA and CEA is that for CBA the 
outcomes are all expressed in monetary units while CEA allows the difference in costs between two 
interventions to be compared with the difference in health outcomes. Another, and perhaps more 
important difference, is that in a resource-constrained healthcare system, using CEA provides 
information as to whether an intervention maximizes the health of a population while CBA aims to 
determine whether the social welfare benefits, which include both health and non-health related 
outcomes and values, are best utilised within the societal budget constraints.  
The history of cost-benefit analysis (CBA) dates to 1848 when an article was published by Dupuit 
(2006). The process was later formalised by Alfred Marshall in 1920. Traditionally, cost-benefit analysis 
was used to assess the monetary value of large private and public sector projects. An example of how 
CBA was used relates to the Federal Navigation Act of 1936, when the Corps of Engineers used it as 
a proposal for a federal waterway infrastructure. After the Flood Control Act of 1939 was promulgated, 
CBA was established as federal policy (Nas, 1996: 67). 
Other examples of using a cost-benefit analysis in the 1950s and 1960s include the investment in 
motorways in both the UK and the USA. Many countries around the world now utilise CBA to evaluate 
transport projects; perhaps the most famous of these is the Victoria Line of London’s underground 
system. 
Cost-benefit analysis is typically an analysis of the cost-effectiveness with different alternatives. It is 
performed to measure whether the benefits offset the costs, thereby evaluating the efficiency of the 
new intervention relative to the status quo. Both costs and benefits are a measure of the public's 
willingness to pay for them (benefits) or willingness to pay to avoid them (costs) and, as such, the 
input is measured in terms of opportunity costs. Cost-benefit analysis attempts to put all relevant 




value of money formulas by converting the future expected streams of costs and benefits into present 
value amounts by means of a chosen discount rate (Drummond et al., 2006: 210). In practice, 
analysts try to estimate costs and benefits by either using survey methods or by drawing inferences 
from market behaviour.  
Some of the basic cost-benefit elements used by various organisations around the world include the 
following: 
 NPV (net present value) 
 Net benefit (= PVB - PVC) 
 PVC (present value of costs) 
 PVB (present value of benefits) 
 BCR (benefit to cost ratio = PVB/PVC) 
 NPV/k (where k is the level of funds available). 
The use of CBA in healthcare dates to the early part of the 1960s as result of research done by 
Burton Weisbrod as published in Economics of Public Health (Weisbrod, 1961). One of the inherent 
problems in using CBA in healthcare is that it requires that a monetary value be placed on human 
life. Many decision makers find this difficult to do and the public in general may question the ethics 
of this approach and thus trying to place a monetary value on health outcomes remains a very 
controversial topic.  
In spite of this, CBA has in many instances a far broader scope than either CEA or CUA. This is 
because all benefits and all costs are translated into money, making it possible to compare two or 
more diverse programmes, for example, a vaccination programme vs speed calming humps near a 
park. In order to assign monetary values to both costs and benefits, a method known as willingness 
to pay is used. Gold et al. (as quoted by Drummond et al., 2006), question the validity of using 
methods such as willingness to pay as they argue that this approach intrinsically favours 
programmes or diseases of the privileged over the underprivileged. 
2.7.4.1 Allocating monetary values to health outcomes 
Drummond et al. (2006) describe three methods used to allocate monetary values to health 
outcomes, namely: the human capital approach; the stated preferences of willingness to pay (WTP) 
approach; and the revealed preferences approach. Each of these methods is briefly explored below. 
 The human capital approach places a monetary weighting on a person’s healthy life and 
uses market-related wages to evaluate the programme’s present value in terms of future 
earning capabilities. Mishan (1971 as cited by Drummond et al., 2006), criticises this 




economics that presumes that each individual in society makes up the welfare of social 
welfare, and that each individual is the best judge of their own welfare. 
 The willingness to pay or contingent valuation approach relies on a survey where 
respondents are offered a hypothetical situation and asked to submit the maximum, they 
would be prepared to pay for such a service or benefit. At the outset it can be expected that 
the responses could have significantly wide deviations based on to whom, by whom and how 
the questions are asked. A young single mother with a brood of children under five years of 
age may not consider it worth paying for an infertility programme, whereas the same young 
mother with breast cancer may regard a new treatment for breast cancer as invaluable (Caro 
et al., 2006). 
 The revealed preferences model utilises the welfare economics approach and is based on 
an individual’s choice with regard to the decreased health risk, such as an injury at work 
traded off against a decreased income. This is also referred to as a wage-risk approach 
(McIntosh, 2006: 855). 
While cost-benefit analysis, in theory at least, is the most powerful method of economic evaluation, 
it is fraught with accuracy problems as both costs and benefits are usually estimated. Flyvbjerg et 
al. (2002: 280) found actual costs for a rail project to be almost 45% higher than the estimated costs 
and, in road projects, actual costs to be 20.4% higher than the estimates. The possible reasons for 
these inaccuracies are set out below. 
The estimates rely heavily on past projects, while not taking into account differences in function, size 
and skill levels of the team members. 
The estimates assume that the project's members will identify all the possible and significant cost 
drivers. 
The estimates may rely on very crude empirical studies to estimate the monetary value of the 
intangible elements. 
There may be unconscious biases of the team members with vested interests in the projects. 
Finally, it should be noted that cost-benefit is a term which is often used to describe new treatment 
options. However, Zarnke et al. (1997: 815) found that in 60% of all studies claiming cost-benefit, 
they were in fact only cost comparison studies as the benefits had not been measured in monetary 
terms, confirming the intrinsic difficulty of measuring these outcomes which could account for the 




2.7.5 Cost-minimisation analysis (CMA) 
Cost-minimisation analysis is another method of health economic evaluation with a far more limited 
scope than some of the methods described above. Cost-minimisation can only be used when 
comparing two or more therapies which have exactly the same efficacy and tolerability. The clinical 
outcome or therapeutic equivalence must be proven to be the same. 
An example of where cost-minimisation would be applicable is where drug A at dose x lowers blood 
pressure by 10mmHg, while drug B at dose Y also lowers blood pressure by 10mmHg. If efficacy 
and tolerability are demonstrated by the author prior to the cost- minimisation study being performed, 
then a comparison of "cost/course of treatment" is an easy measure to make and the “'cost-effective” 
comparator is simply the one which costs less. Table 2.8 illustrates nine possible outcomes when 
two treatment options are compared. Only in Boxes 2 and 8 can the choice really be made on cost, 
as the efficacy is the same. 
Table 2.8: Incremental cost vs incremental effectiveness of a treatment 
 
Source: Adapted from Drummond et al., 2006: 13. 
As a result of the uncertainty around estimates of cost and effectiveness, the results of any study 
rarely fit into any one box; thus, the use of cost-minimisation as a tool for health economic 
evaluations has limited application (Drummond et al., 2006: 13). 
2.7.6 Cost-effectiveness analysis (CEA) 
Cost-effectiveness analysis differs from cost-benefit analysis in that it does not assign an absolute 
value to the cost or the benefits but rather describes the benefit in terms of a ratio of the cost of the 
therapeutic measure to an applicable measure of its efficacy. Cost refers to the resource spent for 




The most common healthcare measure is the QALY which makes CEA similar to CUA, but a number 
of different measures can be used; for example, deaths averted, premature births averted, life years 
gained or years free from atrial fibrillation. 
CEA was first developed for use in the military and received its name after World War II, after which 
it was applied to healthcare in the mid-1960s. It has been suggested by Effective Clinical Practice 
that it was in 1977 that the authors Weinstein and Stason (1977) presented it with fervour to 
clinicians. CEA, like other methods of health economic evaluation, is a technique which allows the 
decision makers the opportunity to compare the relative value of different clinical strategies. Most 
often it is used when a new therapy is introduced into the market and this new therapy is compared 
with what is used in current practice.  
Generally, CEA is used either to assess the consequences of expanding existing programmes or to 
compare alternative programmes with a common health outcome (Rabarison et al., 2015). As 
described above CEA is a ratio between differences in cost and differences in effect, as illustrated 
in the cost-effectiveness ratio in Figure 2.16. 
 
Figure 2.16: Cost-effectiveness ratio 
Source: Adapted from Rabarison et al., 2015. 
An important concept to understand with regard to CEA is that, should a CEA determine a therapy 
to be cost-effective, it is only cost-effective in comparison to the comparator. This does not conclude 
that the cost-effective strategy will necessarily save money. The converse is true in that a therapy 
which saves money is not necessarily cost-effective. In reality, a therapy is cost-effective based on 







Figure 2.17: The cost-effectiveness plane 
Source: Health Knowledge, 2011:6. 
Costs are conventionally placed on the north-south axis (Y axis) while effects are placed on the east-
west axis. These effects can be positive, zero or negative. Incremental cost effectiveness ratios 
(ICERs) can be presented graphically as a combination of the costs and the effects of a health 
intervention comparing a treatment option compared to an alternative treatment.  
Based on this, an intervention can be positioned anywhere on this diagram matching its incremental 
costs and benefits. An example of this is point A, which is found in quadrant I, where the costs of the 
intervention (treatment) are greater than the alternative, while its benefits are less, indicating that the 
treatment option is poorer and said to be dominated by the alternative.  
When one examines quadrant II, the opposite is found. Here the costs are lower, and the benefits 
are greater. In this instance the treatment option is said to dominate the alternative.  
In quadrant III the benefits gained are greater at a net cost over the alternative. In this case we can 
calculate an ICER, which is the cost per unit of effect gained. The ICER is measured as the slope of 
the line from the origin to the point as indicated by the red line in Figure 2.17.  
Finally, in quadrant IV, it may be noted that the costs may be less but so are the benefits. This allows 
for the calculation of an ICER; however, this now refers to a cost saving per unit of effect lost as 
opposed to the cost per unit of effect gained.  
The ceiling ratio can be demonstrated using a cost-effectiveness plane diagram, where it is often 
referred to as demonstrating cost-effectiveness acceptability. 
The threshold line demonstrated in Figure 2.17 as a red line can move up or down in the quadrant 
and in some societies, it may even change in accordance with the disease entity. An example of this 
was Herceptin, a new biotechnical pharmaceutical used to treat breast cancer. Neyt et al. (2006) 




breast cancer. The results showed that from the period of diagnosis to the end of the metastatic 
phase the monthly hospital costs rose from €112.81 to €121.07, an increase of 7% per patient per 
month of treatment. Neyt et al. (2006) found that there was an extra cost of €3 981.44 per extra life 
month or €47 777.28 per life year gained (Neyt et al., 2006: 17). In these early studies, Herceptin 
did not replace any other drug but was rather adjunct to the current therapy. It was obvious that total 
cost would increase. The original study was European based, but the drug and its related costs made 
world headlines when intense public debate ensued in the UK. Tabloids claimed that Herceptin costs 
“would put thousands of other patients at risk” (Boseley, 2006) and it was estimated that to treat 75 
patients for whom the drug was indicated would cost the NHS £1.9 million per year. The public 
debate raged as it became known that not all women being treated by the NHS were receiving the 
same approach to the use of the drug. Patients in Wales were receiving the drug as needed, even if 
they were being treated in a hospital in England, while women in certain areas in England were being 
denied the same drug and were expected to pay £30 000 per year for it. A patient named Ann Marie 
Rogers won a High Court victory against her local healthcare body. The High Court ruled in favour 
of Mrs. Rogers, stating that the Primary Care trust policy which resulted in her treatment being denied 
was irrational and unlawful. The drug, which was estimated to cost four times more than other drugs 
to treat a range of cancers, was approved by NICE supposedly because it was more cost-effective. 
This emphasizes, as demonstrated in Figure 2.17, that the question is not only about the financial 
aspect, but also requires examination of the extra effectiveness. However, in this instance, had there 
not been pressure from the public, the treatment may have been rejected, illustrating the point made 
by Brown and Calnan (2010) who argue that NICE may be influenced by other means besides pure 
evidence-based medicine. 
While CBA, CUA and CEA appear very similar, their main differences are described below: 
 CBA assigns a monetary value to the outcomes attributable to the programme being studied. 
 CEA uses natural units, e.g. number of lives saved, or premature births prevented to express 
the outcomes. 
 CUA is a more specialised form of CEA which uses QALYs or DALYs as a measure of 
morbidity impact. 
By measuring cost-effectiveness in terms of lives saved, all lives are treated equally whether the 
person is an infant who could live to 80 years old or a person in their 40s who may live another 20 
years. This alleviates some of the ethical complexities surrounding CBA, for example (Brock, 2004).  
To perform a rigorous cost-effectiveness study, some critical issues need to be addressed. If one 
considers an example of two strategies for patients with cardiac disease, as demonstrated in Table 
2.9, it can be noted that both strategies A and B improve the outcome in these patients and have an 




Table 2.9: Cost and effectiveness of three strategies for patients with heart disease 
Option Strategy  Cost per year Effectiveness 
(years gained) 
A A. Simple (aspirin and β blockers) $5 000 5 years 
B. B C. Complex (Medication, angio, stent, CABG) $ 50 000 5.5 years 
D. C E. Nothing $ 0 0 years 
Source: Adapted from American College of Physicians (ACP), 2000: 2. 
The first strategy (A) is uncomplicated and inexpensive and requires that the patients take both 
aspirin and β blockers. The second strategy (B) is far more complicated and includes, amongst other 
things, medication, cardiac catheterisation, balloon angioplasty, coronary stenting and, finally, 
coronary artery bypass grafting. The basic assumption is that doing nothing accrues no cost and is 
not effective; this therefore becomes the third strategy (C).  
The underpinning of CEA is about marginal or incremental changes in both cost and benefits. 
Therefore, if one again examines these three strategies examining the incremental changes in costs 
and benefits it is possible to calculate the cost-effectiveness ratio as seen in Table 2.10. 
Table 2.10: Cost-effectiveness ratio of three strategies for treating heart disease 









A. A B. Simple $5 000 $5 000 5 years 5 years $1000/yr. 
C. B D. Complex $ 50 000 $45 000 5.5 years 0.5 years $90 000/yr. 
E. C F. Nothing $ 0 - 0 years - - 
Source: Adapted from ACP, 2000: 2. 
The incremental cost of the uncomplicated strategy (A) is the variance between the uncomplicated 
strategy and the strategy of doing nothing (C) i.e. (A-C). At the same time the incremental cost of the 
complicated strategy (B) is the difference between the complex strategy (B) and the uncomplicated 
strategy (A) or (B-A). The final outcome measure for CEA is the cost-effectiveness ratio or put more 
simply, the ratio of incremental costs to incremental effectiveness (ACP, 2000). 
While in principle these comparisons appear to be straightforward and uncomplicated, it would be 
prudent to note that, when evaluating CEA, the following should be considered to ensure the analysis 
is sound. An important aspect when starting a CEA is to determine whether the pertinent strategies 
being compared as CEA are sensitive to the type of strategies being compared. In the example 
above, had only the complex strategy (B) been compared with the doing nothing strategy (C) the 
cost-effectiveness of strategy B appears positive, completely ignoring strategy A as an option. Using 




$ 9 091 per life year (Table 2.11). 
Table 2.11: Cost-effectiveness ratio comparing only strategy (B) and (C) 










B. B C. Complex $ 50 000 $50 000 5.5 years 5.5 years $9 
091/yr. 
D. C E. Nothing $ 0 - 0 years - - 
Source: Adapted from ACP, 2000: 3. 
Another example of choosing the correct strategy is demonstrated in Table 2.12, which evaluates 
the cost per life year gained when screening for cervical cancer, demonstrating that screening versus 
no screening is very cost-effective while screening every three years versus every four years is less 
cost-effective. 
Table 2.12: Example data from an analysis of cervical cancer screening frequency 
  Screening 
every 4 years 
vs no 
screening 
Screening every 3 
years vs 
screening every 4 
years 
Life expectancy increase (days) 93.8 1.6 
Life expectancy increase days at 5% discount 9.5 0.2 
Cost increase in $ at 5% discount rate $264 $91 
Cost per life year gained $10 101 $184 528 
Source: Eddy, 1990: 113, 214-226. 
Therefore, CEA is useful when the primary goal of the study is to recognise the most cost-effective 
strategy from a group of options that are competing for the same resource. It is of great importance 
at the outset to ensure that the options being compared are clinically relevant. 
A second factor that is very important to consider before starting a CEA is to critically appraise the 
level of evidence to be used. Empirical evidence is needed and for that reason data for cost-
effectiveness analysis should come from either Meta-analysis studies or randomised clinical trials. 
The quality of the data can have an impact on the validity of the CEA. 
Another important aspect when considering the data selected, even if it comes from randomised 
trials, is to consider the clinical significance of the trial. Section 2.6 above refers to the availability of 
the treatment. CEA may not be generalizable to all populations, as there may be differences in the 
prevalence of disease or even access to care. If the study, for example, shows cost-effectiveness in 




really matters. Similarly, if the selection criteria in the randomised trial does not reflect patient 
selection that is easy to replicate then one should consider the generalizability of the effectiveness 
data as it must be accepted that to utilise the data one needs to make inferences. 
Finally, one should pose the question of inherent bias. In spite of the claims made by people in 
academia, it is often difficult to be free of any value judgment or bias. There may or may not be a 
consideration when looking at who funded the CEA. When studies are funded by drug companies, 
the data are more likely to report favourably. While the author does not suggest that all studies 
funded by drug companies are biased, she does caution that such bias may well be present and 
should be noted. 
2.8 CONCLUSION 
Healthcare costs continue to rise in all countries around the world. This may be attributed to the fact 
that people are living longer, are more educated and have greater exposure to information, and that 
huge advances have been made in healthcare technology. Financing for healthcare is complex and 
likely to become more so rather than less so. Decision makers, who may be seen as the gatekeepers 
to treatment options, are required to perform fine balancing acts between ensuring that the lives for 
which they are responsible benefit from the best treatment options with the resources available. This 
is not an easy task. The use of statistical lives rather than real lives may help refine the allocation of 
healthcare resources, but health is an emotive subject and, in spite of empirical data on willingness 
to pay, when faced with a life and death situation, many people find it difficult to place a monetary 
value on life.  
Health economic studies have been designed to help the decision-makers with the allocation of 
resources, but these studies are not perfect. The true complexities of ensuring correct comparisons 
are not well understood. The type of data required to model health economic studies take time to 
gather. Many multi-centre, randomised trials may take five to ten years to complete. But the current 
data are better than nothing in many instances and therefore the use of health economic measures 
is a useful guide to decision-makers. 
The benefit of using a cost-effectiveness analysis is that, unlike cost-benefit analysis, it does not 
assign an absolute value to the cost or the benefits. The measure of benefits in absolute value is not 
only difficult to achieve but has also shown to be inaccurate in as many as 60% of studies. Cost-
effectiveness analysis allows the opportunity to compare different types of medical interventions and 
describes the benefit in terms of a ratio. The measure looks at incremental changes in both cost and 
benefits.  
Therefore, CEA is useful when the primary goal of the study is to recognise the most cost-effective 




Chapter 3 examines the demographic, economic and healthcare outlook for South Africa in order to 
gain a better understanding of the unique needs and challenges within the South African population 




CHAPTER 3: DEMOGRAPHIC, ECONOMIC AND HEALTHCARE 
OUTLOOK FOR SOUTH AFRICA 
3.1 INTRODUCTION 
At a time when there is continued economic stagnation globally and, at the same time, upward 
pressure on costs, especially the costs associated with healthcare, it is important to understand the 
possible implications of introducing high tech medical therapies such as catheter ablation for atrial 
fibrillation into a society such as South Africa. With the European financial crisis and rising 
unemployment, many investors and multi-national companies are looking at the emerging markets for 
growth opportunities. Many of the emerging markets and particularly those in the old Eastern European 
block do not have the same degree of diversity and dichotomous disease profiles as are present in 
South Africa. These potential investors need to understand the uniqueness of South Africa where a 
population of 52 million cannot be expected to offer the same business opportunities as a European 
country with a population of a similar size. The dichotomies within South Africa lie within the social 
sector, income inequality, life expectancy at birth and, in particular, the difference in healthcare 
provision by the public and private healthcare sectors.  
This chapter focusses on the issues mentioned above by describing the demographic, economic 
and healthcare structure of South Africa. The following topics will be discussed in more detail: 
 The demographics of South Africa, including life expectancy, infant mortality and death rates. 
These are described in terms of South Africa but are also compared with other countries 
around the globe 
 The economy at a macro-economic level 
 Healthcare in South Africa; and 
 The proposed National Health Insurance Scheme. 
3.2 THE SOUTH AFRICAN CONTEXT 
South Africa is a middle-income, emerging market that has an abundant supply of natural resources, 
amongst others, gold, platinum and iron-ore (Bassett, 2010). South Africa is considered the 
economic powerhouse of Africa and, more particularly, of sub-Saharan Africa, with a GNI that is 





Table 3.1: The economies of selected African countries 
and South Africa’s provinces, 2009 
Country % of total PPP 
(GNI) USD b 
% of total African 
population, 
million 



















Egypt 16.8 8.2 5 680 
Nigeria 11.4 15.4 2 070 
Algeria 10.1 3.5 8 110 
Angola 3.4 1.8 5 190 
Kenya 2.2 4.0 1 570 
Botswana 0.89 0.2 12 840 
Mozambique 0.72 2.3 880 
Namibia 0.49 0.2 6 350 
Swaziland 0.2 0.1 850 
Lesotho 0.13 0.2 1 800 
Zimbabwe - 1.3 360 
Notes: GNI (gross national income) = total domestic and foreign value added by residents. PPP=purchasing 
power parity. 
Source: Adapted from Roux, 2011. 
South Africa accounts for 17.6% of the total African economy and almost 30% of the sub-Saharan 
economy (Roux, 2011). The financial, legal, communications, energy and transport systems within 
South Africa are well developed (SA INFO, 2009).  
South Africa has a modern infrastructure which is able to support efficient distribution of goods to 
major urban centres throughout the southern African region and a stock exchange that is the 
18th largest in the world. The country was ranked 45th out of 133 countries in 2009, 54th in the 
period 2009/2010 and 52nd in the Global Competitiveness Index of 2012-2013 (World Economic 
Forum, 2010; Schwab, 2012: 13). 
South Africa benefited from macroeconomic stability and the global commodities boom after 2004, but 
the country has also been affected by the global recession of 2009 (World Economic Forum (WEF), 




was growth of 30% by 2009 (Roux, 2011). Unemployment remains a problem at around 25% (Stats 
Online, 2012) and minimal, if any, progress has been made in reducing poverty or narrowing the 
income gaps since 1994 (Basset, 2010; Henry, 2003: 105; Central Intelligence Agency, 2010; Roux, 
2011).  
At the end of 2007, South Africa began to experience an electricity crisis because the state power 
supplier Eskom suffered supply problems as a result of its old and outdated power plants, thus 
necessitating sporadic power cuts ("load-shedding") in many of the major cities. These cuts affected 
both businesses and residents alike and have had an impact on the confidence level in South Africa, 
raising international concerns about the country’s ability to host major international events such as the 
FIFA World Cup of 2010 as well as concern from foreign investors. While daunting economic problems 
and, in particular, poverty, unemployment and lack of economic empowerment among the 
disadvantaged groups remain from the apartheid era, the new government, now in power for 18 years, 
has made some improvement to these situations. However, the country is still influenced by high crime 
rates, corruption and a high prevalence of the Human Immunodeficiency Virus (HIV/AIDS) (Henry, 
2003: 127). Nonetheless, the South African economic policy stance is fiscally and monetarily 
conservative and pragmatic, with a strong focus on controlling inflation through inflation targeting, 
maintaining a low level of government debt, and using state-owned enterprises to deliver basic 
services to low-income areas as a means to increase job growth and household income (Central 
Intelligence Agency, 2010). 
3.3 DEMOGRAPHICS 
The 2011 mid-year estimate of the total population of South Africa was 50.3 million, the 26th largest 
population in the world and 5th largest in Africa (Central Intelligence Agency, 2012). The largest 
provincial population is found in Gauteng, which has approximately 11.3 million people or 22.4% of the 
population. KwaZulu-Natal (KZN) has the second largest population of 10.8 million or 21.4% of the 
total. Of those younger than 15 years, approximately 23% (3.66 million) live in KwaZulu-Natal and 
19.4% (3.07 million) live in Gauteng (StatsSA, 2012: 3). 
Migration has become important in transforming the age structure and distribution of the provincial 
populations and the estimated loss of people from the Eastern Cape through migration for the period 
of 2006 to 2011 was almost 390 000 people with a further 200 000 people migrating from Limpopo 
province. During the same period the estimated net inflow of migrants to Gauteng and Western Cape 
was approximately 450 000 and 140 000 respectively. This raises the challenge in the provinces for 
job creations and also places added burden on the social structures and healthcare system. 
As seen in Table 3.2, data from the general household survey, released in May 2012 reveals that the 




growing at only 2% over the period and Limpopo province at 5%. By contrast, the population of the 
Western Cape and Gauteng grew by some 20% in the same period. 
Table 3.2: Number of individuals per province, 2002-2011 (thousands) 
Province  2002 2005 2008 2011 Total Change 
2002 to 2011 
Western Cape 4 646 4 964 5 258 5 656 20% 
Eastern Cape 6 521 6 574 6 633 6 657 2% 
Northern Cape 1 088 1 115 1 140 1 159 7% 
Free State 2 777 2 826 2 884 2 932 6% 
KZN 9 683 10 025 10 348 10 632 10% 
NW province 3 227 3 325 3 421 3 500 8% 
Gauteng 9 189 9 766 10 348 10 950 19% 
Mpumalanga 3 391 3 493 3 576 3 665 8% 
Limpopo 5 011 5 111 5 230 5 264 5% 
Total 45 533 47 199 48 794 50 324 11% 
Source: StatsSA, 2012:14. 
Almost two-thirds (63.8%) of the total South Africa population is between the age of 15 and 64 years, 
31.4% are younger than 15 years and only 4.8% of the populations are over 65 years. This age 
composition profile differs considerably from developed nations like those of the EU where only 15.7% 
of the population is estimated to be less than 14-years old, while17.1% are above the age of 64. In the 
USA one-fifth of the population is younger than 14-years old, 67.1% between 15-64 years and 12.7% 
are over 65 years. These figures are important as, on average, older members of society tend to 




Table 3.3: World population by age group as % of total 
 
Source: Central Intelligence Agency, 2010. 
In South Africa the female cohort makes up 52.4% of the total population and has a life expectancy at 
birth of 57.2 years (StatsSA, 2010:3). While being higher than in many of the neighbouring countries, 
South Africa’s life expectancy is substantially lower than in the EU, USA and even the Far East (UK 
82, USA, 79 and Japan 83, respectively) (WHO, 2012). The infant mortality rate is estimated at 45.7 
per 1000 live births and the prevalence of HIV infections in South Africa is estimated between 10% 
and 11% where 17% of the age group between 15 to 49 years is HIV positive. This means that 
approximately 5.2 million South Africans are living with HIV (StatsSA, 2010:3). The estimated number 
of new HIV infections in 2009 was 413 000, of which 59 000 were children.  
The birth rate in South Africa is 19.32 births/1000 of the population, when compared with the world 
average of 19.14 (Central Intelligence Agency, 2012). The median age for South Africa is 24.7 years 
(Central Intelligence Agency, 2010). The higher than average for sub-Saharan Africa, but significantly 
lower in the developed world (see Table 3.3). 
The importance of the median age for South African from a healthcare perspective is highlighted to a 
degree in Table 3.4, which explores the death rates. It is significant that South Africa not only has an 
overall younger population when compared with many developed nations but also has a far higher 
death rate per 1000 of the population and is now ranked as having the fifth highest death rate in the 
world out of 222 countries. The healthcare challenges in South Africa are thus very different from those 
in developed nations. 









European Union 15.7 67.2 17.1 +-41 years 
Japan 13.7 64.7 21.6 43.8 years 
Kenya 45.2 55.2 2.6 18.6 years 
Mozambique 44.5 52.7 2.8 17.4 years 
Namibia 36.7 59.5 3.8 20.7 years 
South Africa 29.2 65.5 5.3 24.7 years 
Swaziland 39.9 56.5 3.6 18.7 years 
United Kingdom 16.9 67.1 16 39.9 years 




Table 3.4: Number of deaths per 1 000 of the population 
 
Note: Total of 222 countries in ranking 
Source: Central Intelligence Agency, 2010. 
As seen in Table 3.5, of the 20 countries of the world with the highest infant mortality rate, 19 are in 
Africa, with Angola being the highest with 182 deaths/1000 live births. This is four times the world 
average and 30 times higher than in the USA and EU. South Africa is ranked at 61st place with an 
average at 43.78 deaths per 1000 live births. 
Table 3.5: The 20 countries with the highest infant mortality rates 
measured as deaths per 1 000 live births 
 
      Note: *(deaths/1 000 live births) rankings out of 224 countries.  
Source: Central Intelligence Agency, 2008b. 
The infant mortality rate for the world is ranked 59th, with a mortality rate of 44.13 deaths per 1000 live 
births. While the South African average is better than the world average, it remains seven times higher 










Angola 23.74 1 Zimbabwe 14.90 15 
Zambia 21.15 2 EU 10.39 60 
Mozambique 19.83 3 UK 10.0 62 
Afghanistan 17.65 4 Botswana 9.02 78 
South Africa 16.99 5 USA 8.38 99 




Rank Country Infant 
mortality 
rate* 
Rank Country Infant  
mortality 
rate* 
1 Angola 182.31 11 Chad 100.36 
2 Sierra Leone 156.48 12 Djibouti 99.13 
3 Afghanistan 154.67 13 Nigeria 95.74 
4 Liberia 143.89 14 Malawi 90.55 
5 Niger 115.42 15 Sudan 86.98 
6 Somalia 110.97 16 Burkina 
Faso 
86.02 
7 Mozambique 107.84 17 Equatorial 
Guinea 
83.75 
8 Mali 103.83 18 Rwanda 83.42 
9 Guinea-
Bissau 
101.64 19 DRC 83.11 




Table 3.6: Infant mortality rates of South Africa, some of its neighbours,  
the world average and the EU, USA and Far East 
 
Note: *(deaths/1 000 live births) ranked out of 224 countries. 
Source: Central Intelligence Agency, 2008a. 
3.3.1 Population pyramids and their importance in healthcare related costs 
A population pyramid is a graphical illustration that shows the distribution of various age groups in a 
population. Population pyramids can offer information about the extent of development of a specific 
population as it is broken down by age and sex. In general terms a young population is one where 
more than 30% of the population is younger than 14 years of age and less than 6% is older than 75. 
On the other hand, an “aging population” is often seen in a developed country with adequate health 
services, and where less than 30% of the population is younger than 14 years of age and more than 
6% of the population is older than 75 years. 
It stands to reason that not all countries’ population pyramids will look the same. Based on the fertility 
and mortality rates of countries, four types have been identified, as demonstrated in Figure 3.1. 
 
Figure 3.1: Four different types of population pyramids 
Source: Allaway, 2013. 
As seen in Stages 1 and 2, an expanding population pyramid demonstrates a broad base which tapers 
to the top, illustrating true pyramid shape. This is indicative of a high birth rate, rapid population growth, 
 Rank Country Infant mortality 
rate* 
59 World 44.13 
61 South Africa 43.78 
62 Bolivia 43.41 
143 Botswana 11.79 
180 European Union 6.38 
181 United States 6.30 




a large proportion of children, and a lower proportion of older people or a high death rate; and is typical 
of developing countries such as South Africa. 
Stage 3 illustrates an example of a stationary pyramid, which may also be referred to as a constrictive 
pyramid. Finally Stage 4 shows declining and low numbers of young people as the fertility or birth rate 
drops and the number of older people increases. These populations may be referred to as “greying 
populations” and are typically found in countries with good healthcare systems, such as Australia and 
Canada. 
3.3.2 Life expectancy 
Life expectancy is a statistical measure of the average number of complete years of a person’s life at 
a given point and is based on a particular mortality experience. It is usually measured and calculated 
separately for both men and women. Women often live longer than men. In some instances, life 
expectancy at age 5 is used where infant mortality is high in order to negate the effect on the calculation 
of these early childhood deaths (Sullivan & Sheffrin, 2003). 
The Central Intelligence Agency World Factbook 2008 estimates the life expectancy for the South 
African population at 49.2 years, while StatsSA’s estimates for 2009 are given as 53.5 years for males 
and 57.2 years for females. Globally, South Africa is ranked 215th, with many of the higher ranked 
countries being developing nations. Figure 3.2 illustrates the global median age as described by the 
Central Intelligence Agency (2009).   
 
Figure 3.2: Global median range for 2009 
Source: Central Intelligence Agency, 2009. 
Table 3.7 illustrates average life expectancy at birth through various stages in history. Life expectancy 
has changed significantly over time: for instance, as recently as the early 20th century, the average life 
span was not much more than 40 years. The World Bank  (2010a, as cited by the South African Institute 




birth from 1990 to 2007 declined by almost 20%. Currently life expectancy for the world is estimated 
at 67 years, although the figures range from 38 years in Angola to 90 years in Monaco. 
Table 3.7: Life expectancy variation over time 
 
Sources: Adapted from Kaplan et al., 2000; Caspari & Lee, 2004; Galor & Omer, 2007; 
Conrad, 2006; Britannica Online Encyclopedia, 2010.; Lancaster, 2010. 
What makes the time we live in different is that an ever-increasing number of people are now 
octogenarians. Figure 3.3 illustrates an example of the expected number of people in the UK over the 
age of 65 years by 2025. These numbers are projected to continue increasing beyond 2025. 
The typical population of developed nations as demonstrated by the population pyramid of the UK for 
2000 differs significantly from the population pyramid for South Africa for the same period (see Figures 
3.3 and 3.4) but when examining the population pyramids of South Africa for 2025 and 2050 in Figure 
3.5, changes should be noted with regard to the growing aged population. This is significant because 
of the impact on resources, in particular, healthcare resources.  
Figure 3.3: Population pyramid for the United Kingdom for 2000 and 2025 
Source: Central Intelligence Agency, 2008a. 
 Historical era Average life span in years at 
birth 
Upper Palaeolithic 33 
Neolithic 20 
Bronze Age 35+ 
Classical Greece 28 
Classical Rome 28 
Pre- Columbian North America 25–30 
Medieval Islamic Caliphate 35+ 
Medieval Britain 30 
Early modern Britain 40+ 
Early 20th century 30-45 





Figure 3.4: Population pyramid for South Africa, 2000 (typical of an expanding 
population) 








Figure 3.5: Population pyramid for South Africa, (a) 2025 and (b) 2050 
Source: Central Intelligence Agency, 2008a. 
In 1981 a new syndrome known as acquired immune deficiency syndrome (AIDS) was recognized by 
the USA for the first time. This new disease was at first thought to only affect homosexual men. In 
1983 the virus responsible for AIDS was identified as the human immunodeficiency virus (HIV). 
The first AIDS-related death in South Africa was recorded in 1985 and in the early 1990s, AIDS 
amongst heterosexuals (Type II) had overtaken AIDS amongst homosexual men. (Type I) (McLeod, 
2009e: 2). Today one of the biggest issues facing the South African government and health department 
is the prevalence of HIV. McLeod cites the Mail and Guardian of 1999 which stated that many South 
Africans still did not believe that AIDS existed. This denial, both by the populations at large and the 
government, together with an impasse on the issue of anti-retroviral therapy, saw a growth of around 
750% in HIV infections from an estimated 553 000 in 1994 to 4.7 million in 2003. 
Although the estimated prevalence rate for HIV in South Africa ranges from 10% (StatsSA, 2012) to 
18.1% (Central Intelligence Agency, 2009) both figures are alarmingly high, and the South African 
prevalence is ranked 4th highest in the world, after Swaziland, Botswana and Lesotho. South Africa, 






population and is home to the largest number of infected people. This figure is more than double the 
2nd ranked country, Nigeria (McLeod, 2009a: 1). 
While the number of HIV infections continue to grow, so did the debate about providing anti-retroviral 
therapy to infected patients. In 2003 the South African government finally approved the plan to 
provide anti-retroviral treatment to infected patients. The plan was implemented in 2004 and South 
Africa is now considered to have the largest ARV programme in the world (McLeod, 2009e: 3). 
From January 2005 it was mandated that all medical aid schemes provide the treatment for HIV as a 
prescribed minimum benefit (PMB). This is an example of where the private and public sector provide 
the same level of care. (McLeod, 2009e: 10). 
The population pyramids for South Africa by age and race for 2008 are shown in Figure 3.6 to 3.9. It 
is important to note that the most striking feature of these pyramids is the impact that HIV/AIDS has 
had on black South Africans. The significant decrease in the number of black South Africans between 
the ages of 35 to 45 years can be explained solely by the high prevalence of HIV/AIDs in this group 
(Dimant et al., 2009: 11). 
 
 
Figure 3.6: Population pyramid of black South Africans, 2008 






Figure 3.7: Population pyramid of White South Africans, 2008 
Source: South African Survey 2008/2009 (Dimant et al., 2009: 13). 
 
Figure 3.8: Population pyramid of Coloured South Africans, 2008 
Source: South African Survey 2008/2009 (Dimant et al., 2009: 12). 
It should be noted that there is also a marked decrease in the white South Africa population, aged 25-
34 years old. This can be attributed to the high rate of emigration of the white working age population. 
This emigration trend has attributed to the critical shortage of trained young professional and has 
become known as the “brain drain.” When compared to all the other race groups it is note that there 
are far greater numbers of elderly people in the white population. This is as result of the fact that 
traditionally the white populations have had better access to private healthcare, experience less 
poverty and generally has a better quality of life. In 2008, of the estimated 308 900 octogenarians, 
33% were white. This also points to the fact that needs within the healthcare sector have and are 
changing.  
Another trend of importance is found in the coloured population where there is a high mortality rate in 
the age group 15 to 24. SAIRR suggests that this is due to the increased incidence of violence and 




As seen in Figure 3.9, the population pyramid for South African Indians is more representative of a 
developed economy and is similar to that of white South Africans. 
 
Figure 3.9: Population pyramid of Indian/Asian South Africans, 2008 
Source: South African Survey 2008/2009 (Dimant et al., 2009). 
The economic impact of HIV/AIDS is of great importance for a number of reasons, not least of which 
the fact that most of the people infected with HIV are between 15 and 49 years. Patients with HIV/AIDS 
may also be too ill or weak to work, they are at a greater risk of opportunistic diseases like TB, and 
productivity levels may be lower than age matched populations in countries with a low prevalence of 
HIV/AIDS. There is a high mortality rate among these patients, which adds to the economic burden 
through loss of skills and costs associated with dying. Many thousands of children are left orphaned 
by AIDS, which imposes a further economic burden on the country through the need for welfare grants 
and heightens the problem associated with child-headed households or households being cared for 
by grandparents. (Dimant et al. 2009: 11). 
From a medical point of view, a significant proportion of the budget for healthcare is allocated to treating 
HIV/AIDS with ARVs or to costs related to the treatment of opportunistic diseases associated with 
HIV/AIDS even at a primary level. While the epidemic cannot be ignored, a significant volume of 
healthcare resources is funnels into education, prevention and treatment of the disease. This raises 
questions about the more limited focus on the management of cardiovascular risk with 32 million heart 
attacks and strokes annually in what the WHO terms “only the tip of the iceberg” (WHO, 2002: 14). 
While research about the risks of cardiovascular disease in South Africa occurs, the focus may not be 
sufficient. 
3.3.3 Death rates 
Data from the Actuarial Society of South Africa (ASSA) as quoted by SAIRR suggests that between 




grew by 50%. While KwaZulu-Natal (KZN) has the second largest population, in 2008 it recorded the 
highest number of deaths (see Table 3.8). This was 23% higher than Gauteng which has the largest 
population in the country. The Free State and North West provinces with only 5.9% and 7% of the 
population respectively recorded death rates of 6.8% and 8.3% in 2008. As pointed out above, many 
of these deaths are HIV/AIDS related.  
Table 3.8: The percentage of the population in each province and the number of 
deaths in each province as well as the percentage of deaths per province 
 
Source: Dimant et al., 2009: 18 & 55. 
The Western Cape attracts a lot of retirees, meaning that on average it has a slightly older population 
and that the expected death rate should be higher than average. With 11% of the total population living 
in the Western Cape the number of recorded deaths was only 7.3% of all deaths. This may be 
attributed to the fact that the Western Cape has the lowest HIV prevalence and also may be as a result 
that many of the population of the Western Cape are members of medical aid schemes, suggesting 
that they possibly have access to private healthcare and are not dependent on public healthcare. 
The number of AIDS-related deaths was recorded at 0 per 1000 of the population in 1985 but had 
reached 375 per 1000 of the population in 2008. As discussed above, HIV/AIDS has made a significant 
impact on the death rates in South Africa. Table 3.9 illustrates the changes in AIDS-related deaths by 
province between 2000 and 2010, where in a ten-year period the number of AIDS-related deaths grew 
by 167%.  
 
Province % of population by 
province 
Number of death in 





Eastern Cape 13.5 110 343 14 
Free State 5.9 53796 6.8 
Gauteng 21.5 162 796 20.7 
KZN 20.8 200 476 25.5 
Limpopo 10.8 65 295 8.3 
Mpumalanga 7.4 59 117 7.5 
North West 7 65 024 8.3 
Northern Cape 2.3 12 261 1.6 
Western Cape 10.8 57 762 7.3 




Table 3.9: AIDS-related deaths by province for 2000, 2008 and 2010 
 
Source: Dimant et al., 2009: 64. 
The Western Cape, which has the lowest prevalence of HIV/AIDS, has shown the fastest growth in 
HIV/AIDS-related deaths, from only 4114 in 2000 to an expected 17623 in 2010. This represents a 
growth of 328%. KZN was expected to record 116720 HIV/AIDS-related deaths in 2010, a growth of 
124% since 2000. It is however important to note that the rate of growth slowed down significantly from 
2008 to 2010 when compared to the previous eight years. The rate of infection seems to have 
plateaued in all provinces since 2008. This may be attribute to the successful implementation of the 
ARV programme (see Figure 3.10). 
 
 
Figure 3.10: AIDS-related deaths in South Africa in 2000, 2008 and 2010 
Source: Dimant et al., 2009: 64. 
 Province 2000 2008 2010 Change 
2000 -2010 
Eastern Cape 15 566 44 942 49 811 220% 
Free State 11 385 28 012 28 537 151% 
Gauteng 33 770 90 389 92 851 175% 
KZN 52 167 115 483 116 720 124% 
Limpopo 9 996 26 715 29 290 193% 
Mpumalanga 16 239 33 340 33 439 105% 
North West 12 748 34 561 36 343 185% 
Northern Cape 1 135 4 039 4 670 311% 
Western Cape 4 114 14 794 17 623 328% 




Finally, the Human Development Index (HDI), which is a worldwide index of a combination of measures 
including standard of living as measured by GDP per capita at PPP in US$, life expectancy at birth 
and educational attainment and literacy is used to measure standard human development over time. 
The HDI for South Africa showed an improvement between 1980 and 1995 with the trend line was 
ahead of the HDI median development, the world measure and that of Sub-Saharan Africa. 
However, while this improvement continued, albeit slowly, South Africa showed a sharp decline from 
1995 to 2005. For the period 2005 to 2011 there was again a slight improvement in the HDI for South 
Africa. This is illustrated in Figure 3.11. 
 
Figure 3.11: South Africa, sub-Saharan Africa and World Human Index, 1980-2011 
Source: Dimant et al., 2009: 64. 
3.4 THE ECONOMY 
South Africa is an upper-middle income economy with the 24th largest GNI (as measured by PPP) 
and a GDP (at PPP) estimated at $578.6 billion in 2012 (Central Intelligence Agency, 2013). It is 
also considered the economic powerhouse of Africa. The economy of Gauteng is only exceeded in 
size by the following African countries namely Nigeria, Algeria and Egypt (Roux, 2011).  
South Africa contributes close to 18% of the total African economy dominates the sub-Saharan 
economy by contributing 29% towards that entire economy. South Africa thus leads the continent in 
industrial output, mineral production. It is also responsible for generating a large proportion of Africa's 
electricity. In addition to this, the South African financial system are sophisticated and robust, and the 
banking regulations are ranked among the best in the world.  
The primary sectors within the South African economy are mining and agriculture while the major 
components of the secondary sector are manufacturing, electricity, gas, water and construction, as 




Table 3.10: Contribution by sector to the South African economy measured as 
percentage value added at 2005 constant prices 
 
Source: Roux, 2011. 
While South Africa is an emerging economy, it is also a gateway to other African markets, playing 
an important role in supplying among other things energy, transport, communications, investment, 
and relief aid to the rest of the continent. The road and rail system allow for ground transportation 
deep into Africa (South Africa Info, 2010). 
Between 1946 and 1974 the real GDP growth was on average 4.8% per annum, which realised a 
significant growth in the GDP per capita of 42% greater than the GDP per capita in 1960 and more 
than 85% growth in the GDP per capita since 1946. However, the political instability between 1974 
and 1993 had a significant impact on the economy where the real growth in GDP was about 1.6% 
per annum at a time when the population was growing on average 2.2% per annum. 
South Africa experienced 16 years of positive economic growth after the 1993/1994 period where 
the average annual growth was 3.6% compared to a population growth for the same period of about 
1.7% per annum. The growth rate has declined since 2008, largely as a result of negative and 
constrained growth in the economies of the country’s major trading partners, combined with various 
domestic structural constraints (see Figure 3.12).  
Sector 1960 1970 1980 1990 2000 2010 
Primary 
• Agriculture, forestry and fishing 
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Figure 3.12: GDP growth in South Africa from 1999 to 2010 
Sources: StatsSA, 2012; World Bank, 2012. 
In 2008 the total imports into South Africa were worth ZAR721 billion, with Germany and China being 
the two largest contributors at ZAR81.4 billion and ZAR81.2 billion respectively. Exports on the other 
hand were worth ZAR637 billion in 2008. Japan received ZAR65.6 billion in exports and the second 
largest export market was the USA, accounting for ZAR65.3 billion (Dimant et al., 2009: 78). 
The GDP per capita was estimated at US$10 000 for South Africa in 2009, which was below the 
world average of US$10 500. This is however, the third highest in Africa with Gabon at US$13 900 
and Botswana at US$13 100 per capita (Central Intelligence Agency, 2012). In ZAR terms the 2008 
GDP per capita at constant 2000 price was ZAR25 897. At provincial level, Gauteng had the highest 
regional GDP per capita for 2008 at ZAR44 735 with the Western Cape second at ZAR38 214. KZN, 
with the second largest population, and as a percentage, the highest death rate, had at ZAR20 753, 
the 7th highest regional GDP per capita. Finally, Limpopo had the lowest GDP per capita of all 
provinces at only ZAR14 651. 
Table 3.11 compares various industries’ contribution to the GDP in 1951, 2008 and 2011. 
Table 3.11: Breakdown of the value added by industry to the GDP in 1951,  
2008 and 2011 as percentage of total GDP 
 
Source: Dimant et al., 2009: 100. 
Sector 1951 2008 2011 
Agriculture 16.6 3.3 2.3 
Construction 3.1 3.1 3.1 
Electricity 1.7 2.3 1.9 
Finance 9.3 21.7 21.1 
Government 7.4 14.8 16.7 
Manufacture 18.1 18.8 12.4 
Mining 12.1 9.5 5.4 
Personal services 8 5.7 5.5 
Trade 13.2 12.7 12.2 






3.4.1.1 Consumer Price Index (CPI)  
It is evident that for the 1990s as well as the first few years of the new century, inflation in both OECD 
countries and emerging markets was lower than in the 1980s (see Table 3.12).  
Table 3.12: Consumer price inflation for selected countries, 1980-1990, 1990-2000,  
2000-2008, mid-2009 and mid-2011 
 
Sources: World Bank, 2006; 2010c; The Economist, 2010: 109. 
After recording an average inflation rate of 14% in the 1970s and 1980s, South Africa realized an 
average inflation rate below 10% between 1992 and 2007 (see Figure 3.13). It was during this time 
(23 February 2000) that the Minister of Finance announced in the Budget Speech that South Africa 
would adopt a policy of inflation targeting, with a target range of 3 to 6% (Henry, 2003: 114). Prior to 
the global financial crisis, inflation crept up to above 7% and in 2008 reached 11.5%, the highest 
average since 1992. Since 2009 there has again been a decrease in inflation, reaching 4.3% in 
2010, and 5% in 2011 and close to 6% in 2012 (StatsSA, 2010, 2012). 
 
Country 
Average annual inflation rate (%) 
1980-1990 1990-2000 2000-2008 Mid- 2009 Mid-2011 



















































































































Figure 3.13: Average annual inflation in South Africa, 2000-2012 (%) 
Source: StatsSA, 2012. 
3.4.1.2 Medical inflation 
Medical inflation refers to the annual increase in the prices of healthcare goods and services. It arises 
from a variety of sources. Figure 3.14 illustrates the increase in costs broken into four categories, 
two of which should be considered “outside” of the healthcare sector. These two components are 
general inflation or CPI (labelled “economy wide”), which includes goods and services that affect all 
sectors within an economy. The second component referred to as “population” refers to the growth 
of the population as well as the growth of the ageing population, which some may argue is as a direct 
result of improvements in healthcare services (Boonin, 2009).  
The third component is an increase in demand for healthcare services, which refers to an increased 
utilisation per capita, which in Figure 3.14 is referred to as intensity. Intensity or increased utilisation 
refers to the fact that in 2005, for instance, a diagnosis or hospitalisation would likely have involved 
more tests, procedures, and supplies compared to what would have been requested or required for 
the same condition in 1995.  
The fourth component driving medical inflation is the consequence of the higher cost of goods from 
suppliers, referred to in Figure 3.14 as “medical”. This is often interpreted as high cost and high profit 
by companies, but it is often the result of new technologies introduced into the system. These new 
technologies often contribute significantly to the success of the treatment but unlike the rest of the 
economy, for example laptop computers or refrigerators, these newer technologies in healthcare are 
usually at higher costs. Other factors which may contribute to inflation of health care costs can be the 
outcomes of inefficiencies in various parts of the system. These include inefficiencies in consumption 




services, for example, when health services could be delivered in a way which is less costly but without 
compromising on quality (Freudenheim, 2009; Boonin, 2009). 
 
Figure 3.14: The drivers of medical inflation in the USA from 1960-2005 
Source: Boonin, 2009. 
As mentioned earlier, expenditure on healthcare as a percentage of GDP between 1960 and 2008 
has grown rapidly, with the Unites States of America showing over 200% growth for this period, 
(Zweifel & Breyer, 1997; OECD, 2010). In the ten-year period from August 2000 to August 2010 
medical costs in the USA increased by 48%, while the overall CPI for the same period increased 
26% (Commins, 2010). This trend is not unique to the USA as revealed in a global survey performed 
by Towers Watson (2011), which showed that medical costs have risen rapidly since 2006 in nearly 
all the markets surveyed, with many of the countries experiencing double-digit growth trends. In most 
countries medical inflation exceeded the rate of general inflation. 
The key findings of the survey were as follows: 
In 95% of the countries included in the survey, the medical trends (inflation) exceeded the rate of 
general inflation. 
The rate of growth of medical trend (inflation) showed signs of slowing in the emerging markets, 
whereas some developed markets continued to record higher rates compared to the previous five 
years (2006-2011). 
Almost three-quarters (72%) of total survey respondents expected higher medical costs over the 
next five-year period (2012-2017). 
The average gross medical inflation for 2009 was 10.2% compared with an average of 6.9% for 
general inflation. Latin America and Middle East/Africa recorded the highest rates in the regions. 




In 2011, the average medical inflation rate globally was expected to be 10.5%, with medical inflation 
being on average 2.5% higher in emerging economies than in advanced economies. The survey 
noted that respondents from Europe expected a single digit growth of 9.1% for 2011 while Latin 
America expected a growth in medical inflation of 13.7% and North America of close to 11.6% 
(Towers Watson, 2011). Since significant growth in demand for medical products in the Middle East 
and Africa is expected as some of these countries move towards mandated healthcare coverage, it 
is not unexpected to see high medical inflation. The same situation was expected in South Africa, 
with the return of double-digit medical inflation rates forecast. 
Figure 3.15 demonstrates the annual medical inflation rate and compares it to the headline CPI 
inflation rate between 2000 and 2007 for South Africa. Medical inflation slowed down over this period 
and in 2007 was equal to or below that of the overall inflation rate.  
Figure 3.15: Headline CPI vs medical inflation in South Africa from 2000 to 2007 
Source: Twine, 2008. 
Table 3.13 illustrates the global medical trend in inflation for selected countries and compares it with 
the net medical trend (net of general inflation) for the same countries for the period 2006, 2009, 2010 
and 2011. Medical inflation in South Africa is of great concern to the government and medical aid 
schemes; however, it should be noted that for the years 2006, 2009, 2010 and 2011, the medical 
inflation rate in South Africa was lower than that of the other emerging markets surveyed and 




Table 3.13: Global average medical trends from 2006 to 2011 (percentage) 
 
Source: Towers Watson, 2011: 3. 
3.4.2 Inequality 
Among the countries that have been assessed globally, the Gini coefficients for income ranges from 
the highest at 0.7 in Namibia to the lowest (approximately 0.25) in Denmark. The Gini coefficient for 
South Africa for 2005 was estimated at 0.65, highlighting the vast income inequalities in the country 
(see Figure 3.16). 
 
Region Global medical trend Net medical trend (net of general 
inflation) 
 2006 2009 2010 2011 2006 2009 2010 2011 
All regions 10.6 10.2 9.8 10.5 6.8 6.9 5.7 6.8 
Advanced economies 6.6 9.1 8.9 9.3 4.7 8.8 7.2 7.7 
Emerging economies 13.9 11.3 10.7 11.8 8.5 5.0 4.2 5.8 
         
China 15.2 10.1 8.9 9.4 13.7 10.8 5.3 6.7 
India 22.0 12.0 13.2 12.2 15.8 1.1 0.0 5.7 
         
France 5.6 6.5 6.1 8.4 3.7 6.4 4.5 6.8 
Italy 5.5 8.3 8.3 9.5 3.3 7.5 6.6 7.8 
UK 6.0 9.3 8.8 9.5 3.7 7.1 5.7 7.0 
         
Saudi Arabia 13.3 12.0 10.0 10.8 11.0 6.9 4.5 5.5 
Egypt 10.0 13.3 10.8 11.3 5.8 -3 -1 1.3 
South Africa 7.4 12.5 10.4 9.3 2.7 5.4 4.8 3.4 
         
Canada 12.3 12.5 12.5 13.3 10.3 12.2 10.7 11.3 
USA 8.3 9.1 10.1 9.9 5.1 9.4 8.7 8.9 
         
Brazil 9.2 10.4 9.8 11.0 5.0 5.5 4.8 6.4 
Chile 5.8 13.9 13.8 18.3 2.4 12.3 12.1 15.3 






Figure 3.16: GINI coefficients, World Central Intelligence Agency Report 
Source: Central Intelligence Agency, 2009. 
Available data from the World Bank on the Gini index for South Africa is limited to 5 measurements 
as seen in Table 3.14. Between 1993, (one year prior to the first democratic elections in South Africa) 
and 2009 the index rose from 0.59 to 0.63. 
Table 3.14: GINI Index for South Africa 
 
Source: World Bank, 2009 
In South Africa the amassed income of the top 10% of earners is 90 times greater than the amassed 
income of the bottom 10% of earners. In 2010 more than 80% of all Black/African households had a 
monthly expenditure of less than ZAR2500 per month, compared with the more than 84% of white 
households who spent more than ZAR2500 per month.  
In 2009 approximately 4.6 million households or 25% of the population did not have access to either 
sanitation or electricity (see Table 3.15), and the country’s Human Development Index had whittled 
away by more than 30% as a result of inequality in particular education, income and healthcare 
(Roux, 2011).  
South Africa 
Year  1993 1995 2000 2006 2009 





Table 3.15: Basic services in South Africa 
 
Source: The Presidency, 2011. 
3.4.3 Poverty in South Africa 
The definition of poverty and the poverty line may vary significantly based on where in the world the 
measurement is made. A common method used to measure poverty is based on income or 
consumption levels. Someone is thought to be poor if their consumption or income level falls below 
a minimum level necessary to meet basic needs. This minimum level is often referred to as the 
"poverty line". 
The World Bank (2010b) uses a more defined reference of poverty by setting the poverty line at 
$1.25 and $2 per day in 2005 purchasing power parity (PPP) terms. The global poverty goal calls 
for reducing the proportion of people living on less than a dollar a day by half by 2015. This requires 
a reduction from 28 percent of the world’s population in 1990 who lived in poverty to 12.7% by 2015, 
thereby reducing the number of extreme poor people by 363 million. Poverty estimates released in 
August 2008 based on a new measurement, indicated that in 2005 about a quarter or 1.4 billion 
people in the developing world lived on less than $1.25 a day. This had decreased from 1.9 billion 
or 50% of the population in 1981. This change may be attributed to the fact that in 1981, East Asia 
which was the world’s poorest region with almost 80% of the population living on less than $1.25 a 
day had by 2005 only 18% or 340 million living on less than $1.25 per day. This change is largely as 
a result of the meaningful progress in poverty reduction in China and the goal of halving extreme 
poverty between 1990 and 2015 which has already been achieved in East Asia. 
While poverty has been seen to decline in the previously poorest place in the world, the opposite is 
true in Sub-Saharan Africa where in 1981 about 200 million people were estimated as living on less 
than $1.25 per day; a number that has since increased to 380 million. As the population of sub-
Saharan Africa has almost doubled in the same period, it means that 50 percent of the population 
lives below the poverty line, which is a decrease from 58% in 1996 to 50% in 2005 (World Bank, 
2010b). 
In 2006, Woolard and Leibbrand prepared a report for the National Treasury to propose an official 
poverty line for South Africa, in keeping with practice in many other countries. This measure would 
 1996 2001 2007 2008 2009 
Number of households (millions) 9.1 11.2 12.5 13.5 13.8 
% of households in formal dwellings 64.0 68.5 70.5 73.5 76.2 
% of households with access to water infrastructure 68.5 86.8 95 96.5 97.3 
% of households with access to sanitation 54.1 68.3 72.0 73.0 74.5 
% of households with access to electricity in formal 
dwellings 





assist South Africa to monitor the extent of household poverty and observe progress in poverty 
reduction. The report stated that the idea of a poverty line was not to reduce the household 
vulnerability for analytical purposes to a single index, but rather to propose a consistent measure, to 
gauge household needs, which would serve as a useful comparative index of trends over time and 
of relative wellbeing across the social landscape (Woolard & Leibbrand, 2006: 2). 
While there has been a decrease in poverty in South Africa from 56% in 1993 to 54% in 2008, mainly 
because of a decrease in the incidence of poverty among the black African population, it is important 
to note the following: 
 The incidence of poverty in rural areas remained unchanged at 77% between 1993 and 2008. 
 The incidence of poverty in urban areas increased from 34% in 1993 to 39% in 2008. 
 As a result of the increased urbanisation, the incidence of poverty increased from 30% in 
1993 to 43% in 2008.  
 There is generally a decrease in poverty levels where there is an increase in levels of 
education. In 2008 the poverty incidence in households where there was no schooling was 
80%. 
 Children are more likely to live in poverty than older people and some 50% of all South 
Africans living under poverty are under 20 years of age (see Table 3.16). 
Table 3.16: Poverty measures by age, gender and population group 
for 1993, 2000 and 2008 
 
Source: Adapted from OECD, 2010: 36. 
According to the World Bank (2010b) the poverty headcount ratio in South Africa as a percentage of 
the population was 31% in 1995. This increased to 38% by 2000 and by 2006 had again declined to 
23%. Other poverty measures are tabulated in Table 3.17. 
Share of population % 
Population group and gender 1993 2000 2008 
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Table 3.17: Poverty measures for South Africa, selected years 
 
Source: The World Bank, 2010. 
3.4.4 Unemployment 
According to the strict definition South Africa’s unemployment rate in 2011 was 25.7%, with little 
progress having been made in this regard over the previous 15 years. The unemployment rate in the 
age group 15-24 years was 50.5%. The highest unemployment in 2011 was found in the Northern 
Cape Province where 31.3% of the population was unemployed, while the lowest rates recorded for 
the same period were Limpopo province at 19.3% and KwaZulu-Natal at 20.3% (Roux, 2011). Table 
3.18 tabulates the unemployment by province for the period March 2001, 2003, 2008, 2010 and 
2011.  
Table 3.18: Unemployment rate by province for March 2001, 2003, 2008, 2010 and 2011 
 
Source: StatsSA 2008–2011 (http://www.statssa.gov.za). 
  
Year Number of poor at 
$1.25 per day 
(PPP) (millions) 
Number of poor at 
$2 a day 
(PPP) (millions) 




ratio at $1.25 a 
day (PPP) (% of 
the population 
1993 9 15 - 24 
1995 8 16 - 21 
2000 12 19 16 26 
2006 8 17 7 17 
















Average RSA 24.6 29.3 23.5 25.2 25.0 
Eastern Cape 30.6 33.3 28.1 27.9 26.9 
Free State 24.0 27.5 25.0 27.8 27.9 
Gauteng 27.9 31.2 22.7 26.9 26.9 
KwaZulu-Natal 19.6 28.2 22.7 20.9 20.3 
Limpopo 30.7 42.3 31.7 22.4 19.3 
Mpumalanga 19.1 23.3 23.7 27.7 30.8 
Northern Cape 21.7 25.0 24.8 29.9 31.3 
North West 22.7 26.8 22.3 27.9 25.0 







The South African healthcare sector is a complex system which boasts a highly developed private 
healthcare sector not unlike healthcare systems in developed nations, an under-performing public 
healthcare system and finally a number of non-government, non-profit organisations all under the 
custodianship of the Minister of Health as noted in the National Health Act of 2003 (McLeod, 2009f: 
5).  
The total expenditure on health as a percentage of GDP in South Africa for 2007/8 was 8.5% (this 
amounted to ZAR124.8 billion), increasing to 8.9% in 2010. As shown on Table 3.19, when compared 
internationally, 8.0% to 8.9% of GDP spent on health compares favourably with many developed 
nations, like the UK and Italy, and is higher than other emerging markets like the Russian Federation 
(5.1%) and India (4.1%).  
Table 3.19: Healthcare expenditure in selected countries for 2010 
 
Source: The World Bank, 2010c. 
Since 1996 the total number of medical aid (insured) beneficiaries has remained stagnant at around 7 
million or 14-15% of the South African population. It is often stated that 60% of the total healthcare 
expenditure is for only 15% of the population. This statement could, however, be misleading. McIntyre 
(as cited by McLeod, 2009d), suggests that as many as 21% of the population who are not covered 
by medical insurance choose to utilise the private sector for their healthcare needs. This would thus 
 Total health expenditure 
as % of GDP 
Per capita expenditure in 
USD (2010) 
USA 17.9 8 362 
Switzerland 11.5 7 812 
Germany 11.6   4 668 
Italy 9.5 3 248 
UK 9.6 3 503 
South Africa 8.9 649 
Botswana 8.3 615 
Uganda 9.0 47 
Egypt 4.7 123 
Russian Federation 5.1 525 
Ghana 5.2 67 
Mozambique 5.2 21 
India 4.1 54 





indicate that 64% of the South African population is wholly dependent on the public sector for their 
healthcare needs. It is important to note that there is a very large disparity in healthcare services 
provided by these two sectors, as can be seen in Tables 3.20 and 3.21, with regard to per capita 
expenditure and the number of medical practitioners.  
Figure 3.17 illustrates the growth in per capita expenditure in both the medical aid population as well 
as the public sector from 1996 to 2008. The per capita expenditure in the medical aid population grew 
from about ZAR5 000 in 1996 to close to ZAR9 500 in 2008. The public sector expenditure declined 
from about ZAR1 500 in 1996 to about ZAR1 000 in 1999, where it remained flat until 2003 and since 
2008 has again grown to about ZAR2 000 per capita. General inflation in South Africa was between 5 
and 10% from 1996 to 2000 and close to 5% from 2001 to 2008, indicating the government’s 
expenditure per capita on healthcare did not keep pace with general inflation. 
 
Figure 3.17: Per capita expenditure from 1996 to 2008 for 
public and medical aid patients (ZAR) 
Source: Ataguba & Akazili, 2010. 
Data from 2005 suggest that private insurance, known in South Africa as Medical Aid schemes 
accounted for 55% or 66.5 billion of the healthcare expenditure. The second largest contributor was 
the public healthcare system at 32.7% (ZAR39.2 billion). Almost 21% or ZAR14.7 billion of all 
healthcare expenditure comes from out of pocket spending (SA INFO, 2009; McLeod, 2009f: 5). 
Figure 3.18 illustrates the number of people in millions with or without medical aid cover between 
1993 and 2008. This does not reflect any out-of-pocket expenditure, which is demonstrated in Table 
3.20. It is particularly noteworthy that an estimated ZAR2.9 billion is spent on traditional medicines 
each year by approximately 27 million people. This is 5.6% of the government’s budget for health, 
but it is rarely accounted for as part of the healthcare expenditure. It is important to note that, as in 
the case of traditional medicine, fully private healthcare expenditure does not contend with other 





Figure 3.18: Number of people with and without medical aid from 1993 to 2008 
Source: Harrison, 2009: 35. 
Table 3.20: Healthcare coverage and resources in South Africa in 2005 
 
Notes: (a) Private care for primary health and private hospitals; (b) primary care in private and hospitalisations in public; 
and (c) both primary and hospital care in public. 
Source: Adapted from McLeod, 2009f: 5. 
Many South Africans choose to pay for the privilege of private healthcare by sacrificing part of their 
income which may have been spent on luxuries like entertainment. However, when the poor choose 
to access private healthcare it often means that they choose private healthcare over essential items 
such as food (McLeod, 2009f: 6). When evaluating the available resources within both the public 
and the private sector and with particular reference to this study and the treatment of patients with 
abnormal heart rhythms it should be noted, as seen in Table 3.21, that in the private sector, the 
number of patients per electrophysiologist is 875 000, while the number of patients in the public 
sector per trained electrophysiologist is 1:42 million lives.  












Population covered 7 million 9.8 million 30.2 million 
Percentage of population 14.8% 21% 64.2% 
Expenditure per beneficiary per 
annum 
ZAR9,500 ZAR1,500 ZAR1,300 
Percentage of total expenditure 55% 12.3% 32.7% 





Table 3.21: Healthcare staff in South Africa in 2005 
 
Source: Adapted from McLeod, 2009f: 5. 
3.5.2 Healthcare financing 
The Director General of WHO, Bro Harlem Brundtland as cited by McLeod (2009f: 1) states that the 
purpose of healthcare financing is to first make funds available and second to provide incentives for 
the providers of services to ensure that all people have access to effective healthcare. In order to 
make this access available three main functions of healthcare financing are vital. These are the 
collection of revenue, the pooling of resources and finally the procurement of interventions. 
Revenue may be collected through a number of different means, such as from general taxation or 
mandatory social insurance, which is most often related to the individual’s income rather than the 
individual’s risk. In other words, a person (a) with no risk factors for disease and a healthy lifestyle 
who earns a higher income will contribute more than a person (b) with high risk factors with low or 
no income, even if the risk factors in person (b) are as a result of being for example overweight, or 
cigarette smoking. Voluntary health insurance is another means of collecting funds to finance 
healthcare and the contribution may or may not be related to the individual’s risk factors. Finally, 
healthcare can be financed by means of out-of-pocket expenditure. 
Once revenue has been collected by whichever means used, the accumulation and management of 
the revenue is referred to as pooling, which ensures that the cost of healthcare and risk profile is 
carried by all members of the pool and not by the individual contributors. Finally, the collective funds 
are used to pay providers for services rendered. 
If general taxation revenue is used to fund the healthcare sector, it is referred to as a “tax funded” 
healthcare system. This refers to a system where all citizens and, at times, to obtain healthcare 
services free of charge. The coverage is therefore universal. In a social health insurance system, 
the contributions are collected from workers, government, enterprises and the self-employed and 
then pooled into a single “health insurance fund.” Social health insurance uses the funds available 
from these various sources to pay for services, with government paying the contributions of those 
who are unable to pay for themselves, for example the unemployed, children and the infirm. 




Population per specialist 470 10 811 
Population per nurse 102 616 
Population per hospital bed 194 399 
Population by physician performing 
electrophysiology (EP) ** 





In South Africa in 2005/6, general tax accounted for about 40% of the total healthcare funding, 
medical aids 45% and out‐of‐pocket payments 14% (Harrison, 2009: 24).  
Harrison suggests the South African healthcare sector financing is very progressive. This is 
attributes to the fact that the contributions made by the wealthiest 20% of the population as a share 
of their income was approximately three times higher than the contributions made by the poorest 
60% of the population as a share of their income. Thus, as demonstrated in Figure 3.19, the 
wealthiest quintile, who earn 68.7% of total income, contribute 82% of the total health care funding. 
Of this amount 45% is used for direct healthcare benefits, 32% for private health care and 13% is 
allocated to public healthcare services. Finally, 55% of total contribution made by the wealthiest 
quintile is redistributed to the other quintiles. This means that all the other income quintiles derive a 
greater share of the benefit than the actual financial contributions they make (Harrison, 2009: 24). 
 
Figure 3.19: The relative distribution of healthcare financing and benefit across income 
quintiles for 2005/06 
Source: Harrison, 2009: 24. 
3.5.3 Private healthcare in South Africa  
The private healthcare sector is made up of those members who belong to medical aids and those 
who choose to pay for healthcare out-of-pocket. In 2008 there were 119 registered medical schemes 
in South Africa which offered 200 different types of benefit options. The number of members who 
belong to medical schemes has remained largely unchanged since 1996, viz. approximately 15% of 
the country’s population. The number of principal members of these schemes rose by 3.5% in 2008 to 
3.38 million, while the number of dependents rose by 2.6% to a total of 2.4 million. The total number 
of medical aid beneficiaries for 2008 was 7.8 million (Council for Medical Schemes (CMS), 2009: 16). 
Figure 3.19 illustrates an observation which is commonly made regarding the disproportionate 
expenditure on the private sector, relative to the number of beneficiaries. In 2008 the public sector 
expenditure per capita was close to ZAR2 000. This is one-fifth of the amount spent on each person 
who was on a medical aid. What is important to note is that, while the distribution of benefits is 




financial cross‐subsidisation of these medical aid patients by the poor. The private sector generates 
significant tax benefits for the government which could be used to improve the public sector 
healthcare if the latter improved its efficiency. It is important to acknowledge the fact that healthier 
or wealthier people who are prepared to spend more on private health care do not interfere with 
public sector financing. Within the private sector, the poorest 20% of people on medical aids 
contribute twice as much of their income compared to the wealthiest 20% of the medical aid 
population. Unaffordability has been cited as a reason why the size of the medical aid population 
has remained essentially unchanged since 1994.  
In 2008 alone, it was suggested that as much as ZAR17 billion was spent as out-of-pocket expenditure, 
most of this in the private sector (Day & Gray, 2008: 365). This expenditure is more difficult to measure, 
not only from the total expenditure but also from its source. Not all costs incurred by those who are 
privately insured are covered by the medical aids, and not all patients who are uninsured rely on the 
public sector for health. It is known that various components make up out-of-pocket expenditure and 
are discussed below. 
Some of these costs are made up from costs incurred by people who are employed but whose choice 
it is not to join a medical aid but rather cover their own medical costs, or those who are employed 
but for whom medical insurance is too expensive. For those who are insured through a medical aid, 
their contribution to out-of-pocket expenditure is usually the result of costs not covered by the 
medical aid or from having used up their benefits for any year before the end of the same year. Many 
medical procedures now also have a self-payment portion as is often the case where a medical 
prosthesis is required.  
Other patients who contribute to out-of-pocket expenditure are those involved in what is known as 
“medical tourism”. These are patients who travel to South Africa for procedures which may vary from 
cosmetic to cardiac surgery. These visits may or may not include a period of recreation, for example 
a visit to a game park. The total value of medical tourism is undefined.  
The final groups of patients who contribute to out-of-pocket spending are those who traditionally 
would receive treatment at a public hospital but who choose to pay for a private practitioner in the 
case of an emergency or to avoid long waiting times. The SA Health Report of 2008 states that while 
only 6.5% of patients who belong to medical schemes made use of public facilities in the previous 
year, as many as 28.3% of the uninsured population made use of some private healthcare (Day & 
Gray, 2008: 354). 
In the 2008 report, Day and Gray offer another perspective on this claiming that of all the people 
who accessed public healthcare in 2007, 97.1% were uninsured but in contrast almost 52% of people 




Other than visits to traditional healers, uninsured patients who sought the services of the private 
healthcare sector did so because of dissatisfaction with long waiting times, medication not being 
available, staff shortages and the attitude of the medical staff. Figure 3.20 illustrates data from the 
2011 General Household Survey. In 2004 29.1% of respondents said that they would consult either a 
private doctor (20.5%) a private clinic (3.5%) or a private hospital (5.1%). This declined to 28% in 2011, 
with consulting a private doctor increasing to 24.3% while private clinic consultations declined to 1.7% 
and private hospital consultations declined to 2%. 
 
Figure 3.20: Type of healthcare facility consulted first by the households when members 
fall ill or get injured, 2004-2011 
Source: StatsSA, 2012: 16. 
It is difficult to accurately define the number of South Africans who regularly make use of private 
healthcare resources but no matter what the reason is for people incurring out-of-pocket expenditure 
it has increased significantly over the past 10 years. This increase in out-of-pocket spending for 
healthcare is not unique to South Africa; in the UK, for example, where many patients tire of the long 
waiting lists of the NHS prefer to self-fund their medical treatment. 
The Council for Medical Schemes in their 2011/12 report showed that a total of ZAR107.4 billion was 
made in medical aid contributions. This was an increase of 11.3% over 2010. A total of ZAR93.2 
billion (86.7%) was paid as healthcare benefits for 2011, an increase of 10% since 2010. As seen in 
Figure 3.21, private hospital visits accounted for the largest portion of the pay-out, amounting to 
ZAR33.8 billion in 2011, an increase of 129.9% since 2000, when private hospitals accounted for 
29.9% of all benefits paid. In 2011 private hospitals accounted for 36.3% of all benefits paid. Benefits 
paid to medical specialists accounted for 22.8% of all benefits paid and totalled ZAR21.3 billion in 
2011. The total bill for medicines in 2011 was ZAR15.2 billion, or 15.2% of the total benefits paid. 




visits to general practitioners cost the medical schemes a total of ZAR6.8 billion in 2011 (Council for 
Medical Schemes (CMS), 2012: 36). 
 
Figure 3.21: Total healthcare benefits paid 2000-11; at 2011 prices 
Source: Council for Medical Schemes, 2012: 36. 
The average number of GP visits in 2011 was three (per average beneficiary per annum), while the 
average number of visits to a dentist was 0.4. Both of these were unchanged over 2010. The 2011 
report indicated that there was a 5.3% increase in the number of beneficiaries admitted to private 
hospital with a total of 178.81 hospital admissions per 1 000 beneficiaries. The total number of 
hospitalisations in the private sector is influenced by gender; in 2011 the hospital admission rate for 
females in the age band 15-59 was higher than for men. This seems to be affected by the 
reproductive years of women. However, in the age band from 60-64 years the hospital admissions 
in men were higher. The average time spent in hospital per beneficiary in 2010 was 3.2 days as 
seen in Figure 3.22. 
 
Figure 3.22: Average length of stay in hospital by age group in 2011 





McLeod and McIntyre (as cited by Day & Gray, 2008) suggest that the private medical schemes 
have shown a trend away from primary healthcare to major medical benefits including chronic 
disease. This long-term shift may be noted in the fact that in 1974 major medical expenditure 
accounted for 42.5% of pooled funds; by 2005 this ratio had reached 71.4% (Day & Gray, 2008: 
368). 
While primary healthcare may meet the needs of the majority of the population of South Africa, the 
well-established private sector demands medical treatment that is on a par with any first world country. 
This is illustrated in Figure 3.21 which demonstrates that almost 60% of private healthcare expenditure 
is on hospitalisation costs and specialist fees. Section 3.5 reports that the GDP per capita is highest in 
Gauteng province.  
Figure 3.23 demonstrates that more than 36% of all beneficiaries of medical aids schemes are from 
Gauteng. The 2011 mid-year population statistics for South Africa indicate that the population of 
Gauteng was 11 328 203 (StatsSA 2012: 3). There are 3 095 086 people in Gauteng who are covered 
by medical aid (CMS, 2012: 117). This means that close to one out of every three people in Gauteng 
has private health insurance, while only one out of 13 people in Limpopo Province have private 
insurance. This supports the argument that private health insurance favours those who can afford it 
(StatsSA, 2012: 3; CMS, 2012: 118). 
 
Figure 3.23: Distribution of beneficiaries by province, 2011 (%) 
Source: Council for Medical Schemes, 2012: 118. 
In 2011 67% of all the medical aid beneficiaries were found in only three of the nine provinces, 
namely Gauteng (36.2%), KwaZulu-Natal (15.4%) and the Western Cape (15.3%). These three 
provinces comprise only 54% of the country’s population. Private health insurance not only differs 




Table 3.22: Medical aid coverage by province and ethnic group, 2011 (’000s) 
 
Source: StatsSA, 2012: 83. 
The General Household Survey of 2011 demonstrates that 62% of all people belonging to a medical 
aid scheme were from the previously disadvantaged groups (StatsSA, 2012). However, in spite of 
significant changes and job opportunities among the African population, only 9% of all Africans in 
South Africa are members of medical aids (illustrated in Table 3.23). This again supports the 
argument that private insurance benefits mainly the white population while the previously 
disadvantaged populations remain disadvantaged with regard to healthcare. 
Table 3.23: Percentage of ethic group who are covered by medical aid, 2011 
 
Source: Adapted from StatsSA, 2012: 81. 
  








Black 186 370 53 287 622 353 1001 353 307 3533 
Coloured 594 92 48 19 38 11 90 15 9 916 
Indian/Asian 11 12 * 1 346 1 148 16 3 539 
White 601 261 49 192 294 113 1361 140 61 3070 












Black 1475 5468 622 2264 8540 2865 7284 2994 4816 36329 
Coloured 2461 337 346 62 70 54 231 26 5 3591 
Indian/Asian 11 14 2 11 539 6 171 11 6 771 
White 206 81 36 92 99 92 609 89 32 1337 
Total 4153 5900 1005 2428 9248 3018 8249 3121 4860 42028 
 









3.5.4 Public healthcare in South Africa 
Public sector healthcare in South Africa is funded by the National Treasury. In 2010/2011 this budget 
was ZAR21.7 billion. This grew by 15.3% to ZAR25.7 billion in 2011/12. The following programmes 
benefited from the additional funding: 
 The HIV and AIDS conditional grant. 
 The hospital revitalisation conditional grant. 
 The mass measles immunisation campaign. 
 Stabilising personnel expenditure. 
 The improving of the conditions of service for employees in the department, including the 
National Health Laboratory Service and South African Medical Research Council. 
The increased funding for the comprehensive HIV/AIDS conditional grant is based on an expected 
increase in the number of people on treatment, which more than doubled from 1.2 million in 2011 to 
2.6 million by 2013/14. In 2011/12 an additional amount of ZAR442 million was allocated and 
ZAR692 million was set aside for 2012/13. A further ZAR2.28-billion has been budgeted for 2013/14 
to improve the quality, strengthen public healthcare teams, upgrade and maintain nursing colleges, 
and to improve maternal and child health. Additional funding of ZAR16.1 billion over a three-year 
period was allocated at provincial level for preparatory work for the National Health Insurance 
scheme. This funding is earmarked for registrar posts, specialist posts at district level, for family 
health teams and for helping hospitals comply with norms and standards. Although the state 
contributes about 40% of all expenditure on health, the public health sector is under pressure to 
deliver services to about 80% of the population. Despite this, most resources are concentrated in 
the private health sector, which sees to the health needs of the remaining 20% of the population 
(Media Club South Africa, 2012). 
A study conducted by Castro-Leal et al. (2000) under the auspices of the WHO asked whether the 
poor benefited from public spending on health in Africa (Castro-Leal et al., 2000: 66). The study 
investigated healthcare expenditure in seven countries, namely Cote d’Ivoire, Ghana, Guinea, 
Kenya, Madagascar, South Africa and the Republic of Tanzania. In all these countries except for 
South Africa, typically two-thirds of all health care expenditure is in public facilities. In South Africa 
about 40% of all healthcare expenditure is from public institutions. Data in Table 3.24 is from 
household surveys in these countries who responded to the occurrence of either injury or illness. 
The authors believe that the responses reflect the availability of healthcare services, the quality of 




Table 3.24: Public health expenditure in selected countries for 2006 
 
Source: Dimant et al., 2009: 513. 
The evidence from this study indicated that, as seen in South Africa, there are vast differences in 
healthcare spending among different households. There are some of the poor who seek private 
healthcare, but these are obviously less than the wealthy, while in most countries the poor relied 
mainly on the public healthcare sector. The fact that the private healthcare sector was of growing 
importance in all of these countries, is noteworthy. This observation verifies the earlier argument that 
there is a continual increase in out of pocket spending by the poor.  
The study found that often the allocation of resources was not favourable to the poor who were often 
rural and more likely to use primary health centres as opposed to tertiary care cents. Governments 
were inclined to allocate more resources to hospital-based services which can be justified to an 
extent as it is here where medical personnel are trained (Castro-Leal et al., 2000: 69). 
As discussed above, most of the healthcare expenditure in South Africa is in the private sector, with 
an increasing amount of out-of-pocket expenditure. While disparity is known to exist between the public 
and the private sector, there appears to be a degree of disparity between the budgets for public 
healthcare in the various provinces when compared to the percentage of total expenditure allocated 
to each province, the percentage of the population in each province, the GDP per capita per province 
and finally the expected growth in the budget for the period 2009/10 to 2010/11 and 2011/12 (Table 
3.25). 
 Public spending as % of 
total health expenditure 
Out of pocket spending as % 
of total private  expenditure 
Botswana 76.5 27.5 
Egypt 41.4 94.9 
Germany 76.9 57.1 
Ghana 34.2 77.8 
India 25 91.4 
Italy 77.2 88.5 
Mozambique 70.8 40.6 
Russia 63.2 81.5 
South Africa 37.7 17.5 
UK 87.3 91.7 





Table 3.25: Public healthcare budget by province for period 2009/10 to 2011/12 
(ZAR millions) 
 
Source: Adapted from Dimant et al., 2009: 101 & 512. 
While issues such as GDP per capita or HIV prevalence may be factors to justify this disparity in the 
budgets these, in fact, do not seem to have a significant impact on the budgets at provincial level. This 
can be seen by comparing the budgets of the Western Cape (WC) with the Eastern Cape. On the one 
hand the WC, which boasts the second highest GDP per capita of ZAR38 214 and the lowest HIV 
prevalence rate of 5.8%, is allocated a growth in the budget from 2009 to 2012 of 19%. On the other 
hand, the Eastern Cape, with the second lowest GDP per capita of ZAR14 883, or one-third of the 
GDP per capita of the WC, and a HIV prevalence rate of 10.8% (almost double that of the WC), is 
allocated a growth in the public healthcare budget of only 16% for the same period. 
The World Health Report, as cited by Day and Gray (2008: 357), suggests that countries with fewer 
than 230 nurses, physicians and midwives per 100 000 of the population were unlikely to achieve 
the WHO’s Millennium Development Goals (MDGs). It was reported that in certain geographical 
areas in South Africa only 7% of the number of medical practitioners required in the system were in 
fact available. The same report stated that at the time a total of 34.6% of medical practitioner posts 
and 40.3% of registered nursing posts were vacant in the public sector. This is in spite of the fact 
that the number of health professional posts in the public sector had grown from 123 268 in 2005 to 
136 985 in 2008. 
In 2008 the number of enrolled nurses per 100 000 of the population was 55.4, while nursing assistants 
accounted for 83 per 100 000 of the population. Professional nurses were 116.6 per 100 000, medical 
practitioners only 26 per 100 000, and medical specialists were 9.8 per 100 000. This is 290.8 medical 




























































































































































































10.8 14 651 7.3 LP 9 017 11 10 076 10 786 12 7.0 20 
13.5 14 883 10.8 EC 11 328 14 12 108 12 146 7 8.6 16 
20.8 20 753 15.8 KZN 17 769 22 20 688 22 211 16 7.5 25 
7.0 21 294 13.0 NW 4 919 6 5 578 6 054 13 8.5 23 
5.9 21 976 14.1 OFS 5 179 6 5 883 6 297 14 7.0 22 
7.4 22 286 13.5 MP 5 429 7 5 874 6 316 8 7.5 16 
2.3 23 952 7.5 NC 2 240 3 2 561 2 714 14 6.0 21 
10.8 38 214 5.8 WP 9 892 12 10 925 11 764 10 7.7 19 
21.5 44 735 14.7 GP 16 589 20 18 351 19 877 11 8.3 20 





In 2006/07 costs associated with staff accounted for almost 54% of total public health expenditure and 
while large investments have been made at a tertiary care level for the revitalisation of hospitals, 
medicines and equipment, the focus of the public sector remains primary healthcare. This focus on 
primary healthcare is not unique to South Africa as noted in the idealistic Alma Ata declaration which 
was signed in 1978 by 134 countries declaring the principle of “Health for All” where Primary Healthcare 
“based on practical, scientifically sound and socially acceptable methods and technology made 
universally acceptable through people’s full participation” in order to deliver health for all by the year 
2000 (SA Health Report, 2008: 4). At that time South Africa was at the height of Apartheid ideology 
and did not sign the declaration. A number of community health centres erected in the 1940 to 1950 
period became models for primary healthcare centres later.  
In 2000, the United Nations set out the MDGs which were to, inter alia, eradicate poverty, hunger, ill 
health and lack of access to education and clean water by 2015. All of these factors have either a 
direct or indirect impact on health. In 2008, halfway through the given time to reach the MDGs and 
the 30th anniversary of the signing of the Alma Ata Declaration, a renewed focus on primary 
healthcare was ushered in, which was to become a central theme in many developing nations. 
In 2008/09 funding for the public sector health services was 14.1% of total government expenditure 
and accounted for 3.5% of the GDP. The largest health service programme on a provincial level is 
the District Health Services. The total amount spent on primary healthcare, excluding the cost of 
district hospitals and HIV and AIDS, amounted to 22% of total health expenditure in 2008/09 and 
represented an increase per capita in real terms from ZAR263 in 2004/05 to ZAR395 in 2010/11. 
Data from the National Treasury publications, as shown in Table 3.26, illustrate how the public funds 
are spent, along with the annual growth in this expenditure. 
Table 3.26: Public sector healthcare services expenditure from 2004/05 to 2010/11 
 















































































PHC sub programmes 7128 8164 8983 11069 12923 14291 15838 8.4 
Local government revenue 1247 1317 1478 1566 1597 1 629 1662 (0.4) 
Community Health 
facilities 
445 588 620 968 984 1 467 1515 16.4 
PHC training 65 85 74 148 133 199 213 15.6 
Total 8885 10154 11156 13751 15637 17586 19229 8.0 
Rand per capita uninsured 224 255 277 337 380 424 460 7.0 
Rand per capita 2007/8 263 287 297 337 358 381 395 7.0 





Public spending in district hospitals has grown from ZAR7 552 million in 2004/05 to ZAR13 411 
million in 2010/11 which represents an annual growth of 4.5%. In the same period the expenditure 
on HIV and AIDS grew from ZAR1 147 million to ZAR5 068 million, an increase of almost 22% 
(National Online Statistics, 2008: 182). While it is clear that the government is placing a lot of 
emphasis on the focus of the Alma Ata declaration and the MDGs of healthcare for all, the question 
remains as to whether enough is being done to bridge the gap in healthcare provision in South Africa 
between the “haves” and the “have-nots” and whether, under the current framework, these 
inequalities can ever be overcome. 
3.5.5 Universal coverage for health 
Different types of universal coverage systems exist, namely Social Health Insurance and National 
Health Insurance. The usual distinction made between these two systems is as follows: 
 National Health Insurance (NHI): contributions are made by the tax-payer but everyone is 
entitled to benefits. 
 Social Health Insurance (SHI): only those who contribute are entitled to benefits. 
In the case of NHI, the main source of funding comes from general tax revenue which is pooled to 
manage risk. All citizens and even some foreign residents are entitled to services and coverage is 
universal. In the case of SHI, specific contributions are collected from employers, employees and 
government and placed into a single pool; however, entitlement is linked to the contributions made 
by or on behalf of individual. SHI often combines different sources of funds and the government 
usually makes contributions on behalf of those who are unable to pay. 
In the 2008 annual report of the Council for Medical Schemes, the author states that the strategic 
plan for 2009 to 2012 of the Department of Health indicates their intention to establish an NHI system 
in order to ensure healthcare that is efficient, equitable and sustainable for all (CMS, 2009: 25). This 
was in fact not the first occasion that the subject of National Health had been on the agenda for 
South Africa. As early as 1944 the WHO proposed the introduction of a National Health system for 
South Africa on similar lines as the British system. The proposal was rejected at that time by the 
government of the day and it was not until the ANC came into power in 1994 that a system of National 
Health again became part of the government’s agenda, as laid out in the ANC’s health plan (McLeod, 
2009b: 3). 
The 2009 election manifesto of the ANC included proposals for a National Health system and stated 
amongst other things that the National Health Insurance system would be phased in over a period 
of five years. This system would be publicly funded and administered and would provide the right of 




the patient would also have the choice of who delivered the service (McLeod, 2009d: 1). The 
proposal of the NHI also states the following: 
Contribution will be less than what members and their employers currently pay to medical 
schemes. Certain categories of workers, due to their low-income status, will be exempt 
from the contribution. All these funds would be placed in a single pool that would be 
available to fund the entire healthcare in the public and the private health sector under 
conditions that would apply to all healthcare service providers (Econex, 2009). 
This begs the question as to how quality healthcare should be defined. For those members of the 
public who currently belong to medical aids, nothing less than what they currently have access to 
may constitute quality, while those who currently only have access to the public sector and who 
experience long waiting times and lack of resources, may expect that quality healthcare will be in 
line with the services experienced in the private sector. 
In February 2008 Trevor Manuel, then minister of finance, was quoted as saying: 
... The same goes for the national health insurance (NHI) scheme…l. It’s another 
ambitious and potentially expensive commitment in the manifesto. The budget makes no 
promises on the NHI and, at most, promises to ‘investigate’ it (Paton, 2009). 
This is an example of how healthcare often becomes politicised as it is used by politicians to secure 
votes. Many South Africans expectations are raised by these statements and at the same time the 
medical industry has to prepare itself for the possibility of such a change. 
It is estimated that in order to offer every South African access to healthcare at the same standard 
as that found in private practice in South Africa, the total cost would be between 15.7% to 20.8% of 
GDP (ZAR318 to ZAR358 billion per year). This would be considered unaffordable in all countries 
whereas illustrated in Table 3.9 above, the highest expenditure as a percentage of GDP, is in the 
USA at 15.3% (McLeod, 2009d: 14). Moreover, included in this expenditure is an amount of ZAR127 
billion for service providers that as yet, do not exist in South Africa (McLeod; 2009d: 14). 
Yet, in spite of the affordability issues of the NHI system, the government continues to raise the 
expectations of voters and the NHI has been carved into the strategic plan of the ANC for realisation 
over coming years. In order to fulfil this promise, one of the first reforms approved by cabinet in 
January 2005 was to create a Risk Equalisation Fund (REF). While no money exchanged hands, 
the idea was to shadow transfers as a way to monitor this process with the expectation that the REF 
would be fully implemented in January 2007. At the time of writing (September 2012) no 
implementation had taken place and transfer was delayed (Private Practice Review, 2012: 2). The 
creation of the REF is the first step required towards universal coverage as it ensures that all 




When analysing what a PMB should include, it is vital to examine the cost of healthcare by gender 
and age in both the public and private sectors. Although relevant public sector data availability is 
problematic, a comparison can be made against other countries. Figure 3.24, which illustrates the 
cost of providing a PMB in the private sector by age and gender, reveals some interesting figures. 
 
Figure 3.24: Price by age and gender of prescribed minimum benefits in 2009 
Source: Adapted from McLeod, 2009c: 4. 
From Figure 3.24 we can see that the medical costs for children under the age of 1 year old are 
significantly higher than children younger than 14 years. Much of this cost may be attributed to the 
costs associated with pre-term babies. We would expect this cost to be different in the public sector 
where premature babies are not always resuscitated. Male babies have higher associated costs than 
female babies, which may be attributed to the procedure of circumcision which is performed on 
young males. 
Costs remain low for those older than one and up to the age of 20 years. However, there is a sharp 
increase from about the age of 20. This sudden increase in costs can most likely be attributed to 
maternity costs, motor vehicle accidents, substance abuse and in some population groups an increase 
in violence. It is noteworthy that the cost among the young female population associated with maternity 
costs is significantly higher in South Africa than in other countries. The reason for this has been cited 
as the high number of elective Caesarean sections performed on South African women. Lifestyle 
choices affect the cost of healthcare for both men and women around the age of 40. However, after 
40 men utilise more healthcare resources than women. One of the major differences in healthcare 
expenditure between the public and private sectors are the costs associated with HIV/AIDS. These 
data are vital when estimating the costs of healthcare expenditure for the country as well as stratifying 




As seen in Figure 3.25, the second step in setting up the NHI for South Africa could involve rescinding 
the current tax subsidy received by those members of society who belong to medical aids and in return 
provide a subsidy to each person, thereby making contributions to a mandatory healthcare system 
more affordable. The third reform would involve a mandatory income related contribution to cover the 
difference between the cost of the public sector subsidy and the PMB package. This amount is 
estimated to be approximately 50% of the current medical aid contributions (McLeod, 2009b). 
 
Figure 3.25: The envisaged flow of funds under Mandatory Health Insurance 
Source: McLeod, 2009c: 11. 
Finally, the question remains: What is to happen with medical aids? In 2009, the ANC task team 
proposed that Medical Aids Schemes should continue but on a purely voluntary basis. Contributions 
toward the NHI will be mandatory; payroll related contributions to be collected by the South African 
Revenue System (SARS).  
While the country may be hopeful of a healthcare ‘Utopia’ where all South African have the right to 
the same level of healthcare provision, the reality is that a single tier system of healthcare provision 
as is found in developed countries with social security systems like Italy, will most likely not be 
sustainable for all. In a country with a legacy of Apartheid and legislated discrimination, a multi-tier 
system may be seen as a drawback. In spite of this it must be remembered that South Africa is a 
developing nation and the implementation of a mandatory healthcare system where all members of 
society have access to the same level of PMBs, while those who choose to pay for additional cover 






South Africa is a middle-income emerging market with a high degree of income inequality. More than 
30% of the population is under 14 years old, which is double that of countries in the EU and the USA. 
The life expectancy at birth of the average South African is a little over 50 years and there is a high 
prevalence of HIV/AIDS and its related co-morbid diseases.  
While the economy is the 24th largest in the world, the economic growth rate has slowed to below 
3% per annum. Levels of unemployment and poverty are high, and the country has the second 
highest Gini coefficient confirming the economic inequality of the society. 
One of the areas where these inequalities are reflected is the healthcare sector, which has a highly 
developed private healthcare sector servicing approximately 15% of the population with the other 
85% serviced by a less efficient public healthcare sector. While National Health Insurance is an 
attractive option for creating equal rights for all, the preceding leads quite clearly to the conclusion 
that South Africa simply does not have the financial resources, trained manpower and infrastructure 
to implement a mandatory healthcare system at present. If we can accept this conclusion, we are 
bound to look at other means or methods of providing healthcare for the population. It is in this light 
that exploring the most cost-effective medical therapies is imperative to the South African society. 
These alternatives are not always obvious and the possibility of offering superior healthcare at a 
lower cost by utilising modern technology should not be excluded. 
The subject of this study focusses on the treatment of the condition known as atrial fibrillation and 
challenges not only the efficacy of the current standard of care (drug therapy) but also the cost 
effectiveness of this seemingly less expensive option. The next chapter introduces the disease of 
atrial fibrillation and explores among other things the causes, the mechanism of atrial fibrillation, the 
incidence and prevalence of the disease and the complications of atrial fibrillation, including stroke 




CHAPTER 4: ATRIAL FIBRILLATION - THE DISEASE 
4.1 INTRODUCTION 
Atrial fibrillation (AF) is a ubiquitous yet diverse cardiac arrhythmia (abnormal heart rhythm). Its name 
comes from the fibrillating (i.e. quivering) of the heart muscles of the two upper chambers of the 
heart. AF accounts for the majority of arrhythmia-related hospitalisations. The incidence of AF 
increases with age and it is more frequent in men than women (Allessie et al., 2001). It is believed 
that, in the USA alone, there are more than 2.2 million people with AF (Fogel, 2004). The condition 
carries an increased risk of arterial thromboembolism (blood clots) and stroke which can be up to 
seven times that of the average population, depending on the presence of additional risk factors 
(Allessie et al., 2001). Stroke in patients with AF is associated with greater mortality, morbidity, and 
longer hospital stays than that in patients without AF. 
With an estimated population of 50.5 million people in South Africa, 89% of whom are younger than 
55 years old (StatsSA, 2012), the estimated prevalence of non-Rheumatic AF in the South African 
population is between 204 455 and 215 147. This is based on data from Go et al. (2001) and 
Heeringa et al. (2006), which also reveal that there are an estimated 342 135 new patients at risk of 
developing the disease each year. 
Chapter 4 is a descriptive chapter which introduces the reader and, in particular, the non-medical 
reader to the disease of atrial fibrillation. The chapter covers the following topics: 
 The nature of the disease. 
 The classification of the disease. 
 The epidemiology. 
 How the disease is diagnosed. 
 The causes of atrial fibrillation. 
 Thromboembolism and the risk thereof. 
 Mortality and AF. 
 The clinical impact of AF. 
4.2 BACKGROUND OF ATRIAL FIBRILLATION 
Atrial fibrillation is the most common of all cardiac arrhythmia (irregular heartbeat) which involves 
the two upper chambers (atria) of the heart. While it may not cause any symptoms it is often 
associated with palpitations, fainting, chest pain, or congestive heart failure. It is a disease that is 
defined by the absence of co-ordinated atrial systole (contractions) as the normal regular electrical 
impulses generated by the Sino-atrial node are subjugated by disorganised electrical impulses which 
often originate in the pulmonary veins, resulting in irregular conduction of impulses to the ventricles 




Although AF is typically associated with other structural heart diseases, there are a significant 
number of patients with "lone" AF, that is, patients with AF without any identifiable cause and who 
do not have any significant cardiac history. AF is also closely associated with other conditions such 
as hypertension, valvular heart disease, coronary artery disease, congestive heart failure, left 
ventricular hypertrophy, sinus node dysfunction, congenital heart disease, endocrinopathy (thyroid 
disease or diabetes), pulmonary disease, neurologic disease, familial/genetic predisposition, and 
alcoholism. Additionally, a self-limited form is frequently seen after cardiothoracic surgery (Allessie 
et al., 2001; Fogel, 2004; Gage et al., 2004). 
During atrial fibrillation, the heart's two upper chambers beat chaotically and out of coordination with 
the two lower chambers (the ventricles), resulting in an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body with symptoms of heart palpitations, shortness of 
breath and weakness (see Figure 4.1). Blood not completely pumped out of these chambers may 
pool and clots may develop. If a fraction of a blood clot in the atria leaves the heart and becomes 
lodged in an artery in the brain, a stroke results. About 15% of all strokes occur in people with atrial 
fibrillation (Adams et al., 2008). 
 
Figure 4.1: Atrial fibrillation - many electrical impulses causing the atria to fibrillate 
Source: US National Library of Medicine, 2013.  
In AF the normal electrical impulses that are generated by the sino-atrial (SA) node are overwhelmed 
by electrical impulses that originate in the atria and pulmonary veins. These irregular electrical 
impulses are then conducted to ventricles that generate the heartbeat. These irregular heartbeats 
may occur in episodes lasting from minutes to weeks, or they could occur continuously. The natural 
tendency of AF appears to become a chronic condition. Chronic AF is associated with an increase 
in the risk of death. 
In patients with AF, the p waves, which on electrocardiogram (ECG), are characteristic of normal 




irregular ventricular tachycardia (see Figure 4.2). The rate at which the atrial electrical impulses are 
transmitted to the ventricle is determined by a number of factors, including the relative refractory 
period within the atrioventricular (AV) node, hydration status and the presence or absence of 
pharmacological agents used to control the rate. When the ventricular rate increases to tachycardic 
levels, a situation of atrial fibrillation with rapid ventricular response (AF with RVR) ensues. This, in 
turn, can lead to decompensation in the form of either myocardial ischemia or advancement to 
congestive heart failure (CHF). 
 
 
Figure 4.2: ECG of normal sinus rhythm (top) and atrial fibrillation (below) 
Note: The purple arrow indicates a p wave as found in sinus rhythm; the red arrow demonstrates the loss of p 
wave in atrial fibrillation. 
Source: Heuser, 2005. 
AF increases mortality up to two-fold, primarily due to embolic stroke. This risk exists as the lack of 
coordinated atrial contraction leads to an unusual fluid flow state through the atrium that allows for 
the formation of thrombus, which, as stated, is at risk to embolise. This risk is particularly present 
upon return to normal sinus rhythm when coordinated atrial contraction can entrain a thrombus into 
the blood flow. The risk of embolism associated with cardioversion is stated to be as high as 2%. 
Thus, part of the challenge for physicians is the question of managing rate versus rhythm and the 
issue of when cardioversion through any mechanism should be attempted. 
Atrial fibrillation is often asymptomatic and, in general, is not life-threatening, but may result in 
palpitations, fainting, chest pain, or congestive heart failure. People with AF usually have a significantly 
increased risk of stroke (up to seven times that of the general population). The level of increased risk 
of stroke depends on the number of additional risk factors for each individual patient. If a person with 
AF has no risk factors, then the risk of stroke is similar to that of the general population (Dresing & 
Schweikert, 1985). However, many people with AF have additional risk factors and then AF becomes 
a leading cause of stroke (Rietbrock et al., 2008). 
Atrial fibrillation may be treated with medications which either slow the heart rate or restore the heart 
rhythm back to normal. Synchronised electrical cardioversion may also be used to convert AF to a 
normal heart rhythm. Surgical and catheter-based therapies may also be used to prevent the 
P wave  




recurrence of AF in certain individuals. People with AF are often given anticoagulants such as 
Warfarin to protect them from stroke (Watson et al., 2007). 
Atrial fibrillation may be identified by taking a pulse and observing that the heartbeats occur at 
irregular intervals. However, a conclusive indication of AF is the absence of p waves on an ECG, 
which are normally present when there is a coordinated atrial contraction at the beginning of each 
heartbeat (see Figure 4.2) (Lazar & Clark, 2007). 
4.3 THE CLASSIFICATION OF ATRIAL FIBRILLATION 
As recommended in the guidelines of the American College of Cardiology (ACC), the European 
Society of Cardiology (ESC) and the American Heart Association (AHA), the following classification 
system is based on simplicity and clinical relevance. AF may be classified on the basis of the 
frequency of episodes and the ability of an episode to convert back to sinus rhythm. According to 
these guidelines, if a patient has two or more episodes of AF, it is considered to be recurrent. 
Recurrent AF may be paroxysmal or persistent. If the AF terminates spontaneously, it is designated 
as paroxysmal and, if the AF is sustained, it is designated as persistent. In the latter case, termination 
of the arrhythmia with electrical or pharmacological cardioversion does not change its designation. 
The category of persistent AF also includes permanent AF, which refers to long-standing AF 
(generally longer than one year), for which cardioversion is not indicated or attempted (Dressing & 
Schweikert, 1985). 
All atrial fibrillation patients are initially in the category called first detected AF (see Table 4.1). These 
patients may or may not have had previous undetected episodes. If a first detected episode self-
terminates in less than seven days and another episode begins later on, the case has moved into 
the category of paroxysmal AF. Although patients in this category may have episodes lasting up to 
seven days, in most cases of paroxysmal AF the episodes will self-terminate in less than 24 hours. 
Table 4.1: Categories of atrial fibrillation (AF) 
AF Category Defining Characteristics 
First Detected Only one diagnosed episode 
Paroxysmal Recurrent episodes that self-terminate in less than 7 days 
Persistent Recurrent episodes that last more than 7 days 
Permanent An ongoing long-term episode 





Episodes lasting more than seven days are unlikely to self-terminate (Dressing & Schweikert, 1985), 
and are thus referred to as persistent AF. Termination of AF in persistent AF may be attempted by 
cardioversion. If cardioversion is not attempted or is unsuccessful and the episode is ongoing for a 
long time (e.g. a year or more), the patient's AF is referred to as permanent AF. 
Episodes that last less than 30 seconds are not considered in this system of classification. Also, this 
system does not apply to cases where the AF is a secondary condition that occurs in the setting of 
a primary condition that may be the cause of the AF, for example after cardiac surgery. Using this 
system, it is not always clear how to classify AF. For example, a patient presenting with AF may fit 
into the paroxysmal AF category some of the time, while at other times their AF might present with 
characteristics similar to persistent AF. It may be possible to decide which category is more 
appropriate by determining which one occurs most often in the case under consideration (see Figure 
4.3). 
 
Figure 4.3: Patterns of atrial fibrillation (AF) 
Notes: (1) Episodes lasting less than 7 days (2) Episodes lasting more than 7 days (3) Cardioversion failed or not 
attempted (4) Both paroxysmal and persistent AF may be recurrent. 
Source: Fuster et al., 2006. 
In addition to the four categories above, which are mainly defined by episode timing and termination, 
the ACC/AHA/ESC guidelines describe additional AF categories in terms of other characteristics of the 
patient. These are described below (Fuster et al., 2006): 
 Lone Atrial fibrillation (LAF) – This is the absence of clinical or echocardiographic findings 
of other cardiovascular disease (including hypertension) or related pulmonary disease, and 
in patients under the age of 60 years. 
 Non-valvular AF – This is the absence of rheumatic mitral valve disease, a prosthetic heart 




 Secondary AF – This occurs in the setting of a primary condition which may be the cause of 
the AF, such as acute myocardial infarction, cardiac surgery, pericarditis, myocarditis, hyper-
thyroidism, pulmonary embolism, pneumonia, or other acute pulmonary disease. 
 Acute atrial fibrillation is rapid, irregular, with chaotic atrial activity that lasts less than 48 
hours. It includes both the first symptomatic onset of chronic or persistent atrial fibrillation 
and episodes of paroxysmal atrial fibrillation. It is sometimes difficult to distinguish new-onset 
atrial fibrillation from previously undiagnosed long-standing atrial fibrillation. Atrial fibrillation 
within 72 hours of onset is sometimes called recent-onset atrial fibrillation. By contrast, 
chronic atrial fibrillation is more sustained, and can be described as paroxysmal (with 
spontaneous termination and sinus rhythm between recurrences), persistent, or permanent 
atrial fibrillation (Watson et al., 2007). 
Although atrial fibrillation is not usually life-threatening, it is a medical emergency that can lead to 
complications. Treatment for atrial fibrillation may include medication and other interventions to try 
to alter the heart's electrical conduction (Mayo Clinic, 2009). 
4.4 EPIDEMIOLOGY 
4.4.1 The incidence of atrial fibrillation 
The Framingham Study revealed that nearly 2% of the USA population had AF. Men were more 
likely to be diagnosed with AF than women. Both the incidence and prevalence of this disease 
increases with age. Go et al. (2001) found in their prospective study that the incidence of AF in 
people younger than 40 years old was less than 0.1% per year. The incidence of AF in patients aged 
50 to 59 years was 0.5%, and 8.8% of the 80- to 89-year-old group was diagnosed with AF (Dressing 
et al., 1985). The incidence of AF among older adults studied over a three-year period in the 
Cardiovascular Health Study (Lip & Watson, 2009) was 19.2/1000 person years. In the West 
Birmingham atrial fibrillation project (Rietbrock et al., 2008), the prevalence of AF, as found in general 
practices, was 2.4%. The most common aetiological causes were hypertension and ischaemic heart 
disease (Fogel, 2004). Crijns et al. (2000) demonstrated in a study published in the European Heart 
Journal that patients with congestive heart failure (CHF) had a three-year incidence of AF of almost 
10% (Crijns et al., 2000).  
A recent study by Chugh et al. (2014) confirmed that both the incidence and prevalence of atrial 
fibrillation were increasing. This, they stated, as have others, is the consequence of an ageing 
population and the resultant inverted population pyramids in many geographical areas. However, 
the study added that, even when adjusted for age, there was an increase in the incidence and 




This data, which are based on the Worldwide Epidemiology of Atrial Fibrillation (Chugh et al., 2014)) 
serve to confirm that the incidence of atrial fibrillation was higher in men than in women. The 
methodology used to estimate the incidence of atrial fibrillation was the number of new cases of 
atrial fibrillation divided by the population at mid-year. Based on this data it was shown that the 
estimated annual incidence of atrial fibrillation in 2010 was 60.7 per 100 000 population in men and 
43.8 per 100 000 in women (as seen in Figure 4.4). 
 
 
Figure 4.4: Worldwide incidence of AF per 100 000 of the population for both men and 
women in 1990 and 2010 
Source: Chugh et al., 2014.  
From the 2014 world epidemiology data by Chugh et al. (2014), it may be noted that, when 
comparing the age standardized incidence of atrial fibrillation in South Sub-Saharan Africa for 1990, 
the male population had a similar incidence to the male population in Western Europe, while the 
female population incidence was more similar to that of the female population of Central Europe. 
The incidence of atrial fibrillation in both males and females was lower than that in North America 
for both 1990 and 2010. The reason for comparing these groups is because most of the previous 
studies referenced in this document were performed in these regions. The full detail of the incidence 
by age group and region may be found in Appendix B. 
Table 4.2 illustrates the growth in the incidence of atrial fibrillation between 1990 and 2010 by age 




Table 4.2: Percentage growth in the age-standardised incidence of atrial fibrillation by region 
from 1990 to 2010 
 
Source: Adapted from Chugh et al., 2014: 71-74. 
4.4.2 The prevalence of atrial fibrillation 
It was estimated in 2014 that there were more than 2.5 million Americans living with atrial fibrillation 
(Heart Rhythm Society (HRS), 2014). This has increased from 2.2 million in 2001. The longevity of 
the world’s population is increasing and, as a result, more patients will suffer from this disease, as 
up to 10% of the population older than 80 years are diagnosed with AF at some point. The prevalence 
of diagnosed AF in the general population is 0.95% (95% CI, 0.94%-0.96%). Figure 4.5 shows how 
the prevalence of AF increases with age in both men and women, ranging from 0.1% in persons less 
than 55 years old to 9.0% among patients more than 80 years old. While women have a lower 
prevalence of AF at every age group compared to men, the overall number of affected women is 







Figure 4.5: Prevalence of AF increases with age in both men and women 
Source: Go et al., 2001. 
More recent data published in 2014 by Chugh et al. (2014) indicate that the global prevalence of atrial 
fibrillation in 1990 as measured per 100 000 of the population was 569.5 for men and 359.9 for women. 
This prevalence showed only a modest increase up to 2010 when the prevalence for men and women 
was 596.2 and 373.1 respectively (Figure 4.6).  
 
Figure 4.6: Worldwide prevalence of AF per 100 000 people for men and women,  
1990 and 2010 
Source: Chugh et al., 2014. 
Figure 4.7 illustrates that the highest prevalence rates were found in North America at 925.7 for men 
and 520.8 for women, while the lowest were found in the Asian Pacific region at 340.2 for men and 
196.0 for women. The estimated age adjusted prevalence of atrial fibrillation in the sub-Saharan region 





Figure 4.7: Prevalence of atrial fibrillation and atrial flutter (per 100 000 of the population) 
by regions in 2010 
Source: Chugh et al., 2014. 
Table 4.3: Prevalence rates for atrial fibrillation in 2010 by region with 95% uncertainty 
intervals (per 100 000 population) 
2010 Global estimated atrial 
prevalence rates 
North America Asian Pacific region Sub Saharan 
super region 
Men 596.2 925.7 340.2 659.8 
Women 373.1 520.8 196.0 438.1 
Source: Chugh et al., 2014. 
Table 4.4 shows the median percentage change in the prevalence of atrial fibrillation in North 
America, Central and Western Europe and Southern Sub-Saharan Africa from 1990 to 2010. The 
greatest change was noted in North America at 15% with an increase in Southern Sub-Saharan of 
almost 9%. No distinction is made between Rheumatic and Non-Rheumatic Atrial fibrillation in these 
data (See Appendix C for full details). 
Table 4.4: The median percentage change in prevalence of atrial fibrillation for North America, 
Central and Western Europe and South Sub-Saharan Africa from 1990 to 2010 
 
Source: Chugh et al., 2014: 69. 
Table 4.5 illustrates the growth or decline of the age standardized prevalence of atrial fibrillation in 




especially in North America and Western Europe. There is also growth in the prevalence of atrial 
fibrillation in the male population of Southern Sub-Saharan Africa, which, for all age groups, is 
greater than the growth in the female group of this Southern Sub-Saharan population. 
Table 4.5: Percentage growth in the age-standardised prevalence of atrial fibrillation by region 
from 1990 to 2010 
 
Source: Adapted from Chugh et al., 2014: 65-69. 
Figure 4.8 illustrates that the number of American adults with AF is projected to continue to increase 
as a result of the aging population, and as a result of the increased prevalence of coronary heart 
disease, heart failure and hypertension which may also contribute to this trend (Crijns et al., 2000; 
Madrid et al., 2002; Go et al., 2001). 
.  
Figure 4.8: Projected numbers of American adults with AF 
between 1995 and 2050 
Source: Go et al., 2001. 
In 2000 in the USA, it was shown that of the patients who had AF nearly 82% were over the age of 
65 years and 37% were over the age of 80 years. These data are confirmed by Chugh et al. (2014) 




of 65 years. Tables 4.6 and 4.7, as discussed by Go et al. (2001), suggest that 88% of Americans 
suffering from AF will be older than 65 years by 2050 and the group of patients over the age of 80 
years will increase to 53% of the total American population. 
Table 4.6: Projected gender distributions of adults with AF in the 
United States in 2000, 2025 and 2050 
 Year 
Gender 2000 2025 2050 
Female 48.6% 46.3% 47.4% 
Male 51.4% 53.7 52.6% 
Source: Go et al., 2001. 
Table 4.7: Projected age distribution of adults with AF in the  
United States between 2000 and 2050 
 Year 
Age group 2000 2025 2050 
<65 years 18% 15.5% 11.5% 
65 -79 years 45.3% 48.7% 35.9% 
>80 years 36.7% 35.8% 52.6% 
Source: Go et al., 2001. 
Analysis from the Framingham Heart Study demonstrated that when patients with AF were 
compared to patients without AF but matched by age, sex, and calendar year, the patients with AF 
were more likely to have risk factors for cardiovascular disease, pre-existing disease including 
hypertension, myocardial infarction, left ventricular hypertrophy, congestive heart failure, stroke or 
transient ischaemic attack and valvular heart disease. Women with AF were more likely to develop 
diabetes and, as illustrated in Table 4.8, an increased relative risk for AF may be related to increased 
BMI and obesity. This risk for AF in patients with obesity is increased by 50%, as a result of 





Table 4.8: Adjusted relative risk for atrial fibrillation from Multivariate Cox Model 
Variables Relative risk 95% confidence interval 
Myocardial infarction 3.62 2.59 - 5.07 
Angina 2.84 1.91 - 4.21 
ST or T wave change 2.21 1.62 - 3.00 
Valvular disease  3.15 1.99 - 5.00 
Congestive heart failure 3.37 2.29 - 4.96 
Hypertension 1.42 1.10 -1.84 
Cardiomyopathy 4.07 1.45 -11.45 
Palpitations 2.22 1.24 - 2.97 
Obesity 1.28 1.02 - 1.62 
Supra-ventricular rhythm 
disturbance 
2.28 1.74 - 2.98 
Ventricular rhythm disturbance 1.37 1.06 -178 
Source: Stewart et al., 2002. 
Chugh et al. (2014: 3) estimated that in 2010 there were 33.5 million individuals globally living with 
atrial fibrillation (20.9 million males and 12.6 million females). This translates to one person in just 
over every 200. A simple extrapolation of these data indicates that in South Africa where the 2012 
population was 51.19 million there could have been as many as 248 000 South African affected by 
AF (Central Intelligence Agency, 2001; StatsSA, 2012). 
This type of extrapolation is very crude as it does not take into account any differences in the 
demographics of the various countries with particular regard to age distribution of the population. 
However, by examining the population pyramids as seen in Figure 4.7 to 4.8 it is at least possible to 
begin to project the potential impact the ageing population may have for a disease like AF.  
Figures 4.9, 4.10 and 4.11 demonstrate the significant differences between the population pyramids 
of South Africa and the United Kingdom and the USA in 2000, and projected for 2025 and 2050. . 
 
Figure 4.9: Population pyramids of South Africa, UK and the USA in 2000 





Figure 4.10: Population pyramids of South Africa, UK and the USA in 2025 
Source: Fathers for Life, 2010. 
 
Figure 4.11: Population pyramids of South Africa, UK and the USA in 2050 
Source: Fathers for Life, 2010. 
The South African pyramid is typical of a country with a high birth rate, a rapid decline in age groups 
indicating a high death rate and short life expectancy. The UK and USA pyramids are examples of 
countries with a low to declining birth rate, a low death rate, an increased number of people reaching 
older ages and a higher dependency rate. The 2011 mid-year population statistics of StatsSA estimate 
that 41% of the South African population is younger than 20 years old and nearly 81% of the population 
is younger than 45 years of age. The proportion of the South African population older than 65 years is 
5%, while that older than 80 years is 0.7% (StatsSA, 2009; StatsSA, 2012). 
This is a vast difference from the USA and UK where, in the USA, only 60% of the population is younger 
than 45 years old and nearly 13% is over 65 years old (United Nations Statistics Division, 2007). 
In the UK in 2008, for the first time, the population of state pensionable age was greater than the 
population aged less than 16 years, which has shown a decline since 1995. In the UK, the fastest 
growing age group of the population is over 80 years old. The population over the age of 80 years was 
estimated at 2 749 507 (or 4.5% of the total population); this had grown from 1.5 million (or 2.8% of 
the total population) in 1981.  
This rapid increase in the number of octogenarians has been attributed to the decrease in mortality at 
older ages over the course of the second half of the 20th century. Between 1911 and 1915 the mortality 
rate of the population over 75 was reported at 137 deaths per million of the population. This has 




noted that the mortality rate for the population aged between 65 and 74 declined by two-thirds over 
the same period, from 57 to 19 deaths per thousand (Stats SA, 2009). 
Schnabel et al. (2009) used data acquired from the Framingham Heart Study to develop a risk score 
for atrial fibrillation. The outcome of the study was to determine the first episode of AF among this 
community-based cohort who were aged between 45 and 95 and who were free of AF at baseline. 
The participants were followed for a maximum of 12 years. The predictors of AF were based on a 
point system, as noted in Table 4.9 below, and the points were allocated to the participants. The 
greater the number of points, the higher the risk for developing AF based on the following criteria: 
 Age. 
 Gender (male). 
 Body Mass Index (mass/height2). 
 Systolic blood pressure. 
 Current treatment for hypertension. 
 PR interval on ECG. 
 Significant heart murmur. 
 Prevalence of heart failure... 
Table 4.9: Points and risk estimates for development of AF 
 
Source: Schnabel et al., 2009. 
Table 4.10 illustrates the significant role that increased age has for the risk of developing AF when 
compared with other risk factors, for example structural heart disease. 
Table 4.10: Age of men and women as a predictor of risk for development of AF 
Age 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 >85 
Women -3 -2 0 1 3 4 6 7 8 
Source: Schnabel et al., 2009. 
4.4.3 Incidence and prevalence of atrial fibrillation in South Africa 
There are no specific data on the incidence and prevalence of AF in South Africa. By using the 2011 
mid-year population statistics of South Africans younger than 55 years old for both genders and 
based on the data in the Go et al. (2001) study and the Heeringa et al. (2006) study, an estimation 
was calculated for the incidence of AF in South Africa as seen in Table 4.11. 
Total points and risk estimates 
Total points 0 1 2 3 4 5 6 7 8 9 >10 





Table 4.11: Estimated incidence of AF by gender and age group in South Africa 
 
Sources: Adapted and computed from Heeringa et al., 2006; StatsSA, 2012. 
Table 4.12 shows the projection of the general population of South Africa from 2010 to 2040 by age, 
adjusted for the impact of HIV/AIDS. (See Appendices D and E). It should be noted that, between 
2010 and 2040, the total population is only expected to grow by 5.5%. However, the growth in the 
number of people over the age of 55 years old, who are potentially impacted by non-rheumatic atrial 
fibrillation, increases by 82%. In 2010 the total number of the population under the age of 55 years 
was 88%; by 2040 this is expected to decrease to 79%. 
Table 4.12: Age specific projections of the total South African population,  
2010 to 2040 (with AIDS projections) 
 
Source: Haldenwang, 2011. 
Based on the data for Southern sub-Saharan Africa presented in Table 4.4, the number of people in 
South Africa who may be affected by atrial fibrillation was estimated at 225 435 in 1990 and 316 354 
  Females   Males 
 Age Incidence Population Total 
 
Incidence Population Total 
56-59 0% 928 220 -   2.60% 745 049 19 371 
60-64 2.10% 768 502 16 139   4.90% 582 801 28 557 
65-69 4.70% 569 547 26 769   6.60% 419 152 27 664 
70-74 10.10% 425 931 43 019   12.40% 289 184 35 859 
75-79 11.50% 288 117 33 133   19.90% 172 858 34 399 
80-84 18.20% 249 138 45 343   25.50% 125 028 31 882 





in 2010. This is an increase of some 8.7% over a 20-year period. However, using another method 
of analysis and based on data that shows that 33.5 million people in the world are suffering from AF, 
it can be estimated that, with a world population of around 7 billion people, one in every 209 people 
have atrial fibrillation. Applied to South Africa, this would imply that there were 242 094 people with 
AF in South Africa in 2011.  
Using data from both the ATRIA and Rotterdam studies, the estimated number of South Africans 
possibly affected by AF in South Africa is between 204 253 and 207 478, as seen in Table 4.13. This 
is lower than both the estimates by Chugh et al. (2014) and the crude estimation based on ratio of 
AF to total world population and may be explained by the fact that the study by Chugh et al. (2014) 
did not define the number of Rheumatic cases of AF and that 89% of the South African population 
is less than 55 years old (see Appendix F). 
Table 4.13: Estimated prevalence of AF by population group in South Africa, 
based on 2011 population statistics 
 
Sources: Adapted and computed from Go et al., 2001; Heeringa et al., 2006; StatsSA, 2012. 
Using data from Chugh et al. (2014) the average increase in prevalence rates was calculated in five-
year cycles for both males and females and projected, based on the 2006 data from Heeringa et al. 
(2006), as demonstrated in Tables 4.14 and 4.15. This data can be found in Appendices D and E. 
The prevalence was shown to increase across all age groups and both genders, with the exception 
of females in the age group of 80-84 years old, where the prevalence is shown to decline (Chugh et 
al., 2014). 
The data were then used, together with the population projections by Haldenwang (2011) for both 
males and females, to estimate the prevalence of AF in five-year periods from 2006 up to 2040. 
These can be seen in Figure 4.12, Table 4.14 and Table 4.15.  Tables 4.14 and 4.15 indicate the 
estimated prevalence of AF in both the male and female population of Southern Sub-Saharan Africa 
between from 2006 to 2040. 
Full details can be found in Appendix F.  
Race % of 
population 
Number % under 










Total population 100% 50 586 757 89% 207 478 204 253 
Black South African 79.5% 40 206 275 91% 140 356 129 363 
Coloured South Africans 9% 4 539 790 88% 17 345 16 976 
Indian/Asian South Africans 2.5% 1 274 869 84% 7 305 6 452 





Based on the data in Table 4.16 the estimated number of South Africans currently affected by AF is 
just under 300 000. Using these data, that number will reach 352 855 by 2015, 526 633 by 2025, 
767 572 by 2035 and 884 546 by 2040. This represents a 210% increase in total people affected 
with AF from 2010 to 2040. When calculating the prevalence of population with AF, it is estimated to 
increase from 0.6% of the population to 1.7%, as seen in Figure 4.12. 
By using the data presented in Tables 4.5, 4.6 and 4.7 the estimated prevalence was calculated by 
age standardised groups from 56 years old to those older than 80 years old for both males and 
females. This is presented in Tables 4.16. 
 
Figure 4.12: Percentage of the South African population living with AF from 2010 to 2040 
Source: Adapted from data from Chugh et al., 2014: 65-67; Heeringa et al., 2006; StatsSA, 2012; Haldenwang, 
2011. 
Table 4.14: The estimated prevalence of AF in the male population of Southern Sub- Saharan 
Africa between from 2006 to 2040. 
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Table 4.15: The estimated prevalence of AF in the female population of Southern Sub- Saharan 
Africa between from 2006 to 2040. 
 
Source: Adapted by Chugh et al., 2014: 65-67. 
By using these data, together with the data from Go et al. (2001), Heeringa et al. (2006), StatsSA 
(2012) and Haldenwang (2011), the estimated prevalence of AF was calculated for both males and 
females from the age of 55 years and older from 2010 to 2040 in five-year increments, as seen in 
Table 4.16.  
Table 4.16: Projection of AF in the South African population from 2010 to 2040 
Year Total Population Male Female 
2010       285,428  139,649 145,779 
2015       352,855  180,097 172,758 
2020       427,904  232,121 195,784 
2025       526,633  297,732 228,901 
2030       643,908  375,337 268,571 
2035       767,572  460,804 306,768 
2040       884,546  549,062 335,484 
Source: Adapted from data from Chugh et al., 2014: 65-67; Go et al. (2001), Heeringa et al., 2006; 
StatsSA, 2012; Haldenwang, 2011. 
Figure 4.13 illustrates the growth in the estimated number of South Africans who may be affected by 





Figure 4.13: Projection of AF in the South African male, female and total population from 
2010 to 2040 
Source: Adapted from data from Chugh et al., 2014: 65-67; Heeringa et al., 2006; 
StatsSA, 2012; Haldenwang, 2011. 
4.5 DIAGNOSING ATRIAL FIBRILLATION 
Many patients present at their physician with symptoms related to a rapid and irregular heart rate or 
palpitations. These patients may also experience exercise intolerance, occasionally angina, 
congestive symptoms, and shortness of breath or oedema. Based on the history, physical 
examination of the patient, and their ECG, the diagnosis of atrial fibrillation (AF) may be made. It is 
not uncommon for a patient to first become aware of AF during a routine physical examination, or 
when an ECG is performed for another reason, as AF is asymptomatic in as many as one in five 
cases (Page et al., 2003). For some patients, the first diagnosis of AF may be at the onset of a stroke 
or a transient ischaemic attack (TIA).  
Often, atrial fibrillation is secondary to other medical problems, and the patient may present with 
symptoms of hyperthyroidism (an overactive thyroid gland) such as weight loss and diarrhoea, or the 
presence of chest pain (angina pectoris), or symptoms suggestive of lung disease that would indicate 
an underlying cause. In patients with a previous history of stroke, TIA, heart failure, high blood pres-
sure, diabetes, and rheumatic fever, there may be a higher risk of complications associated with AF.  
The physician will take a history, which will include the following details:  
4.5.1 Family and medical history 
The symptoms and history will include, among other things, blood pressure, a history of palpitations 
or the sensation of a racing, irregular or uncomfortable heartbeat, shortness of breath, chest pain or 
discomfort, dizziness and impaired effort tolerance. The medical history includes other health-related 
problems, as well as a history of heart disease, high blood pressure, lung disease, diabetes and, 




pressure, is significant. Finally, social habits such as cigarette smoking, alcohol use and caffeine 
use are also noted. 
4.5.2 Physical examination 
The physician should do a complete cardiac examination, listening to the rate and rhythm of the 
heartbeat, feeling the pulse and measuring the blood pressure. Auscultation of the chest will reveal 
heart murmurs and crepitations of the lungs, which could possibly indicate heart valve problems and 
signs of heart failure respectively. The physician may also examine the patient for swelling of the 
legs or feet and look for an enlarged thyroid gland or other signs of hyperthyroidism. 
4.5.3 Diagnostic tests and procedures 
4.5.3.1 Electrocardiogram (ECG) 
Atrial fibrillation is diagnosed on a standard 12 lead ECG, which is a simple and painless test that 
detects and records the electrical activity of the heart. It is the most useful test for diagnosing AF, as 
it shows how fast the heart is beating, as well as the rhythm (steady or irregular). It also records the 
timing of the electrical signals as they pass through each part of the heart and is usually carried out 
in a GP surgery or at a local hospital.  
Characteristic findings in AF include the absence of p waves, with unorganised electrical activity in 
their place, and irregularity of R-R interval due to irregular conduction of impulses from the atria to 
the ventricles. 
Paroxysmal AF or episodes that “come and go” may not be detected or documented during an office 
visit as the standard ECG records the heartbeat for only a few seconds. If paroxysmal AF is 
suspected, but is not captured on a regular ECG, it may be necessary for the patient to wear a 
portable or ambulatory Holter monitor for between 24 and 48 hours to increase the likelihood of 
documenting such an episode. If the episodes are too infrequent to be detected by Holter monitoring 
with reasonable probability, the patient can be monitored for longer periods (e.g. a month) with an 
ambulatory event monitor that can record the heartbeat for longer periods. Under certain 
circumstances, a small device called a loop recorder may be implanted under the skin. This 
measures the electrical activity of the heart for periods of up to one year. 
The use of modalities such as Colour M Mode (CMM) and Tissue Doppler Imaging (TDI) improve 
the accuracy of the assessment of estimated filling pressures and diastolic function. However, 
patients in AF are often more difficult to assess for systolic and diastolic left ventricular function as 
the test may be complicated by irregular RR interval and a rapid ventricular rate. The use of TTE 




inadequate in terms of sensitivity and specificity for diagnosing left atrial appendage (LAA) thrombus 
(Omran et al., 1999; Troughton et al., 2003). 
4.5.3.2 Blood tests 
Depending on an individual’s medical history, a variety of blood tests may be performed, but in 
almost all cases the function of the thyroid gland is measured as hyperthyroidism may provoke AF. 
Other blood tests may include urea and electrolytes and, in the case where the patient presented 
with or experienced a form of chest pain, Troponin, a marker of damage to the heart muscle, may 
also be measured (Prystowsky, 2008). 
4.5.3.3 Transthoracic echocardiograph (TTE) 
Echocardiography or Echo utilises ultrasound waves to generate a moving picture of the heart, as seen 
in Figure 4.14. It is a non-invasive test and is performed by placing an echo “probe” on the chest wall. 
Transthoracic echocardiography (TTE) presents information about the size and shape of the heart, 
including two dimensional (2D) imaging and complete Doppler assessment of the valves. TTE is a 
quick, rapid, safe and relatively comprehensive assessment of cardiac structure and function and can 
be extremely useful in helping to define the underlying aetiology of AF as well as the potential risk of 
complications and is recommended for all subjects with AF (Fuster et al., 2006; Troughton et al., 2003). 
 
Figure 4.14: Apical four chamber view with transthoracic echocardiography 
Source: Lynch & Jaffe, 1999.  
Echo can also be performed as transoesophageal echo or as intra-cardiac echocardiography, each 




Table 4.17: Summary of the indices measured by different echocardiographic modalities 
 
Notes: *Radiofrequency ablation, valvuloplasty, PFO/ASD closure devices, LAA occlusion device insertion. ASD, atrial 
septal defect; LA, left atrium; LAA, left atrial appendage; LV, left ventricle; LVEF, left ventricular ejection fraction; PFO, 
patent foramen vale; RA, right atrium; RAA, right atrial appendage; SEC, spontaneous echo contrast. 
Source: Troughton et al., 2003.  
4.5.3.4 Transoesophageal echocardiogram (TEE) 
The use of TTE in visualising LAA thrombus is limited and, in those cases where TTE results are not 
definitive, it is often prudent to perform a transoesophageal echo (TEE) (Omran et al., 1999). While 
transthoracic echo is a non-invasive procedure, transoesophageal echo is a minimally invasive 
procedure, where a transoesophageal probe is passed down through the oesophagus and the heart 
is viewed from behind (Omran et al., 1999; Abdulla, 2009). The images produced are generally far 
clearer and the physician is able to view, amongst other things, blood clots, masses and tumours 
that may be located inside the heart. TEE can also be used to gauge the severity of valve problems, 
and to help detect infection of heart valves, certain congenital heart diseases like atrial septal defects 
(ASDs), and dissection of the aorta. TEE is often very useful in evaluating patients who have had 
strokes as a result of blood clots. The procedure may detect the responsible clot or thrombus inside 
the left atrium. 
Thrombus is thought to represent the main source of disabling cardio-embolic ischaemic strokes in 
patients with AF. Thrombus formation is believed to be the result of stasis of blood in the left atrial 
appendage (LAA). Thrombi are more often encountered in AF patients with ischaemic stroke than in 
those without stroke (Chimowitz et al., 1993). Although clinical management is based on the 
Echocardiographic modalities 
Transthoracic echo • LA dimensions and volumes 
• LV dimensions and volumes 
• LVEF 
• LV diastolic function 
• Valvular function 
 
Transoesophageal echo • LA/LAA: structure, function, SEC, and thrombus 
• RA/RAA structure, function and thrombus 
• Pulmonary vein anatomy/flows 
• Inter-atrial septum (PFO, etc.) 
• Ascending aorta and arch atheroma 
• Valvular function 
• Guide therapy* 
 
Intra-cardiac echo LA/LAA 
structure and function 
• LA/LAA thrombus 
• Inter-atrial septum 
• Pulmonary vein anatomy/flows 





presumption that thrombus formation requires continuation of AF for approximately 48 hours, thrombi 
have been identified by TEE within shorter intervals (Manning et al., 1995; Stoddard et al., 1995). 
On average, these thrombi cannot be seen on standard echo (TTE), as discussed. The sensitivity 
and specificity of TTE is often insufficient to visualize these thrombi (Lundstrom & Ryder, 1988) and, 
for this reason, performing TEE is a more reliable way to assess LAA function and detect thrombus 
formation (Fuster et al., 2006; Mugge et al., 1994). 
A series of studies has been conducted in patients with AF where TEE was performed during the 
conversion from AF back into sinus rhythm, to improve the understanding of the mechanical impact 
that cardioversion has on the heart and, in particular, the LA (Manning et al., 1989) and LAA (Grimm 
et al., 1993). These studies reveal that the flow velocities in the LAA were reduced at cardioversion 
and this was related to loss of organised mechanical contraction during AF (Chimowitz et al., 1993). 
4.6 ATRIAL PATHOLOGY AS A CAUSE OF ATRIAL FIBRILLATION 
Histopathological changes most frequently observed in AF are the loss of atrial muscle mass and 
atrial fibrosis. It is important to note that these changes may also be associated with other heart 
disease (Page, 1992). Page (1992) described how the onset of AF may be preceded by atrial fibrosis 
and that a concurrence of patchy fibrosis with normal atrial fibres may explain the non-homogeneity 
of conduction (Allessie et al., 2002). Aime-Sempe et al. (1999) propose that apoptosis may cause 
interstitial fibrosis, resulting in the atrial myocytes being replaced, a deficit of myofibrils, amassing of 
glycogen granules, and interference of cell coupling at the gap junctions (Polontchouk et al., 2001). 
This concludes that the loss of atrial muscle mass and atrial fibrosis is the most frequently observed 
changes in AF. 
4.6.1 The mechanism of atrial fibrillation 
The most popular theory, that AF consists of multiple wavelets of a functional re-entry nature, has 
existed since the 1960s (Veenhuyzen et al., 2004). More recently, strong evidence from both animal 
models as well as evidence in the human heart, indicates that wandering wavelets could circulate 
around electrically silent areas (Page, 1992). The mechanism of AF associated with CHF remains 
under consideration as both focal and re-entrant mechanisms have been observed in animal models 
with CHF (Everett & Olgin, 2007). These data support both a ‘focal’ triggering mechanism, involving 
automaticity, and multiple re-entrant wavelets and are not mutually exclusive, i.e. they may coexist 
(Allessie et al., 2002). 
Figure 4.15 denotes focal activation as indicated by the star and where the foci frequently lie within 





Figure 4.15: Posterior view of left atrium illustrating the focal activation mechanisms of 
atrial fibrillation 
Notes: LA = left atrium; PV = pulmonary vein; ICV = inferior vena cava; SCV = superior vena cava; RA = right atrium. 
Source: Konings et al., 1994. 
The resulting wavelets represent fibrillatory conduction, as seen in multiple-wavelet re-entry in Figure 
4.16, which illustrates these multiple-wavelets (indicated by arrows). These electrical impulses 
randomly re-enter tissue previously activated by the same or another wavelet, resulting in varied 
routes being traversed by the wavelets.  
 
Figure 4.16: Posterior view of left atrium illustrating the multiple wavelet mechanisms of 
atrial fibrillation 
Notes: LA = left atrium; PV = pulmonary vein; ICV = inferior vena cava; SCV = superior vena cava; RA = right atrium. 
Source: Konings et al., 1994. 
Jaïs et al. (1997) demonstrated how ablation could extinguish the source of AF, thus supporting the 
evidence of focal origin of AF (see Figure 4.17). Most frequently the source of the rapid atrial foci in 
AF originates from the pulmonary veins, but other areas of the heart have also been identified as the 
root of these foci, namely the superior vena cava, ligament of Marshall, left posterior free wall, crista 
terminalis, and coronary sinus (Jaïs et al., 1997; Fuster et al., 2006). Histological studies have 
ascertained that cardiac muscle, with conserved electrical function, stretches into the pulmonary 
veins (PV) and that, in patients with AF, the atrial tissue inside the pulmonary veins is documented 





Figure 4.17: Angiogram of a left inferior pulmonary vein depicting the source and exit of 
ectopic activity 
Notes: The electrogram showed characteristic changes in timing depending on the position of the recording 
catheter in the specific pulmonary vein. With an increasingly distal catheter position (toward the source), the 
spike was recorded progressively later during sinus rhythm (left-hand panel, arrows) and correspondingly 
earlier during ectopic activity (arrowhead). Conversely, in a proximal position at its exit into the left atrium (right-
hand panel), the spike was not as delayed during sinus rhythm (arrows) nor as precocious during ectopic 
activity (arrowhead).  
Source: Haïssaguerre et al., 1998. 
The application of radio-frequency energy at the source of ectopic activity eliminated the local spike 
during sinus rhythm and ectopic beats and atrial fibrillation on a short-term basis. The dotted lines mark 
the onset of the ectopic p wave, and 1-2 and 3-4 are bipolar recordings from the distal and proximal 
poles of the mapping catheter. A indicates near-field atrial activity. The radiograph (centre panel) 
shows the position of electrographic recordings inside the pulmonary vein at the source and exit. 
4.6.2 Atrial electrical remodelling 
Re-establishing and maintaining sinus rhythm in AF through either pharmacological or direct-current 
cardioversion is better achieved when AF has been present for 24 hours or less, while AF episodes 
sustained for longer periods make the restoration to sinus rhythm less likely and contribute to the truism 
that ‘atrial fibrillation begets atrial fibrillation’ (Allessie et al., 2001; Alessie et al., 2002; Haïssaguerre 
et al., 1998). The increasing propensity to AF and the progressive shortening of effective refractory 
periods with increasing episode duration, result in a phenomenon known as ‘electrophysiological 
remodelling’. In addition to the remodelling and the changes in electrical refractoriness, episodes of 
prolonged AF are shown to affect the contractile function of the atria negatively. After successful 
restoration of sinus rhythm, subsequent to a period of persistent AF, the recovery of atrial contraction 
can be delayed for days or even up to weeks. This has important implications for the duration of anti-




4.6.3 The pathophysiology of thrombus formation 
After successful cardioversion by any method, i.e. spontaneous, electrical, or pharmacological, 
stunning of the left atrial appendage (LAA) may result. This stunning of the LAA may account for an 
increased risk of thromboembolic events. Atrial stunning has shown to be at maximum effectiveness 
immediately after cardioversion and progressive improvement of the atrial transport function occurs 
from within days to three to four weeks after cardioversion. The rate of improvement is dependent on, 
among other things, the duration of the episode of AF. Clinical evidence has shown that more than 
80% of all thromboembolic events are likely to occur within the first three days after cardioversion and 
almost all such events occur within the first ten days after cardioversion. Data, including TEE studies, 
have not only shown evidence of LA/LAA dysfunction following conversion for AF but have also 
confirmed the tenacious nature of thrombus in a significant number of patients. These findings provide 
evidence for the need for anti-coagulants for patients both before and after successful cardioversion 
except where contra-indications may exist. In spite of the fact that stunning of the LAA may be 
negligible in some patients with certain associated conditions, or when the episode is of short duration, 
all patients with AF, including lone AF where the episode has lasted longer than 48 hours, should be 
anti-coagulated at the time of cardioversion and for at least four weeks afterwards (Fuster et al., 2006). 
Current clinical and therapy guidelines are founded on the hypothesis that, for thrombus formation to 
occur, the patient needs to be in AF for at least 48 hours. This was identified by Stoddard in 1995, but 
is not always the case (Lin et al., 2003). A study where echo was performed on 317 patients, indicated 
that thrombi may occur in patients within 48 hours of onset of AF (Stoddard et al., 1995; Manning et 
al., 1989). Reduced blood flow in the LAA/LA at the time of AF can often be recognisable on echo as 
“smoky” or “hazy” with variable echo density or spontaneous echo-contrast (SEC). SEC is associated 
with stasis and thrombus formation in AF (Agarwal & Venugopalan, 2001: 64), as noted in Figure 4.18. 
 
Figure 4.18: TEE of a mobile thrombus of approximately 2cm in diameter detected in the 
LAA 







Almost 50% of all elderly patients with AF suffer from hypertension, a key risk factor for the 
development of cerebrovascular disease. Almost 12% of these patients have carotid artery stenosis, 
although carotid atherosclerosis is not significantly more common in the patients who have AF and 
who have had a stroke, than in the patient group with no AF (Kanter et al., 1994). Each year the risk 
of stroke as result of atrial fibrillation ranges from 3% to 8%, but may be as high as 10 to15%, 
depending on the patients’ associated risk factors (Wolf et al., 1991). AF is known to increase a 
patient’s risk for stroke, but other factors, such as cardiac sources of embolism, atheromatous 
pathology in the proximal aorta and intrinsic cerebrovascular diseases cause up to 25% of strokes 
in patients. These data demonstrate that the pathogenesis of thromboembolic stroke is complicated 
(Miller et al., 1993; Bogousslavsky et al., 1990; Halperin & Hart, 1988). 
Figures 4.18 to 4.21 demonstrate a series of TEE ultrasound examinations performed on a patient 
over a period of almost six weeks. Figure 4.18 shows a thrombus in the body of the left atrium, as 
indicated by the arrow, and is closely associated with the mitral annulus, in the posterior part of the 
atrium. The thrombus was measured at about 12mm in size and was mobile.  
 
Figure 4.19: The first in a series of transoesophageal echocardiograms 
showing clot in the left atrium (LA)  
Source: Adapted from Collins et al., 1995. 
One week after the initiation of Warfarin therapy, TEE revealed that the thrombus persisted but had 





Figure 4.20: The second in a series of transoesophageal echocardiograms showing the 
left atrium (LA) and left atrial appendage (LAA) viewed with a TEE probe 
Source: Adapted from Collins et al., 1995. 
Three weeks after the commencement of Warfarin the thrombus continued to be seen, as indicated 
by the arrow in Figure 4.21.  
 
 
Figure 4.21: The third in a series of transoesophageal echocardiograms showing the left 
atrium (LA) and left atrial appendage (LAA) viewed with a TEE probe 
Source: Adapted from Collins et al., 1995. 
Finally, after 5.5 weeks of Warfarin therapy, complete thrombus resolution was observed, as seen 





Figure 4.22: The fourth in a series of transoesophageal echocardiograms showing the 
left atrium (LA) and left atrial appendage (LAA) viewed with a TEE probe 
Source: Adapted from Collins et al., 1995. 
4.8 ATRIAL FIBRILLATION AND MORTALITY 
Benjamin et al. (1998) reported, after evaluating the original cohort of the Framingham study, that 
the mortality rate in both men and women was higher in those with AF when compared to those who 
did not suffer from the arrhythmia (P<0.0001) (Benjamin et al., 1998). From 1980 to 1998, the age 
standardised death rate per 100 000 of the population in the USA who suffered from AF increased 
from 27.6 to 69.8 and by 1998, the number of patients with AF was almost double those patients 
who were in normal sinus rhythm (Fuster et al., 2006). 
The Kaplan-Meier mortality curves in Figures 4.23 and 4.24 identify the risk of death related to AF 
at the follow-up Framingham Heart Study in subjects 55-74 years old (Figure 4.23) and 74 to 95 
years (Figure 4.24) (Benjamin et al., 1998). The mortality rate, after adjustment for coexistent 
cardiovascular conditions and risk factors associated with AF, demonstrated a 1.5- to 1.9-fold 
increase in both men and women of various age groups. In addition, the first 30 days exhibited an 






Figure 4.23: Kaplan-Meier mortality curve from follow-up Framingham Heart Study of 
subjects aged 55 to 74 years, with AF 
Source: Benjamin et al., 1998. 
 
 
Figure 4.24: Kaplan-Meier mortality curve from follow-up Framingham Heart Study of 
subjects aged 74 to 95 years, with AF 
Source: Benjamin et al., 1998. 
A community-based cohort of 4618 adult residents of Olmsted County Minnesota (mean age 73.7 
years for men and 76.4 years for women, range 18 to 95 years, 51% men), was studied and those 
patients who had AF confirmed on ECG, documented between 1980 and 2000, were followed up 
until 2004 or death. Miyasaka et al. (2006) reported that, after first AF diagnosis 3 085 patients had 
died during a mean follow-up time of 5.3 years. Of these deaths, 761 occurred within the first four 
months after diagnosis and the other 2 324 during the follow-up period (Miyasaka et al., 2006). The 




months of 83% (95% CI 82% to 85%), compared to 77% (95% CI 76% to 78%) at one year, 63% 
(95% CI 62% to 65%) at three years, and 52% (95% CI 51% to 54%) at five years, respectively. 
Relative to age- and gender-matched general Minnesota population, the mortality risk for AF patients 
was substantially higher (log rank p<0.0001). Of the early deaths (within four months), coronary 
artery disease (CAD) accounted for 22% of deaths, while congestive heart failure (CHF), and 
ischaemic stroke accounted 14%, and 10%, respectively. Of the deaths after four months CAD, CHF 
and ischaemic stroke accounted for 15%, 16%, and 7%, respectively (Benjamin et al., 1998). 
The most common non-cardiovascular cause of death was malignancy, which accounted for 18% of 
the early deaths and 14% of the late deaths. Figure 4.25 illustrates on the left graph the survival for 
the entire study population of patients diagnosed with first atrial fibrillation and on the right the 
subgroup of survivors who lived beyond the first four months after the initial AF diagnosis compared 
with the age- and gender-matched general Minnesota (MN) population. 
 
Figure 4.25: Survival for AF patients compared with the age- and 
gender-matched general Minnesota population 
Source: Miyasaka et al., 2007. 
In more recent data by Chugh et al. (2014), it was demonstrated that less than one percent of the 
deaths reported by the World Health Organisation was associated with atrial fibrillation. This is 
demonstrated in Figure 4.26. However, it was stressed that AF is often accompanied by other 
medical conditions, for example, heart failure and myocardial infarction, and that in these cases, the 






Figure 4.26: The percentage of deaths attributed to atrial fibrillation 
and flutter in 2010 by region 
Source: Chugh et al. (2014). 
Chugh et al. (2014) also illustrated that, in 1990, the age-adjusted mortality rate for AF as measured 
by 100 000 of the population was 0.8 (95% UI, 0.5–1.1) for men and 0.9 (95% UI, 0.7–1.2) for women. 
By 2010 there was an almost two-fold increase in the age-adjusted mortality rate, which was 1.6 in 
men (95% UI, 1.0–2.4) and 1.7 in women (95% UI, 1.4–2.2). Figure 4.27 shows that mortality in AF 
was higher for women than for men and, also, that the mortality rate increased between 1990 and 
2005. 
 
Figure 4.27: The mortality associated with AF per 100 000 of the population  
from 1990 to 2010 




4.9 THE CLINICAL IMPACT OF ATRIAL FIBRILLATION 
Miller et al. (1993) found that, of 71 patients with non-rheumatic atrial fibrillation, who suffered 
ischaemic strokes, the cause of death was unknown in 17%; 18% were found to be non-cardio-
embolic; and 65% were cardio-embolic (Miller et al., 1993). This finding serves to confirm that the 
thromboembolic events at play in AF are complex and are related not only to atrial stasis, but also to 
systemic and local hypercoagulability, and may include endothelial dysfunction. There is a positive 
correlation between stroke in patients with AF and hypertension and it must be remembered that the 
risk of non-cardio-embolic strokes in patients with AF is further increased by hypertension.  
Progressing age is cited as increasing the risk of stroke in patients with AF, but this is a highly 
complex situation as atherosclerotic disease and the presence of plaques in the aortic arch are also 
associated with aging and these are independent risk factors of stroke in AF (Blackshear et al., 
1999). Increasing age, especially over 75 years in women with AF, when pooled with risk factors like 
hypertension, have a significant bearing on the risk for stroke (Feng et al., 2001). 
4.9.1 Silent or asymptomatic atrial fibrillation (AF) 
Silent or asymptomatic AF is believed to increase the risk of stroke in patients. In a study by Page et 
al. (2003), the investigators followed up patients in sinus rhythm who had a history of symptomatic AF. 
The double-blind study included 1 380 patients from the USA, 489 of whom received a placebo while 
the others received 35-125mg Azimilide daily for six to nine months. Within six months and before 
recurrence of symptomatic supra-ventricular arrhythmia, 17% of patients had experienced 
asymptomatic AF. 
In the three trials evaluating Azimilide using therapeutic doses (100 and 125mg), asymptomatic atrial 
fibrillation occurred in 13% of patients receiving Azimilide, compared to 18% receiving the placebo. At 
least one asymptomatic atrial fibrillation event was recorded within the first four weeks in 12% of 
patients. The Kaplan-Meier curve in Figure 4.28 estimates the proportion of patients with at least one 
asymptomatic event within four weeks and 26 weeks to be 13% and 21% respectively. 
After the evaluation of each of the four trials, the authors reported that asymptomatic atrial fibrillation 





Figure 4.28: Kaplan-Meier plot for time to first documented occurrence of asymptomatic 
atrial fibrillation in all patients receiving placebo from the four trials 
(n=303 patients receiving placebo) 
Source: Page et al., 2003. 
Finally, Krahn et al. (1995) report that patients with AF had almost double the mortality rate compared 
to patients in sinus rhythm (Krahn et al., 1995). The ACC/AHA/ESC 2006 guidelines for the 
management of patients with atrial fibrillation refers to large heart failure trials COMET and Val-
HeFT, that cite AF as a strong independent risk factor for mortality and morbidity. Heart failure (HF) 
promotes AF, while AF aggravates HF, resulting in a poor prognosis in individuals with either 
condition who then go on to develop the alternate condition. 
4.9.2 Atrial fibrillation and stroke  
Current data widely accepts that the long-term risk of stroke, heart failure and all-cause mortality is 
increased in patients who suffer from AF (Adams et al., 2008; Benjamin et al., 1998; Go et al., 2001) 
and that this risk is greater in women (Stewart et al., 2002). Pooled data from five randomized trials 
were analysed comparing Warfarin only to Warfarin and aspirin. The mean age at time of 
randomization was 69 years and the mean blood pressure was 142/82mm Hg. The results showed 
that patients younger than 65 years with no other predictive factors (15% of all patients) had an 
annual rate of stroke of 1.0%, (95% CI, and 0.3% to 3.0%). However, the annual stroke rate in the 
patients on Warfarin was 1.4%, compared to the control group, 4.5%. This represents a 68% risk 
reduction (95% CI, and 50% to 79%) (Kanter et al., 1994: 1449-57).  
Wolf et al. (1991) evaluated the effect which non-rheumatic atrial fibrillation, hypertension, coronary 
heart diseases, and cardiac failure had on the incidence of stroke in 5070 patients after 34 years of 
the Framingham study. The results were published in Stroke and the authors concluded that the 
age-adjusted incidence of stroke in the presence of coronary heart disease was more than doubled 




where both heart failure and hypertension existed, the increase in risk was fourfold (p<0.001). 
Patients with AF had a fivefold increase in risk of stroke (p<0.001). 
This landmark trial by Wolf et al. (1991) revealed that one in every six strokes occurs in a patient 
with atrial fibrillation and that, of all ischaemic strokes, 10% were as a result of emboli that originated 
as left atrial thrombi. When considering the patients who present with TIAs (transient ischaemic 
attack) or clinically “silent” stroke (detected by brain imaging), the rate of brain ischaemia 
accompanying non-valvular AF is observed to exceed 7% per year. Thus, the rate of ischaemic 
stroke among patients with non-valvular AF averages 5% per year; this is two to seven time that of 
people without AF (Wolf & Singer, 1997). 
Clinical stroke is not a complication for all patients with atrial fibrillation, and the stroke rate may vary 
more than 20-fold, from 0.5% per year for young patients without organic heart disease or lone atrial 
fibrillation, to 12% per year in patients with atrial fibrillation that have had previous stroke (Fuster et 
al., 2006). As noted, there is an increasing age-related risk of developing AF and it follows that the 
risk of stroke also increases with age. This was further demonstrated by Wolf et al. (1991) who 
reported that, in a study of participants aged 50 to 59 years old, the annual risk of stroke attributable 
to AF was 1.5%; this increased to 23.5% in those aged 80 to 89 years. Furthermore, in the 
Framingham Heart Study, in patients with rheumatic heart disease and AF, the risk of stroke was 
increased 17-fold compared with age-matched controls (Wolf et al., 1978) and the attributable risk 
was five times greater than in those with non-rheumatic AF (Wolf et al., 1991). The identification of 
risk factors for stroke in non-valvular atrial fibrillation is imperative, as it defends the need for 
individualised anti-thrombotic prophylaxis to be given according to stroke risk. 
Founded on the data from the Framingham study, the investigators further researched the risk 
associated with stroke. This research was performed over a ten-year period and the population of 
interest was stroke-free individuals at baseline and between the ages of 55 and 84 years (D'Agostino 
et al., 1994). The investigators established that the predictors for stroke were as follows: 
 Age. 
 Systolic blood pressure. 
 Diabetes mellitus. 
 Cigarette smoking. 
 Prior cardiovascular disease. 
 Atrial fibrillation. 
 Left ventricular hypertrophy. 
 Use of hypertensive medication. 
 
Wang et al. (2004) went on to describe the risk of stroke or death in patients with new onset of AF 




4.18. For their study, the population of interest included 705 individuals between the ages of 55 and 
94 years from the original and offspring cohorts of the Framingham Heart Study (Wang et al., 2004). 
Table 4.18: Step 1-5 of risk factors associated with risk of stroke in AF 
 
Source: Wang et al., 2004.  
The inclusion criteria were the following: 
 The patients had an occurrence of new-onset atrial fibrillation (AF). 
 They were not treated with Warfarin at baseline. 
 They had not had a stroke or transient ischaemic attack (TIA), or died within 30 days of AF 
diagnosis. 
 They were without rheumatic mitral stenosis. 
Wang et al. (2004) followed up these patients for a maximum of ten years (mean four years) and a 
five-year risk was estimated. To estimate five-year risk, a six-step scoring system was developed, as 
seen in Tables 4.18 and 4.19. For the purpose of the study, the investigators narrowed the predictors 
down from the previous scoring system and the following were included:  
 Age. 
 Gender. 
 Systolic blood pressure. 
 Diabetes mellitus. 
 Prior stroke or ischaemic attack. 




55-59 0  78-81 6 
60-62 1 82-85 7 
63-66 2 86-90 8 
67-71 3 90-93 9 
72-74 4 >93 10 
75-77 5   
Step 2 Gender 
 Male 0 
Female 6 
Step 3 Systolic BP 





Step 4 Diabetes Mellitus 
 No 0 
 Yes 6 
Step 5 Prior stroke of TIA 
 No 0 
 Yes 6 





Table 4.19: Step 6: Predicted five-year risk of stroke with atrial fibrillation (AF) 
 
Source: Wang et al., 2004.  
4.9.3 Atrial fibrillation and heart failure 
The first physician to describe an association between AF and heart failure, almost a century ago, 
was Paul Dudley who wrote:  
Since auricular fibrillation so often complicates very serious heart disease, its occurrence 
may precipitate heart failure or even death, unless successful therapy is quickly instituted 
(Anter et al., 2009). 
Anter et al. (2009) describe heart failure and atrial fibrillation as the new cardiovascular epidemic of 
the last decade. The incidence of heart failure in the United States has remained stable over the 
past 50 years. Up to 2009, 550 000 new patients were diagnosed with heart failure each year in the 
United States. However, the prevalence of heart failure has steadily increased, and it is estimated 
that more than five million Americans are affected by heart failure (Anter et al., 2009). 
In modern heart failure studies, the reported prevalence of AF ranges from 13% to 27%. In the 
Framingham Heart Study, 1 470 participants developed either AF or heart failure between the years 
1948 and 1995 and 26% of these participants developed both AF and heart failure (n=383). The 
investigators found that the prevalence of AF in patients with concomitant heart failure increased in 
parallel with the severity of the disease, ranging from as little as 5% in patients with mild heart failure 
to between 10% and 26% among patients with moderate heart failure and as much as 50% in 
patients with severe heart failure.  
The pathophysiological connection between heart failure and AF is not fully understood, but it is 
believed that AF may facilitate the onset and or progression of heart failure by a number of 
mechanisms, as seen in Figure 4.29. 
Total points 5-year risk 
(%) 






<1 5% 13 18% 23 44% 
2-3 6% 14 19% 24 48% 
4 7% 15 21% 25 51% 
5 8% 16 24% 26 55% 
6-7 9% 17 26% 27 59% 
8 11% 18 28% 28 63% 
9 12% 19 31% 29 67% 
10 13% 20 34% 30 71% 
11 14% 21 37% 31 75% 






Figure 4.29: AF and heart failure (HF): A vicious pathophysiological cycle 
        Notes: LA indicates left atrial; MR, mitral regurgitation; and TR, tricuspid regurgitation.  
Source: Anter et al., 2009. 
Despite the fact that the causative relationship between AF and heart failure has not been fully 
established, both conditions have common risk factors, including increasing age, diabetes, 
hypertension, valvular disease, ischaemic and non-ischaemic structural heart disease, and obesity. 
All of these risk factors are coupled with changes in myocardial cellular and extracellular function, 
alterations in electrophysiology, and neuro-hormonal modifications. These changes may all 
predispose the patient to both AF and heart failure.  
In 1913 the first case of a tachycardia-mediated cardiomyopathy was described in a young man with 
atrial fibrillation with a rapid ventricular response, heart failure and inexplicable LV dilation. A similar 
case was again described in 1937. However, this case of heart failure was reversed after restoration 
of sinus rhythm as illustrated in Figure 4.30. The most common cause of tachycardia-induced 
cardiomyopathy is AF where the increase in resting heart rate as well as the heart rate during 
exercises results in decreased diastolic filling time, and a reduction in cardiac output. In patients with 
AF the decrease in left ventricular filling during a short R-R interval is not completely compensated 





Figure 4.30: Ventricular reverse remodelling in an 18-year-old patient with  
unrecognised atrial tachycardia-induced cardiomyopathy 
Notes: EDD= end diastolic diameter, ESD= end systolic diameter, EF= ejection fraction, LVEF=left ventricular ejection 
fraction. 
Source: Anter et al., 2009. 
Anter et al. (2009) discussed a prospective study that included 344 patients who were in sinus rhythm 
with heart failure where the onset of AF was linked with a significant deterioration of their New York 
Heart Association (NYHA) functional class, peak oxygen consumption, and cardiac indices, as well 
as increased mitral and tricuspid regurgitation. As illustrated in Figure 4.30 patients may experience 
an improvement in cardiac output, exercise capacity, and maximal oxygen consumption once sinus 
rhythm is restored. 
Little consensus exists about the prognostic consequence of AF as an independent risk factor of 
adverse outcome in patients with coexisting heart failure, as demonstrated from the Framingham 
Heart Study which indicated that AF was associated with double the cardiovascular mortality when 


























































































Carson et al. 
V-HeFT I 1993 II–III 632 15 2.5 64 54 0.86 No 
V-HeFT II 
 
II–III 795 13 2.0 52 46 0.68 
 
Dries et al. 
SOLVD 
1998 I–IV 6517 6 2.8 23 34 <0.001 Yes 
Mahoney et al. 1999 III–IV 234 27 1.1 16 23 0.21 No 
Middlekauf et al. 
1985–1989 1998 III–IV 359 20 2.0 45 61 0.002 Yes 
1990-1991 1991 III–IV 395 19 1.5 29 48 0.0013 Yes 
1990–1993 1993 III–IV 391 24 2.0 25 34 0.09 No 
Mathew/DIGa 2000 I–IV 7788 11 3.0 32 43 0.0001 Yes 
Crijns/PRIME IIb 2000 III–IV 409 84 3.4 47 60 NS* No 
Køber/VALIANT 2006 I–IV 14703 15 3.0 20 37 <0.0001 Yes 
Swedberg et al 
COMET 
2005 II–IV 3029 20 5.0 37 42 NS No* 
 
Notes: SR indicates sinus rhythm; DIG, Digitalis Investigation Group; PRIME II, Prospective randomised study of Ibo 
amine on Mortality and Efficacy, *After adjustment for important prognostic variables. 
Source: Anter et al., 2009. 
However, these trials may serve to highlight that AF may be a negative prognostic marker in patients 
with systolic heart failure, and that the independent effect of AF on mortality is inversely related to 
the severity of the heart failure. Ahmed & Perry, as cited by Anter et al. (2009), found that, of the 944 
aged patients who were hospitalised with heart failure, those with onset of new AF had significantly 
higher mortality risk when compared with patients with no AF or those with chronic AF (HR, 1.41; 
95% confidence interval, 1.08 to 1.83). More than 80% of patients who were hospitalised with heart 
failure and found to have new-onset AF died within four years of discharge, compared with only 61% 





4.9.4 Other clinical consequences of atrial fibrillation 
Haemodynamic function during an episode of AF is affected by, among other things, loss of 
synchronous atrial mechanical activity within the ventricles. This may cause an irregular ventricular 
response (R-R interval), rapid heart rate, and impaired coronary arterial blood flow. Cardiac output 
may be markedly decreased through the loss of atrial contraction, particularly when the diastolic 
filling of the ventricles is impaired by other co-morbidities such as mitral stenosis, hypertension, 
hypertrophic cardiomyopathy (HCM), or restrictive cardiomyopathy. 
A persistently elevated ventricular rate during AF may adversely affect mitral regurgitation, resulting 
in a dilated ventricular cardiomyopathy (tachycardia-induced cardiomyopathy). In this instance, the 
cause of the cardiomyopathy is due to the heart failure rather than the AF, therefore the ability to 
control the ventricular rate may initiate the reversal of the myopathic process (Tracey, 1998). 
4.10 CONCLUSION 
Atrial fibrillation is a complex disease that affects millions of people around the globe. Data indicate 
that the number of people affected by the disease is increasing as the world’s population lives longer. 
Stroke, TIA, CHF and a myriad of other co-morbidities are associated with AF, some with deleterious 
outcomes for the patient. Early diagnosis may help to prevent some of the risks associated with AF 
and improve the outcome for the patient as it has been shown that there is an increased four-year 
mortality rate in patients with new onset AF.  
Management of this disease should focus not only on reducing symptoms but also on preventing 
complications linked with AF. Unfortunately, the management of the disease is in many instances as 
complex as the disease itself. This has prompted numerous approaches to treat and manage the 
disease, all with varying degrees of success. Chapter 5 explores these management options, in 
order to determine the risk associated with each, as well as the documented success rates and 
complications. This is important to ensure that the proposed model is a relevant option challenging 





CHAPTER 5: THE MANAGEMENT OF ATRIAL FIBRILLATION 
5.1 INTRODUCTION 
The management of atrial fibrillation is, at times, as complex as the disease itself. Each management 
option yields varying degrees of success. The standard of care for treating AF remains drug therapy 
which, in spite of a considerable number of drug trials, remains only marginally effective, with a large 
number of patients returning to AF.  
Chapter 5 is again a descriptive chapter which focuses on the treatment options for AF that are found 
in peer-reviewed journals, all with varying degrees of success and also with different risks attached. 
This chapter is not only of value to the non-medical reader, but also the medical reader who is not 
involved in the treatment of AF on a daily basis. The importance of this chapter is that it explores all 
the options that are available and narrows the choice down to two options, which can be used to 
build a cost effectiveness model with appropriate therapies.  
The topics covered in this chapter include the following: 
 Pharmacological treatment options. 
 Non-pharmacological options. 
 Surgery. 
 Various types of permanent pacemakers. 
 Radiofrequency ablation. 
 Cryoablation. 
5.2 BACKGROUND 
The management of patients with atrial fibrillation involves three therapeutic goals, namely, to control 
the heart rate (rate control), maintain sinus rhythm, and prevent thromboembolism. These goals are 
not mutually exclusive, and the risks and benefits of each treatment must be considered for each 
individual patient. The initial management decision involves primarily a rate control or rhythm control 
strategy. Under the rate control strategy, the ventricular rate is controlled with no commitment to 
restore or maintain sinus rhythm. On the other hand, the rhythm control strategy attempts restoration 
and/or maintenance of sinus rhythm. The latter strategy also requires attention to rate control. 
Depending on the patient's course, the strategy initially chosen may prove unsuccessful and an 
alternate strategy is then adopted. Regardless of whether a rate control or a rhythm control strategy 
is pursued, attention must also be directed to anti-thrombotic therapy for the prevention of 




5.3 TREATMENT OPTIONS FOR PATIENTS WITH ATRIAL FIBRILLATION 
The therapeutic choice of the physician depends on how symptomatic each individual patient is, as 
well as the specific symptoms each patient experiences. For example, where a patient with AF has 
a rapid ventricular response, the symptoms are often described as palpitations and treatment may 
be directed at the AV-nodal conduction system so as to decrease the rate. This can be achieved 
either through the use of drugs or, if this fails, through the implementation of non-pharmacological 
methods. 
In contrast, a patient with a controlled ventricular response during AF, who experiences shortness 
of breath and or fatigue, often benefits from the restoration and maintenance of sinus rhythm. 
Depending on the circumstances, an asymptomatic patient and, in particular, one with good rate 
control, may not need any further therapy other than the consideration for anti-coagulation 
(Prystowsky, 2008). 
Both drugs and catheter ablation are effective for rate and rhythm control strategies, but in some 
special circumstances surgery may be the preferred option. Regardless of the approach, the need 
for anti-coagulation is based on the risk of stroke and not on whether sinus rhythm is maintained. 
For rhythm control, drugs are typically the first choice and left atrial ablation is a second-line choice, 
especially in patients with symptomatic lone AF. In some patients, especially young people with very 
symptomatic AF, in whom sinus rhythm is preferable, radiofrequency ablation may be preferred over 
years of drug therapy. Patients with pre-operative AF undergoing cardiac surgery face a unique 
opportunity to undergo a Maze procedure at the time of surgery as there are otherwise only a few 
candidates for a stand-alone surgical procedure to treat AF by means of the Maze or LA ablation 
techniques. These approaches can, however, be an effective adjunct to coronary bypass or valve 
repair surgery to prevent recurrent post-operative AF. Because more than 95% of detected thrombi 
are found in the LAA, this structure is commonly removed from the circulation during cardiac surgery 
for patients who are at risk of developing post-operative AF, although this has not been proven to 
prevent stroke (Healey et al., 2005b). 
5.3.1 Primary prevention 
In spite of the fact that AF is a disease with an incidence of up to 10% per annum, there are no landmark 
primary prevention studies as there has been with, for example, cholesterol management. Young-Xu 
et al. (2004) report, in a study of 449 patients with CAD who were on statins for five years, that there 
was a reduction in the incidence of AF, while other studies have suggested that statins may also protect 
one against AF (Young-Xu et al., 2004; Siu et al., 2003). While this has not been observed with the 
use of other lipid-lowering drugs, the data is deemed inadequate to recommend statins for primary 




The use of angiotensin receptor antagonists in the CHARM and LIFE studies showed that the 
incidence of AF was reduced in patients who were hypertensive with left ventricular hypertrophy 
(LVH) and who had symptomatic HF (Wachtell et al., 2005; Maggioni et al., 2005; Olsson et al., 
2006). 
Similar results were found during the secondary analysis of placebo-controlled trials using 
Angiotensin Converting Enzyme (ACE) inhibitors for treatment (Pedersen et al., 1999; Alsheikh-Ali 
et al., 2004). Data from eleven clinical trials, which included more than 56 000 patients with various 
cardiovascular diseases, suggested that the use of Angiotensin Receptor Blockers (ARBs) and or 
ACE inhibitors has the propensity to diminish the episodes and re-emergence of AF (Healey et al., 
2005a). 
5.3.2 Rate vs. rhythm control 
While the long-term goal for patients with symptomatic AF, lasting many weeks, may be the 
restoration of sinus rhythm, the initial treatment is often anti-coagulation and rate control. When the 
duration of AF exceeds 48 hours or is not known and the patient requires electrical cardioversion, 
the guidelines suggest that they may benefit from short-term anti-coagulation even if long-term anti-
coagulation is not required. Where rate control does not offer adequate symptomatic relief for the 
patient, the restoration of sinus rhythm becomes the long-term goal. Patients who suffer from 
hypotension or whose heart failure is worsened due to episodes of AF often require early 
cardioversion. In contrast, older patients whose symptoms improve through rate control may not 
require attempts to restore sinus rhythm. There are situations such as thyrotoxicosis or post-cardiac 
surgery, when the initiating pathophysiology of AF is reversible and, under these conditions, no long-
term therapy may be necessary (Fuster et al., 2006: 25). 
Large randomized trials investigating both rhythm and rate control in AF have shown similar findings, 
as seen in Table 5.1. In the RACE trial (Rate Control vs. Electrical cardioversion for persistent AF) 
the investigators did not find rate control inferior to rhythm control for the prevention of death and 
morbidity in patients with AF, while the AFFIRM trial (Atrial Fibrillation Follow-up Investigation of 
Rhythm Management) showed no difference in stroke or mortality rate between patients assigned to 
either rate or rhythm control. It is thought that clinically silent recurrences of AF in asymptomatic 
patients who are treated with anti-arrhythmic drugs, but in whom anti-coagulation therapy is 
withdrawn, may be responsible for thromboembolic events after the withdrawal of the anti-
coagulation, and that patients who are at high risk for stroke may require anti-coagulation regardless 
of whether the rate control or rhythm control strategy is chosen. It is important to remember that the 
AFFIRM study was not designed to address this question (Sherman et al., 2005: 194). 
Patients with similar health status, for example AF, may experience an entirely different quality of life 




agree that treatment must be tailored to each individual, depending on the nature, intensity, and 
frequency of symptoms, patient preferences, co-morbid conditions, and the ongoing response to 
treatment in many patients, medications that use both anti-arrhythmic and rate-controlling effects 
may be necessary. A further option to be considered in order to maintain sinus rhythm in selected 
patients who failed to respond to anti-arrhythmic drug therapy may be catheter ablation (Oral et al., 
2006). 










































































Rate Rhythm Rate Rhythm 
AFFIRM 
(2002) 
4 060 NR 3.5 70±9 
35% vs. 63% 
at 5 yrs. 
88/202
7 







10% vs. 39% 
at 2.3 yrs. 







10% vs. 56% 
at 1y 
0/125 2/127 2/125 2/127 
STAF 
(2003) 
200 6±3m 1.6 66±8 
11% vs. 26% 
at 2yrs. 






1.7 61±11 NR vs. 64% 1/101 1/104 1/101 3/104 
Notes: Comparison between rate and rhythm control groups. Approximately one third of patients were 
enrolled with first episode of Atrial fibrillation (AF).AFFIRM indicates Atrial fibrillation Follow-Up Investigation 
of Rhythm Management; ECV, internal or external electrical cardioversion; HOT CAFÉ, How to Treat 
Chronic Atrial fibrillation; IA, quinidine, procainamide; IC, propafenone and/or Flecainide; NR, not reported; 
PIAF, Pharmacological Intervention in Atrial fibrillation; RACE, Rate Control Versus Electrical Cardioversion 
for Persistent Atrial fibrillation; SR, sinus rhythm; STAF, Strategies of Treatment of Atrial fibrillation; and TE, 
thromboembolism. 
Source: Sherman et al., 2005. 
5.3.3 Pharmacological rate control during atrial fibrillation 
It has been demonstrated that drugs with a mode of action aimed at prolonging the refractory period 
of the AV node are by and large effective in rate control. This is because the functional refractory 
period of the AV node during AF is inversely correlated with the ventricular rate. No evidence exists 
to prove that controlling the rate pharmacologically results in any unfavorable effect on LV function. 
It is important to note that ensuing bradycardia and heart block, unwelcome side effects of beta 




be present specifically in patients with paroxysmal AF, and more particularly in the elderly. 
Combinations of drugs from different pharmacological classes may be required to achieve rate 
control in both acute and chronic situations. Patients who develop symptomatic bradycardia may 
require permanent pacing as discussed in section 5.10. When optimal pharmacological measures 
fail to control the patient’s symptoms, non-pharmacological treatment options should be considered. 
5.3.4 Pharmacological cardioversion 
While a sizeable segment of patients with recent-onset AF revert spontaneously to sinus rhythm 
within 24 to 48 hours, it is less likely to occur in patients whose AF has been present for longer than 
seven days (Azpitarte et al., 1997). Cardioversion may be achieved through the use of 
pharmacological agents, and current data suggests that this is most effective when the drug therapy 
is initiated within seven days after the onset of an episode of AF (Suttorp et al., 1990). Thereafter, 
the efficaciousness of pharmacological cardioversion is noticeably diminished in these patients 
(Kochiadakas et al., 1999). 
The use of beta blockade or non-dihydropyridine calcium channel blockers may be encouraged in 
patients with atrial flutter to prevent rapid AV conduction (Feld, 1990; Leitch et al., 1990). When 
deciding whether to initiate anti-arrhythmic drug therapy in hospital or on an outpatient basis for the 
pharmacological cardioversion of AF the potential for serious adverse effects, including torsade’s de 
pointes exists and must be considered. Fuster et al. (2006) state that a large majority of studies 
examining pharmacological cardioversion of patients with AF, except those involving low-dose oral 
Amiodarone, were conducted on hospitalised patients. It should be considered that frequent and 
repeated hospitalisation not only has a financial impact for the patient but also an effect on the quality 
of life for the patient (Alboni et al., 2001). 
5.3.5 Prevention of thromboembolism 
The risk of stroke in atrial fibrillation has been discussed in Section 4.8.2. In the SPAF trial (Stroke 
Prevention in Atrial fibrillation III) the yearly incidence of ischaemic stroke in patients with paroxysmal 
AF, who were treated with aspirin, was comparable with those who were in permanent AF (3.2%:3.3%) 
(Hart et al., 2000). The annual stroke rate in patients with a previous history of TIA or stroke, when 
treated with aspirin, had subsequent stroke rates of 10% to 12% per year. Moreover, it is now accepted 
that prior thromboembolism, increasing age, diabetes mellitus, hypertension and heart failure are 
recognized as independent risk factors for ischaemic stroke associated in non-valvular AF (Hart et al., 
1999). These patients benefit substantially from adjusted-dose oral anti-coagulation (Blackshear et al., 
1996). It has been argued that prior TIA or stroke remains the greatest independent predictor of stroke, 
and that all patients with prior TIA or stroke should be anti-coagulated save those in whom contra-




people are at increased risk of bleeding associated with anti-coagulant use and to err on the side of 
caution with older patients constitutes effective stroke prophylaxis (Landefeld & Goldman, 1989; 
Moulton et al., 1991). 
The goal of anti-coagulation therapy with Warfarin is to achieve a therapeutic international normalized 
ratio (INR) range of between two and three, and this is a suitable target for most patients with atrial 
fibrillation. These are tabulated in Table 5.2. Values of less than 2.0 are associated with an increased 
incidence of thromboembolic events while INR values exceeding 4.0 are linked to an increased risk of 
bleeding complications (Cox et al., 1996). A meta-analysis by Cox el al demonstrates the outcomes 
for patients who received Warfarin had a better outcome than the control group (Figure 5.1). 
Table 5.2: ACC/AHA/ESC guide to anti-thrombotic therapy for patients with AF 
Risk category  Recommended therapy 
No risk factors Aspirin, 81 to 325mg daily 
One moderate-risk factor 
Aspirin, 81 to 325mg daily, or 
Warfarin (INR 2.0 to 3.0, target 
2.5) 
Any high-risk factor or more than 1 
moderate-risk factor 
Warfarin (INR 2.0 to 3.0, target 
2.5) 
Source: Fuster et al., 2006. 
 
Figure 5.1: A comparison of studies demonstrating the use of 
Warfarin in AF for stroke risk reduction 
Source: Cox et al., 1996. 
5.4 THE NON-PHARMACOLOGICAL TREATMENT OF ATRIAL FIBRILLATION 
The unpredictability of the efficacy, as well as the potential toxicity and side effects associated with 




alternatives to pharmacological therapies for the prevention and control of AF. These therapies are 
discussed below. 
5.4.1 Direct current (DC) cardioversion 
Cardioversion (also known as electrical cardioversion, "direct-current" or DC cardioversion), is a 
short procedure where a timed electrical shock is delivered to the heart through the chest wall in an 
attempt to convert an abnormal heart rhythm back to a normal rhythm. This can be achieved by 
using either paddles or special electrodes placed on the front and back of the chest. The procedure 
is usually performed in a hospital environment with a cardiologist, a nurse and/or an anesthesiologist 
present. The aim of DC shock as shown in Figure 5.2 is to disrupt the abnormal electrical circuit(s) 
in the heart and to restore to sinus rhythm.  
 
Figure 5.2: ECG of patient undergoing DC shock for atrial fibrillation 
Source: Shilling, 2009a. 
The shock is believed to cause all the heart cells to contract simultaneously, thereby interrupting and 
terminating the abnormal electrical rhythm (typically fibrillation of the atria) without damaging the 
heart.  
If a patient presenting with AF is not on anti-coagulants such as Warfarin, and the episode of AF is 
less than 48 hours, cardioversion may take place after an echo has established that there are no 
evident thrombi in the LAA. Patients in whom the episode is longer than 48 hours, or who don’t know 
when the onset was, or where a clot is seen on echo, should first be anti-coagulated for a few weeks 
before attempting cardioversion. 
For new-onset AF, electrical cardioversion is usually effective at converting the heart back into 
normal sinus rhythm, but it may have a low success rate in keeping it there, and reversion to AF 
after cardioversion is common, with 50% of patients being in AF only six weeks after cardioversion. 
The number of patients reverting to AF after cardioversion increases as time goes by, which may 
necessitate multiple attempts to electrically cardiovert the patient. The most common problem after 
a DC cardioversion is painful skin burns. The procedure itself is safe, but it is associated with 
between 1% and 7% of complications of stroke in patients who are not adequately anti-coagulated 




nor is it a cure for AF. The benefit of performing cardioversion is that it is a relatively simple and easy 
procedure to perform which is successful in restoring sinus rhythm in 60-95% of patients, and 
particularly in patients where the AF has been induced by a reversible cause such as a chest 
infection (Shilling, 2009b; Russo, 2006). 
5.4.2 Surgery  
Based on the hypothesis that the chief mechanism for AF is a re-entry circuit in the LA, the first 
surgical procedure for the treatment of AF, known as the Cox Maze, was performed at the St. Louis' 
Barnes Hospital in 1987 (Cox et al., 1996). 
The purpose of the surgical approach is to eradicate macro re-entrant circuits in the atria (see Figure 
5.3) while conserving the function of the sinus node and maintaining atrial transport functions. This 
is achieved through creating transmural lesions in the atria to create barriers to these macro re-
entrant circuits and thereby preventing sustained AF (Cox, 2004). 
 
Figure 5.3: Two-dimensional representation of the original 
Maze I procedure for atrial fibrillation 
Source: Cox et al., 1996. 
The evolution of the surgical technique has resulted in an accepted theory which purports that 
creating transmural lesions to isolate the pulmonary veins and then joining the scar lines to the mitral 
valve annulus results in electrical barriers in the atria which prohibit macro re-entrant circuits from 
developing. These macro re-entry circuits are responsible for atrial flutter or AF becoming sustained 
(Cox et al., 1995). 
The long-term success rates of the Maze procedure are reported at between 70% and 95% over a 
10 to 15-year follow-up period in patients undergoing mitral valve surgery (Damiano et al., 2003; 




that when, at the time of surgery, the LAA is eliminated, the risk of thromboembolism post-surgery 
is significantly reduced. 
The Cox-Maze procedure has a very high success rate and the associated adverse events, namely 
death (less than 1% when performed as an isolated procedure), bleeding, atrial-oesophageal fistula, 
complete heart block (requiring permanent pacing), and other arrhythmia is low, but the need for 
cardiopulmonary bypass means that the Maze operation has not been widely accepted and is not 
performed routinely for patients undergoing cardiac surgery. While not commonly performed, the 
Maze procedure has promoted investigation into less invasive procedures and, in particular, 
catheter-based procedures (Gillinov & McCarthy, 2004). 
5.4.3 Regulation of atrio-ventricular nodal conduction by pacing 
5.4.3.1 The case for right ventricle (RV) apex pacing 
Some patients with AF who are on medication develop bradycardia at rest while others are particularly 
sensitive to the variability of R-R interval, which increases their symptoms. Both of these groups of 
patients may benefit from ventricular pacing, which prolongs the AV nodal refractory period as a result 
of concealed retrograde penetration, thus reducing the longer ventricular cycles which may reduce the 
number of short ventricular cycles related to rapid AV conduction during AF. By pacing at roughly the 
mean ventricular rate during spontaneous AV conduction, the ventricular rhythm during AF is regulated 
(Wittkampf et al., 1988). 
5.4.3.2 The case for atrial-based pacing or dual-chamber pacing 
Other studies have concluded that atrial or dual chamber pacing rather than RV apex pacing may be 
the preferred method of pacing in patients with sinus node dysfunction and normal AV conduction with 
AF (Connolly et al., 2000: 1998). The rationale underpinning atrial pacing as opposed to ventricular 
only pacing is that atrial pacing thwarts bradycardia-induced dispersion of repolarisation and 
suppresses atrial premature beats and is supported by both the electrical and mechanical theory in 
preventing the onset of AF. Atrial pacing prevents potential triggers for AF such as bradycardic 
episodes and ectopic atrial beats. Atrial and dual-chamber pacing promote AV synchrony, thus 
preventing retrograde VA conduction. Atrial-based pacing prevaricates the stretching of the atria, which 
is as a result of increased atrial pressure associated with atrioventricular AV desynchrony (Lamas et 
al., 2002). 
Knight et al. (2005) report on five prospective randomized trials which compare single chamber 
pacing, either atrial or ventricular to dual-chamber pacing for evidence on AF in patients with 
symptomatic bradycardia, the results of which demonstrate superiority for atrial- based pacing for 




dual-chamber pacemakers is ≤3% when compared to an incidence of between 6% and 15% per 
year in patients with single-chamber ventricular pacemakers (VVI) (Knight et al., 2005). 
In the presence of SA node dysfunction and concomitant disease of the AV conduction system and 
where dual-chamber pacing is unavoidable, the evidence is less clear that atrial-based pacing is 
superior. Andersen et al. (1997) reported on a study with a mean follow-up time of 3.3 years in patients 
with sick sinus node disease, who were randomized to receive either a single-chamber atrial 
pacemaker (AAI) or single-chamber ventricular pacemaker (VVI), which found that the atrial-based 
pacing was linked with a lower risk of AF and stroke than ventricular-based pacing, although there was 
no difference in mortality or CHF (Andersen et al., 1997). They continued to follow-up with the patients 
for eight years, at which time their findings showed that the cumulative incidences of atrial fibrillation 
and chronic atrial fibrillation were significantly lower in the atrial group compared with the ventricular 
group (0·54 [0·33-0·89], p0·012 and 0·35 [0·16-0·76], p0·004, respectively). While thromboembolic 
events occurred in thirteen patients in the atrial group, this was half the occurrence in the ventricular 
group (0·47 [0·24-0·92], p0·023). The heart failure was less severe in the atrial group compared with 
the ventricular group (p<0·05). In spite of these data, Andersen et al. (1997) concluded that the value 
of pacing as a primary therapy for prevention of recurrent AF had not been proven (Wozakowska-
Kaplon et al., 2004). 
5.4.3.3 The case for bi-ventricular pacing (cardiac resynchronisation therapy) 
Leon et al. (2002) describe distinct improvement in patients with impaired LV function not due to 
tachycardia, who had a bi-ventricular pacemaker implanted. The results of the study conducted on 
20 patients showed an improvement in the NYHA functional classification of 29% (p=0.001), as seen 
in Figure 5.4.  
 
Figure 5.4: Improvement in New York Heart Association (NYHA) functional class  
after upgrade from a RV pacemaker to a biventricular pacemaker (BVP) 




The left ventricular ejection fraction (LVEF) improved by 44% (p=0.001), with a simultaneous 
reduction in the end-systolic diameter of 8.5% (p=0.01) and a decrease in the LV diastolic diameter 
of 6.5% (p=0.003). The number of hospitalisations also showed a decrease of 81% (p=0.001), while 
the Minnesota Living with Heart Failure survey scores showed an improvement of 33% (p=0.01). 
The current recommendations from the ACC/AHA/ESC guidelines are that for these patients bi-
ventricular pacing with or without defibrillator capability should be considered. It should also be 
considered that patients with HF and a right ventricular pacing system that have undergone an AV 
node ablation should be upgraded to a bi-ventricular device (Fuster et al., 2006; Leon et al., 2002). 
Data presented at the Late Breaking Clinical Trials at the 32nd Heart Rhythm annual scientific 
sessions in San Francisco in May 2011, showed that there was indeed clinical benefit of cardiac 
resynchronization therapy compared with right ventricular apex pacing for improving heart failure in 
patients with AF who were undergoing atrioventricular junction ablation. 
The study, known as the APAF study, was a prospective, multi-centre study which included 186 
patients. All patients had successfully undergone an AV node ablation and were randomized to 
receive either the traditional RV apex pacing (n=89) or echo-guided CRT (n=97). The median follow-
up was 20 months and the CRT group had 26% reduction in primary endpoints for heart failure, 
worsening of heart failure and hospitalisation for heart failure. Total mortality was similar in both 
groups. The CRT mode was the only independent predictor of absence of clinical failure during 
follow-up (Brignole, 2011). 
5.4.3.4 The case for internal atrial defibrillators  
As discussed in Section 5.3.1, performing electrical cardioversion in patients with AF is highly effective 
for restoring sinus rhythm, but, as previously discussed, maintaining sinus rhythm remains a challenge 
in spite of the use of anti-arrhythmic drugs and often the patient requires multiple shocks over a period 
of time. The time from onset of AF to cardioversion is important, especially in patients who are not 
adequately anti-coagulated to reduce the risk of thromboembolism (Geller et al., 2003). 
The use of implantable cardioverter defibrillators (ICD) have, since first human implant in February 
1980, shown success in treating ventricular tachycardia. This resulted in an interest in internal 
cardioversion for AF (Geller et al., 2003). 
An implantable defibrillator consists of two parts: Firstly, the implantable atrial defibrillator/generator, 
which keeps track of the heart rhythm and sends out electrical pulses and shocks when needed and, 
secondly, a set of wires called leads or electrodes that are placed inside the heart and are connected 
to a generator. The power source or generator is implanted subcutaneously in the chest or abdomen 






Figure 5.5: A schematic view of the implanted METRIX device, showing the two atrial 
shock leads, one in the right atrium and one in the coronary sinus, and the right 
ventricular lead for shock synchronisation and pacing 
Source: Geller et al., 2003. 
A number of different types of implantable defibrillators are available at present. The greatest number 
are used for the treatment of ventricular arrhythmia, but dual-purpose defibrillators exist, and these 
can treat either atrial or ventricular fibrillation by means of anti-tachy pacing (ATP) before delivering 
either a low or high energy shock as programmed. 
The programming of an internal cardioverter defibrillator is specific and tailored to each individual 
patient’s underlying disease and takes into account the type of arrhythmia, the cycle length or rate 
of the arrhythmia and the defibrillation threshold of the patient. The aim of the ICD, which is implanted 
for ventricular arrhythmia, is to prevent life-threatening arrhythmia, where ATP is unable to stop the 
arrhythmia. After a predetermined number of ATP attempts, the device is set to deliver a shock or 
shocks until sinus rhythm is restored. 
Atrial fibrillation is not a fatal arrhythmia and the programming of an ICD for AF allows for greater 
flexibility. The different modes are as follows: the off mode, monitor only, pacing only, patient-
activated mode and automatic mode. In general, the implantable devices constantly monitor the 
heart rate and, when programmed to monitor only, the devices monitor all episodes of AF. This 
valuable information can be downloaded to a disk or printed out for evaluation by the patient’s 
physician. When programmed in automatic mode, the device continues to monitor the episodes of 
AF, but will deliver a defibrillation shock when AF is confirmed, based on what the device has been 
programmed to deliver, unless interrupted by a conventional pacemaker magnet which will prevent 
the shock from being delivered. In the pacing-only mode, the device paces the atria as programmed 
by the physician but will not deliver any defibrillation therapy. Finally, the patient-activated mode 
allows the patients greater control of the management of their AF and, with the use of a pacemaker 




If the patient activator confirms the presence of AF, it will deliver a shock to terminate the arrhythmia. 
The benefit of this mode is that the patients can time their own shock so as not to occur at an 
inopportune moment. The downside to this device is that when the patients are cardioverted in a 
hospital setting by a physician, they are generally given a form of sedation to tolerate the discomfort 
of the shock. With the use of an ICD, they do not have this benefit. 
For patients who suffer from paroxysmal AF, the device offers a degree of control over their 
arrhythmia and this may result in fewer emergency room visits and hospitalisations. However, the 
limitations associated with this approach include not only the significant discomfort of the DC shock, 
but also the likelihood of concomitant anti-arrhythmic drugs to prevent excessive shocks.  
Lévy et al. (1997) in a prospective, multi-centre trial investigated the efficacy and safety of low energy 
shocks during atrial fibrillation in a diverse cohort of patients by delivering synchronized shocks 
between two electrode catheters, one placed in the right atrium and the other in the coronary sinus. 
The defibrillation protocol started with a test shock of 20V (volts), and the shocks increased in 40V 
increments with a maximum of 400V or until sinus rhythm was restored. The greatest success (92%) 
was achieved in the patients in whom AF was paroxysmal, requiring a mean of 2.0 joules of energy 
(229V) to restore sinus rhythm, while only 70% of the patients with chronic AF were cardioverted 
with an average of 3.6 joules of energy required to achieve cardioversion (Lévy et al., 1997). 
A prospective trial was conducted by Daoud et al. (2000: 1407) to evaluate the safety, efficacy, and 
patient acceptance of the Metrix Atrioverter in 105 patients (75 men, 30 women; mean age 59 years) 
in an ambulatory setting. All patients had recurrent AF and were symptomatic and medically refractory. 
Of the 105 patients, 27 had no structural heart disease, while the other 78 patients had a combination 
of congenital heart disease, valvular disease, CHF, CAD or cardiomyopathy. The mean LVEF was 
57% (±8) and the mean follow-up period was 11.7 months. 
The treatment efficacy was measured as 85% and the atrial defibrillators delivered 5 523 shocks, of 
which the majority (4 261) were delivered for AF induction and defibrillation testing. The remaining 
shocks were as follows: 365 shocks were delivered during ambulatory treatment and a further 897 
were delivered before the patient's transition to ambulatory treatment to treat episodes of AF. 
Out of the 105 patients enrolled in the study, fifteen had their devices explanted for the following 
reasons: three patients experienced lead complications; one patient had pacemaker site infection; 
and eleven other patients’ devices were explanted for the inadequate control of AF. It is reported 
that, in spite of the fact that some patients reported moderate discomfort, the overall satisfaction 
among patients was high (Mekel et al., 2006). At one-year follow-up, efficacy of the defibrillator in 48 
patients was 90% and 70% of the AF episodes were successfully treated with a single shock.  
Timmermans et al. (1999a) propose that the use of a low energy shock during internal atrial 




cardioversion, as demonstrated by a group of twelve patients who experienced 213 episodes of AF 
of which 92% were successfully treated without the use of intravenous sedation (Timmermans et al., 
1999b). 
In another study, Geller et al. (2003) reviewed the outcome of implantable atrial defibrillators in 106 
patients for a period of seven to 66 months (median 40 months) after implantation. The results 
indicated that in 13% (n=14) of patients the device was used to monitor the arrhythmia, but no shocks 
were delivered, while in 50% of patients (n=53) the devices were either explanted or turned off and 
only 37% of the patients (n=39) received therapy from the devices. The most significant reasons for 
the discontinuation of the therapy were the patient intolerance of multiple cardioversion shock 
(n=15), the increase in defibrillation thresholds (n=7), bradycardia requiring pacing (n=12) and early 
depletion of the devices’ battery. The investigators concluded that a critical limitation of the 
implantable atrial defibrillators, which was unrelated to the efficacy of the device, was the one Joule 
discharge from the device, which was not well tolerated by most patients and that technical 
improvements were required to assure long-term use (Geller et al., 2003). 
The investigators suggested that implanted devices had limited utility, with the exception of patients 
with LV dysfunction, who are candidates for implantable ventricular defibrillators. The use of 
implantable atrial defibrillators is feasible, but the patient selection criterion remains crucial. Finally, 
the investigators commented that for patients who were possible candidates for atrial cardioverters 
because of infrequent episodes of poorly tolerated AF, the option for catheter ablation was an 
alternative treatment option. 
5.4.3.5 The case for atrioventricular nodal ablation 
A further way to treat patients with AF is to use radiofrequency ablation to render the AV node 
ineffective. This procedure results in complete heart block for the patients, i.e. it prevents conduction 
of impulses from the atria to the ventricles. A permanent pacemaker is implanted, either as a single 
chamber with a single lead in the ATP apex (VVI), or as a bi-ventricular pacemaker with a second 
lead that is passed down the coronary sinus to the surface of the left ventricle, via the great cardiac 
vein. 
Wood et al. (2000) describe the meta-analysis of 21 studies that included 1 181 patients with 
medically refractory atrial tachyarrhythmia’s, where 97% of these were primary atrial fibrillation. The 
focus of the study was to measure nineteen clinical outcomes including quality of life, ventricular 
function, exercise duration, and healthcare use in patients who had undergone AV node ablation 
and permanent pacemaker implantation (Wood et al., 2000). Wood et al. (2000) demonstrated 
improved quality of life and left ventricular function after AV nodal ablation and insertion of a 
permanent pacemaker for patients with AF who were refractory to medical therapy and for whom 




Table 5.3: Summary of findings from the 21 studies included in the meta-analysis on AV node 












Olgin  54 24 months - - Improved Improved 4 (7) 2 (4) 
Geelen  235 20 months - - - - 0 6 (2) 
Wong  11 3 months - - - - 0 0 
Jackman  17 8 months - - - - 3(18) 1(6) 
Heinz  10 48 days - Improved - -   
Bubien  44 6 months - - Improved -   
Twidale  14 9 months - Improved - - 1(7)  
Brignole 22 3 months Improved - Improved - 1(4)  
Darpo 220 31months - - - - 31(14) 11(5) 
Natale 14 12 months - Improved Improved -   
Kay 156 12 months - - Improved Improved 23(15) 5(3) 
Brignole 43 6 months - - Improved - 0(0) 0(0) 
Fitzpatrick 107 2.3 years - - Improved Improved 17(16) 2(2) 
Jensen 50 17 months - - Improved Improved 6(12) 2(4) 
Morady 20 12 months - - - - 0(0) 0(0) 
Edner 29 216 days - - - -   
Geelen 11 6 months - Improved Improved - 0(0) 0(0) 
Buys 25 7 months - - - - 0(0) 0(0) 
Lee 30 6 months Improved Improved Improved Improved 0(0) 0(0) 
Twidale 22 14 months Improved Improved Improved Improved 2(23) 2(9) 
Jordaens 47 25 months - - - -  0(0) 
Notes: QOL= quality of life; Sx= symptoms; improvement = improvements or favourable change after 
ablation and pacing; = no change after ablation and pacing. 
Source: Wood et al., 2000. 
Anter et al. (2009), in reference to a paper by Manolis et al. (1998), described 46 patients who 
underwent radiofrequency ablation of the AV node and subsequent permanent pacemaker 
implantation (Anter et al., 2009). All of these patients were refractory to medical therapy and had a 
rapid ventricular response to their atrial tachyarrhythmias. At the start of the study the mean left 
ventricular ejection fraction (LVEF) was measured at 42% (±16%). The patients were followed up 
for two years and the LVEF improved to a mean of 50% (±14%). The improvement of the LVEF was 
significantly better in the sub-group of patients with heart failure, who had a mean LVEF at the start 




a concurrent improvement in NYHA functional class from 2.7(±0.6) to 1.4(±0.8) (p<0.001) (Manolis 
et al., 1998). 
The ACC/AHA/ESC guidelines indicate that patients with symptoms or tachycardia-mediated 
cardiomyopathy related to rapid ventricular rate during AF that cannot be controlled adequately with 
anti-arrhythmic drugs or negative chronotropic medications, are most likely to benefit from the ablate 
and pace strategy (Fuster et al., 2006).  
While the symptomatic benefits of AV node ablation and pacemaker implantation are accepted, it 
must be noted that several limitations exist with this treatment regime, including but not limited to 
irreversible complete AV block with lifelong pacemaker dependency, a tendency of ventricular rate 
to rise over the six month period following ablation, lifelong anti-coagulation, and a finite risk of 
sudden death due to Torsade’s de pointes or ventricular fibrillation and the loss of AV synchrony. 
While some patients are not adversely affected by the loss of AV synchrony, patients with anomalies 
of diastolic ventricular functions, such as those with hypertrophic cardiomyopathy (HCM) or 
hypertensive heart disease that rely on AV synchrony to maintain cardiac output, may experience 
persistent symptoms even after AV nodal ablation and pacemaker implantation (Brignole et al., 
1997). 
A study of 71 patients suggested that, in some patients, the long-term outcome for heart failure may 
be less favourable when undergoing AV nodal ablation and permanent pacing. In a study by Tan et 
al. (2008: 460), where 71 patients over the age of 65 years with pharmacologically refractory AF, 
who were assigned to either AV nodal ablation and pacing or ablation for AF for a period of five 
years’ follow-up, the patients assigned to AV nodal “ablate and pace therapy” demonstrated a higher 
incidence of new heart failure when compared with those who underwent AF ablation (53% vs. 24%). 
Table 5.4 illustrates this as well as other indices where differences were seen in favour of AF 
ablation. 
Table 5.4: Comparison of five-year outcome between AV-node ablation and permanent pacing 
therapy (ablate and pace) vs. AF ablation in 71 patients over 65 years of age 
 Group 1 Group 2 
 Ablate and Pace AF Ablation 
Development of new CHF 53% 24% 
LVEF 44% (±8%) 51% (±10%) 
NYHA functional class 1.7(±0.9) 1.4± (0.7) 
Source: Tan et al., 2008. 
Data from the APAF study, presented at the HRS Congress in May 2011 reveal the results of the 




junction ablation and randomized to receive echo-guided CRT (97 patients) or RV apical pacing (89 
patients). During a median follow-up of 20 months, the CRT group had fewer worsening HF 
symptoms and hospitalisation for heart failure; however, the total mortality was similar in both groups. 
Additionally, only the CRT mode remained an independent predictor of absence of clinical failure 
(defined as death due to HF, hospitalisation due to HF or worsening HF) during the follow-up period. 
5.5 CATHETER ABLATION 
The surgical approach for the treatment of refractory tachycardia was the mainstay of non-
pharmacologic therapy until the late 1960s, when the first intra-cardiac catheters were used to 
stimulate the heart and record rhythms. Initially, direct current (DC) from an external defibrillator was 
used as the energy source. This form of high voltage energy was not ideal as it was difficult to control 
and resulted in widespread tissue damage. 
Catheter ablation is a minimally invasive procedure whereby catheters are inserted in the body via 
veins in the groin or neck and directed with X-ray up into the heart. The ablation may be in the form 
of RF energy or cryoablation and the application of the energy is dependent on the site of ablation. 
Each catheter has between four and 20 electrodes which, when placed in the heart, collect electrical 
measurements from the heart. This data helps determine where the arrhythmia foci are and, once 
determined, RF energy is delivered to the site to obliterate a small amount of tissue, the result being 
that the abnormal electrical impulses are disrupted, and the normal heart rhythm is restored. 
5.5.1 Types of ablation for atrial fibrillation 
There are two main types of ablation that are utilised for the treatment of atrial fibrillation, namely 
radiofrequency ablation and cryoablation. 
5.5.1.1 Radiofrequency ablation  
The introduction of radiofrequency catheter ablation transformed the way that tachyarrhythmia is 
treated, and this has become first-line therapy for many types of tachycardia. Radiofrequency (RF) 
energy uses energy that is high-frequency but low-voltage. The RF energy causes the tissue to heat 
up and a small uniform lesion is created. The size of the lesion is determined by the length of the 
distal ablation electrode as well as the type of catheter (irrigated or non-irrigated.) used. Other factors 
that affect the size of the lesion include the amount of power delivered to the tissue and the contact 
the catheter has with the tissue. RF ablation lesions will typically measure about five to seven 
millimetres in diameter and three to five millimetres in depth. Success rates for catheter ablation are 
highest in patients with common forms of supra-ventricular tachycardia (SVT), for example 





5.5.1.2 Cryoablation  
Catheter or balloon-based cryoablation is an alternative source of energy that requires pressurized 
liquid nitrous oxide to be injected into closed catheter tip or balloon. The result is the rapid 
evaporation of the nitrous oxide which cools the underlying tissue to about minus 75ºC. An ice ball 
or hemispherical block is formed at the catheter tip, and the underlying tissue is frozen. As the tissue 
thaws out, tissue injury results, which may include haemorrhaging and inflammation and the end 
result is a fibrotic lesion in the heart. There is minimal risk of permanent total heart block when 
ablation is near the AV node. This is due to the fact that the rapid warming of tissue results in the 
reversing of the electrophysiological outcome. Cryoablation has a number of potential advantages 
over RF ablation and these include the following: 
 The ice ball creates excellent stability of the catheter during ablation; 
 The patient does not experience any pain during energy delivery, and  
 There is less risk of damaging vascular structures such as the coronary arteries and 
pulmonary veins.  
In spite of this, cryoablation has been shown to be less effective clinically than RF ablation. It may 
be useful in specific clinical circumstances, in particular when the ablation site is close to the AV 
node. Radiofrequency catheter ablation remains the dominant and most useful energy source in 
clinical practice (Prystowsky, 2000).  
5.5.2 Indications for radiofrequency catheter ablation 
Catheter ablation may be indicated for patients with arrhythmia which are not controlled by either 
medication or lifestyle management. In some circumstances, certain medications may be contra-
indicated for some patients, or the patients express the desire not to take life-long anti-arrhythmic 
medications, because of side effects that interfere with their quality of life. The following are class 1 
indications for catheter ablation: 
 Symptomatic supra-ventricular tachycardia (SVT), for example, atrioventricular nodal re-
entrant tachycardia (AVNRT). 
 Wolff-Parkinson-White syndrome, unifocal atrial tachycardia, and atrial flutter. 
 Atrial fibrillation with lifestyle-impairing symptoms, after inefficacy or intolerance of at least 
one anti-arrhythmic agent.  
 Symptomatic ventricular tachycardia in structural heart disease. 




5.5.3 Complications of radiofrequency catheter ablation 
As fluoroscopy is used for the procedure, there is a risk of radiation, which is higher than the risk 
from common radiologic procedures. However, this risk remains low. The average risk for genetic 
defects is one case per million births, while the average risk for fatal malignancies ranges from 0.3-
2.3 deaths per 1 000 cases for every 60 minutes of fluoroscopy. The time required per procedure is 
dependent on factors that include complexity of the arrhythmia and skill of the operator but seldom 
requires more than 60 minutes of fluoroscopy for simple cases. Major complications are reported to 
affect approximately 3% of patients who undergo ablation procedures. The risk of death is less than 
0.3% and thromboembolism occurs in less than 1% (although this is higher in some atrial fibrillation 
ablation data). The list below describes reported complications, most of which are rare or uncommon: 
 Death (0.1-0.2% of all procedures) 
 Cardiac complications (incidence varies based on site and type of ablation) 
o AV block 
o Cardiac tamponade (highest in atrial fibrillation ablation, up to 6%) 
o Coronary artery spasm/thrombosis 
o Pericarditis 
o Valve trauma 
o Vascular complications (~2-4%) 
 Retroperitoneal bleeding 
o Hematoma 
o Vascular Injury 
o Transient ischaemic attack/stroke 
o Hypotension 
o Thromboembolism or air embolism 
 Pulmonary complications 




 Left atrial-oesophageal fistula 
 Acute pyloric spasm/gastric hypomotility 
 Phrenic nerve paralysis 
 Radiation or electrically induced skin damage 
 Infection at access site 





5.5.4 Results of radiofrequency catheter ablation 
The success rate of RF catheter ablation for many of the common supra-ventricular tachycardia such 
as atrioventricular nodal re-entrant tachycardia (AVNRT), or Wolff-Parkinson-White syndrome, is 
typically between 90% and 95% with a single procedure. The success rates for right atrial flutter and 
other unifocal atrial tachycardia is in the region of 90%. Some tachyarrhythmia may recur in the first 
few months following ablation and success may only be achieved after the second procedure 
(Greenberg et al., 2008). 
The ablation for AF is complicated and it is now accepted that AF is a progressive disease that is 
unlikely to be cured (Kuck, 2010). Success rates for terminating atrial fibrillation with RF ablation in 
patients with paroxysmal atrial fibrillation and in the absence of structural heart disease was reported 
in 2006 as 87%. The patient group with persistent atrial fibrillation in the presence of structural heart 
disease and left atrial enlargement had a success rate of 50% or less, and a repeat procedure was 
needed in more than 25% of patients. 
To deal with the complexities of RF catheter ablation for atrial fibrillation, new techniques such as 
3D mapping systems (Carto and Ensite) are evolving (see Figure 5.6). These 3D mapping systems 
can be merged with MRI or CT scan images of the left atrium, enabling the navigation of the ablation 
catheter, mapping of ectopic foci and atrial scars, and finally the evaluation of the transmurality of 
ablation lines. Intra-cardiac echocardiography (ICE) offers the physician the ability to avoid collateral 
damage to the pulmonary veins or oesophagus and ensures adequate endocardial contact. The use 
of robotic catheter navigation (Hansen or Stereotaxis) is now available to assist in delivering 
radiofrequency catheter ablation (RFCA) (Greenberg et al., 2008). 
At the 2011 Heart Rhythm Society’s 32nd annual scientific sessions in San Francisco, findings from 
the DISCERN AF trial were announced. The DISCERN AF trial utilised the Medtronic Reveal XT, 
which is an implantable loop recorder to monitor the incidence of symptomatic vs. asymptomatic AF, 





Figure 5.6: Carto 3D map of left atrium, illustrating the pulmonary veins 
Notes: Right superior pulmonary vein (RSPV), right inferior pulmonary vein (RIPV), left superior pulmonary 
vein (LSPV), and left inferior pulmonary vein (LIPV). The red circles represent actual discrete radiofrequency 
applications, predominantly delivered in a circumferential pattern around the pulmonary veins. This ablation 
strategy can isolate pulmonary vein foci that initiate atrial fibrillation, and/or alter the substrate of the left 
atrium to inhibit fibrillatory activity due to re-entry. 
Source: Kabra & Singh, 2010.  
The DISCERN study was a prospective, multi-centre study of 50 patients with symptomatic AF. All 
the patients had the Reveal XT, with an automated detection algorithm, implanted at least three 
months prior to the RF ablation and all patients were monitored for 18 months after the ablation 
procedure. 
The study showed an 86% decrease in burden of AF, (i.e. the total amount of time the patient was 
in AF). The burden of AF decreased from a pre-ablation period of 2.0 hours per day (±0.5 hours) to 
a post ablation time of 0.3 hours (±0.2 hours) (p=0.005). It was also found that 56% of the entire AF 
burden was asymptomatic. It is important to note that, when analysing symptoms only, 58% of 
patients were free of AF, suggesting that symptoms alone underestimate the overall burden of 
disease in these patients and this may impact the treatment regimens of patients in the future 
(Verma, 2011). 
5.6 ABLATION FOR ATRIAL FIBRILLATION 
Nademanee et al. (2004) argue that, despite the advancements made in the treatment of 
cardiovascular diseases, the management of AF has remained a frustrating dilemma for physicians. 
The publication of studies like the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm 
Management) as well as several other randomized trials, which compared the two main strategies of 




the addition of anti-coagulants to the therapeutic regime, the use of anti-arrhythmic drugs to maintain 
sinus rhythm offers no benefit to reduce mortality or stroke in AF patients when compared with the use 
of drugs for rate control (Nademanee et al., 2004; Wilber et al., 2010). 
Nademanee (2004) recognises that the use of rate-control treatment is acceptable as a 
pharmacological approach. However, he states that physicians are unsatisfied with the fact that 
many of their high-risk patients remain in AF. Nademanee cites the AFFIRM investigators, who 
suggest that the unwanted effects of anti-arrhythmic drugs might offset the benefits of being in sinus 
rhythm (Nademanee, 2008). Wilber et al. (2010) submit that the effectiveness of drugs remains 
inconsistent and that the likelihood of AF recurrence within six to 12 months is almost 50% with most 
drugs therapies (Wilber et al., 2010). 
Catheter ablation of atrial tissue to treat atrial fibrillation is still evolving (Greenberg et al., 2008). The 
procedure is technically demanding, riskier, and less successful than the other ablation procedures 
described above. Early radiofrequency catheter ablation for AF emulated the surgical Maze 
procedure by introducing linear scars in the atrial endocardium (Fuster et al., 2006). It was 
Haïssaguerre et al. (1998) who, in the mid-1990s, observed that pulmonary vein foci triggered atrial 
fibrillation resulting in scientific enthusiasm that this tachyarrhythmia, which affected millions of 
people, could be amenable to catheter ablation (see Figures 5.7 and 5.8). 
 
 
Figure 5.7: Diagram illustrating the site of the four pulmonary veins in the left atrial body 





Figure 5.8: Diagram illustrating the Lasso mapping catheter across the intra-atrial 
septum and mapping electrograms at the left inferior pulmonary vein 
Note: Ablation catheter performing RF ablation circumferentially around the veins. 
Source: Greenberg et al., 2008. 
The initial success rate for this procedure was between 40% and 50% and had relatively high 
complication rates. It did, however, encourage observations which indicated that the electrical 
potentials which arose in or near the ostia of the pulmonary veins often provoked AF and it further 
demonstrated that when these foci were eradicated the AF terminated. At the outset, it was only 
areas in the pulmonary veins where automaticity was found that were targeted. Jaïs et al. (1997) 
later demonstrated over a follow-up period of eight months, in a series of 45 patients, all of whom 
had paroxysmal AF, that 62% were free of symptomatic AF, but 70% of these patients required 
multiple procedures (Jaïs et al., 1997). It was Chen et al. (1999) who then established a success 
rate over a six months’ follow-up period of 86% (Chen et al., 1999). 
Figure 5.9 illustrates one of the mechanisms apparent to start an episode of AF as a single ectopic 
foci and, in a study of 240 patients, Lin et al. (2003) described that, of the 358 ectopic foci that started 
paroxysmal atrial fibrillation (PAF), 28% of patients’ AF was initiated by an ectopic foci, while 20% 
were from non-pulmonary vein areas and included the left atrial free wall in 38.3%, the superior vena 
cavae (SVC) in 37% of patients, the crista terminalis in 3.7% of patients, the ligament of Marshall in 
8.2%of patients, the coronary sinus ostium in 1.4% of patients and a further 1.4% from the intra-





Notes: (A) Bigeminal ectopic beats (arrow) followed by initiation of tachycardia in the surface ECG. (B), Ectopic foci 
initiating tachycardia from SVC-D (distal) and conducting to SVC-P (proximal). (C), Ectopic beats initiating AF from SVC 
after isoproterenol infusion (basket catheter recording inside SVC, with the earliest ectopic beat from E3 and F3). 
Figure 5.9: The initiation of AF from superior vena cava (SVC) 
Source: Lin et al., 2003. 
When catheter ablation was performed to terminate the AF, the acute success rates varied according 
to the site of the initiation of the AF and were as follows: 63% in left atrial posterior free wall, 96% in 
the superior vena cava, 100% at the crista terminalis, 50% at the ligament of Marshall, 100% in the 
coronary sinus ostium, and 0% at the intra-atrial septum respectively. The patients were followed up 
for 22(±11) months and 43 patients or 63.2% were found to be free of AF and no longer on anti-
arrhythmic drugs (Chen et al., 1999).  
Subsequent research by Hocini et al. (2004) from the Bordeaux group in France confirmed that 
potentials arise in a number of different regions in both the right atrium and the left atrium and include, 
among others, the SVC, intra-atrial septum, the LA posterior wall, the coronary sinus, ligament of 
Marshall, and the crista terminalis. Modifications, as seen in Figure 5.10, were made to the procedure 
of pulmonary vein isolation, which now includes linear ablation in the left atrium and/or mitral isthmus 





Figure 5.10: Pulmonary vein isolation using advanced imaging techniques 
Notes: A CT scan is shown of the left atrium which has been merged with a 3-dimensional mapping system (Carto 
Merge). Individual ablation lesions are represented by red and pink icons; the pink icons represent low-power lesions 
over the area where the oesophagus is in close contact with the posterior wall of the left atrium. The pulmonary veins are 
completely surrounded by ablation lesions, electrically isolating the pulmonary vein myocardial sleeves that provide the 
trigger beats that initiate episodes of atrial fibrillation. 
Source: Adapted from Anter et al., 2009.  
5.6.1 Results of ablation for atrial fibrillation (AF) 
Despite these advances, the long-term efficacy of catheter ablation to prevent recurrent AF requires 
further study. Available data demonstrates one or more years free from recurrent AF in most (albeit 
carefully selected) patients (Hindricks et al., 2005; Karch et al., 2005). Of importance is the fact that 
AF can recur without symptoms and may therefore not be recognised by either the patient or the 
physician. Hindricks et al. (2005) concluded in their study that, if centring the success of AF ablation 
on symptoms only, the success rate of the procedure may be substantially overestimated.  
Therefore, it remains uncertain whether apparent cures represent elimination of AF or transformation 
into an asymptomatic form of paroxysmal AF. The distinction has important implications for the duration 
of anti-coagulation therapy in patients who are at risk of stroke associated with AF. In addition, little 
information is available about the late success of ablation in patients with HF and other advanced 
structural heart disease, who may be less likely to enjoy freedom from AF recurrence (Hindricks et al., 
2005). 
A study evaluating the outcome of catheter ablation in high risk patients was published in the Journal 
of American College of Cardiology (JACC) in 2008. The investigators evaluated 2 356 patients with 
symptomatic and refractory AF. Of these patients, 771 met the inclusion criteria, as they all had a 
Ablation lines 




high risk of stroke and were similar to the patients studied in the AFFIRM trial. Of these 771 patients, 
674 underwent catheter ablation for AF. Of the 97 patients who were not treated, 27 were excluded 
because of a left atrial thrombus, while the other 70 patients declined to undergo the procedure. 
In total, 1065 ablations were performed, with 53% (329) patients requiring only one procedure, 32% 
(204) undergoing two procedures, 12.6% (80) requiring a third procedure, and 2.5% (22) patients 
requiring a total of four procedures. 
The mean follow-up period was 836 days (±605) from the last ablation procedure, and 517 of the 
635 patients, or 81.4%, remained in sinus rhythm. The remaining 118 patients (18.6%) still had atrial 
tachyarrhythmia and of the 517 patients who remained in sinus rhythm (SR), only 13% required anti-
arrhythmic agents to maintain SR. Table 5.5 illustrates that AF ablations are significantly more 
effective in maintaining sinus rhythm in patients with paroxysmal or persistent AF when compared 
with those with permanent AF.  
Table 5.5: Comparison of baseline clinical characteristics of patients maintaining SR vs. 
patients remaining in AF after ablation 
 SR (n=517) AF (n=118) P value 
Age (years) 67 ±12 67 ±12 0.9 
Duration of AF (months) 36± 57±79 0.008 
Ejection fraction 51±14 51±12 0.97 
LA size (mm) 45±6 48±7 <0.0001 
Types of AF    
Paroxysmal (n=254) 226 28  
Persistent (n=146) 124 22 <0.0001 
Permanent (n=235) 167 68  
Source: Nademanee et al., 2008.  
When evaluating the effects of sinus rhythm on mortality, Nademanee et al. (2008) described that 
29 deaths occurred over the follow-up period. Of the 517 patients who remained in SR, fifteen died 
(2.9%), four from CHF, one from sudden death, and ten from non-cardiac death. In comparison, 
fourteen of the 118 patients with recurrent AF died (11.9%), eight from CHF, two from sudden death, 
two from non-cardiac death, two from stroke, including one patient with a spontaneous intracranial 
haemorrhage on Warfarin). This showed that the cardiac death rate was lower in the patient cohort 
who remained in sinus rhythm (0.96% vs. 8%; p<0.0001) (Nademanee et al., 2008). 
Further to this, the investigators showed that the five-year mortality rate was lower where AF ablation 
was effective in maintaining SR. Figure 5.11 illustrates that the five-year mortality rate was 8% for 




(p<0.0001). Sinus rhythm was shown to be the strongest independent factor associated with a lower 
mortality (HR 0.14, 95% CI 0.06 to 0.36, s<0.0001) (Nademanee et al., 2008). 
 
Notes: Kaplan-Meier curve demonstrating improved survival in patients who remained in normal sinus rhythm (NSR) (red 
circles) from all-cause mortality compared with patients who remained in atrial fibrillation (AF) (green circles). 
Figure 5.11: Survival effect of maintaining normal sinus rhythm (NSR) after AF ablation 
Source: Nademanee et al., 2008 
This study systematically evaluated the safety and effectiveness of catheter-based substrate 
ablation in high-risk patients with AF. The mean follow-up period was 836 days (±605) and the patient 
population had a median age of 69 years. In spite of this high-risk patient profile, the data supported 
the fact that ablation of AF substrate with complex fractionated atrial electrograms (CFAE) mapping 
was effective in maintaining sinus rhythm and that, at 2.3-year mean follow-up, the highest success 
rates of 89% and 85%, respectively, were the patient group with paroxysmal or persistent AF while 
the success rate of the patients with permanent AF was only 71% (p<0.0001). 
In spite of the fact that a large majority of the patients who remained in sinus rhythm stopped their 
anti-coagulants, their rate for both stroke and embolic complications were low. The annual stroke 
rate among the successfully treated patients who discontinued anti-coagulation was 0.4%, compared 
with 2% in the patients with recurrent AF. The Kaplan-Meier curve derived a five-year stroke 
incidence of 3% compared with 23% for patients who required ongoing Warfarin therapy (p = 0.04). 
For the patients who remained in sinus rhythm and, as result of their age, were not ideal candidates 
for anti-coagulation, the benefits were remarkable with respect to stroke and mortality reduction 




5.6.2 Results for RF ablation for AF vs. anti-arrhythmic drugs for AF 
Anti-arrhythmic drug therapy (ADT) is at present considered the first line of therapy to prevent 
symptomatic and recurrent atrial fibrillation (AF). However, many of the anti-arrhythmic drugs (AADs) 
are cited as being not only ineffective but also often associated with serious adverse effects (Fuster et 
al., 2006). Little data exist to compare RF ablation to anti-arrhythmic drugs for AF but where data 
exists, they exhibit a positive trend in favour of RF ablation. Ablation for atrial fibrillation is an effective 
alternative to chronic ADT in patients with AF (Haïssaguerre et al., 2000; Nademanee et al., 2008). 
Three randomized trials by Wazni et al. (2005), Stabile et al. (2006) and Oral et al. (2006) demonstrated 
superiority of AF ablation strategy over ADT. The first study, by Wazni et al. (2005), evaluated the 
recurrence of AF, hospitalisation, and the quality of life scores in 70 patients between the ages of 18 
and 75 years, all of whom had an initial history of paroxysmal AF (PAF) and were untreated. The 
second study, by Stabile et al. (2006), reported that ablation therapy, combined with AAD, was superior 
to AAD on its own for patients with paroxysmal or persistent AF. 
Oral et al. (2006) demonstrated that, at one-year, pulmonary vein isolation by means of 
circumferential pulmonary vein ablation was more effective than Amiodarone in maintaining sinus 
rhythm. The APAF (ablation for paroxysmal atrial fibrillation) trial was conducted to establish whether 
circumferential pulmonary vein ablation was superior to ADT for maintaining SR at one year in 
patients with a long history of PAF. 
In the randomized control study by Pappone et al. (2006) a total of 334 patients were screened and 
198 were enrolled in the study. Figure 5.12 demonstrates that 198 patients were enrolled either to 
receive ADT or undergo an ablation. All patients received a one-month period of AAD, after which 
they either had the ablation procedure or stayed on medication. Of the 99 patients assigned to the 
drug group, 42 underwent ablation after a mean of 5.8 months and, after a mean of 6.2 months of 
follow-up after crossover, 36 were free of recurrent AF in the absence of ADT, compared with 6 in 






Notes: Circumferential pulmonary vein ablation (CPVA) (n = 99), anti-arrhythmic drug therapy (ADT) (n = 
99). After four weeks of anti-arrhythmic therapy (run-in phase), patients proceeded to the randomized 
treatment (i.e., catheter ablation or solely continuing ADT). AAD = anti-arrhythmic drug. 
Figure 5.12: Randomisation of patients to either circumferential 
pulmonary vein ablation or anti-arrhythmic drug therapy 
Source: Pappone et al., 2006: 2341. 
As noted in Figure 5.13 the Kaplan-Meier analysis showed that 86% of patients who were 
randomized to the ablation arm were free of all atrial tachycardia at the end of the follow-up period, 
compared with only 22% of patients randomized to receive ADT (p<0.001).  
Of further interest in this trial were the numbers of hospital admissions in each group. Among patients 
assigned to ablation, nine patients had a total of 24 hospital admissions for cardiovascular causes, 
which included repeat procedures. In contrast, in the ADT group, there were 167 cardiovascular 
event-related hospital admissions. These hospitalisations did not include the hospitalisations for 





Figure 5.13: Outcomes in the APAF (ablation for paroxysmal atrial fibrillation) trial 
Source: Pappone et al., 2006: 2345. 
The main findings of this study demonstrated that a single circumferential pulmonary vein ablation 
procedure was more effective in preventing relapses of AF in selected patients with paroxysmal AF, 
than ADT and that ablation resulted in the maintenance of sinus rhythm at one year without the need 
for ADT in 86% of patients.  
This finding is significantly different from the patients in the ADT group, where only 22% of the 
patients remained in sinus rhythm at one year. The authors purport that the maintenance of sinus 
rhythm after ablation could be associated with reverse left atrial remodelling, fewer adverse events 
and less hospital admissions due to cardiovascular causes. 
Of interest was the fact that, in the ablation arm of the study, the patients who underwent ablation 
with an irrigated-tip catheter were less likely to have AF recurrences compared with those ablated 
with an 8-mm catheter. The findings also confirmed that, by including additional posterior lines, the 
incidence of atrial tachycardia was decreased to 3.9%. 
In January 2010, the Journal of the American Medical Association (JAMA) published a prospective, 
multi-centre, randomized study designed to compare catheter ablation with ADT in patients with 
symptomatic AF, who had not shown clinical improvement on at least one drug. The primary goal of 
the study was to evaluate freedom from symptomatic AF recurrence after treatment (Wilber et al., 
2010). 
Randomisation sequences were generated by the sponsor statistician, and patients were randomly 
assigned on a 2:1 basis to receive either ablation or a previously unused anti-arrhythmic drug 





Figure 5.14: Patient flow diagram for selection and randomisation 
Source: Wilber et al., 2010. 
These patients were followed up for comparable nine-month effectiveness evaluation period. ECGs 
were done at all follow-up visits and trans-telephonic monitoring was performed during the nine-
month period for patients in both groups. Patients from both groups were required to transmit all 
symptomatic cardiac episodes and, for those patients undergoing ablation therapy, a CT scan or 
MRI was performed within 30 days before the procedure and then at intervals of three months and 
12 months after the procedure, in order to identify pulmonary vein stenosis. This was defined as at 
least 70% reduction of the PV diameter when compared with the baseline scan.  
For the cohort of patients randomized to drug therapy, drugs were administered only if the patient had 
not previously received that drug and a choice of dofetilide, Flecainide, propafenone, Sotalol, or 
quinidine were prescribed at the discretion of the investigator. The patients who underwent PVI all did 
so with the use of a Navistar Thermocool Irrigated Tip Catheter (Biosense Webster, Diamond Bar, 
California) and Carto (Biosense Webster). Circumferential lesions were performed and additional 
ablation for CFAE, left atrial linear lesions, and cavo-tricuspid isthmus were at the discretion of the 
investigator. Up to two repeat ablations were considered acceptable within 80 days. 
The Kaplan-Meier curves for the effectiveness outcomes are illustrated in Figure 5.15. It can be 
noted that, after the nine months’ effectiveness evaluation period, 70% of patients treated with 
catheter ablation were free of symptomatic and recurrent atrial tachycardia vs. 19% of patients 
treated with medication (HR, 0.24; 95% CI, 0.15-0.39; p<0.001). A total of 66% of patients in the 
catheter ablation group were free from protocol-defined treatment failure compared to only 16% of 




of the patients treated in the ablation cohort were free of any recurrent atrial arrhythmia vs. 17% of 
patients treated with medication (HR, 0.29; 95% CI, 0.18-0.45; p<0.001)  
 
Figure 5.15: Kaplan-Meier curves of time to protocol-defined treatment failure, recurrence 
of symptomatic atrial arrhythmia, and recurrence of any atrial arrhythmia by treatment 
group 
Source: Wilber et al., 2010.  
In the study, the baseline measure for the two treatment groups for quality of life (QoL) were similar. 
As early as three months into the effectiveness evaluation period, the mean SF-36 physical and SF-
36 mental summary scores in the patient group who had undergone AF ablation had improved 
compared with the scores of patients treated with medication. As illustrated in Table 5.6, the patients 
who underwent ablation reported significantly lower (improved) frequency and severity of symptoms 
after only three months.  
Table 5.6: Quality of life assessment with change from baseline to three months 
 
Notes on abbreviations: CI = confidence interval; SF 36 = short form health survey. 
Source: Wilber et al., 2010. 
The results of this study demonstrate that radiofrequency catheter ablation had significantly better 
outcomes for patients with frequent symptomatic paroxysmal AF who were unresponsive to drug 
therapy versus rhythm control with alternative drug therapy. The results also showed that there was 
Absolute change from baseline 
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a substantial reduction in the risk of recurrent atrial arrhythmias and clinically meaningful 
improvement in symptoms and QoL and that catheter ablation was associated with a favourable 
safety profile. No major adverse events, i.e. thromboembolic events, atrial oesophageal fistula, 
cardiac perforation, phrenic nerve paralysis, or death occurred in this study, while major adverse 
events or drug intolerance requiring early withdrawal of the assigned drug occurred in approximately 
10% of study patients. This is comparable with other studies. 
5.6.3 Results for cryoablation for AF vs. anti-arrhythmic drugs for AF 
Little data exist on the use of cryoablation for AF in comparison with RF ablation techniques. 
Weerasooriya et al. (2008) reported that there is an inherent risk with the use of radiofrequency 
energy because of the relatively thin-walled left atrium. The risks cited were the risk of cardiac 
tamponade due to the steam pop phenomenon, and risk of injury to adjacent structures such as the 
pulmonary veins and oesophagus, nerve-plexi, the aorta, bronchi, pericardium, as well as phrenic 
nerve and lungs. In addition to these potential complications, it was observed that the procedure is 
extremely demanding in terms of operator competency and dexterity and has a steep learning curve. 
At the time of publication, the investigators reported that the use of cryo-energy as an alternative 
energy source in the clinical setting may be less likely to cause pulmonary vein stenosis or 
oesophageal damage, but they did comment on the fact that studies of cryoablation for slow and 
accessory pathways demonstrated a higher recurrence rate than RF ablation.  
In theory, balloon technology offers the advantage of being simpler, faster, and a more widely 
applicable means of achieving pulmonary vein isolation. One major drawback of this type of technology 
is the highly variable anatomy of pulmonary veins. It is estimated that as many as 70% of people have 
abnormal pulmonary veins. In practical terms, it means that one size balloon does not fit all different 
types of anatomies and the physical effect of oversizing the balloon in the right superior pulmonary 
vein may result in a higher rate of phrenic nerve palsy (Weerasooriya et al., 2008). 
Weerasooriya et al. (2008) referred to a study by Van Belle et al. (2008) and reported that the mean 
procedure times for AF ablation in 138 patients with cryoablation was 207min, while the fluoroscopic 
duration was 57min. These times were from an experienced group who were very early adopters of 
this new platform, and used it exclusively, suggesting that this is not as simple a procedure as 
alleged. It was also noted that 40% of patients also required extra ‘touch up’ ablation using an 
additional point-by-point ablation catheter illustrating that the technique did not reduce the 
requirements of manual dexterity or understanding of pulmonary vein electrograms.  
While cryo-technology was considered a safe alternative to RF ablation, the rate of serious 
complication was high, at 8.6% of patients, and these included phrenic nerve palsy in four patients 




Weerasooriya et al. (2008) finally commented that, until better alternatives are available, the use of 
balloon-based cryoablation offers only a modestly effective alternative to radiofrequency ablation for 
patients with paroxysmal atrial fibrillation in whom pulmonary vein isolation was planned 
(Weerasooriya et al. 2008). 
During the recent American College of Cardiology meeting held in Atlanta from 14 to 16 March 2010, 
the results of the STOP-AF trial were announced.  
A total of 245 patients with paroxysmal AF from 26 centres were enrolled for the STOP-AF trial. 
Patients were randomized to receive either cryoablation or anti-arrhythmic drug therapy. The 
randomisation was done as 2:1 (163 Cryoablation and 82 AAD). Inclusion criterion was two or more 
episodes of AF within two months, documented on electrocardiogram, or the failure of at least one 
anti-arrhythmic drug. As described by Packer, the patients were relatively young, with little 
documented heart disease and, based on their CHADS2 score, were a low risk cohort of patients. 
However, they all had frequent, highly symptomatic AF, failing, on average, 1.2 anti-arrhythmic drugs 
(Packer, 2010).  
After one year (three-month blanking period and nine-month follow-up) 69.9% of patients treated 
with cryoablation were free from AF, compared with 7.3% of patients treated with anti-arrhythmic 
drug therapy. Of the successfully ablated patients, 58% were free from AF at one year without the 
use of anti-arrhythmic drug therapy, and 60% were free from AF after a single ablation procedure. 
While the study met both primary safety outcomes of less than 14.8%, it should be noted that slightly 
more than 3% of patients treated with cryoablation experienced serious complications requiring 
intervention. Of the complications in the cryoablation cohort, phrenic nerve paralysis occurred in 29 
(11%) patients and five (3.1%) had pulmonary vein stenosis with two requiring intervention. In the 
cryoablation group, the stroke rate was 2.5% vs. 1.2% for the AAD group and myocardial infarction 
was 1.2% in the cryoablation group vs. 0% in the AAD group. Newly diagnosed atrial flutter was 
found in 3.7% of the cryoablation group vs.15.9% in the AAD group, and the death rate was 0.6% in 
the cryoablation group vs. 0 in the AAD group. This death occurred at 288 days and was due to a 
myocardial infarction. The mean procedural duration was 371 minutes, involving a cryoablation time 
of 65.7min and fluoroscopy time of 62.8min (Cox, 2010; Packer, 2010; Raible et al., 2010). 
Finally, it may be noted that, while cryoballoon technology could potentially represent a very quick, 
simple and safe approach to the treatment of paroxysmal atrial fibrillation, the data does not yet 
indicate this, nor does the single freeze approach support data that show the increased success rate 
of AF ablation when also ablating the posterior wall, SVC, mitral valve annulus or CFAE, in which 





5.7 CLINICAL EFFECTIVENESS OF CATHETER ABLATION 
A study published in Journal of Cardiovascular Electrophysiology (Bunch et al., 2011) compared the 
outcome of rates of death, stroke and dementia in patients with AF. A total of 37 908 patients were 
enrolled in the trial, with 4 212 patients undergoing AF ablation. These patients were compared in a 
1:4 analysis with 16 848 AF patients who were age- and gender-matched but not treated with ablation, 
and a further 16 848 age- and gender-matched patients who did not suffer from AF (Bunch et al., 2011: 
839).  
The patients were enrolled in the prospective AF study and were followed-up for at least three years 
for myocardial infarction, dementia, Alzheimer’s disease, heart failure, cardiovascular hospitalisation 
and death. Death included all-cause mortality and coronary artery disease- related mortality. 
Approximately 55% of the patients had paroxysmal AF, while 27% were considered to have 
persistent AF, and a further 18% permanent. The actual follow-up period by cohort was as follows: 
The patients with no AF had a mean follow-up period of six years (±4.6 years); the AF patients who 
did not undergo ablation were followed up for a mean of 5.1 years (±4.7 years); and the AF patients 
who underwent catheter ablation were followed up for 3.1 years (±2.4years). Table 5.7 illustrates the 
baseline demographics of the patients who were enrolled in the study. 
As indicated in Table 5.7, the main difference between the three cohorts was that there was a lower 
incidence of hypertension, CHF, CVA, or TIA and renal failure in the patients without AF compared 
to those with AF. Among the two cohorts of patients with AF, there was a higher rate of diabetes and 
TIA in the group who did not undergo ablation. The cohort who received catheter ablation was found 





Table 5.7: Baseline demographics of patients who underwent AF ablation, patients with AF who 
did not receive AF ablation, and control population age- and sex-matched with patients, who 
did not have AF 










Age (years) 64.1 ± 13.0 66.0± 13.3 64.8±12.7 <0.0001 
Sex (male) 60.8% 60.8% 60.8% 1 
Diabetes 19% 21.1% 16.3% <0.0001 
Hypertension 41.2% 45.3% 47.8% <0.0001 
Hyperlipidaemia 58.4% 37.3% 44% <0.0001 
CHF 14.5% 23.6% 29.5% <0.0001 
Renal Failure 5.6% 7.8% 7.5% <0.0001 
TIA history 4% 4.2% 4.6% 0.16 
CVA history 4.4% 6.3% 4.5% <0.0001 
MI history 10% 6.4% 6.4% <0.0001 
Source: Bunch et al., 2011: 841. 
Cranial computed tomography (CT) scans were performed in the patients with dementia (5.7%) and 
an additional 3.7% of the study patients with dementia underwent an MRI scan. Table 5.8 illustrates 
the outcomes, with regard to dementia and Alzheimer’s disease.  
Table 5.8: Alzheimer’s rate and rate of dementia at three years 
Outcome No AF 
n=16 848 




Alzheimer’s dementia 0.5% 0.9% 0.2% 
Other dementias 0.7% 1.9% 0.4% 
Source: Bunch et al., 2011: 841. 
Specific mortality rates for the three groups at one year, three years and five years is illustrated in 
Table 5.9. The one-year, three-year and five-year mortality rate was significantly lower in patients 
who underwent ablation, compared with the patients with AF who did not receive catheter ablation. 





Table 5.9: Mortality rates at one year, three years and five years 
Outcome No AF 
n=16848 




1-year mortality 4.7% 16.2% 3.0% 
3-year mortality 8.7% 23.5% 6% 
5-year mortality 11.4% 27.9% 7.6% 
Source: Bunch et al., 2011: 841. 
Bunch et al. (2011) reported that, at three-year follow-up, 64.4% of patients who underwent AF 
ablation had no documented episodes of AF. Finally, a multivariate analysis was performed which 
compared, among others, the outcomes of patients with AF and ablation vs. AF and no ablation 
(Table 5.10). In the following categories of total mortality, CVA, total dementia, Alzheimer’s dementia 
and senile dementia, the odds ratio was in favour of the AF ablation cohort with a p value <0.00001. 
With regard to heart failure and vascular dementia, the odds ratio was in favour of the AF ablation 
group, but it was not found to be statistically significant. 
Table 5.10: Long-term multivariate outcomes comparing patients with AF and  
ablation vs. AF no ablation 
 OR/HR P value 
Total mortality 1 year OR=6.45 <0.0001 
Total mortality 3 years OR=5.16 <0.0001 
Total mortality long-term HR= 2.81 <0.0001 
CVA 1 year OR=2.12 <0.0001 
CVA 3 years OR=1.9 <0.0001 
CVA long-term HR=1.68 <0.0001 
Total Dementia 1 year OR=8.27 <0.0001 
Total Dementia 3 years OR=4.00 <0.0001 
Total Dementia long-term HR=2.88 <0.0001 
Senile Dementia 1 year OR=8.07 <0.0001 
Senile Dementia 3 years OR=4.12 <0.0001 
Senile Dementia long-term HR=3.32 <0.0001 
Heart failure 1 year OR=1.03 0.81 
Heart failure 3 years OR=1.06 0.55 
Heart failure long-term HR=0.77 0.001 
Vascular Dementia 1 year OR=4.91 0.03 
Vascular Dementia 3 years OR=2.12 0.08 
Vascular Dementia long-term HR=1.35 0.37 




Complication rates as result of the ablation procedures were recorded as follows: 0.6% (n=25) had 
pericardiocentesis; 0.2% (n=7) had AV fistulas which required surgical intervention; and 0.4% (n=16) 
suffered TIAs. There were two documented oesophageal perforations; one of these patients died 
from multi-system failure. Four (0.1%) patients had pulmonary vein stenosis and a total of 27.6% 
(n=1162) patients required a second AF ablation over the long-term. 
5.8 CONCLUSION 
The management of atrial fibrillation is complex. The risks of thromboembolism and stroke remain a 
real issue for both the patient and the physician. Large-scale community-based studies have shown 
that patients with AF have high rates of both morbidity and mortality. Drug therapy has failed many 
of these patients and, even with new generations of drugs, the ability to control rhythm 
pharmacologically has shown no mortality or morbidity benefits over rate control strategies in major 
studies (Van Gelder et al., 2002: 1840). Bunch et al. (2011) have shown in an epidemiological study 
that patients who achieved sinus rhythm after AF ablation have clinical outcomes similar to patients 
who do not have AF. At present, drugs seem inferior to catheter ablation for achieving and 
maintaining sinus rhythm and the long-term outcome of catheter ablation should be investigated with 
regard to safety, efficacy and cost-effectiveness.  
Chapter 5 has thoroughly investigated all the treatment options that are available for patients with 
AF. Based on this information it is evident that building a cost-effectiveness model using both anti-
arrhythmic drugs and radiofrequency ablation is appropriate.  
Chapter 6 delves deeper into the literature about both of these therapies and probes and challenges 
all the data required to construct such a cost-effectiveness model. 
 
Both Radiofrequency ablation and Cryoablation are used extensively to treat 
Paroxysmal Atrial Fibrillation. There are a number of reviews that compare the two. An 






CHAPTER 6: TOWARDS THE DEVELOPMENT OF A MODEL TO 
EXPLORE THE COST-EFFECTIVENESS OF CATHETER ABLATION 
6.1 INTRODUCTION 
Chapter 2 investigated the relevance of health economic studies, described the various techniques 
that are available to examine costs associated with medical treatment and settled on the alternative 
of cost effectiveness analysis as the choice of models to use. Chapter 3 contained detailed 
information about South Africa from a demographic, economic and healthcare point of view. This 
was to highlight some of the issues that pertain to a country like South Africa, which is an emerging 
market with a medium-sized GDP and an advanced private healthcare sector, but also a country 
with high inequality, unemployment, death rate and disease entities like HIV/AIDS and its co-morbid 
diseases. The reason for this in-depth analysis was to ensure that the need for treatment of non-
rheumatic AF was appropriate within this society. Chapters 4 and 5 introduced the reader to the 
disease of AF by describing the disease and investigating all the various treatment options available 
to patients. All of these earlier chapters have built the foundation for Chapters 6 and 7.  
Chapter 6 researches all the factors that are required to build a cost effectiveness model, including 
the following: 
The economic burden of AF. 
Literature comparing anti-arrhythmic drugs and RF ablation. 
Literature review on the cost effectiveness of catheter ablation. 
Literature review on the quality of life associated with AF. 
Finally, an in-depth review of the APAF study which forms the framework of the model. 
6.2 BACKGROUND 
Atrial fibrillation is the most commonly occurring and sustained arrhythmia and poses a major public 
health burden. The lifetime risk of developing AF after the age of 40 is about one in four for both men 
and women. Large-scale, population-based studies have estimated that the prevalence of AF in the 
US population is 0.9%, with similar estimates for the UK. The prevalence of AF increases with age, 
from around 3 to5% in people over the age of 65, increasing to 10% in people over the age of 80 
years (Bajpai et al., 2007). 
Bajpai et al. (2007:15) and Reynolds et al. (2007: 628) predict that the population of patients with AF 
will increase between twofold and fourfold by 2050. There are two reasons for this increase, cited by 
Stewart et al. (2004). Firstly, the population is ageing, meaning that there is a larger pool of patients 
who are at risk of AF each year and, secondly, the co-morbid conditions associated with AF, like 
hypertension, congestive heart failure and coronary artery disease are also increasing as more 




projections may be conservative, as AF is often silent and the prevalence of sustained silent AF in 
people over the age of 65 years may, in fact, be as high as 25 to 30%. 
Congestive heart failure and thromboembolic stroke are the most severe and debilitating 
complications of AF. A number of large-scale studies in AF have shown increased risk of death from 
all causes and cardiovascular causes ranging from 1.3 to 2.8-fold for men and women. 
Thromboembolism and stroke are increased in patients with AF with the Framingham study reporting 
an annual risk of 1.5% in patients aged 50 to 59 years and up to 23.5% in those patients over 80 
years old. Stroke in patients with AF is often more severe and disabling than in those without it 
(Fuster et al., 2006). 
The Central Intelligence Agency World Factbook indicates that the 2011 population of the world is 
6.9 billion. Of these, close to 8% or close to 552 million are over the age of 65 years (Central 
Intelligence Agency, 2011). If one makes a simple extrapolation using population-based studies, one 
could estimate that as many as 55 million people in the world may currently be affected by AF. A 
crude estimate suggests that approximately 387 000 South Africans are affected by AF, or 8% of the 
total number of patients living with HIV/AIDS.  
Anti-arrhythmic drug therapy (ADT) is used widely for the treatment of AF but continues to show 
limited efficacy, even in large, controlled trials. Many of these drugs are known to cause toxic side 
effects and may, in some cases, be arrhythmogenic. Some trials have shown that rhythm control 
strategy has little or no benefit over a rate control strategy for the management of AF (Van Gelder 
et al., 2002). Evidence supporting the fact that patients who achieve sinus rhythm have better 
survival highlights the lack of efficiency in the treatment of AF with ADT (Noheria et al., 2008: 581). 
Pulmonary vein isolation (PVI) by means of radiofrequency ablation is becoming more widely 
accepted as a treatment option for the treatment of AF in patients who are symptomatic (Camm et 
al., 2010: 2409). 
6.3 THE ECONOMIC BURDEN OF AF  
AF undoubtedly imposes a significant economic burden on a country’s healthcare system, mainly 
owing to the severity of the co-morbid diseases. However, there has not been much research into 
the actual costs of managing patients with atrial fibrillation. Two studies published in 2004 and 2007 
attempted to demonstrate the economic burden of AF. The first study, published in Heart in 2004, 
was a UK-based survey that showed that the direct cost of managing AF in 1995 accounted for 
between 0.6 and 1.2% of the total National Health Service (NHS) budget. This increased to between 
0.9 and 2.4% in 2000 (Bajpai et al., 2007: 15).  
The results of the study indicate that, in 1995, 534 000 patients in the UK were treated for AF as a 
primary diagnosis. This accounted for 0.9% of the entire population and 5% of the population over the 




million GP consultations by these patients in 1995 or three GP consultations per patient per year for 
AF. Figure 6.1 demonstrates the components of healthcare expenditure related to AF in the UK in 
1995. 
 
Figure 6.1: Component of healthcare expenditure related to AF in the UK, 1995 
Source: Stewart et al., 2004. 
In addition to these 58 700 hospital admissions for AF as a primary diagnosis, a further 101,000 
admissions occurred in 1995, where AF was the secondary diagnosis. The total number of hospital 
days was 89 000, which accounted for seven hospital days per admission. The cost of AF to the 
NHS in 1995, excluding hospitalisations where AF was a secondary diagnosis and excluding the 
cost of nursing home care after discharge, amounted to £243.9 million out of the total NHS budget 
of £39 118 million. This means that, in 1995, where AF was the primary diagnosis, excluding post 
discharge nursing home care for patients, the cost of managing AF accounted for 0.62% of all NHS 
expenditure for the year. The greatest portion of this was spent on hospitalisation, which accounted 
for 0.31% of the total NHS budget (Stewart et al., 2004: 289). 
The authors again examined costs in 2000, five years after the first measurement. Their findings 
included the fact that the prevalence of AF had increased from 0, 9% to over 1% of the population, 
a growth in total number of patients of 13%. The total number of admissions where AF was the 
primary diagnosis had increased from 58 700 admissions in 1995 to 109 000 admissions, with an 
average of 6.1 days per patient per admission (2% growth in days in hospital and an 86% increase 
in the number of hospital admissions). The total cost for AF in 1995, where AF was the primary 
diagnosis and including the admissions to hospital where AF was the secondary diagnosis, was 
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A study by Reynolds et al. (2007) published in Journal of Cardiovascular Electrophysiology 
examined the costs of treating new-onset AF in the USA. This US-based study, known as the 
FRACTUAL Registry, was an inception cohort study of 973 patients with AF who were followed up 
at three- and six-month intervals for a mean of 24 months (±9 months). The treatment options for 
AF, as well as the clinical outcomes, and in-patient and out-patient resource utilisation were tracked 
at each follow-up interval. The patients in the registry were managed primarily with anti-arrhythmic 
drugs and cardioversion. Table 6.1 tabulates the reason for hospitalisation that were associated with 
the primary diagnosis of AF. 
Table 6.1: Profile of hospitalisations associated with the principal diagnosis of atrial fibrillation 
in 1995 and subsequent outcomes 
 Men Women Total 
Admissions 31 200 27 500 58 700 
Alive at discharge 30 500 26 400 56 900 
% admissions alive at discharge 98 96 97 
Age over 65 years 17 160 15 125 32 285 
% over 65 years 55 55 55 
First Diagnosis 22 152 20 350 42 502 
% patients in whom first diagnosis 71 74 72 
Admitted to specialised units 7 176 6 050 13 226 
% of admissions to specialised units 23 22 22.5 
Subsequent outcomes 
Heart failure 4 992 3 850 8 842 
% of heart failure 16 14 15 
Stroke 2 496 3 025 5 521 
% of stroke 8 11 9.4 
Acute myocardial infarction (AMI) 2 184 1 650 3 834 
% of AMI 7 6 7 
Readmission at 1 year 5 795 3 696 9 491 
% readmissions at 1 year 19 14 17 
Source: Adapted from Stewart et al., 2004: 288. 
Reynolds et al. (2007) estimated that more than 400 000 hospital admissions occur each year for 
atrial fibrillation. These costs were for the management of AF and excluded any out-of-pocket 
expenditure, patient time spent on care, lost productivity, as well as non-acute nursing home care or 
rehabilitation. All hospitalisations were recorded, but only those related to cardiovascular disease or 




assigned in 2002 $US. Of the 1 005 patients enrolled in the study, only 973 completed at least three 
months’ follow-up. Of these, 3.5% (n=34) were considered to have chronic AF, 503 patients had 
paroxysmal AF (51.7%) and, in 436 (44.8%), the AF was terminated by electrical cardioversion. 
During the follow-up period, a further 31 patients progressed to chronic AF (3.19%). No patients 
received pulmonary vein isolation (PVI) or underwent surgery for their AF (MAZE procedure).  
During the follow-up period, 319 patients (33%) had more than one recurrent episode of AF. It is 
important to note that the majority of patients in whom AF became permanent were from the older 
group of patients and that there were more women than men in this group. In those who developed 
permanent AF, the prevalence of heart failure and valvular disease was higher.  
During the follow-up period, 259 patients (27%) were admitted to hospital a total of 395 times. This 
is an average of 1.5 admissions per patient admitted, but the data show that the range was between 
1-9 admissions per patient.  
A total of 190 admissions (48%) were for arrhythmia and a further 75 admissions were for heart 
failure. The average length of stay was 4.4 days (±7.2 days). This is lower than the data from the UK 
where the average hospital stay was six days in 1995 and seven days in 2000. The average hospital 
cost was US$9 358 (±9 670) per admission. By using the data in Figure 6.2 and the average cost 
associated with treating AF, it is possible to estimate the total cost for managing AF, as tabulated in 
Table 6.2. 
 
Figure 6.2: Principal diagnoses for hospital admission related to cardiovascular 
disease, AF, AF therapy or complication in the FRACTUAL registry 


















Table 6.2: The total estimated cost of AF using mean and median for hospital costs 
 Cost at Median value US$ 
(2002) 
Cost at Mean value US$ 
(2002) 
Hospitalisation 2. 5 Billion 3.7 Billion 
Drug costs including INR 1.8 Billion 2.78 Billion 
Outpatient visits 958 million 1.4 Billion 
Total costs 5.37 Billion 8 Billion 
Source: Adapted from Reynolds et al., 2007: 630. 
Given the mean cost of hospitalisation of US$9 358 per admission, with an estimated number of 
admissions in the US of 400 000 per year for AF, the cost of hospitalisation only for AF could be 
US$3.7 billion. On the other hand, by using a more conservative estimate of the median cost of 
hospitalisation, while still utilising the 400 000 admissions each year, the cost of hospitalisation 
would be US$2.5 billion. 
The data reveal that, for the nearly 1 000 patients included in the study, the average healthcare cost 
was almost $4 700 per year during the first year following diagnosis. Of note was the fact that 
patients who accepted permanent AF had lower costs than those patients who did not accept the 
symptoms. Approximately half of all the costs in AF are attributed to hospitalisations. The study 
demonstrated that each recurrence of AF increased the average cost by about $1 600, which 
represents 34% of the initial cost. Table 6.3 demonstrates resource utilisation by group over the full 
follow-up period. 
Table 6.3: Resource utilisation by group over entire follow-up period  
measured per 100 patients 
AF Recurrences 








Cardioversion 2.9 8.1 49.3 160.6 
AF related hospital admissions 0.21 0.24 0.64 1.61 
Total hospital days 0.32 1.3 2.7 4.5 
AF emergency room visits 2.9 10 25.2 54.5 
Trans-oesophageal ECHO 0 12.9 30.8 45.4 
Trans thoracic ECHO 14.7 33.1 44.4 60.6 
Ambulatory monitors 14.7 25.2 35 54.5 
Source: Adapted from Reynolds et al., 2007: 631. 
Reynolds et al. suggests that, given the limited effectiveness of anti-arrhythmic drugs, it may be 
conceivable that, for highly symptomatic patients, other alternatives including catheter ablation, may 




6.4 STUDIES COMPARING CATHETER ABLATION WITH DRUGS FOR AF 
The ACC/AHA/ESC guidelines indicate that catheter ablation is a reasonable alternative to drug 
therapy for the treatment of atrial fibrillation and the prevention of the recurrence of AF. Numerous 
studies show that pulmonary vein isolation is superior to drugs at one year with regard to maintaining 
sinus rhythm.  
There are a number of randomized clinical trials designed to evaluate catheter ablation vs. drug 
therapy, but, because of the small number of patients in each trial and the fact that many are single 
centre studies, the clinically relevant efficacy of catheter ablation for patients with AF remains in 
question. Therefore, in the absence of large, randomized, multi-centre clinical trials comparing 
catheter ablation to drug therapy, the author examined the rationale and results of three systematic 
reviews and meta-analysis published in 2008 and 2009 for efficacy of catheter ablation vs. anti-
arrhythmic drugs for the maintenance of sinus rhythm at one-year follow-up. 
6.4.1 The Calkins et al. study 
The first study by Calkins et al. (2009) included studies that focussed on the ablation of the 
pulmonary veins but may also have included additional ablation lines like roof lines, flutter ablation 
and lines around the superior vena cavae.  
Of the 537 studies that were identified, 142 met the inclusion criteria, but only 63 studies were 
included in the final selection. Studies were considered eligible for inclusion irrespective of whether 
the design was prospective or retrospective. Studies were excluded if they were done in animals or 
in vitro. Studies in any language other than English, French, German, Italian, Portuguese or Spanish 
were also excluded. Any studies performed before 1990 or after January 2007 were also excluded. 
Finally, paediatric studies and studies with less than 40 patients, or more than one type of catheter 
ablation, were also excluded. 
In the systematic review of the drug therapy arm, a total of 3 383 abstracts were reviewed, but only 
44 of the studies met the inclusion criteria and only 34 were finally analysed. The review on the drug 
arm focussed on five specific anti-arrhythmic drugs, namely Amiodarone, propafenone, dofetilide, 
Flecainide and Sotalol. In the drug therapy arm, any studies in any language other than English were 
excluded as were studies before 1990 and after 1 January 2007. Again, animal or in vitro studies, 
paediatric studies or studies with fewer than 40 patients were excluded. Studies with less than a 30-
day follow-up period were also excluded (Calkins et al., 2009: 351). 
Of the 63 eligible studies in the radiofrequency ablation (PVI) dataset, nine were randomized 
controlled, 11 were prospective comparative, 31 were single arm prospective studies and 12 were 
retrospective studies. Two-thirds of the studies were published after 2004. Of the 34 studies included 




control studies, there was one non-randomized, comparative study, and nine studies were single 
arm trials. Some of the characteristics of the two patient groups are tabulated in Tables 6.4 and 6.5. 
Table 6.4: Characteristic of patients undergoing either catheter ablation or 
receiving anti-arrhythmic drugs 
 Catheter ablation AAD 
 Mean Range Mean Range 
Age (y) 55.5 42-67 62.6 38-80 
Mean no of drugs refractory  2.6 1-5 1.7 0-3 
Mean duration of AF (y) 6.0 1-9 3.1 0-1 
Mean LA size (mm) 42.6 35-50 43.7 33-49 
Mean LV ejection fraction (%) 57.5 49-71 49 25-67 
Source: Calkins et al., 2009: 353. 
Table 6.5: Baselines characteristic of patients with AF undergoing catheter ablation or 




Sex (male) 72 64.6 
Paroxysmal AF 69.8 56.4 
Persistent 14.9 35.1 
Permanent (long standing) 13.9 7.5 
Previous ablation 4.2 0 
Ischaemic heart disease 10 18.2 
Valvular heart disease 5.6 16 
CHF 15.7 24.6 
Stroke 3.3 0 
Diabetes 4.8 12.1 
Hypertension 30.3 38.4 
Previous anti- arrhythmic 95 36.3 
Anti-coagulants 100 100 
Source: Calkins et al., 2009: 353. 
What can be noted from the baseline characteristics of the two groups is that the average age of 
patients in the PVI group was lower (mean age 55 years vs. 62 years). The PVI group had all failed 




the PVI groups were reported to have paroxysmal AF, compared to the 56% in the drug therapy 
group. Finally, the patients in the PVI cohort had a longer duration of AF (6 years vs. 3.1 years). 
In the drug therapy cohort there were sixteen Propafenone treatment groups, eleven Amiodarone 
treatment groups, nine groups treated with Sotalol, seven with Flecainide and two groups with 
Dofetilide. 
Calkins et al. (2009) report that almost half of the procedures performed in the PVI studies were 
done using a catheter navigation system, the use of which increased markedly from 2002. The use 
of irrigated catheters also increased over this period.  
The efficacy of the outcomes for the PVI cohort (where efficacy was defined as a lack of recurrence 
of AF during the follow-up period), with an average follow-up period of 14 months, is illustrated in 
Table 6.6. 
Table 6.6: Efficacy outcomes for radiofrequency ablation 






Single ablation, no AAD 2 800 57 50 to 64 
More than one ablation with no AAD 3 481 77 65 to 77 
More than one procedure on AAD 3 562 77 73 to 81 
Single ablation on AAD 4 782 72 Not stated 
Source: Calkins et al., 2009: 354. 
In the drug therapy cohort, Amiodarone showed the greatest success over placebo; however, the 
overall success rate of all drugs was 52% (47% to 57%) in 3 180 patients. 
Complications associated with catheter ablation are well documented and Calkins et al. (2009) report 
a total of 28 adverse events (4.9%). The most common complication associated with the PVI 
procedure is pulmonary vein stenosis (1.6%), cardiac tamponade (0.7%), pericardial effusion (0.6%), 
peri-procedural stroke (0.3%) and peri-operative TIAs (0.2%). The overall mortality rate in all 
treatment groups was 0.7%. 
While the types of adverse events differ in the drug therapy group, the following were reported from 
the Calkins et al. (2009) publication: 
 Overall mortality rate was 2.8%.  
 The total number of adverse events in the drug therapy arm was 24 or 29.8% (Calkins et al., 
2009: 354).  
 Adverse events caused 10.4% of patients to discontinue their drugs while another 13.5% 




Calkins et al. (2009) state, in their concluding remarks, that catheter ablation is associated with a 
higher efficacy than AAD, even though most of the patients who were enrolled had already failed 
more than one AAD. They also remarked that modification of the ablation procedure did not make 
an impact on the data, but that more difficult and older patients were being treated in the later studies.  
It may be relevant to question the fact that this study was published in 2009, when the cut off for 
inclusion of studies was January 2007. Ablation for AF is a relatively new procedure which requires 
skill and has a steep learning curve. As noted in the Calkins study, two-thirds of the trials were 
published after 2004 while only 12% of the studies on ADT were published at the same time. There 
was also an increase in the adoption of both catheter navigational technologies and irrigation 
technologies, which not only improve the accuracy (and implying, thereby, the efficacy) but also the 
safety of the procedure. Is this a fair comparison? 
6.4.2 The Noheria et al. review 
A second systematic review employed a methodology similar to that used in the Calkins et al., review 
described above. Success in both the ADT cohort and the PVI cohort was described as free of 
recurrent atrial tachycardia. This study differed in that it looked only at studies where both drugs and 
PVI were compared (Noheria et al., 2008: 581). Figure 6.3 illustrates the flow diagram of the literature 












Figure: 6.3: Flow diagram of the stages of the literature search to find 
relevant randomized control trials (RCT) 
Source: Noheria et al., 2008: 581. 
688 References identified on 
PubMed, EMBASE and Cochrane 
Central Library of controlled trials 
20 Potentially relevant trials found 
18 RCT including AV node ablations 
9 RCT with relevant interventions 





The following five criteria were important for inclusion:  
 Appropriate allocation sequence of generation. 
 That no exclusions occurred after randomization. 
 The attrition rate was less than 15%. 
 The assessments were blinded. 
 There was an intention to treat analysis. 
Those that did not meet at least three of these criteria were excluded.  
The four trials reviewed in the meta-analysis are Krittayaphong et al. (2003), Wazni et al. (2005), 
Stabile et al. (2006) and Pappone et al. (2006). The characteristics of the four trials are tabulated in 
Table 6.7. 
Table 6.7: Characteristics of the trials reviewed in the meta-analysis comparing catheter 
ablation vs. ADT for AF 
 
 Note: *These 44% of “failures” included 4 patients who had atrial flutter. 
Source: Adapted from Noheria et al., 2008: 582. 
A total of 432 patients were included in this analysis: 218 received ADT while the other 214 
underwent catheter ablation. At the end of the follow-up period, a total of 75.7% of patients from the 
catheter ablation cohort were considered free from AF, while only 18.8% of those in the ADT cohort 
were free of AF. Table 6.8 demonstrates the results of each study as well as the number of adverse 
events. 
Author Year N Age Type Previous ADT Repeat Cross 
over 
      % 





≥1 Not stated Not stated 
Wazni 2005 70 
PVI 53±8 
ADT 54±8 
PAF Naïve to ADT 12 49 





≥2 No 57 
Pappone 2006 198 
PVI 55±10 
ADT 57±19 





Table 6.8: Results from individual trials 
 
Source: Noheria et al., 2008: 582. 
The Forest plot illustrated in Figure 6.4 shows that, in each of the four studies, the evidence is in 
favour of PVI. What makes this analysis different from the previous meta-analysis by Calkins et al. 
(2009) is the fact that all four studies in the Noheria study had Holter monitors at three, six and 12 
months follow-up, while fewer than 50% of the studies in the Calkins trial used Holter monitors to 
evaluate whether or not patients were free of AF recurrence. 
 
Figure 6.4: Forest plot of four randomized controlled trials evaluating PVI vs. ADT for 
recurrence free survival during the follow-up periods. Width of diamond represents 95% 
confidence interval 
Source: Noheria et al., 2008: 584. 
The authors reported on the Beg and Egger tests for publication bias and showed that there was no 
statistically significant publication bias. They acknowledge that there were only a small number of 
studies included in the analysis, which made the meta-analysis underpowered to detect publication 
bias. They did, however, state that there was little evidence to suspect any such bias. This is shown 
in Figure 6.5 (Noheria et al., 2008: 583). 
 PVI Arm Control Arm  










RR for AT 
(95% CI) 
Krittayaphong 
et al. (2003) 
15 12 5 15 6 7 
3.73 
(2.47-5.63) 
Wazni et al. 
(2005) 
32 27 4 35 7 4 
2.00 
(1.02-3.91) 
Stabile et al. 
(2006)  
68 38 3 69 6 4 
6.43 
(2.91-14.21) 
Pappone et al. 
(2006) 













Figure 6.5: Funnel plot with 95% CI for assessing for publication bias 
Source: Noheria et al., 2008: 584. 
6.4.3 The Piccini et al. meta-analysis 
The final meta-analysis evaluated was that by Piccini et al. (2009). The goal of their meta-analysis 
was to determine whether PVI was more efficacious than ADT and to evaluate the adverse events 
and safety of the two comparators. To do this, the authors analysed studies in which patients were 
randomly assigned to either catheter ablation or anti-arrhythmic drugs.  
Studies were excluded from the analysis based on any of the criteria below: 
 If catheter ablation was used in both treatment arms. 
 If the follow-up period was <12 months. 
 If the control arm had <10 patients.  
 If surgical ablation was included.  
 If only patients with atrial flutter were included.  
 If patients were in a previously reported publication (e.g., a sub-study).  
The primary endpoint was freedom from AF at 12 months with all recurrences after the blanking periods 
considered, regardless of anti-arrhythmic drug status. Secondary outcomes included the number of 
repeat catheter ablations, cross-over from the drug arm  to the catheter ablation, hospitalisation for 
cardiovascular causes, pulmonary vein stenosis, oesophageal injury, thromboembolic events 
(including stroke/transient-ischaemic attacks) and, finally, all-cause mortality. All outcomes were 
analysed according to the intention-to-treat principle.  
After reviewing 102 abstracts for inclusion and exclusion criteria the authors excluded 96 studies. 
The six remaining studies were reviewed and included in the analysis. The reasons for the exclusion 




 Studies comparing two catheter ablation or surgical techniques without a medical therapy 
only arm. 
 Trials of imaging or mapping techniques. 
 Observational studies. 
 Studies of medical therapy only (e.g., rate vs. rhythm control).  
 Trials of pacing strategies or atrioventricular nodal ablation. 
 Studies of supraventricular tachycardia or atrial flutter only.  
The six randomized, controlled trials incorporated in this meta-analysis included a total of 693 
enrolled patients. Only one trial was in a single centre study, whereas all the others were multi-centre 
studies. The baseline patient characteristics of these 693 patients are presented in Table 6.9. Most 
of the patients in the meta-analysis had paroxysmal AF (70%). In five of the studies that included 
information on the sex of the patients, it was found that 73% of the patients were male. The mean 
age was 55 years, the mean left ventricular ejection fraction was 60% (±4%) and the mean left atrial 
diameter among patients randomly assigned to ablation was 42mm (±3 mm). In the trials that 
specifically looked at pre-trial enrolment drug failure, the average number of drugs which were 
ineffective before enrolment was two.  
Table 6.9: Patients characteristics in randomised trials of catheter ablation vs. ADT 
 
Source: Piccini et al., 2009: 628 & 629. 
The primary endpoint in all six trials was freedom from AF at 12 months of follow-up. It is important 
to note that catheter ablation was decidedly more successful than drugs (77% vs. 29%). When, 
because of heterogeneity, the trial that enrolled only patients with persistent AF was removed from 
the analysis, catheter ablation was associated with even greater odds of AF-free survival (15.78; 
95% CI) compared with the odds ratio when this study was included (9.74; CI 95%). With respect to 
freedom from both AF and anti-arrhythmic drug therapy, only two trials reported the number of 








































































































52 63 67 33 63 39 Not stated 
Wazni et al. (2005) 54 Not stated 96 4 54 42 0 
Stabile et al. 
(2006)  
62 59 67 33 59 46 Not stated 
Oral et al. (2006) 57 88 0 100 456 45 2 
Pappone et al. 
(2006) 
56 67 100 0 61 39 2 





(n=131/152) of those randomly assigned to catheter ablation were free from AF without an anti-
arrhythmic therapy at 12 months.  
Three of the trials in the analysis reported on hospitalisations. The total number of hospitalisations 
was significantly lower in the catheter ablation groups with only 14 hospitalisations per 100 person 
years in the catheter ablations groups compared with 93 in the ADT group. In four of the trials that 
reported on repeat catheter ablation, a total of 17% of the patients randomised to the catheter 
ablation arm underwent another catheter ablation. In the trials where cross-over was allowed, a total 
of 51% of patients in the drug therapy arm underwent catheter ablation. While the authors were 
interested in the left atrial diameter as well as left ventricular ejection fraction, they concluded that, 
due to the significant differences in how these were reported in the studies, it would not have been 
possible to obtain an unbiased summary on these measures and, as such, they were not reported 
on in this meta-analysis. 
The rate of serious complications is often cited as a reason why catheter ablation should not be 
considered as a first-line option. However, Piccini et al. (2009) found that the major complication rate 
for catheter ablation was only 2.6%. These complications included the following: 
 Cardiac tamponade, n=2 (<0.6%) 
 Symptomatic pulmonary vein stenosis, n=1 (<0.3%) 
 Pericardial effusion, n=2 (<0.6%) 
 Phrenic nerve paralysis, n=1 (<0.3%) 
 Thromboembolic events, n=3 (<0.9%) 
 Total n=9 (2.6%) 
Of those patients who were randomized to ADT, the reported adverse event rate was 8% (n=29). 
This is lower than that reported in other studies like Noheria et al. (2008) who reported adverse 
events at 17%. The following adverse events were reported by Piccini et al. (2009): 
 Cases of pro-arrhythmia with Flecainide, n=3 (<0.9%) 
 Cases of thyroid dysfunction secondary to Amiodarone, n=9 (2.6%) 
 Cases of sexual impairment caused by Sotalol, n=11 (3.18%) 
 Gastroenterological adverse event, n=1 (<0.3%) 
 Corneal micro deposits, n=2 (<0.6%) 
 Abnormal liver function tests, n=2 (<0.6%) 
 Case of sinus node dysfunction caused by Amiodarone. n=1 (<0.3%) 
 Total n=29 (8%)  
Similar to the Noheria meta-analysis, Piccini et al. (2009) evaluated the impact of potential 




no publication bias among the five studies which were included in the determination of treatment 
effect. The three main findings in this meta-analysis were as follows: 
 Catheter ablation had more than a twofold greater efficacy at 12 months for maintaining sinus 
rhythm than did ADT and was measured across the studies at 75%. 
 Patients treated with catheter ablation had two-thirds reduction in hospitalisation for cardio-
vascular causes. 
 Catheter ablation had a procedural complication rate less than major complication rates 
associated with high risk percutaneous coronary interventions at 2.6%. 
The authors concluded that, when catheter ablation was compared with an ADT strategy, the catheter 
ablation results showed a significantly increased freedom from AF at one year and that catheter 
ablation appeared to be associated with significantly decreased hospitalisations for cardiovascular 
causes. Although the procedure is associated with major complications, including stroke, cardiac 
perforation, and pulmonary vein stenosis, these events appear to be rare. Finally, the authors stated 
that the current American College of Cardiology/American Heart Association/Heart Rhythm Society 
guidelines recommend catheter ablation as a class IIa indication as an alternative to pharmacological 
treatment to prevent recurrent AF in those with symptoms and little to no left atrial enlargement. It can 
be argued that catheter ablation should be elevated to a class I recommendation for the prevention of 
recurrent AF.  
6.5 COST-EFFECTIVENESS ANALYSIS OF CATHETER ABLATION 
Research by Stewart et al. (2004) showed that the cost of treating AF in the UK rose by 49% in the 
five years between 1995 and 2000. This was due to the increase in prevalence of AF and the 
resultant increase in hospitalisations. A number of studies have indicated that catheter ablation is 
more effective at preventing the recurrence of AF at one year than ADTs. ADTs are also associated 
with more hospitalisations and significantly more, but often less severe, side effects (Piccini et al., 
2009; Noheria et al., 2008). When evaluating the costs associated with treating patients with AF, 
both the costs associated with catheter ablation and the cost of treating patients with medication 
must be considered (Martin-Doyle & Reynolds, 2010: 727). AF is also associated with a negative 
quality of life and Reynolds et al. (2008) reported that several studies showed that achieving and 
maintaining sinus rhythm resulted in improved quality of life scores. Based on a number of studies 
with AF cohorts, the baseline utility value has been reported as 0.725 for patients in AF and the 





6.5.1 Costs associated with ADT 
The FRACTUAL study revealed that almost half of all costs associated with treating AF with ADTs 
were related to hospitalisation. In some instances, the cost of using a rhythm control strategy is 
associated with higher costs than a rate control strategy as, in some countries, patients are admitted 
to hospital when drug dosing needs to be changed. These are not the only reasons for hospitalisation 
of AF patients, as many patients may be admitted in order to undergo cardioversion or require 
hospitalisation for heart failure or stroke. Piccini et al. (2009) state that in patients treated with 
catheter ablation for AF, the cost of hospitalisation decreased by two-thirds when compared to the 
patients treated with ADT alone. Other costs associated with treating patients with ADTs include the 
costs associated with INRs if patients are required to take anti-coagulants. This may, however, affect 
both the catheter ablation group and the ADT group. 
6.5.2 Costs associated with catheter ablation 
A literature review found several studies that have investigated both cost and cost-effectiveness of 
catheter ablation vs. ADT. 
1. The first study was published in Pacing Clinical Electrophysiology in 2003. The authors were 
Weerasooriya et al. (2003). The study was titled ‘Cost Analysis of catheter ablation for 
paroxysmal atrial fibrillation’. This was a single-centre study in Bordeaux, France, comprising 
188 consecutive patients who underwent catheter ablation. The patients had, on average, 1.52 
ablations, but ranged from one to four procedures. Their findings were based on the fact that 
72% of the patients were free from AF at the end of the study. Their findings, calculated at 
2001 Euros were as follows: The authors estimated that over a five-year period, the total cost 
of the ablation strategy was €6 730 compared with a five-year cost of ADT of €7 194. They 
concluded that the upfront costs of ablation were significantly more than those of ADT, but that 
the patients on ADT had higher annual costs. They stated that, after five years, the costs 
continued to diverge, implying that catheter ablation was not only better from an efficacy point 
of view, but also from a cost point of view at five years. Of note was that in 2011 this group 
published a study which evaluated the same group of patients. This cohort of patients required 
an average of 1.75 catheter ablations to remain free of AF recurrence at five years. With the 
additional ablation, the number of patients who were free of AF recurrence was 87%, 81%, 
and 63% at one, two, and five years, with major complications occurring in less than 3% of 
patients (Weerasooriya et al., 2003).  
2. The second study was published in the Journal of the American College of Cardiology in 2006. 
The authors were Chan et al. (2006). The study was titled ‘Cost-Effectiveness of 




assess the cost-effectiveness of catheter ablation with rate control or Amiodarone. The authors 
looked at hypothetical cohorts with AF at low or moderate risk of stroke and evaluated short 
and long-term outcomes like stroke, haemorrhage procedural complications and drug toxicity. 
The authors state that their model was conservative and biased against catheter ablation 
(Chan et al., 2006: 2516). The costs were measured in 2004 US$ and the authors reported 
that the lifetime costs for patients undergoing ablation ranged from between $43 036 to 
$59 380 for ablation compared with $24 540 to $50 509 for rate control and $38 425 to $55 795 
for rhythm control. The authors concluded that catheter ablation was unlikely to be cost-
effective in patients with a low risk of stroke but that, in patients with a moderate risk of 
developing stroke, catheter ablation may be cost-effective if the efficacy rate of catheter 
ablation is sufficiently high.  
3. The third study was published in the Journal of Cardiovascular Electrophysiology in 2007. The 
authors were Khaykin et al. (2007). The title of the study was ‘Cost Comparison of Catheter 
Ablation and Medical Therapy in Atrial Fibrillation’. The authors evaluated the costs relating to 
medical therapy, which included rate and rhythm control medications, physician follow-up 
visits, hospital admissions, the cost of anti-coagulation, all non-invasive testing, and any cost 
of complications related to this management strategy. On the other hand, costs related to 
catheter ablation included the cost associated with the ablation procedure (electro-anatomic 
mapping or intra-cardiac echocardiography-guided pulmonary vein ablation), all the physician 
costs and hospital costs and, finally, costs related to peri-procedural medical care and 
complications. To model the efficacy, they did a sensitivity analysis, looking at a range of initial 
success rates (50-75%), late attrition rates (1-5%), and the prevalence of congestive heart 
failure (CHF) (20-60%). The discounting was performed at between 3% and 5% per year. 
Costs were calculated in Canadian dollars. The results of this study showed that the cost of 
catheter ablation ranged from $16 278 to $21 294, with an annual cost of $1 597 to $2 132, 
while the annual cost of medical therapy ranged from between $4 176 to $5 060. When 
estimating the on-going costs of ADT vs. catheter ablation for PAF, the costs equalised at 
between 3.2-8.4 years of follow-up. The authors concluded that catheter ablation was a 
“fiscally sensible” alternative to ADT for patients in PAF with costs converging at four years.  
4. The fourth study was published in Heart (BMJ) in 2009. The authors were McKenna et al. 
(2009). The title of the study was ‘Cost-effectiveness of radiofrequency catheter ablation for 
the treatment of atrial fibrillation in the United Kingdom’. The authors used a probabilistic 
decision analytical model to evaluate the short-term and long-term costs of treating AF patients 
with either drugs or catheter ablation. The outcome of the study was freedom from arrhythmia 
at 12-months and the outcomes were expressed in terms of QALYs. They used the CHADS2 
index as the baseline risk for stroke. The study staged their results in two formats. The first 




effectiveness by means of incremental cost-effectiveness ratios (ICER). The second reported 
on the probability that each strategy would be considered the more cost-effective option for a 
given cost-effectiveness threshold. McKenna et al. (2009) found that, when evaluating the 
lifetime analysis for cost-effectiveness, the ICER for catheter ablation vs. AADs was between 
£7 763 and £7 910 for each additional QALY across the CHADS2 scores. They also reported 
that the probability that catheter ablation was cost-effective at both thresholds, £20 000 and 
£30 000, per QALY was between 0.981 to 0.992 and 0.996 to 1.00. The authors reported on 
the ICER at the point of the five-year follow-up: When comparing catheter ablation and ADT, 
the ICER was £20 831 and £27 745 per QALY gained, respectively. At these values, the 
probability of being cost-effective at the commonly used thresholds in the UK of £20 000 and 
£30 000 was lower, at 0.091 to 0.418 and 0.577 to 0.881 respectively.  
5. The fifth study to be evaluated for cost analysis was published in Health Technology 
Assessment in 2008. The authors, Rodgers et al. (2008), had previously published a cost-
effectiveness analysis on the subject for submission to NICE. This study was titled ‘Curative 
catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic 
evaluation’. The aim of the study was to determine clinical effectiveness, safety and finally 
cost-effectiveness of treating patients with AF and flutter with catheter ablation or ADT. The 
primary outcome was the number of patients who were free of arrhythmia at 12month follow-
up. The authors completed a systematic review on relevant literature which suggested that 
catheter ablation was effective at reaching the primary endpoint of being free of arrhythmia at 
12 months in between 28% and 85.3% (mean 76%) of patients with AF. It was also found to 
be effective in between 85% and 92% (mean 88%) of patients with atrial flutter. They reported 
findings that were robust over a range of assumptions and resulted in between £7 763 and 
£7 910 per additional QALY. The authors made the assumption that, if the benefits of catheter 
ablation were not maintained for more than five years, then the cost-effectiveness in favour of 
catheter ablation would be dependent on the following factors: 
 The prognostic benefit of being in sinus rhythm 
 The magnitude of differences in quality of life between catheter ablation and ADTs 
 The long-term reduction of risk factors.  
Rodgers et al. (2008) reported that catheter ablation was a safe and efficacious procedure for 
the management of AF and typical atrial flutter and cost-effectiveness ranged from £23 000 
and £38 000 when factors a-c above were explored.  
6. The next study to be investigated was published in the Journal of Cardiovascular Electro-
physiology in January 2009. The title was ‘Cost comparison of ablation versus antiarrhythmic 




study’. The authors, Khaykin et al. (2009), evaluated the data from the Pilot RAAFT study and 
evaluated the costs related to medical therapy which included, among others, the cost of drugs, 
costs associated with anti-coagulation, physician follow-up visits, non-invasive testing, hospital 
admissions, and the costs which were related to managing any complications. Ablation-related 
costs included costs associated with equipment and disposables used, hospital and physician 
costs, as well the cost of managing any peri-procedural complications. Costs were based on 
the Canadian Registry of Atrial Fibrillation (CARAF), government fee schedules, and published 
data. Included in the analysis was a range of success rates between 50 and 75%, late attrition 
rates of between 1% and 5% and the prevalence of congestive heart failure (20-60%). A simple 
decision tree was used and, although the RAAFT pilot study only had data just beyond one 
year, the authors modelled the data to two years. The upfront costs of ablation were four times 
higher than ADT and, at two months, the cost of ablation was $10 465 compared with $2 556 
for the ADT arm. At one year, the costs in the ablation arm were still significantly higher, at 
$12 823 compared to ADT costs of $6 053. By the end of the second year, the costs had 
converged and the costs in the catheter ablation arm were $15 303 vs. $14 392 for the ADT 
arm. The authors concluded that, in patients with symptomatic AF, the costs were cost neutral 
at two years.  
7. Martin-Doyle and Reynolds (2010) concluded, in the Journal for Atrial Fibrillation in 2010, ‘after 
evaluating a number of studies discussed above that catheter ablation is somewhat cost-
effective in the short term vs. ADT.’ 
8. Finally, Khaykin and Shamiss (2011) reported that 70 to 80% of all AF patients are admitted 
to hospital at some stage of their disease. They stated that catheter ablation appeared most 
cost-effective in the younger patients, who were at moderate risk of stroke ($28 000/QALY 
gained). Catheter ablation was still cost-effective, although less so, in older patients at 
moderate risk of stroke ($51 800/QALY gained). It was least cost-effective in young patients 
with a low risk of stroke ($98 900/QALY gained) (Khaykin & Shamiss, 2011: 3). 
6.6 QUALITY OF LIFE AND ATRIAL FIBRILLATION 
When investigating mortality, morbidity and quality of life related to AF, the following was discovered. 
Pappone et al. (2003) examined 1 171 consecutive patients from all over Italy, who all had 
symptomatic AF. Circumferential pulmonary vein ablation (PVI) was performed on 589, while 582 
patients were treated with ADT. Of the ADT group, 33% were treated with Amiodarone, 15% with 
Flecainide, 13% Sotalol, 9% Quinidine, 6% Disopyramide and 7% were on more than one ADT. 
Table 6.10 demonstrates the baseline characteristics of patients in both groups. Recurrence of atrial 





Table 6.10: Baselines characteristics of patients receiving PVI or ADT 
 
Source: Pappone et al., 2003: 188. 
In this study, the overall median follow-up was 900 days with 19 (2%) of patients lost to follow-up. The 
mortality results are tabulated in Table 6.11. At the end of the follow-up period, 6% of the patients in 
the ablation group had died, compared with 14% in the group treated with ADT. There was a 69% 
reduction in cardiovascular deaths in the catheter ablation group compared to the ADT group. There 
were no deaths due to sudden cardiac death in the catheter ablation group, compared with 2.1% of 
deaths in the ADT group. It is important to note that of the 77 patients who died from cardiovascular 
deaths, 75% were in AF at the time and that 74% of the deaths from heart failure and 61% from 
myocardial infarction were in patients who were in AF at the time. 
Table 6.11: Adverse events in the catheter ablation and ADT group,  
measured per 100 of the population 






CHF 5.43 9.79 1.80 
AMI 1.19 1.37 1.15 
Peripheral embolism 0.17 0.52 3.06 
TIA 1.36 4.64 3.41 
Ischaemic stroke 0.68 2.58 3.79 
Haemorrhagic stroke 0.34 1.2 3.53 
Total 9.17 20.1 2.19 
No of patients with events 46 98 144 
Source: Adapted from Pappone et al., 2003: 189. 





Age 65 ±9 65 ±10 0.99 
Gender (male) 58 59 0.95 
Follow-up days 861 (161-1491) 911 (179-1508) 0.22 
Duration of AF (years) 5.5 ± 2.8 3.6 ±1.9 <0.001 
% patients with PAF 69 71 0.45 
No of trials on ADT 3.1 ±2.1 2.3 ±1.5 <0.001 
% patients with no cardiac disease 34 35 0.72 
% patients with hypertension 46 43 0.29 
% patients with diabetes 11 10 0.60 
Patients with prior stroke of TIA 16 15 0.12 
LVEF on Echo 54 ±12 55 ±14 0.22 





Figures 6.6 and 6.7 illustrate the cause of deaths by percentage in the catheter ablation and ADT 
groups. In the catheter ablation group, 46 (8%) had adverse events compared with 98 (19%) in the 
ADT group. 
 
Figure 6.6: Cause of death in the catheter ablation group 
Source: Pappone et al., 2003: 189. 
 
Figure 6.7: Cause of death events in the ADT group 





































Table 6.12 demonstrates the side effects in both the catheter ablation and ADT groups. 
Table 6.12: SF-36 quality of life scores across AF and five control groups 
 
Notes: *Patients 6 months after PTCA from St Michael’s Hospital Toronto 
       **Patients after PTCA  
Source: Krumholtz et al., 1997. 
The total number of serious adverse events per 100 of the population in the ADT group was more 
than double that of the catheter ablation group. Congestive heart failure contributed to the greatest 
number of adverse events in both the catheter ablation group and the ADT group. However, there 
was almost a twofold increase in the number of adverse events from CHF in the drug group 
compared to the ablation group. TIA, haemorrhagic stroke and ischaemic stroke in the ADT group 
was almost a fourfold increase from that of the catheter ablation group. 
Finally, Pappone et al. (2003) stated that circumferential ablation improved not only the mortality and 
morbidity of patients with AF, but that there was an associated improvement in quality of life, as 
illustrated by Figures 6.8 and 6.9.  
 
Figure 6.8: Computation aggregates scores for physical component 
of the SF-36 questionnaire 
Source: Pappone et al., 2003: 195. 
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General health 54±21 51±23 65±22 47±24 59±19 78±17 
Physical function 68±27 60±29 76±25 48±31 70±26 88±19 
Role physical 47±42 47±45 71±39 34±40 51±39 89±28 
Vitality 47±21 48±26 60±20 44±24 58±19 71±14 
Mental health 68±18 74±18 75±16 75±21 76±16 81±11 
Role emotional 65±41 64±44 83±35 64±43 73±38 92±25 
Social functioning 71±28 74±29 87±21 71±33 85±21 92±14 






Figure 6.9: Computation aggregates scores for mental component 
of the SF-36 questionnaire 
Source: Pappone et al., 2003: 195. 
Dorian et al. (2000) investigated the impact that paroxysmal atrial fibrillation had on health-related 
quality of life. They assessed 194 patients with PAF from outpatient units in four centres where the 
patients were requested to complete the Medical Outcomes Study Short Form 36 (SF-36), Specific 
Activity symptoms checklist, Illness intrusiveness and University of Toronto AF severity scales. Five 
control groups were used. The first group (n=47) were healthy individuals. The other four control 
groups were comprised of cardiac patients: published data (n=78), a PTCA group (n=69), published 
heart failure group (n=216) and, finally, a published post myocardial infarction group (n=107).  
The patients in the AF group were eligible to enter the study if they were over the age of 18, could read 
English or German, had no cognitive or sensory limitations and had at least one documented episode 
of paroxysmal AF. Patients with permanent AF with a continuous duration of more than six months 
were excluded. Patients where AF was secondary to other causes, e.g. post-op cardiac surgery or 
hyperthyroidism, were also excluded. Of the 194 consecutive patients with AF who were referred to 
the four participating centres, 175 met the inclusion criteria and 152 completed all the required forms. 
The average age of the AF group was 58 (±12 years), and 73% were male. AF was paroxysmal in 
60.5% of patients and the other 39.5% of patients had persistent AF. In the entire AF group, 99% were 
considered NYHA class I or II with respect to exercise capacity at a time when the patients perceived 
themselves to be in sinus rhythm. This was similar to the NYHA status of the post-PTCA control group. 
Only a small number of patients had other cardiac arrhythmias- Wolff-Parkinson-White syndrome in 
2%, atrioventricular (AV) nodal re-entrant tachycardia in 2%, and other supraventricular tachycardias 
in 5% and atrial flutter in 16%. A total of 5% had coronary artery disease (CAD) which required prior 
PTCA, 4% had coronary artery bypass surgery and 4% had heart valve replacement surgery. The 
mean left ventricular ejection fraction, when available, was 61 (±16%) and the mean LA diameter was 
42mm (±6mm). At the time of assessment, 76% of patients were on anti-coagulants, 61% were 




patients, 51% had undergone at least one cardioversion with a mean number of 1.2 (±1.4). More than 
half of all patients (51%) had been hospitalised for their AF at least once in the previous year, while 
44.6% had visited an emergency room at least once in the previous year. Almost 90% of patients had 
seen a specialist on at least one occasion, with a median of three visits per year for each patient, and 
33% had had five or more visits to a specialist in the previous year.  
The outcome measurements incorporated the following: patient demographics, including age, 
gender, and clinical history, such left ventricular function, anti-arrhythmic medications, history of 
hypertension, history of heart failure, echocardiographic left atrial diameter and New York Heart 
Association classification (NYHA). Patients were given questionnaires to evaluate QoL and symptom 
burden in the arrhythmia clinic and were requested to mail them back within a two-week period in 
postage-paid envelopes. 
The results indicated that, during AF (perceived or documented), the exercise function in the AF 
group was poorer, with only 38% in NYHA class I. Most patients (90%) had some symptoms during 
AF, including palpitations (68%), fatigue (62%) and shortness of breath (60%).  
The healthy control group was comprised of 47 healthy subjects with a mean age of 54 (±14 years) 
and 55% were female. There were significantly more men in the AF group compared with the group 
of healthy subjects (p=0.0025), and the patients in the AF group were also significantly older than 
the healthy control group (p=0.0329). There was no record of ventricular function in this group, but 
their exercise tolerance, as measured by the SAS, was excellent (92 ±6 14, range 58 to 100). In the 
cardiac control group of patients, all who had coronary artery disease with prior angioplasty were 
significantly older and had worse left ventricular function than patients with AF (p=0.001 and p=0.004 
respectively).  
The authors found that, when comparing the AF patients with the healthy group among all scales, 
both for the disease specific as well as generic QoL, the patients with AF were significantly worse 
than those in the control groups (Table 6.12). The extent of these differences was, in almost all 
cases, close to a full standard deviation.  
When comparing the AF patients with patients from the cardiac control groups for all spheres of the 
SF-36, the patients in the AF group were either worse than those in the published group or the same 
as study-created PTCA patients. This was in spite of the fact that the patients in the created PTCA 
group were older, had worse left ventricular function and required a major procedural intervention. 
When compared to the patients in the congestive heart failure group, the physical functioning scores 
were all worse than in the AF group. The only exception was vitality, which was as impaired in the AF 
group as in patients with heart failure (47 ±21 vs. 44 ±24, p=NS). In contrast, the psychological and 
social domains were either significantly better (mental health 68 ±18 vs. 75 ±21, p<0.01) or the same 




the same vein, AF patients, despite being younger and having better LVEF, were either significantly 
more impaired in general health, vitality, mental health, and social function or equivalently impaired 
with regard to physical function, role physical, role emotional and bodily pain, as the post myocardial 
function patients. 
Finally, the atrial fibrillation patients were the same as the PTCA group with regard to illness 
intrusiveness and the Specific Activity Scale, but they compared significantly worse than the PTCA 
group on global life satisfaction (62 ±20 vs. 68 ±18. p<0.05). Compared to the PTCA group, the AF 
group was significantly worse on the measures of symptom frequency and severity (22 ±10 vs. 16 
±10 and 19 ±8 vs. 13 ±9, both p<0.01).  
The authors concluded that quality of life in patients with paroxysmal AF was significantly more 
impaired in relation to healthy patients and equal to patients with significant cardiac disease. 
There are at least 34 different QoL instruments that have been used in published AF studies. Reynolds 
et al. (2008) believe that this reflects a lack of consensus on a single optimal approach. The most 
consistently used generic QoL scales in AF studies include, among others, the Medical Outcomes 
Study Short Form Health Survey (SF-36), the Short Form-12 (SF-12), which is derived from the SF-
36, and the EuroQOL/EQ-5D. The SF-36 is a 36-item questionnaire aimed at assessing eight health 
domains, namely, general health perception, physical functioning, social functioning, role limitations 
due to physical problems, bodily pain, mental health, role limitations due to emotional problems, and 
vitality. There are also an additional eight subscales in the SF-36 scale which generate physical (PCS) 
and mental component summary (MCS) scores. The SF-36 scale has been used successfully in a 
number of prior AF studies where the greatest changes are typically seen in the scales relating to 
physical function. The biggest limitation of such generic measures is that, by design, they reflect 
general health and functioning and, therefore, scores among AF patients are strongly influenced by 
patient demographics and co-morbid conditions. Cardiac-specific questionnaires have been used in a 
few studies, but typically these have not been designed for patients with AF. Of these, the most 
commonly used is the Arrhythmia Symptom Checklist: Frequency and Severity. Developed in the late 
1980s, it was used to evaluate the impact of early catheter ablation and pacing technologies on a 
variety of arrhythmias. This checklist asks respondents to rate the frequency (from 0 to 4) and severity 
(from 1 to 3) of sixteen symptoms commonly associated with AF. Frequency and severity scores 
therefore range from 0 to 64 and 0 to 48, respectively. 
The authors suggest that, as AF is often entirely asymptomatic, the impact of AF on QoL may be 
strongly influenced by the segment of the AF population that is studied. The converse of this may 
also be true, in that some patients with AF are severely symptomatic and thus, evaluating only their 
QoL scores may reflect scores that do not represent the asymptomatic patients. While this may hold 
true, it must not be forgotten that when evaluating treatment options for patients with AF, the aim is 




maintenance of sinus rhythm is associated with lower mortality and stroke. Therefore, even if a 
patient is asymptomatic with AF, their risk of stroke or death is not necessarily decreased but may, 
in fact, be increased as they may go undiagnosed and not be anti-coagulated (Reynolds et al., 2008: 
765). It should therefore be remembered that QoL is only one concern with these patients and that 
prevention of complications such as stroke is vital. 
The FRACTUAL registry, which looked at healthcare resource utilisation and costs associated with 
recurrent episodes of AF, included in their analysis a SF-12 derived physical component summary 
scales (PCS) and mental component summary scales below age-adjusted population norms, and 
the AF symptom checklist. The result from the FRACTUAL registry indicated that the results were 
not as poor as in typical clinical trials as, with treatment, the QoL scores improved to approximate 
population norms within three to six months, and generally remained stable thereafter. Some of the 
factors that influence the QoL in patients with AF are the fact that many studies have traditionally 
relied on these “generic” instruments and it may be expected that results may be influenced by age 
and co-morbid medical conditions.  
This was noted in the FRACTAL, where NYHA class, valvular heart disease, and chronic pulmonary 
disease had the biggest impact on QoL scores. Other factors existent at baseline, such as the 
presence of coronary artery disease and diabetes, revealed a worsened QoL over time in the RACE 
trial. Table 6.13 is a summary of some of the studies in AF which have used QoL in the study. 
In conclusion, of the thirteen studies reviewed and summarised in Table 6.13 no less than 12 (92%) 
used the SF-36 scale, five (38%) used the symptoms checklist and two (15%) used the University 
of Toronto severity scale. The biggest improvement in QoL scores seem to be among the ablation 
group, where 100% of the studies cited a statistically significant improvement in QoL in the catheter 
ablation group. When compared to the studies looking at either rate or rhythm control with ADT, 





Table 6.13: Selected quality of life studies in atrial fibrillation 
Trial 
name 




CTAF 264 patients with 
recent paroxysmal 
or persistent AF 











of Toronto AF 
Severity Scale 
Modest improvements 
in SF-36 PCS and 
MCS scores and ~20% 
reduction in Symptom 
Checklist scores. No 
differences between 
groups, despite less 
AF in Amiodarone 
group 





or placebo. Those in 











By intention to treat, 
no differences 
between groups at 1 
year except for 
decreased mental 
health score in 
Amiodarone group 
Rate vs. rhythm control studies 
PIAF 252 patients with 






rate Control. QoL 
data obtained at 
baseline and 12 
months 
SF-36 4/8 subscales 
improved in rhythm 
control versus 6/8 in 




STAF AF for >4 weeks, 
excluding those 
with low and very 





AAD) vs. rate control 
(drugs). QoL data 
obtained at baseline 
and 12 months 
SF-36 At 12 months, 2/8 
subscales improved in 
rhythm control group 
vs. 5/8 in rate control 
group. No overall 
between group 
differences 
RACE 352 patients with 
persistent AF 
included in the 
RACE study 
Randomized to rate 
(drugs) or rhythm 
control 
(Cardioversion, 
AADs). QoL data 
collected at baseline, 
1 year, and 24–36 
months 
SF-36 QoL similar between 
groups at study end. 
Rate control group had 
improvement in 3 
subscales versus 0 
subscales in rhythm 
control group 
AFFIRM 25% of AFFIRM 
sites participated in 
QoL sub-study (n 
=716) 
Patients randomly 
assigned to rate or 
rhythm control group. 
QoL data collected at 
baseline, 2 months, 
12 months, and 




of life, QoL 
index, Symptom 
Checklist 
Quality of life scores 
improved modestly 
and to a similar degree 






Table 6.13: Selected quality of life studies in atrial fibrillation (continued) 
Trial name Population Study design Measure of QoL Results 
Catheter ablation- Non-randomized series 
Erdogan et al. 30 patients with 
paroxysmal AF 
refractory to multiple 
AADs 
Linear RF ablation in 
the right atrium only 
(“catheter Maze”). QoL 
data obtained pre- and 
3, 6, 9, 12, 24, 36 







Patients without AF 
recurrence (9/30) had 
statistically significant 
improvements in all 
eight SF-36. 
Subscales over 2 
years. Patients with 
AF recurrence had 
little change 
Pappone et al. 589 ablation patients 
with drug refractory 
AF (70% 
paroxysmal), 
compared with 582 
patients who 
declined ablation 
109 ablated and 102 
medically treated 
patients did QoL 
surveys every 3 months 
for 1 year. Patients 
were treated with 
circumferential isolation 
of all PVs using RF  
SF-36 PCS and MCS scores 
significantly rose from 
~40 to ~50 within 6 
months after ablation, 
but did not change in 
reference cohort 
treated with drugs 
Hsu. et al. 58 patients with CHF, 
LVEF <45% and AF 
(>90% persistent or 
permanent) 
Cohort matched (by 
age, sex, AF type) to 
additional 58 patients 
without CHF. RF 
ablation: PVI, usually 
with linear in ablation in 








and SF-36 scores 
reported for both 
groups after ablation. 
PCS/ MCS increased 
24/21 points in CHF 
group, 18/14 points in 
control group 
Chen et al. 377 consecutive 
patients with Symp-
tomatic AF refractory 
to AADs. Study 
performed on 94 
patients with LVEF 
<40% 
Ostial PVI performed 
with closed internally 
irrigated RF catheter; 




improvement in on all 
SF-36 subscales 6 
months following PVI 
irrespective of LV 
function. Scores more 








refractory to ≥2 AADs 
PVI plus linear ablation 
in mitral isthmus and 
cavo-tricuspid isthmus 
using externally 
irrigated RF catheter. 
QoL data collected at 






improvement in 8/8 
SF-36 subscales and 
symptom checklist 
scores at 3- and 12-
months post ablation. 
Largest changes in 
role physical (36 
points) and bodily 
pain (31 points) 
scales 
Wazni et al. 70 patients with at 
least monthly 
symptomatic PAF for 
at least 3 months 
and no prior 
treatment with AADs 
Patients randomized to 
mitral PVI using RF (8 
mm tipped catheter) or 
AAD (Flecainide or 
Sotalol). QoL data 
obtained at enrolment 
and 6 months 
SF-36 Improvement in QoL 
significantly greater 
(by 6-20 points) in PVI 
group than AAD 
group in 5/8 






Table 6.13: Selected quality of life studies in atrial fibrillation (continued) 
Trial name Population Study design Measure of 
QoL 
Results 
Catheter ablation- Randomised study 
Oral et al. 146 patients with 
chronic” AF 
Randomly assigned 
to 1-2 cardioversion 
over 3 months or 
ablation (circum-
ferential PVI + linear 
ablation in LA roof 
and mitral isthmus 
with 8 mm RF ca-
theter). Both groups 
received Amiodarone 






12 months after 
ablation, symptom 
scores fell from17±4 
to 6±2 in patients 
without AF recurrence 
and from 17±4 to 12 




ablation. High rate of 
cross-over to ablation 
Notes: AAD = antiarrhythmic drug; PCS = physical component summary score; MCS = mental component 
summary score. PV = pulmonary vein; PVI = pulmonary vein isolation; CHF = congestive heart failure. 
Source: Reynolds et al., 2008: 762-768. 
6.7 DATA USED TO UNDERPIN TOTAL HEALTHCARE EXPENDITURE (THE)  
Large randomized trials with people in AF who are at risk of stroke have not demonstrated any 
significant mortality benefit when using rhythm control as opposed to rate control strategies for 
managing AF. Neither of these drug strategies is efficacious at maintaining sinus rhythm beyond one 
year. This may be of particular relevance, as post-hoc analyses have indicated that, regardless of 
the method of treatment, patients who achieved and remained in sinus rhythm suffered fewer strokes 
and had better mortality than those patients who were in AF (Chan et al., 2006: 2513). 
Survival is improved in patients who achieve sinus rhythm and the modest efficacy of AAD in 
achieving sinus rhythm is well documented. Radiofrequency ablation for substrate modification or 
electrical isolation of the pulmonary veins (circumferential pulmonary vein ablation) is still a relatively 
new therapy but offers an alternative approach to achieving sinus rhythm. Final outcomes, such as 
being free of AF recurrence at one, two years and quality adjusted life years (QALYs) are useful 
when assessing cost-effectiveness as they provide a standard unit of measure which can be 
compared across a range of therapeutic areas.  
The modelled economic evaluation employed a decision tree and Markov model process to compare 
the costs and healthcare outcomes of radiofrequency catheter ablation (PVI). The model was based 
on the outcomes reported in the APAF trial by Pappone et al. (2006), a single centre, and randomized 
trial.  




 The trial was published in a peer-reviewed journal (Journal of American College of Cardiology, 
2006). 
 Of the three systematic reviews and meta-analysis written, comparing PVI to ADT, the first 
included only studies up to Jan 2007 but did not include this study published in Dec 2006, 
while the other two both included this study in their meta-analysis (Calkins et al., 2009: 
Noheria et al., 2008: Piccini et al., 2009). 
 Finally, on reviewing the content of each study, the Pappone trial allowed tracking of each 
individual patient with relative ease. 
6.7.1 The APAF study  
This study by Pappone et al. (2006) was designed to compare the efficacy of RFA and ADT for the 
treatment of patients with PAF. All the patients had already failed AADs. In the ADT arm, the patients 
were randomized to receive one of three commonly used AADs. In the other arm, consecutive 
patients with PAF, who were referred to the electrophysiology lab at the San Raffaele University 
Hospital starting from January 2005, were screened for the inclusion and exclusion criteria shown in 
Table 6.14.  
Table 6.14: Inclusion and exclusion criteria 
Exclusion criteria Inclusion criteria 
Intra-atrial thrombus, tumour 18 < Age < 70 
LA diameter >65mm Creatinine concentrations <1.5md/dl 
Rheumatic mitral valve disease AF history > 6 months 
Prior treatment with Amiodarone, Flecainide or Sotalol AF burden > 2 episodes/month in last 6 
months 
CHF symptoms > NHYA functional class II  
LVEF <35%  
Contra-indication to beta-blocking agents  
AF secondary to transient or correctable abnormality  
Unstable angina or AMI in < 6months  
WPW syndrome  
Renal or hepatic failure  
Implanted device either pacemaker or ICD  
Need to ADT for arrhythmia other than AF  
Contra-indication to ADT or Warfarin  
History of CVA  
Prior catheter ablation or surgical ablation for AF  




6.7.2 The study design 
The patients were randomized to either the PVI arm or to the ADT arm. Patients randomized to the 
ADT arm were again randomized to receive one of the following three drugs: Amiodarone (n=33), 
Sotalol (n=33) or Flecainide (n=33). The drugs were administered as a single dose, or in 
combination, and at the maximum tolerable dose. Table 6.15 charts the characteristics of the patients 
in each group. 
Table 6.15: Patient characteristics 
Characteristic PVI (n=99) ADT (n=99) p-value 
Age (years) 55±10 57±10 0.24 
Gender % male 70 65 0.54 
AF episodes per month 6±4 6±6 0.81 
Duration of AF (years) 6±4 6±6 0.81 
LA diameter (mm) 40±6 38±6 0.25 
Diabetes 5.1% 4% 1.00 
Hypercholesterolemia 17% 21% 0.59 
Hypertension 56% 57% 1.00 
LVEF (%) 60±8 61±6 0.49 
CAD 2% 2%  
Valvular heart disease 3% 1% 0.22 
Congenital heart disease 2% 1%  
No of previous ADTs 2±1 2±1 0.63 
Source: Pappone et al., 2006: 2343. 
6.7.2.1 The circumferential pulmonary vein ablation arm  
All circumferential pulmonary vein ablations (PVIs) were performed using a navigation system, either 
CARTO (Biosense Webster Diamond Bar, California) or NavX (Endocardial Solutions Inc. St Paul 
Minnesota) (see Figure 6.10). 
Ablation was performed using one of the following catheters: Navistar 8mm (Biosense Webster), 
Livewire TC (St Jude Medical, St Paul Minnesota), Cool-Path (St Jude Medical) or Navistar 
Thermocool 3.5mm (Biosense Webster). All the PVI settings were as follows: 60-100W at 50-65ºC 






Figure 6.10: Pre- and post-ablation voltage maps of the LA with  
(a) CARTO and (b) NavX navigation systems 
Source: Pappone et al., 2006: 2342. 
All the patients underwent an ablation using circumferential pulmonary vein isolation (PVI). The 
mean radiofrequency energy used was 35W (±12). The average procedure time was 81 minutes (± 
31min). Completeness was assessed across the Mitral isthmus and ablation was performed at the 
cavo-tricuspid isthmus to prevent isthmus dependent atrial flutter. All patients were placed on ADT 
for a six-week blanking period (not described in detail) after which a 12-month follow-up period 
started. If there was AF recurrence after the six-week blanking period, a second PVI could be 
performed if the patient so chose.  
6.7.2.2 The anti-arrhythmic drug therapy arm 
Flecainide was given orally at an initial dose of 100mg twice daily up to a total of 300mg per day. 
Oral Sotalol was started at 80mg eight hourly and increased up to a maximum of 320mg per day. 
Amiodarone was started with a loading dose of 600mg per day for the first week, then decreased to 
400mg per day for a week and finally maintained on 200mg per day. If patients presented with 
adverse events, the drug dose was first reduced and then stopped if the adverse events persisted. 
If AF persisted but the investigator deemed the clinical response acceptable with regard to frequency 
and duration of AF, the drug dose could be maintained. This is referred to in the model as “AF 
controlled”. 
In the case of the failure of the first drug, a second drug in single dose could be prescribed, or the 
patients could be placed on a combination therapy of drugs, either Amiodarone 200mg and 
Flecainide 200mg, or Sotalol 240mg and Flecainide 200mg. The minimum period that the second 
drug choice must have been used was three months. Only after two trials of ADT had failed would 




All the patients were anti-coagulated with Warfarin and monitored to maintain an international 
normalised ratio (INR) of between 2.0 and 3.0. Anti-coagulation could be stopped if sinus rhythm 
was achieved for at least six weeks in the absence of concurrent contra-indications. 
6.7.3 Follow-up  
The patients were seen at the outpatient clinic during the screening period before randomisation and 
then at three months, six months and 12 months after randomisation. The following diagnostic tests 
were done at each visit: a 12-lead ECG, 48-hour Holter monitor and a transthoracic echo. At the 
three-month follow-up, thyroid functions, liver function tests and serum chemical measurements 
were obtained. Chest X-ray and potential corneal deposits were evaluated in patients receiving long-
term Amiodarone. Finally, all the patients were provided with an event monitor and asked to record 
their heart rhythm between one and three times daily.  
6.7.4 Endpoint 
The endpoint of the study was freedom of documented recurrent atrial tachycardia during the 12-
month follow-up period. This endpoint was considered to have been reached as soon as the patient 
had a first episode of an atrial tachycardia (AT). Cases where a second ADT was added, or where 
patients required a further PVI, were considered failures. A recurrence of AT was defined as any AT 
that lasted more than 30 seconds. 
6.7.5 The results 
6.7.5.1 The PVI group 
After the six-week blanking period, recurrent AF was documented in eleven patients, while three 
experienced atrial tachycardia (AT). During the follow-up period, a total of 85 patients were free from 
AT. The three patients with AT underwent a further ablation and remained free from AT. Of the 
eleven patients with recurrent AF, five were controlled on ADT (four on Flecainide and one on 
Sotalol) and the other six patients underwent a second PVI, which was successful in five out of the 
six patients. 
The reported complication rate associated with PVI was low. One patient suffered a TIA, which 
resolved in seconds, and a second patient had a pericardial effusion (not as a result of perforation) 
and did not require drainage. As mentioned above, three patients developed atrial tachycardia, and 




6.7.5.2 The ADT group 
Of the patients who were randomized to ADT, only 24 were reported to have their AF suppressed 
by a single ADT drug. There were twelve from the Amiodarone group, seven from the Flecainide 
group and five from the Sotalol group. AF recurrence was present in 75 of the original cohort of 99 
patients, with 27% being symptomatic. Of these 75 patients, 49 were placed onto a combination of 
200mg Flecainide and 200mg Amiodarone, while 26 were placed onto a combination of 200mg 
Flecainide and 240mg Sotalol.  
Eleven of the patients on Amiodarone and Flecainide were free from AF, while the other 64 still had 
AF. Of these patients, 42 elected to have an ablation after a mean of 5.8 months, while the other 22 
were controlled on ADT. At the end of the 12-month follow-up, 36 of the 42 patients (86%) who 
crossed over to ablation were free of AF. 
6.7.5.3 Hospitalisations 
The total number of hospitalisations in the follow-up period in each group can be seen in Table 6.16. 
Nine patients in the catheter ablation group had a total of 24 hospital admissions, which included the 
admissions for the procedure to be re-done. In the ADT group there were a total of 209 hospital 
admissions. There were 42 patients who underwent catheter ablation in the follow-up period and a 
further 167 admissions for other reasons. In total, including all procedures, the PVI group had 123 
hospital admissions compared with the 209 in the ADT group.  
Table 6.16: Total number of hospital admissions after the six-week blanking period 
Reason Catheter ablation 
group 
ADT group 
Ablation 9 42 
Other reason 15 167 
Total 24 209 
Source: Pappone et al., 2006: 2344. 
Figure 6.11 illustrates the outcomes in the APAF study, (A) the Kaplan-Meier analysis.86% of 
patients randomized to receive circumferential pulmonary vein ablation needed only a single 
procedure and were free from AT after 12 months, compared with 22% of the patients in the ADT 






Figure 6.11: Outcomes in the APAF trial 
Source: Pappone et al., 2006: 2345. 
6.8 THE APAF FOUR-YEAR STUDY 
On 15 August 2011, the APAF four-year study results by Pappone et al. (2006) were accepted for 
publication in the American Heart Association’s publication, Circulation: Arrhythmia and Electro-
physiology. This was published online on 23 September 2011, before going to print. This is a 
continuation of the 2006 study, on which the above cost-effectiveness model has been built. At the 
time of being published online, the model and this dissertation were complete. This section is meant 
to determine whether the use of the four-year data as opposed to the two-year data makes any 
material difference to the conclusion regarding cost-effectiveness. 
The study evaluated the efficacy of PVI vs. ADTs over a 48-month follow-up period, according to an 
intention-to-treat analysis. QoL was also analysed at baseline and again at 48 months. Published data 
have shown that paroxysmal AF has a natural progression towards persistent AF, of approximately 
15% to 30% over a period of one to three years.  
6.8.1 Data collection and follow-up 
Patients were followed-up quarterly, or whenever the patients needed medical attention over the 
four-year period. At each visit, a 12-lead ECG, 48-hour Holter monitor and transthoracic echo-
cardiography were performed. Patients were provided with TT 12-lead ECG and patients were asked 




36 QoL questionnaires at baseline, four years after randomisation and before crossover to PVI if 
applicable. Anti-coagulation was stopped in patients with a CHADS2 score of zero. Crossover from 
ADT to PVI was only permitted for the following reasons:  
 After intolerance of the drug.  
 After serious side effects. 
 Failure of ADT in different classes or with combination of drugs occurred. 
 After sustained recurrences of more than 12 hours.  
Figure 6.12 illustrates the cumulative probability of crossover to catheter ablation among patients 
assigned to ADT.  
At follow-up, 99.6% of patients were from the PVI group, compared with 99.5% from the ADT group. 
The mean number of visits to the clinic was 3.3 (±0.7). Among the PVI patients, two had recurrences 
of AF and were deemed silent, compared to 33 patients in the ADT group who had episodes of silent 
AF. The recurrences in patients in the ADT group were often highly symptomatic and lasted longer 
than 12 hours.  
 
Figure 6.12: The cumulative probability of crossover to catheter 
ablation among patients assigned to ADT 
Source: Pappone et al., 2011: 24. 
6.8.2 Results 
When analysing the primary endpoint on an intention-to-treat basis, 72 of the initial 99 patients 
(72.7%) in the PVI group reached the primary endpoint after a single procedure. In the ADT group, 




Among the PVI group, 27 patients underwent a second ablation for recurrence of AF/AT (see 
Figure 6.13). Of the 99 patients randomized to ADT, only 12 were free from AF at the end of the 
follow-up period, while the other 87 patients elected to undergo PVI. Of the 87 patients who 
crossed over to PVI, 68 had paroxysmal AF, while the other 19 had progressed to persistent AF. 
The mean time to crossover was 10.1 months (±7.2). Of the patients who crossed over to PVI, 
71.3% were free from AF at 48 months. 
Figure 6.13: Randomisation, results and follow-up of patients in PVI and ADT 
arm of APAF study at 48 months 
Source: Pappone et al., 2011: 22. 
The Kaplan-Meier curve in Figure 6.14 demonstrates the freedom from AF/AT in both groups four 
years after randomisation after a single PVI procedure.  
 
Figure 6.14: Kaplan-Meier curve of patients free of AF/AT for both PVI and ADT 
Source: Pappone et al., 2011: 23. 








99 included in the analysis
72 (72.7%) reacehd primary endpoint after 
single PVI off ADT
18 (18.2%) had repeat 
9 (9.1%) Recurrent AF/AT
99 Assigned to 
ADT
87 elected to 
undergo PVI for 
recurrent AF/AT
99 included in analysis
56 (56.5%) reached primary endpoint
44 (44.4%) after single PVI off ADT
12 (12.1%) after ADT alone
24 (24.3%) after redo ablation & ADT




6.8.3 Complications and other events 
Among the PVI group there were three femoral hematomas, one transient ischaemic attack (TIA), 
which resolved within seconds, and one pericardial effusion, not requiring drainage. No procedure-
related late complications were observed in the PVI group. In the group assigned to ADT, there were 
68 patients who discontinued their medication due to lack of efficacy or adverse events. Adverse 
events among the patients in the Amiodarone group were transient, but included fifteen patients with 
symptomatic bradyarrhythmias, subclinical thyrotoxicosis in nineteen patients, and hepatitis in one 
patient, and visual or dermatological events in two patients.  
6.8.4 Hospital admissions 
The total number of hospitalisations in the ADT group was more than double the number in the PVI 
group, with a total of 126 admissions at 48 months in the PVI group for catheter ablation, and 130 
admissions in the ADT group for catheter ablation. The PVI group only had 34 admissions at the end 
of 48 months for other causes, compared with 195 admissions in the ADT group for other causes. 
The total number of hospital admissions in the PVI group over the 48-month period was 160 
compared with 325 in the ADT group (see Table 6.17). 
Table 6.17: Hospitalisations at 12 months and 48 months for PVI group and ADT group 
Reason PVI ADT 
 12 months 48 months 12 months 48 months 
Ablation/redo 
ablation/AT 
108 126 42 130 
Other causes 15 34 167 195 
Total 123 160 209 325 
Sources: Pappone et al., 2006: 2344; Pappone et al., 2011: 12. 
6.8.5 Quality of life (QoL) 
The QoL scores shown in Table 6.18 illustrate that patients who underwent PVI showed a significant 
long-term improvement in QoL scores. Analysis of the QoL scores of both groups on an intention-to-
treat basis shows little difference between the PVI and ADT groups. However, it is noted that 90% of 
patients initially randomized to ADT before crossing over to PVI showed significantly poorer QoL.  
Table 6.18 demonstrates QoL scores at baseline, prior to crossover, and at 48 months. The quoted 
p-values refer to the change from the baseline value to that at 48 months and not between the 




Table 6.18: Comparisons of QoL scores for PVI and ADT at baseline,  
before crossover and at 48 months 
 
Notes: Those in italics** indicate a deterioration from baseline. 
Source: Pappone et al., 2011: 20 & 21. 
Based on the results of the 48-month follow-up study, it would appear reasonable to expect that the 
cost-effectiveness results, where PVI dominates ADT in all areas, would not change. This is based 
on the fact that the costs for PVI and ADT break even at approximately 1.5 years. Moreover, given 
that large economic burden studies have shown that 50% of costs are attributed to hospitalisation, 
the likelihood that cost-effectiveness would be in favour of ADT is small. Therefore, the model used 
to test the cost-effectiveness of catheter ablation versus ADT in the South African context will be 
based on the original Pappone et al. (2006) study published in the Journal of the American College 
of Cardiology. 
6.9 CONCLUSION 
There is sufficient evidence from published meta-analysis and controlled randomized trials to build 
a cost-effectiveness model for radiofrequency ablation compared to ADT with a particular focus on 
efficacy. There are also a significant number of trials evaluating the impact on quality of life that AF 
has for patients and also the improvement in quality of life after radiofrequency catheter ablation. 
The focus of Chapter 7 is the model, which is built and used to establish whether the use of 
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months 







69±18 85±12 <0.0001 68±21 **67±16 82±15 <0.0001 
Role 
physical 
63±19 82±14 <0.0001 61±17 61±14 80±15 <0.0001 
Bodily pain 68±19 80±17 <0.0001 66±24 **63±19 77±21 <0.0001 
General 
health 
65±17 79±15 <0.0001 67±17 **63±17 77±16 <0.0001 
Vitality 56±22 71±23 <0.0001 55±18 **53±16 68±21 <0.0001 
Social 
functioning 
68±22 87±14 <0.0001 66±20 **64±17 86±14 <0.0001 
Role 
emotional 
70±24 86±18 <0.0001 70±22 **66±19 84±19 <0.0001 
Mental 
health 
66±21 81±17 <0.0001 67±19 **62±15 78±17 <0.0001 
PCS 44.4±9 52.3±9 <0.0001 45.7±9 **44.1±7 52.6±8 <0.0001 





CHAPTER 7: APPLYING THE MODEL TO EXPLORE THE COST-
EFFECTIVENESS OF CATHETER ABLATION IN SOUTH AFRICA 
7.1 INTRODUCTION 
Five percent of the South African population is over the age of 65, compared with more than 15% of 
the population in Europe and the USA. This means that there are, as a percentage of the total 
population, fewer South African patients per million of the population who are affected by non-
rheumatic atrial fibrillation than in European and American countries. It is, however, not an 
insignificant disease in South Africa, as it is associated with a high morbidity and mortality rate. 
Increasingly, patients search for answers on the internet and other media, and present to 
electrophysiologists for the ablation of their atrial fibrillation. This has increased the awareness of 
the cost implications of treating atrial fibrillation by means of ablation.  
To address the issue of cost and effectiveness, a systematic literature review - discussed in Chapter 
6 - was conducted. The first step in developing a model to explore the cost-effectiveness of catheter 
ablation in South Africa was to establish the relevance of this treatment in clinical practice. This was 
verified by means of interviews and a questionnaire presented to electrophysiologists in South Africa. 
It was important to establish whether the studies performed overseas were aligned with how the 
South African electrophysiologists treat patients with AF in South Africa. It was also critical to 
determine whether the same choice of drugs is available to South African patients. 
The next step in the process was to collect the data relating to cost. These included the costs of 
physician’s visits, diagnostic tests, blood tests and medication, as well as the procedural costs and 
the costs associated with hospitalisation. A decision analytical model was then developed, using 
TreeAge software. Both a decision tree and Markov model were included in the model to input data 
with regard to probabilities, outcomes, costs and transition states. Discounting was calculated at 
3.5% per year. 
The results confirmed the various costs associated with the treatment of AF. A cost-effectiveness 
analysis was run using TreeAge Pro software and, finally, sensitivity analyses were run for all the 
parameters tested. 
Chapter 7 incorporates the following: 
 Establishing the relevance of the chosen studies within the South African context. 
 Designing the model to run a cost-effectiveness model. 
 Data collection for the costs associated with both RFA and ADT. 
 Running the model and getting results. 
 Interpreting the results. 




7.2 ESTABLISHING RELEVANCE IN CLINICAL PRACTICE IN SOUTH AFRICA 
There is a paucity research relating to AF ablation in South Africa. Contributions to research in the 
field of electrophysiology by South African electrophysiologists has typically been conducted in 
Europe or as contribution world-wide registries. No local studies have been performed in South Africa 
comparing catheter-based ablation with drug therapy in the South African population. It was for this 
reason that it was decided to mirror data from a peer reviewed research paper by Pappone et al. 
(2006) and to develop a model for the evaluation of cost-effectiveness in the South African scenario. 
The authors of the APAF study (Pappone et al., 2006), describe their management protocol of 
patients included that were included in the trial. Failing to establish if the manner a correlation in 
which patients with AF were treated in the Pappone et al. (2006) trial and South Africa would render 
our study meaningless. It is for this reason that a questionnaire was developed which would establish 
if the management of South African patients with AF, were similar to the protocols used in the 
Pappone et al. (2006) study.  
At the time there were only ten physicians trained and accredited by the Cardiac Arrhythmia Society 
of Southern African who regularly performed electrophysiology studies in South Africa. (The names 
of the physicians interviewed can be found in Appendix H). Each electrophysiologist was approached 
by means of an email in which the purpose of the interview was explained and permission for an 
interview was requested. Interviews were conducted either telephonically or, where possible, in 
person. At the outset of the interview, the setting was explained, identifying the patient population 
being studied as well as the purpose of the study.  
7.2.1 The questionnaire design 
The questionnaire was divided into a number of sections: 
1. Number of years in practice, number of PVI procedures performed each year. 
2. Type of procedure, use of CARTO, NavX, Cryoablation or PVAC techniques. 
3. First patient consultation, type of diagnostic tests performed e.g. ECG and Echo. 
4. A list of anti-arrhythmic drugs was cited, and the physician was asked to identify drugs that he 
would typically prescribe. Included in the list were all the drugs listed in the Pappone et al. 
(2006) study, but in no specific order. 
5. Practice with regard to cardioversion. Although there is no detail in the Pappone et al. (2006) 
study of cardioversion, this was required to establish costs. The same information was explored 




6. Specific protocols when performing circumferential pulmonary vein ablation (PVI). Here it was 
also established how many times the electrophysiologist would recommend PVI if the first 
procedure was not successful. 
7. What would be expected at a typical follow-up at an outpatient visit. This included any 
diagnostic tests that would be performed as well as the frequency of follow-up visits. 
8. Each physician was asked for their specific recommendations with regard to frequency of INR 
blood tests for their patients on anti-coagulants. This was to establish the average number of 
INR blood tests required in a 12-month period. 
9. Finally, the physician was asked to comment about any aspects with regard to treating a patient 
with PAF that had not been considered, either from a clinical or cost perspective. (Sample 
questionnaire can be found in Appendix G) 
7.2.2 The findings from the South African questionnaire 
A total of 8/10 (80%) electrophysiologists were interviewed. Interviews were conducted in person 
with five (63%) and telephonically with three (37%) electrophysiologists. The mean number of years 
in EP practice was 14.6 (range 1-35). The average number of PVIs performed each year was 24 
(range 7-75). All but one performed catheter ablation for atrial fibrillation (88%). Seven (88%) used 
either a 3D mapping system, such as CARTO (Biosense Webster, Diamond Bar, California), or NavX 
(Endocardial Solutions Inc. St Paul Minnesota). Five (63%) also used cryoablation for their PVI 
procedures and one (13%) used cryoablation exclusively for PVI, but also used 3D mapping if the 
patient developed an atrial tachycardia and required extra ablation. At the time of the interview, only 
one person was known to perform PVI without cryoablation or a 3D mapping system and there was 
only limited use of PVAC after the release of data in 2011 relating to increases in micro-emboli in 
patients who underwent PVAC.  
These interviews confirmed that all of the electrophysiologists performed an ECG and an Echo, 
including 2D, MMode and, in most cases, colour Doppler at the first consultation. Holter monitoring 
varied from some physicians not doing any Holter monitor recordings to some doing Holter 
monitors on 30-50% of patients. There was a large degree of similarity regarding the type of blood 
tests which would be requested, with all the electrophysiologists selecting U&E, FBC, TSH, T 4, 
and INR. Two respondents (25%) request ProBNP, while one routinely requests LFT. 
Table 7.1 illustrates the drugs cited by the South African electrophysiologists as drugs they usually 
prescribe. Not all these drugs would be used in PAF, as some would be used in rate control strategies 
for patients who had persistent or permanent AF. The reason they were included was to establish 





Table 7.1: Drugs typically prescribed for patients with AF by South African electrophysiologists 
Drug Number % 
Warfarin 8/8 100 
Sotalol 6/8 75 
Amiodarone 8/8 100 
Flecainide 7/8 88 
Propafenone 0/8 0 
Digoxin 6/8 75 
Diltizem 5/8 63 
Verapamil 6/8 75 
β blockade 7/8 88 
Source: Results of interviews with electrophysiologists (see Appendix I). 
The loading doses of Amiodarone varied quite significantly among the various practitioners: One 
prescribes 800mg initially, then 600mg and 400mg for four days each, before maintaining at 200mg 
daily; one prescribes 600mg for a month, then maintaining on 200mg daily; and two prescribe 1 200mg 
for two weeks, 800mg for two weeks, 400mg for two weeks, and then 200mg daily. Seven respondents 
request INR testing weekly for between one and six weeks and one suggests INR testing twice a 
month. All respondents suggested testing the INR once a month if the INR was stable. The mean 
number of INR tests in a 12-month period was 16.2. 
When performing a PVI on a patient, all respondents admitted the patient to either a high care unit 
(HCU) or a coronary care ICU (CCU). The average length of stay reported by the doctors was 1.4 
days. Only 3/7 (43%) routinely did a CT scan and one doctor reported that they would only do so on 
the first admission. Follow-up procedures would not require a CT scan. Most cited that the procedure 
took between 240 and 300 minutes while two said it took between 120 and 180 minutes. General 
anaesthesia was used in 4/7 (57%), while the others made use of conscious sedation. Almost all did 
a TEE at the time of the procedure, while one respondent routinely used intra-cardiac echocardio-
graphy (ICE). 
The average number of follow-up visits in the first 12 months was 3.4 (range 2-4) after which the 
patient would be seen annually or sent back to the referring doctor if they were stable. In response 
to the question of diagnostic tests requested at follow-up visits, the respondents named the following:  
 ECG was requested by ten physicians (100%). 
 Echo was requested for an average of 64% of patients.  
 Most stated that they would request Holter monitoring in between 40% and 100% of visits, 





A decision analytical model and Markov model were developed using TreeAge Pro Software from 
TreeAge Software Inc. The first stage of the model is a decision tree, where patients are randomized 
to receive either catheter ablation (PVI) or anti-arrhythmic drugs (ADT). This is followed in each arm 
by a Markov process, where patients go through four health states. These were “No AF”, “AF 
controlled”, “PAF” and “Dead,” in six-month cycles over a period of two years. The probability of 
passing through each health state is different for both the ADT arm and the PVI arm and these data 
are derived from clinical data by Pappone et al. (2006) and McKenna et al. (2009). To calculate cost-
effectiveness using the TreeAge Markov process, three data sets were required: cost, outcome and 
transition probability. 
7.3.1 Measuring costs 
All costs were calculated using Discovery Health rates. This rate was selected as Discovery Health 
administers 41.3% of all schemes and thus represents a good sample size of actual costs (Council 
for Medical Schemes (CMS), 2010: 110). A discount rate of 3.5% per annum was applied to both 
costs and outcome. This is consistent with the lower range of the inflation target set for South Africa 
and in line with the discount rate adopted by agencies such as NICE.  
Resources used are expressed in terms of events associated with each treatment strategy and are 
illustrated in Table 7.2. These include the following four categories: outpatient costs, hospital costs 
for PVI, hospital costs for recurrence of AF and medical therapy (including monitoring of INR). These 
costs were confirmed as the typical costs that would be incurred by a patient who presented with 
PAF to an electrophysiologist in South Africa. Interviews were also held with a sample of 
anaesthesiologists, radiographers and cardiac technologists. The sample of the questionnaires can 
be found in Appendices E-G. Total treatment costs were allocated by multiplying the mean medical 
resource used for each treatment group by the appropriate unit price. 
Outpatient costs were calculated for office visits with electrophysiologists and for major outpatient 
cardiac testing and procedures, including transthoracic echocardiography, ECG, stress ECG, and 




Table 7.2: Costs associated with treating AF in South Africa 
Outpatient costs Hospitalisation  
for PVI 
Hospitalisation for 
recurrence of AF 
Medical therapy 
Consultation in rooms Procedure costs Hospital stay Warfarin 
ECG Hospital stay Electrophysiologist fee Sotalol 
ECHO Anaesthesiologist fee Anaesthesiologist fee Flecainide 
Holter Monitoring Radiographer fee Cardioversion Amiodarone 
Bloods Technologist fee  INR testing 
 Electrophysiologists fee   
Sources: Adapted from Reynolds et al., 2007: 629; Pappone et al., 2006. 
For the hospital costs, data were used from actual patient accounts at Netcare hospitals where more 
than 80% of all PVI procedures with either Carto or NavX mapping systems are performed. All 
patients were assumed to have their PVI procedure using Carto as the 3D mapping system, and the 
costs of all EP catheters were based on Biosense Webster products at 2011 net acquisition price for 
single use. A sample of 51 consecutive patient accounts were used from Sunninghill Hospital after 
the procedure was completed. The author was blinded to the identity of the patient and the data 
were supplied by Netcare head office. A sample size of 51 represents about 19% of all the AF 
procedures done in South Africa in a single year and 23% of all AF procedures performed at Netcare 
hospitals in a single year.  
Hospital costs for the recurrence of AF included the cost of hospitalisation, the in-hospital visits by 
the electrophysiologists, and cost of cardioversion. These costs were based on an average of 5.2 
days, as determined in two major studies where resources were calculated for episodes of AF 
(Reynolds et al., 2007: 630; Stewart et al., 2004: 288).  
The single exit price of drugs was taken from the Department of Health website and was used to 
calculate the average cost of AF-related outpatient prescription medication as required (rate controlling 
agents, anti-arrhythmic agents and Warfarin). All costs were at 2011 prices in ZAR. The prescribed 
dispensing fee was included in the cost of the medication. INR testing was calculated at one test per 
week for the first month, one test every second week for the second month and thereafter one test per 
month for the rest of the year if the patient’s INR was stable. This indicates that a minimum of sixteen 
INR tests were done per patient per year. Hospital re-admissions were calculated for emergency 
admissions for the recurrence of AF and heart failure and were based on actual patient data.  
Costs that were not included in the study were any admission to hospital that related to a change in 
the dosing of ADT. While this is common practice in the USA and some European countries for 
dosing of drugs like Flecainide, which is known to be arrhythmogenic, it is not practiced in South 
Africa because of the cost implications. Also not included in the costs were any out-of-pocket medical 




cost of managing stroke and its complications were not included because of the limited access to 
patient data. However, by including the cost of stroke one would expect the cost of treatment in the 
ADT group in particular to increase.  
7.3.2 Measuring outcomes 
Health outcomes were measured as time free of AF and QALYs gained. The latter was taken from 
published data. Utility values are the numerical representation weighted to represent differences in 
the quality of life and can range from 0 (death) to one (perfect health). Patients who were restored 
to sinus rhythm or the “No AF” state were assumed to return to having the same QoL as the general 
population. Decrements as stated in McKenna et al. (2008: 546) were used for other states i.e. AF 
controlled and PAF after failed PVI or ADT. Table 7.3 defines the QoL parameters. 
Table 7.3: Quality of health parameters 
 
7.3.3 The model 
The model used both a decision tree analysis and a Markov model to capture and simulate costs and 
outcomes over a two-year period. There are four health states, namely “No AF”, “AF controlled”, “PAF” 
and “death”. Each cycle is over a six-month period, with a total of four cycles. In the PVI arm, it is 
assumed that, for patients who require a second PVI, the procedure is done within the first six months, 
while in the ADT arm, the patients were only allowed crossover to PVI at six months if they had failed 
at least two trials of ADT. The study stipulates that crossover was at a mean of 5.8 months. (Pappone 
et al., 2006: 2344). The study states that, at the end of follow-up, all but three of the patients in the PVI 
group who were free of AF (n=82) were on oral anti-coagulants (OAT). It was assumed that all patients 
who had PVI and were successful, were on OAT for six months after PVI. This assumption is based 
on standard South African practice and may add some bias in favour of the ADT arm, although minimal. 
The model design (see Appendix M) shows that all patients entered into the study with paroxysmal AF 
(PAF) (n=198). They were then immediately randomized to either the ADT arm (n=98) or the PVI arm 
(n=98). After randomisation the Markov process started. Patients in the ADT group were again 








AF given PVI No AF given 
ADT 
No AF given PVI 





7.3.4 Transition probabilities 
Figure 7.1 is a schematic representation of the health states and transition probabilities used in the 
model. The model uses a simple decision analysis at the start of the model and thereafter uses a 
Markov model.  
 
Figure 7.1: Possible transitions between health states in the Markov process 
Source: Adapted from Pappone et al., 2006. 
Table 7.4 describes all the possible health states, namely “AF”, “PAF”, “AF controlled” and “Dead”, 
found in the decision tree analysis and the Markov model, together with the source, if applicable. It 
also describes the various treatment options that were available, for example, ADT and PVI.  




AF  All patients enter the decisions tree analysis with AF, having failed at least one 
ADT (Pappone et al., 2006: 2343). 
PVI Patients randomised to circumferential pulmonary vein ablation (PVI). 
ADT Anti-arrhythmic drug therapy. 
No AF This includes patients who are converted to sinus rhythm or who are still in AF 
but with episodes of less than 30 seconds. 
PAF This group includes patients with paroxysmal episodes of AF lasting longer 
than 30 seconds. 
AF controlled This included patients with persistent AF where the investigator (and patient) 
determined that there was an acceptable clinical response with regard to 
duration and frequency of arrhythmia recurrences. 
Dead Patients entered this state based on all-cause mortality as per Calkins et al., 
(2001) and then progression through the model is terminated. 




Table 7.5 tabulates the transition probabilities for both the radiofrequency ablation arm and the ADT 
arm used in the Markov model as well as the source of each. 
Table 7.5: Transition probabilities applied to the Markov process for the ADT arm 
The probability of:  Probability Source 
Receiving Amiodarone 0.33 Pappone et al., 
2006 
Receiving Flecainide 0.33 
Receiving Sotalol 0.33 
Amiodarone suppressing AF 0.36 
Flecainide suppressing AF 0.21 
Sotalol suppressing AF 0.15 
Receiving Amiodarone and Flecainide 0.65 
Receiving Sotalol and Flecainide 0.35 
Crossover from drug to PVI 0.56 
AF Free on Amiodarone and Flecainide 0.22 
AF controlled on Amiodarone and Flecainide 0.33 
AF controlled on Sotalol and Flecainide 0.23 
AF recurring after one year 0.29 McKenna et al., 
2009 
Adverse events (ADT) 0.30 Calkins et al., 2009 
Death (ADT) 0.03 Calkins et al., 2009 
AF free (PVI) 0.86 Pappone et al., 
2006 
Having AF (PVI) 0.03 
Being AF controlled (PVI) 0.05 
Require second PVI 0.06 
AF free after second PVI 0.83 
AF recurring after one year (PVI) 0.0335 McKenna et al., 
2009 
Adverse events (PVI) 0.049 Calkins et al., 2009 
Death (PVI) 0.007 Calkins et al., 2009 





Transition probabilities estimated from nine clinical studies and shown in Table 7.5 are summarised 
below:  
 Pappone et al. (2006) describe PVI vs. ADT in patients with PAF, n=198.  
 McKenna et al. (2009) report on the probability of AF recurring after one year in both PVI and 
ADT group. The study also describes decrements in utilities in health states. 
 Calkins et al. (2009) describe both the death rate in both the PVI arm and ADT arm, these are 
specific to death related to PVI and ADT from a meta-analysis of both treatment options and 
did not include the death rates described in chapter 4.8. 
 Chan et al. (2006) report on stroke rate and death rate from stroke. 
 Stewart et al. (2000) report on hospitalisations and length of stay. 
 Reynolds et al. (2007) report on hospitalisations and length of stay. 
 Bunch et al. (2010) report on one, three- and five-year mortality. 
 Stewart et al. (2002) describe cardiovascular hospitalisations, stroke and cardiovascular 
death. 
 Pappone et al. (2003) report on stroke, number of hospital visits and number of deaths.  
7.4 THE RESULTS 
7.4.1 The costs associated with treating atrial fibrillation (AF) 
7.4.1.1 The outpatient costs 
Outpatient costs were calculated based on the number of visits reported in the Pappone et al. (2006) 
study and the type of diagnostic tests performed with each visit. This was confirmed in the survey of 
the South African electrophysiologists and the only discrepancy was with regard to the number of 
24-hour Holter monitoring performed.  
The Pappone et al. (2006) study included Holter monitoring at each visit, while the South African 
physicians only do Holter monitoring in 40% of the patients. The reason for the discrepancy is 
twofold: 
1. In a clinical study that is evaluating the efficacy of a treatment it is important to be able to track 
that efficacy. In this case, Holter monitoring is a safe, non-invasive and reasonably reliable 




2. South African electrophysiologists recognise the value of doing Holter monitoring, but all stated 
in their interviews that it added extra cost to the patient and, as such, they did not perform a 
Holter with every follow-up visit. 
Table 7.6 illustrates the cost per patient per follow-up visit. This cost applies to both the ADT arm as 
well as the PVI arm. The mean cost was R2 495.40, the median was R2 363.30 and the range was 
from R2 363.30 to R2 891.70.  
Table 7.6: Cost and codes for outpatient visits 
Outpatient 
visit 







Rooms visit 0191 R389.30 Yes Yes Yes Yes 
ECG/stress 1231 R88.10 Yes Yes Yes Yes 
  1233 R114.50 Yes Yes Yes Yes 
  1235 R528.40 Yes No No No 
Echo 3260 R419.70 Yes Yes Yes Yes 
  3621 R209.90 Yes Yes Yes Yes 
  3622 R419.70 Yes Yes Yes Yes 
24-hour Holter 1238 R484.30 Yes Yes Yes Yes 
  1239 R237.80 Yes Yes Yes Yes 
Total cost per visit R2891.70 R2363.30 R2363.30 R2363.30 
Source: Cost calculations adapted from Discovery, 2011. 
7.4.1.2 The costs associated with blood taken at pathologist for management of AF 
Table 7.7 is a summary of the most common blood tests performed on patients under the care of a 
physician for AF. The data were taken from the interviews performed and a conservative estimate 
was used for blood tests. This assumption is based on the fact that patients who revert to sinus 
rhythm are essentially treated as healthy patients and only those on Warfarin require regular and 
careful monitoring of their INR. Based on this, calculations for blood tests were done for U&E, FBC 
and TSH twice yearly and INR sixteen times per year. This is for patients in both the PVI and ADT 





Table 7.7: Cost and codes for blood tests at pathologist laboratory 
Blood Test Billing code Cost Total tests per 
year 
Total cost per 
year 
U & E 4171 R161.31 2 R322.62 
Creatinine 4032 R36.90 2 R73.80 
FBC 3755/3797 R129.73 2 R259.46 
TSH 4507 R199.57 2 R399.14 
Amylase 4006 R52.75 2 R105.50 
ALP 4001 R52.75 2 R105.50 
AST 4130 R55.02 2 R110.04 
ALT 4131 R55.02 2 R110.04 
INR  R61.13 16 R978.08 
INR dosing  R61.13 16 R978.08 
Total pathology costs per year R3 442.26 
Source: Cost calculations adapted from Discovery, 2011. 
7.4.1.3 The costs associated with drugs used for ADT in patients with AF 
In the Pappone et al. (2006) study the following four drugs are used in both the ADT and the PVI 
arms, namely Warfarin, Sotalol, Amiodarone, and Flecainide. The study defines the dosage and 
period of time each drug was used. Based on this data, a search was conducted on the Department 
of Health website to find the cost, dosage and supplier of each of these drugs. Table 7.8 tabulates 
the specific drugs chosen for the model. The specific item was selected to get the most cost-effective 
combination of drugs, based on dose and pack size. The cost also included the dispensing fee. 
Table 7.8: Cost of drugs and pack size as per South Africa 
 
Source: Department of Health (DoH), 2011. 
Once the specific drugs and prices had been identified, a calculation was performed to measure the 
cost per day and per month for each individual drug. This was then entered into the model at the 




Table 7.9: Cost per dosage and cost per day 










Warfarin 5mg R1.50 5mg R1.50 100 
Sotalol 80mg R4.18 320mg R16.72 100 
Flecainide 100mg R7.26 300mg R21.78 60 
Amiodarone 200mg R16.85 600mg R50.55 30 
   400mg R33.70 30 
   200mg R16.85 n/a 
Combination1 Flecainide & 
Amiodarone 
 200mg & 
200mg 
R31.37 n/a 
Combination 2 Flecainide & Sotalol   200mg & 
400mg 
R21.06 n/a 
Sources: Adapted from DoH, 2011; Pappone et al., 2006. 
Table 7.10: Cost of drugs per month and per year 
Cost of drugs Cost per month  Cost per year 
Sotalol R508.29 R6 099.46 
Flecainide R662.12 R7 945.45 
Warfarin R45.49 R545.85 
Amiodarone** R541.73 R6 500.73 
Amiodarone 1st month R866.09  
Amiodarone months 2-12 R512.24  
      Notes: **Cost per month is calculated as the average over 12 months. 
Sources: Adapted from DoH, 2011; Pappone et al., 2006. 
For the ADT group, Pappone et al. (2006) described the following: Oral Flecainide was given at an 
initial dose of 100 mg twice daily with a maximum tolerable dose of 300mg per day. Oral Sotalol was 
started at an initial dose of 80mg three times daily and increased to a maximum tolerable dose of 
320mg per day, while oral Amiodarone was started at an initial loading of 600mg/day for the first 
week, 400mg/day for the next week, after which a daily maintenance dose of 200mg was given daily. 
All of these were based on the clinical response and/or the occurrence of side effects. Doses of each 
drug were reduced if intolerable adverse reactions occurred, and treatment was stopped if 




second drug was at the discretion of the primary physician, who could choose from the other two 
anti-arrhythmic agents or use a combination of two of the three agents used in this study. The patient 
had to remain on the next drug combination for a minimum period of three months before the drug 
trial could be considered unsuccessful. Only after two failed trials of ADT could patients be 
considered for crossover to PVI. Based on this, the monthly cost for each drug was calculated as 
shown in Table 7.10. 
7.4.1.4 The costs associated with catheter ablation for AF 
The costs associated with treating a patient with PVI for AF is made up of the following components: 
hospital costs, the professional fee of the Anaesthetist, the professional fee of the cardiac technologist, 
the professional fee of the radiographer and the professional fee of the electrophysiologist.  
The fee for the electrophysiologist includes consultation at admission, a fee for performing the 
procedure, including EP study, transseptal puncture, TEE and ablation. The fee also includes all 
post-operative visits in the ward or CCU for the duration of each hospital stay. The hospital costs 
can be broken down into the following: 
 Hospital stay, including the CCU/ward fees, monitors, oxygen and medication. 
 Theatre fees, including a fee for the use of specialised equipment, for example, bi-plane X-
ray, 3D mapping system and ablation generator. This fee also includes any drugs used in 
theatre, as well as any disposables used and, in particular, EP and ablation catheters. For 
the purpose of the study, the cost of all EP and ablation catheters were subtracted from the 
actual cost and replaced with equivalent Biosense Webster Carto catheters and diagnostic 
catheters at the 2011 net acquisition price. All catheter prices were calculated at single-use, 
as recommended by the manufacturer. The ablation catheter of choice was the Navistar RMT 
Thermocool as single-use.  
A sample of 51 consecutive patient accounts was used to calculate the costs of PVI. The 
questionnaire responses by the South African electrophysiologists revealed that the average amount 
of time each patient spent in hospital when undergoing a procedure was 1.4 days, while the actual 
number of days calculated from the 51 patients was 2.2 days, with a median of 1.8 days and a range 
between 1.5 days and 5.5 days. The total average cost of the PVI was R134 411 with a median of 





Table 7.11: Costs associated with PVI for AF  
Description Costs of PVI 
Sub-category Value 
Average days  2 
Average hospital costs  R103 327 
 Procedure costs R37 877 
EP catheters R54 101 
Hospital stay R11 350 
Average fee for Anaesthetist  R9 965 
Average fee for radiographer  R1 617 
Average fee for technologist  R2 919 
Average fee for electrophysiologist  R16 582 
Average total cost of hospitalisation for PVI  R134 411 
Sources: Patient accounts, 2011; Discovery price file, 2011; Data from interviews, 2011; Biosense Webster Price 
list, 2011. 
7.4.1.5 The costs associated with hospitalisation for AF 
According to the study by Pappone et al. (2006: 2344) the total number of hospital admissions after 
the six-week blanking period was as follows: a total of 24 admissions in the catheter ablation group, 
nine of which were for a repeat ablation. In the ADT group there were a total of 209 hospital 
admissions, 42 of which were for catheter ablation and the other 167 for recurrence of AF and heart 
failure. When allocating costs for these hospitalisations all hospital admissions related to a repeat 
ablation or a first ablation for those on the ADT arm, costs were allocated as described in Section 
7.3.4. For the admissions related to heart failure or the recurrence of atrial fibrillation a sample group 
of six patient hospital admissions were used. The measures of interest were number of days in 
hospital per admission and the total cost. Included in the total cost were hospital costs, pathologist’s 
costs, cost of cardioversion, daily CCU or ward consultation with electrophysiologist, and one follow-
up visit after discharge.  
From the data collected the mean number of days was 5.1. This is 2% lower than the value of 5.2 
days used in the model, which is based on an average from the Stewart et al. (2004: 288) and 
Reynolds et al. (2007: 631). The median number of days in hospital was 5.5 days with a range from 
2 days to 9 days.  
The average cost per day was R7 787.93 with the median cost per day of R8 096.42 and a range 
between R5 819.48 and R9 419.96. Based on this a value was assigned to hospitalisation per 




Table 7.12: Costs associated with hospital admission for recurrence of AF or heart failure 




Number of days 5.1 5.5 2.4 2 9 
Hospital costs R27 455.97 R21 847.95 R12 630.17 R14 388.40 R46 529.80 
Electrophysiologist R2 348.27 R2 641.80 R1102.22 R880.60 R3 962.70 
Pathology costs R1 616.50 R1 572.63 R782.73 R740.00 R2 812.00 
Cost of cardioversion R572.40 R572.40 R0.00 R572.40 R572.40 
Total Cost R37 791.63 R32801.66 R16 719.74 R18 373.86 R63 576.46 
Cost per day R7 787.93 R8 096.42 R1 651.56 R5 819.48 R9 419.96 
Sources: Patient accounts, 2011; Discovery price file, 2011; Data from interviews, 2011. 
7.4.2 The cost-effectiveness analysis 
7.4.2.1 The analytical methods 
Based on the calculations above, a Monte Carlo simulation model was run using TreeAge Pro 
software (Williamson, Massachusetts) with a simulation sample size of 1 000. As South Africa does 
not have a specific threshold at which a therapy is considered cost-effective, it was difficult to 
measure a cost per QALY threshold, but a sensitivity analysis was performed to assess the impact 
of other variables on cost-effectiveness using TreeAge Pro and, when measuring the total monetary 
benefits, a “willingness to pay” (WTP) threshold of R120 000 was used. 
On questioning the Council for Medical Schemes with regard to a “willingness to pay” threshold for 
South Africa (CMS, 2010), they were unwilling to reveal such a threshold, rather stating that the 
threshold differs with each disease state. Currently, drug therapy is the “gold standard” for treating 
atrial fibrillation and drug therapy, either alone or with cardiac resynchronisation therapy (CRT), is the 
“gold standard” for treating congestive heart failure, one of the major complications of atrial fibrillation.  
Congestive heart failure is one of the prescribed minimum benefits (PMBs) established by the 
Council for Medical Schemes. In the absence of an official WTP threshold for South Africa, the cost 
of treating heart failure patients with drugs and/or CRT is therefore an unofficial threshold. Treatment 
for congestive heart failure with CRT can be with either low power or high-power CRT devices, as 
determined by large, randomized clinical trials. In order to establish the average cost of CRT the 
costs were established for a low power device or Bi-ventricular pacemaker with three endocardial 





The cost was established from two major pacemaker companies (St Jude Medical and Medtronic). 
The average cost for a low power CRT device was quoted as R70 000.00, while the average cost of 
a high-power CRT device was quoted as R150 000.00. In order to establish a WTP threshold, an 
average of the two devices was calculated and 10% was added to cover the cost of implantation. 
The calculation is seen in Table 7.13. 










Source: Adapted from data from Medtronic and St Jude South Africa, 2012. 
This estimate of R120 000 as a “willingness to pay” threshold using CRT devices in South Africa is 
only based on the cost of the device. This is assuming that 50% of all CRT devices are low power 
while the other 50% are high power. An additional 10% has been added to the cost for “other” medical 
expenses. The other medical expenses, which have not been included in detail, are the cost of the 
procedure, hospitalisation costs, cost of the Anaesthetist, radiographer, cardiac technologist and 
electrophysiologist. Other costs not included in this cost are follow-up visits and cost of 
reprogramming the device. All of these costs, if added to the cost of the CRT device, would increase 
the limit of the threshold to over R121 000. 
7.4.2.2 Cost-effectiveness analysis 
A simulation model for cost-effectiveness (C-E) was run using TreeAge Pro software. The input data 
were established from the literature reviews performed. The model simulated 1000 patients who 
were randomised to receive either PVI or ADT. The statistics of the C-E analysis are tabulated in 
Table 7.14 and refer to cost and effectiveness.  
Table 7.14: Summary of cost-effectiveness analysis statistics: Variables cost and efficacy 
Variable PVI-mean ADT-mean 
Cost per patient R168 996 R206 520 
Efficacy per patient 1.64 1.52 
Description Value 
CRT   R70 000 
CRT-D  R150 000 
Total  R 220 000 
Average  R110 000 
10%  R11 000 
  




Figure 7.2 illustrates, in graphical form, the cost-effectiveness analysis of PVI vs. ADT. The -axis 
refers to cost, where the cost increases from left to right on the axis. The y-axis shows effectiveness 
increasing as the axis moves upwards. The PVI group is indicated by a small red square located in 
the top left-hand quadrant. The cost is R168 000 with an efficacy of 1.64 QALYs per patient. In this 
analysis, when compared with the cost of ADT, PVI has high effectiveness at low cost. The ADT 
treatment group is represented by a small blue triangle in the far-right corner of the bottom right 
quadrant. The cost of the ADT group is R187 000 per patient with an effectiveness of 1.52 QALY. 
This indicates that the ADT group has high cost but low effectiveness. The blue triangle of ADT is 
encircled by a small yellow dot demonstrating domination of ADT by PVI as more cost-effective.  
 
Figure 7.2: Cost-effectiveness analysis of PVI vs ADT for AF showing the ADT is 
dominated 
Source: Markov model dated 27 February 2012. 
7.4.2.3 Sensitivity analysis 
When performing a cost-effectiveness analysis, it is prudent to also perform a sensitivity analysis. 
The sensitivity analysis determines the impact on the model’s output or results if the variables or 
inputs are changed. In this study the variables of particular interest for the sensitivity analysis were 
cost, QALY, duration of hospital stay, the duration of the treatment, and the relative risk of death. 
These are discussed below: 
 The change in cost is referred to as the discounted cost and is denoted by dCosts. Cost was 
measured as the actual cost which formed the baseline value and the sensitivity analysis 
was performed at a discounted rate of 3.5%. 
 The baseline value of the QALY was determined in the study from the literature review. The 




 The duration donated as tDuration. The original study by Pappone et al. (2006) was performed 
over a period of two years. This became the baseline measure and a sensitivity analysis was 
also performed at one year, three years and four years. 
 The average length of stay in hospital for re-admissions for AF or heart failure was denoted as 
kAveLoS. The baseline was measured at 5.2 days as per the literature review. The sensitivity 
analysis was performed using an increase and decrease of 20%.  
 The relative risk of dying (rrADT) is the relative risk of dying when treated with ADT compared 
with PVI. The literature review indicated that the relative risk of death was 2.2 and was used 
as the baseline. The sensitivity analysis was performed with an increase and decrease of 
20%.  
Discounted costs (dCost) 
For all measurements of cost-effectiveness, the period of two years was used as a baseline. The 
first variable to be tested was cost, where actual cost over the two-year period was used and then, 
in order to perform the sensitivity analysis, a discount rate of 3.5% was applied.  
Table 7.15 refers to this sensitivity analysis where the variable of cost was changed. The total cost 
for PVI at two years was R168 790 compared with the cost of R190 728 per patient for ADT. PVI 
dominated ADT as more being cost-effective at both baseline and again at the discount rate of 3.5%. 
Table 7.15: Sensitivity analysis of discounted cost (dCost) per patient 
 
Source: Markov model dated 27 February 2012. 
In Figure 7.3 the -axis refers to the cost, where cost increases from left to right and the y-axis refers 
to effectiveness which increases from the bottom to top. ADT is represented by a blue triangle and 
is found in the bottom right quadrant while PVI (the red square), is in the top left quadrant, indicating 
that ADT, even when discounted, costs more and is less effective than PVI and PVI dominates ADT, 





Strategy Variable Cost/patient Eff CE IC IE ICER Dominated 
PVI 0 R168 790 1.64 102882 0 0 0  
ADT 0 R190 728 1.53 125030 R21937 -0.12 -190 494 (Dominated) 
PVI 0.035 R168 437 1.64 102667 0 0 0  






Figure 7.3: Cost-effectiveness of PVI vs. ADT with reference to change in cost 
Source: Markov model dated 27 February 2012. 
When a sensitivity analysis was performed on the variable of cost and a discount rate of 3.5% was 
applied, the following were noted:  
1. The average cost (Figure 7.4) shows that when discounting cost by 3.5% the impact is greatest 
for ADT, but that ADT, as a treatment, remains costlier than PVI. The average cost for PVI is 
lower than ADT and remains reasonably constant for the period of two years. 
 
Figure: 7.4: Sensitivity analysis when a discount rate of 3.5% was applied to costs 
Source: Markov model dated 27 February 2012. 
 
2. Incremental cost (Figure 7.5) shows the impact of discounting cost on the incremental cost-





Figure 7.5: Sensitivity analysis of the incremental cost-effectiveness when a 
discount rate of 3.5% was applied to costs 
Source: Markov model dated 27 February 2012. 
Discounted QALY (dQALY) 
The second step in the sensitivity analysis was to establish what impact there would be on the 
variable QALY if discounting methodology was applied. The same discount rate of 3.5% was applied 
for QALYs. Table 7.16 demonstrates that PVI dominated over ADT when testing the variable QALY 
at both baseline and a discount rate of 3.5%.  
Table 7.16: Sensitivity analysis of discounted QALY (dQALY) 
 
Source: Markov model dated 27 February 2012. 
In Figure 7.6 the -axis refers to the cost, which increases from left to right and the y-axis refers to 
effectiveness and increases from the bottom to top. ADT is represented by a blue triangle and is found 
in the bottom right quadrant while PVI (the red square), is found in the top left quadrant. In the previous 
sensitivity analysis where a discount rate of 3.5% was applied it was noted that the blue triangle (ADT) 
was at the intersection of R190 000 on the -axis and 1.53 on the y-axis. The red square (PVI) was at 
the intersection of R170 000 on the -axis and 1.65 on the y-axis. Discounting was applied to QALY 
and the blue triangle (ADT) was found between R185 000 and R190 000 on the -axis and 1.54 QALYs 
on the y-axis, showing an improvement in cost-effectiveness. The red square (PVI) was found at the 
intersection of between R165 000 and R170 000 on the -axis and between 1.65 and 1.70 QALYs on 
the y-axis, which also indicates an improvement in cost-effectiveness. When a discount rate of 3.5% 
was applied to QALY, PVI dominated over ADT.  
Strategy Variable Cost Eff CE IC IE ICER Dominated 
PVI 0 R168 437 1.67 100950 0 0 0  
ADT 0 R187 357 1.55 120852 R18 920 -0.1182 -160 057 (Dominated) 
PVI 0.035 R168 437 1.64 102667  0 0  






Figure 7.6: Cost-effectiveness of PVI vs. ADT when measuring impact of change on QALY 
Source: Markov model dated 27 February 2012. 
When a sensitivity analysis was performed on the variable of QALY and a discount rate of 3.5% was 
applied, the following were noted:  
1. The average cost showed no change when a discount rate of 3.5% was applied to QALY. The 
average cost of PVI remained lower than ADT (Figure 7.7). 
 
Figure 7.7: Measure of average cost when a discount rate of 3.5% is applied to QALY 
Source: Markov model dated 27 February 2012. 
2. The incremental cost for ADT remained around R18 000, while the incremental cost for PVI 





Figure 7.8: Measure of incremental cost when a discount rate of 3.5% is applied to QALY 
Source: Markov model dated 27 February 2012. 
3. The average effectiveness showed a decrease in effectiveness of less than 2% in both the 
ADT group and the PVI group (Figure 7.9).  
 
Figure 7.9: Measure of the average effectiveness when a discount  
rate of 3.5% is applied to QALY 
Source: Markov model dated 27 February 2012. 
4. The incremental effectiveness showed no change in the incremental effectiveness in the PVI 






Figure 7.10: Measure of the incremental effectiveness when a discount 
rate of 3.5% is applied to QALY 
Source: Markov model dated 27 February 2012. 
5. The incremental cost-effectiveness is demonstrated in Figure 7.11 and illustrates that, in spite 
of the fact that PVI did not change and there was a small change in the ADT group, PVI still 
dominated over ADT. 
 
Figure 7.11: Measure of the incremental cost-effectiveness when a discount 
rate of 3.5% is applied to QALY 





6. The net monetary benefit at a willingness-to-pay value of R120 000 shows that, for the PVI 
group, the benefit drops from about R32 000 to about R29 000, while the net monetary benefits 
for ADT start at below zero and drop further to about -R2 500 (Figure 7.12). 
  
Figure 7.12: The net monetary benefits when a discount rate of 3.5% is  
applied to QALYs at a WTP 120 000 
Source: Markov model dated 27 February 2012. 
Duration of the study (tDuration) 
The baseline for the measurement of duration of the study was two years. This was based on the 
fact that the original APAF study performed by Pappone et al. (2006) was over a two-year period. 
Other reasons for using two years as the duration of the study were as follows: 
2. Most of the data found in literature reviews for ablation vs. ADT do not extend beyond a two-
year period. 
3. There is a perception that South African medical aids tend to base their decisions on a short-
term rather than long-term view, taking into consideration the number of patients who change 
from one medical aid scheme to another. If this is indeed the case, then two years may be too 
long. 
The -axis refers to the cost, where cost increases from right to left and the y-axis refers to 
effectiveness and increases from the bottom to top. Figure 7.13 represents a period of one year. 
Again, the ADT group is represented by a blue triangle and is found in the bottom left quadrant. The 
red square (PVI) is also found in the bottom left quadrant. This indicates that, while PVI is marginally 








Figure 7.13: Cost-effectiveness of PVI vs. ADT with reference to 
change in duration of the study 
Source: Markov model dated 27 February 2012. 
However, at a period of two, three and four years, PVI dominates ADT as being more cost-effective. 
This is shown is Table 7.17. Assuming that the same efficacy is found at three years and four years, 
then PVI would continue to dominate ADT.  
Table 7.17: Sensitivity analysis of duration (tDuration) 
 
Source: Markov model dated 27 February 2012. 
When a sensitivity analysis was performed on the variable for the duration of the study, with two 
years as the baseline and with the variable changed to one year, three years and four years, the 
following emerged:  
1. The average cost showed that up to 1.587 years, the cost of PVI is more than that of the ADT 
group; thereafter, the cost of PVI flattens out, while the cost of ADT continues to grow 
exponentially (Figure 7.14). At one year, the cost of the ADT group is about R130 000, compared 
to R160 000 for the PVI group. After four years, the cost of the ADT group is about R340 000 
while the cost of PVI has increased to about R190 000. This represents an increase in cost of 
19% for the PVI group and 162% for the ADT group. 
Strategy Variable Cost Eff CE IC IE ICER Dominated 
PVI 1 year R132 275 0.77 171 247 0 0 0  
ADT 1 year R158 866 0.82 193 600 R26 591 0.048 552059  
PVI 2 years R168 437 1.64 102 667 0 0 0  
ADT 2 years R187 357 1.53 122 821 R18 920 -0.12 -164295 (Dominated) 
PVI 3 years R180 471 2.43 74 250 0 0 0  
ADT 3 years R259 999 2.20 118 208 R79 527 -0.23 -344163 (Dominated) 
PVI 4 years R194 621 3.19 60 990 0 0 0  






Figure 7.14: Measure of average cost when the duration of the study  
was measured at one year, two, three and four years  
Source: Markov model dated 27 February 2012. 
2. Up until 1.587 years, the incremental costs for PVI were greater than the incremental costs for 
ADT. From the start of the study, the incremental costs for PVI decreased and flattened out at 
two years, at well below R5 000. This can be accounted for by the fact that the main costs 
associated with PVI are incurred at the time of ablation. The converse is true for the ADT group, 
where the costs started at less than R5 000 and, over the four- year period, increased to close 
to R140 000 (Figure 7.15). 
 
Figure 7.15: Measure of the incremental costs when the duration of the  
study was measured at one year, two, three and four years 
Source: Markov model dated 27 February 2012. 
3. Figure 7.16 is a measure of the incremental effectiveness when the duration of the study was 
measured at one year, two, three and four years. The incremental effectiveness decreased in 
both the ADT and the PVI group, but the decline in effectiveness in the ADT group was greater 




continued beyond two years. After two years, the graph in the PVI group appeared to remain 
unchanged. The decline in the ADT group was greater than the decline in the PVI group. From 
the results of the four-year APAF study, we know that the effectiveness declines further in both 
groups but that the decline is greater in the ADT group than in the PVI group.  
 
Figure 7.16: Measure of the incremental effectiveness when the duration  
of the study was measured at one year, two, three and four years 





4. Figure 7.17 demonstrates the average cost-effectiveness at one, two, three and four years. Up 
until 1.587 years, ADT is, on average, more cost-effective than PVI. However, at 1.587 years, 
the costs break-even and, thereafter, PVI dominates ADT as being more cost-effective. 
 
Figure 7.17: Measure of the average cost-effectiveness when the duration of  
the study was measured at one year, two, three and four years 
Source: Markov model dated 27 February 2012. 
5. The net monetary benefits (NMB) at a “willingness to pay” threshold of R120 000 shows that the 
ADT group starts at about -R40 000, compared to the PVI group, which starts at about -R60 000. 
At year three, the NMB for the ADT group has reached a value of zero but declines again at year 
four to about -R20 000. The PVI group changes from -R60 000 at the start of the study to about 
R190 000 by year four, with the break-even point at 1.387 years. (Figure 7.18). 
 
Figure 7.18: Measure of the net monetary benefits when the duration of the  
study was measured at one year, two, three and four years 





Average length of stay in hospital (kAveLoS) 
Based on two large published studies by Stewart et al. (2002) and Reynolds et al. (2007) it was 
established that the average length of stay in hospital for admission, where AF was the primary or 
secondary diagnosis, was 5.2 days. With this in mind, the author built the model with 5.2 days as the 
baseline value and a sensitivity analysis was performed at values of 20% below and 20% above the 
baseline. The findings are seen in Table 7.18 where, at the baseline of 5.2 days, PVI dominated ADT. 
If the length of stay was reduced by one day (-20%), it produced an ICER of R11 770. 80 indicating 
that PVI was more cost-effective, with a cost of R11 770 per QALY gained. When the length of hospital 
stay was extended by one day to 6.2 days (+20%), it was found that PVI completely dominated ADT.  
Table 7.18: Sensitivity analysis of the average length of stay per hospital admission (kAveLoS) 
 
Source: Markov model dated 27 February 2012. 
In Figure 7.19 the -axis refers to the cost, where cost increases from left to right and the y-axis refers 
to effectiveness and increases from the bottom to top. ADT is represented by the blue triangle and is 
found in the bottom left quadrant and PVI, represented by the red square, is found in the top left 
quadrant. At 4.2 days, the cost of ADT was R164 544 or 0.8% lower than PVI at R165 900. However, 
the effectiveness at 4.2 days for ADT was 1.52 vs. 1.64 for PVI, or 7% lower for ADT. 
 
Figure 7.19: Cost-effectiveness of PVI vs. ADT with reference to the length of 
stay in hospital for AF episodes (measured at 4.2 days) 
Source: Markov model dated 27 February 2012. 
Strategy Variable Cost Eff CE IC IE ICER Dominated 
ADT 4.2 days R164 544 1.53 107 866 0 0 0  
PVI 4.2 days R165 900 1.64 101 120 R1 355 0.12 11770  
PVI 5.2 days R168 437 1.64 102 667 0 0 0  
ADT 5.2 days R187 357 1.53 122 821 R18 920 -0.12 -164295 (Dominated) 
PVI 6.2 days R170 973 1.64 104 213 0 0 0  





At the baseline value of 5.2 days, the ADT cost was 11% higher than that of PVI, but 7% less effective 
and, at 6.2 days, the cost of ADT was 22% higher than PVI but still 7% less effective. Therefore, PVI 
dominated ADT at both 5.2 days and 6.2 days and, at 4.2 days, had an ICER of R11 770. This finding 
is not unexpected, as we have seen from the large economic burden studies that almost 50% of the 
total cost of treating AF was allocated to hospitalisation.  
When a sensitivity analysis was performed on the variable of the average length of stay in hospital, 
with two years as the baseline and with the variable decreased by 20% to 4.2 days or increased by 
20% to 6.2 days, the following was found: 
1.  At 4.2 days the average cost for ADT was R164 544 and R165 900 for PVI. At 6.2 days the 
cost for ADT was R210 170 compared with R170 973 for PVI, indicating an average increase 
in cost of 28% for ADT compared with an average increase of only 3% for the PVI group. The 
break-even point was at 4.275 days (Figure 7.20). 
 
Figure 7.20: Measure of the cost-effectiveness based on the average length of 
stay in hospital for the treatment of the complications of AF 
Source: Markov model dated 27 February 2012. 
2. The incremental cost for PVI decreases as the number of hospital days increases from 4.2 
days to 6.2 days, while the incremental costs for the ADT changes from less than R2 000 to 





Figure 7.21: Measure of the incremental cost, based on the average length of 
stay in hospital for the treatment of the complications of AF 
Source: Markov model dated 27 February 2012. Figure 7.22 demonstrates that changing the variable of average 
length of stay in hospital has no impact on the average effectiveness for either PVI or ADT. 
 
Figure 7.22: Average effectiveness of PVI and ADT when the variable average 
length of stay is changed by +20% and -20% 
Source: Markov model dated 27 February 2012. 
3. Figure 7.23 shows that, for both ADT and PVI, the incremental effectiveness decreases from 






Figure 7.23: Measure of the incremental effectiveness based on the average length  
of stay in hospital for the treatment of the complications of AF 
Source: Markov model dated 27 February 2012. 
4. The incremental cost-effectiveness, as seen in Figure 7.24, indicates that, for PVI, there is little 
change in cost-effectiveness whether the length of stay is 4.2, 5.2, or 6.2 days. This is due to 
the fact that there are significantly fewer episodes of hospitalisation in the PVI group. The 
converse is true for the ADT group, where the incremental cost-effectiveness decreases as 
the length of stay increases from 4.2 days to 5.2 and finally 6.2 days. 
 
Figure 7.24: Measure of the incremental cost-effectiveness based on the average  
length of stay in hospital for the treatment of the complications of AF 
Source: Markov model dated 27 February 2012. 
5. The net monetary benefits (NMB) at a willingness to pay threshold of R120 000 shows that the 
PVI group started at 4.2 days at approximately R31 000 and declined by 19% to R25 000 at 
6.2 days. At the baseline of 5.2 days, the NMB for PVI were approximately R29 000 (-6%). For 
the ADT group, the NMB at 4.2 days was R20000 and declined to -R27500 by 6.2 days, 





Figure 7.25: Measure of the net monetary benefits based on the average length  
of stay in hospital for the treatment of the complications of AF 
Source: Markov model dated 27 February 2012. 
Relative risk of dying on ADT vs. PVI for AF (rrADT) 
The final sensitivity analysis that was performed was the relative risk of dying from ADT as tabulated 
in Table 7.19.  
Table 7.19: Sensitivity analysis of the relative risk of death from ADT (rrADT) 
 
Source: Markov model, dated 27 February 2012. 
The literature by Calkins et al. (2009) indicates that the treatment of AF with ADT has a 2.2 relative 
risk of death over PVI. Using relative risk of ADT of 2.2 as the baseline, a sensitivity analysis was 
run by changing the variable rrADT by +20% and -20%. For all three scenarios, ADT was dominated 
by PVI, which was therefore more cost-effective. 
In Figure 7.26 the -axis refers to the cost, increasing from left to right, and the y-axis refers to 
effectiveness and increases from the bottom to top. ADT is represented by the blue triangle in the 
bottom right quadrant. The red square, representing PVI, is found in the top left quadrant. ADT has a 
cost of between R185 000 and R190 000 per patient, with an effectiveness of approximately 1.53 
QALY. PVI has a cost of between R165 000 and R170 000 per patient, with an effectiveness of 1.65 
QALYs. ADT is encircled by a yellow dot and is therefore dominated by PVI for the variable of rrADT.  
 
Strategy Variable Cost Eff CE IC IE ICER Dominated 
PVI 1.8 R168 437 1.64 102 667 0 0 0  
ADT 1.8 R187 560 1.53 122 641 R19 123 -0.11 -171858 (Dominated) 
PVI 2.2 R168 437 1.64 102 667 0 0 0  
ADT 2.2 R187 357 1.53 122 821 R18 920 -0.12 -164295 (Dominated) 
PVI 2.6 R168 437 1.64 102 667 0 0 0  







Figure 7.26: Cost-effectiveness of PVI vs. ADT with reference to the  
relative risk of dying from ADT (rrADT) 
Source: Markov model, dated 27 February 2012. 
For all the variables tested in the sensitivity analysis for rrADT the cost of ADT was 11% higher than 
PVI and 7% less effective. The full sensitivity analysis is discussed below with reference to Figures 
7.29 to 7.34. 
The average cost for ADT was R188 000, compared with PVI at R168 000. ADT shows a small 
decline in cost between the baseline of 2.2 and 2.6, as indicated in Figure 7.27. The same is noted 
in Figure 7.28 when testing for incremental cost.  
.  
Figure 7.27: The average cost for ADT and PVI when testing for the 
relative risk of death between ADT and PVI 





Figure 7.28: The incremental cost for ADT and PVI when testing for 
the relative risk of death between ADT and PVI 
Source: Markov model, dated 27 February 2012. 
Figure 7.29 explores the impact that the rrADT had on the effectiveness of both ADT and PVI. There 
was no change in effectiveness for the PVI group and a -1% change for the ADT group. 
 
Figure 7.29: Measuring the effectiveness for ADT and PVI when testing  
for the relative risk of death between ADT and PVI 
Source: Markov model, dated 27 February 2012. 
The incremental effectiveness was unchanged in the PVI group as the rrADT changed, while the 





Figure 7.30: Measuring the incremental effectiveness for ADT and PVI when  
testing for the relative risk of death between ADT and PVI 
Source: Markov model, dated 27 February 2012. 
The incremental cost-effectiveness (ICER) was unchanged in the PVI group. The ICER for the ADT 
group improved by 9% when the relative risk of dying increased from 1.8 to 2.6. This indicates that, 
for the ADT group, the more people on ADT who die, the more cost-effective the treatment option 
becomes (Figure 7.31).  
 
Figure 7.31: Measuring the incremental cost-effectiveness for ADT and PVI when  
testing for the relative risk of death between ADT and PVI 
Source: Markov model, dated 27 February 2012. 
Figure 7.32 demonstrates that for the PVI group, the net monetary benefits (NMB) remained at 
R28 000 in spite of the changes in the rrADT from 1.8 to 2.2 and, finally, to 2.6. The NMB for the 
ADT group declined from a negative R4 000 to a negative R4 500 from a relative risk of 1.8 to 2.2 
and 2.6. Again, this is a small change in the NMB for the ADT group, as money is saved with each 





Figure 7.32: Measuring the net monetary benefits (NMB) for ADT and PVI when  
testing for the relative risk of death between ADT and PVI 
Source: Markov model, dated 27 February 2012. 
Finally, a series of one-way sensitivity analysis was conducted on key parameters within the model 
to test for variation in results associated with parameter change. These results are graphically 
represented as a Tornado diagram in Fig 7.33 where ranges of results associated with particular 
parameters are staked according to descending variation. The one-way sensitivity analysis showed 
that the model was reasonably robust to the cost estimations of medicines and quality of life 
valuations for atrial fibrillation. 
 
Figure 7.33: Tornado Diagram-ICER PVI vs. ADT 
Source: Model 25th August 2019 
The model was most sensitive to variations in annual admission rate for ADT patients, length and 




extreme of the sensitivity analysis the predicted ICER did not exceed R100,000/QALY for PVI vs 
ADT, providing reasonable confidence in the results of the analysis. A one-way sensitivity analysis 
is limited in that it assumes parameter variation ceteris paribus when in practice certain parameters 
are likely to vary in correlation i.e. if medicine costs are greater, cost of hospital stay is also likely to 
be greater. A gold standard sensitivity analysis would have included sensitivity analysis where all 
parameters are varied across a given distribution, however, given the availability of data and 
resources available for the analysis the authors have provided a one-way analysis to provide 
indicative understanding of the implications of parameter variation 
7.5 CONCLUSION 
The 2010 ACC/AHA/European guidelines for AF, which were published in the European Heart 
Journal (2010: 2369-2429), recommend anti-arrhythmic drug therapy before catheter ablation for 
symptomatic paroxysmal and persistent AF in patients with relevant organic heart disease. The 
guidelines cite the fact that successful ablation is more difficult to achieve and that patients may 
require more than one procedure. Results of meta-analysis and randomised trials, comparing 
ablation with anti-arrhythmic drugs, have found that, although medical therapy remains the 
foundation of the treatment of AF, catheter ablation is assuming an increasingly greater role. 
Currently, the guidelines are as follows: 
1. Catheter ablation for paroxysmal AF should be considered in symptomatic patients who have 
previously failed a trial of anti-arrhythmic medication. This is based on Ila evidence and level 
A evidence. Class II is determined by the fact that there is conflicting evidence and/or a 
divergence of opinion about the usefulness/efficacy of the given treatment or procedure, and 
Class Ila suggests that there is a weight of evidence/opinion in favour of usefulness/efficacy. 
Level A evidence refers to the fact that there is data derived from multiple randomised clinical 
trials or meta-analyses, which is favourable over single centre studies, or non-randomised 
studies.  
2. Ablation of persistent symptomatic AF that is refractory to anti-arrhythmic drug therapy should 
be considered as a treatment option (Class Ila) with level of evidence B, where the level of 
evidence B refers to data derived from a single randomised clinical trial or large non-
randomised studies. 
Recent reports of meta-analyses cited in the 2010 ACC/AHA guidelines showed that PV isolation for 
paroxysmal or persistent AF was associated with markedly increased odds ratio of freedom from AF 
at one year. 
The body of evidence is increasing in favour of PVI for the treatment of paroxysmal AF. The results 
from this study, which reviewed a number of clinical studies and meta-analysis for both ADT therapy 




1. Effectiveness of therapy: At the end of two years there were more patients who were initially 
randomised to PVI free from AF compared with the patients who were initially randomised to 
ADT. 
2. There were fewer hospitalisations among the patients who were randomised to PVI compared 
with the ADT group. 
3. Although there were adverse advents in both treatment arms, the adverse events in the PVI 
group were of a more serious nature than in the ADT group. However, the total adverse events 
in the PVI group were less than 5%, while the adverse events in the ADT group were close to 
30%. 
4. Treating patients with ADT had a 2.2 relative risk of death over two years compared with 
treating patients with PVI. 
5. In all the categories tested, i.e. cost, effectiveness, QALY, duration of hospital stay, average 
length of stay in hospital and relative risk of death and net monetary benefit, PVI was more 
cost-effective compared to ADT. PVI dominated ADT in all but two categories. 
Based on these results, there are several issues which should be addressed in South Africa. The 
2010 ACC/AHA/European guidelines for AF suggest that successful ablation is more difficult to 
achieve and that patients may require more than one procedure. There are a limited number of 
electrophysiologists in South Africa who perform this procedure and it should be ensured that these 
physicians receive adequate training to overcome the concerns cited by the ACC/AHA/European 
guidelines. A second issue to address is to educate the patients and referring physicians about the 
benefits of each therapy option available. Finally, the funders need to be made aware of the 
significant cost and effectiveness benefit available to their patients if they receive the correct 
treatment, performed in the hands of a skilled operator. This could not only save a lot of money but 
also have a positive impact on many patients’ lives. 
Chapter 8 will summarise this study, recognise the limitations of the study and make recommenda-




A summary of this chapter, carrying the title ‘Cost-effectiveness of Radiofrequency 
Ablation vs Anti-arrhythmic Drugs for PAF’, has been prepared for submission as a 





CHAPTER 8: CONCLUSION 
8.1 OBJECTIVES 
The primary objective of this study was to measure the cost-effectiveness of radiofrequency catheter 
ablation compared with anti-arrhythmic drugs for the treatment of paroxysmal atrial fibrillation in the 
South African population. The secondary objectives of this study were to explore the various aspects 
of healthcare expenditure in South Africa and to understand how health technology is defined. 
Together with this the review of available literature indicated the need to analyse the rising costs in 
South African healthcare expenditure and, in particular, costs related to treatment of various cardiac 
and cardiovascular diseases. 
These objectives were met in this study, as the principles of health economics were introduced, and 
the healthcare sector in South Africa was explored and compared with other developed and developing 
nations. The study determined a value of “willingness to pay” within the context of one of the 
complications of AF, namely congestive heart failure. All the current therapy options were scrutinised 
for efficacy, practicality, complication rate and side effects, and RFA ablation was determined to be an 
appropriate alternative to ADT. Finally, real patient cost data were collected and used in the cost-
effectiveness model. 
8.2 SUMMARY 
Atrial fibrillation is a debilitating disease with increased mortality and is a major cause of stroke and 
worsened heart failure which adversely influence the quality of life of patients who suffer from the 
disease. The “gold standard” of treatment in patients with symptomatic AF remains anti-arrhythmic 
drugs and anti-coagulation. However, some drug therapies – either as single agents or in 
combination - are at best ineffective, with efficacy reported at two to four years of between 12% and 
24%. At worst, they are associated with a high incidence of adverse events and a relative risk of 
death compared to catheter ablation of 2.2. 
Pulmonary vein isolation by means of radiofrequency ablation is associated with less AF recurrence, 
improved quality of life, and a lower hospitalisation rate during 48 months’ follow-up. In addition, the 
benefits of restoring sinus rhythm may be greater in younger patients as doing so may prevent 
progressive atrial re-modelling that leads to chronic AF (Wazni et al., 2005: 2637). Furthermore, Wazni 
et al. (2005) cite Corley et al. (2004). In an analysis examining the predictors of mortality, they found 
that sinus rhythm was associated with a 47% reduction in the risk of death, whereas the use of anti-
arrhythmic drug therapy was associated with a 49% increase in mortality. Based on this, one may pose 
the question as to whether applying a treatment regime which restores sinus rhythm while 
simultaneously avoiding the deleterious effects of anti-arrhythmic drugs would improve survival. In this 




paroxysmal to persistent and permanent AF was higher in the ADT group than the PVI group, and 
suggest that the early use of PVI may be of benefit to avoid and limit arrhythmia recurrence and 
progression. 
At present PVI is reserved for patients who have failed medical therapy. Reasons for this are, firstly, 
the concern about the complications associated with the catheter ablation procedure and, secondly, 
the costs associated with the procedure. Cappato et al. (2010) published their data from a worldwide 
survey of more than 8 700 AF ablation procedures. They reported an overall major complication rate 
of 4% (Cappato et al., 2010). The most serious complications resulting in permanent disability were 
uncommon. These included death (0.05%) and stroke (0.28%). These data were updated in 2010 
and a total of 16 309 procedures done between 2003 and 2006 were reported on. What was 
important to note was that, in the 2005 survey, the typical patient age was between 18 and 82 years 
of age, while the 2010 survey included patients between 15 and 90 years of age. Also, important to 
note was the fact that, in the 2005 survey, the average number of procedures per patient was 1.5, 
while, in 2010, the average number of procedures was 1.3, a decrease of 13%. The overall success 
rate in 2005 was listed at 75.5% and this had increased to 80% by 2010, an improvement of 6%. 
The greatest success rate was found in the patients with paroxysmal AF where the success rate was 
recorded as 84%. The complication rate in the 2010 survey was a total of 4.5% with death accounting 
for 0.15%, tamponade 1.31%, stroke 0.23% and TIA, 0.71%.  
The conclusions from the worldwide survey in 2010 indicate that not only is catheter ablation being 
increasingly offered to patients with AF, but it is also being offered to sicker and older patients with 
AF. Radiofrequency remains the dominant energy form used for catheter ablation, with 90% of the 
procedures reported on in the worldwide survey having used RF ablation. While the success rate of 
the procedure seems to increase with experience, this increase in experience does not appear to 
translate to a decrease in the complication rate. 
Based on these data and the fact that other meta-analyses indicate that catheter ablation had more 
than a twofold greater efficacy at twelve months for maintaining sinus rhythm than ADT, that patients 
treated with catheter ablation had a two-thirds reduction in hospitalisation for cardiovascular causes, 
and finally that catheter ablation had a procedural complication rate at least equal to the major 
complications rate associated with high-risk percutaneous coronary interventions, the author feels 
that catheter ablation for atrial fibrillation should be considered as first-line therapy for patients with 
symptomatic paroxysmal atrial fibrillation as it is not only more efficacious but also more cost-






8.3 STUDY LIMITATIONS 
This study has several limitations in spite of the fact that it has examined many different sources of 
literature, including randomised controlled trials, meta-analysis, internet sites, interviews and 
personal experience. As with any research, it is subject to several potential biases. These will be 
described below. 
Firstly, the model is based on a randomised, controlled trial from a single centre. Although 
randomised, controlled studies are the benchmark for the determination of experimental effect, they 
may not fully represent patients in everyday practice in the real-world environment. The centre where 
the study was performed is a high volume centre and a centre of excellence and one would require 
the same technical skill in everyday practice to achieve the same results for what may be considered 
very complex catheter ablation techniques. However, it should be noted that the results from the 
2005 and 2010 worldwide surveys on catheter ablation, which represent the “real-world” practice, do 
not yield results that are significantly different from the randomised control trials used in this study. 
Secondly, the data collected and used in the model were from the private sector only. As discussed 
earlier, only 15% of the South African population have access private healthcare and, because we 
do not have specific costs for hospitalisation etc. in the public sector, it would be difficult to calculate 
the costs in the public sector. While this is a limitation of the study, the positive results of the study 
indicate that the public sector should investigate the option of treating their AF patients with catheter 
ablation to drive and improve efficiency and efficacy of treatment for the public sector patients.  
Thirdly, the model is based on AF in the ageing population. In spite of the fact that there are as many 
as 387 000 South Africans who are possibly affected by AF as part of the ageing process, this study 
does not address patients with AF as result of rheumatic heart disease. There are no studies that 
examine the outcome of treating patients with rheumatic atrial fibrillation with catheter ablation in 
spite of the fact that these patients generally develop AF at a much younger age and have the same 
or greater risk of stroke and heart failure. 
One of the most severe and debilitating complications of AF is undoubtedly stroke. Many researchers 
confirm that stroke in patients with AF is associated with a higher mortality and morbidity rates 
(Wazni et al., 2005: 2635). One of the limitations of this study was that it did not identify stroke as an 
independent health state. This was largely due to the fact that it was difficult to find patient-specific 
details for patients who suffered stroke as result of AF. While the cardiologist and 
electrophysiologists are the obvious persons to manage patients with heart failure and recurrence 
of AF, patients presenting with stroke may be referred to a general physician or neurologist and, in 




In spite of this limitation, the author believes that adding stroke to the model as a separate health 
state would have added extra cost to the ADT arm, where more strokes are likely to occur. Thus, it 
would not have changed the cost-effectiveness model in favour of the ADT arm.  
8.4 CONSIDERATIONS FOR THE SOUTH AFRICAN SOCIETY 
One of the major considerations to be made when considering South African society as a whole is 
the fact that training electrophysiologists is both a timely and expensive process. A cardiologist, who 
then further specialises in electrophysiology, has undergone the following training: six years of 
general university education plus an additional five years in internal medicine, three extra years in 
cardiology, and finally an additional two years in electrophysiology. This is a total of eighteen years 
of education. When compared with the training of general practitioners (six years plus two years 
community service), training electrophysiologists requires an additional ten years of training. All of 
the training up to the level of cardiologist occurs in the public sector. South Africa has only trained 
one electrophysiologist in the country in the past decade; this was done at the University of Cape 
Town and Groote Schuur Hospital. This was made possible by an education grant offered by Life 
Healthcare and extra funding through the assistance of companies like Biosense Webster and 
Medtronic. A number of other South African physicians have been trained in electrophysiology, but 
it had required them to move to Europe, Canada or the USA to be trained. Funding for this has been 
a combination of self-funding and/or educational grants offered by industry, for example Biosense 
Webster, Boston Scientific, Biotronik, Medtronic and St Jude medical.  
As a result of this research and work done within the EP community, Biosense Webster has 
committed more than R2 million towards the training of electrophysiologists in South Africa in the 
past four years and is currently working with the academic institutions to set up education funds for 
the next few years. 
Besides the input from the industry, the Discovery Foundation was set up in 2006 as an independent 
trust and is investing over R100 million in grants towards developing South Africa’s scarce specialist 
healthcare resources. Over the past six years, the Discovery Foundation has already committed 
over R80 million in grants supporting over 150 specialists in training, and eleven high-achieving 
healthcare institutions in South Africa. 
The Discovery Foundation Awards include scholarships, bursaries and research fellowships, as well 
as support for teaching and research institutions. It is expected to support the training of new medical 
specialists for the public sector over a ten-year period, thereby increasing the number of sub-
specialists in the country (Discovery, 2014). 
The Life Healthcare Foundation in partnership with the College of Medicine SA, has awarded a more 
than thirteen bursaries to doctors to sub-specialize. As mentioned above, one of these bursaries 




spending R13 million over six years (a total of R78 million), which will cover the training of 32 doctor 
sub-specialists (The Life Healthcare Foundation, 2014). 
8.5 RECOMMENDATIONS 
A number of recommendations arise from this study, not only from the perspective of further 
research, but also pertaining to “real world” policies. These recommendations are as follows: 
1. Data needs to modelled out to five years to show the long-term efficacy of the two treatment 
options. This data will also help clarify if indeed the Pappone et al. (2011) study, which showed 
less progression in AF patients, treated with ablation, from paroxysmal to persistent and 
permanent.  
2. A further recommendation is to include the cost of stroke in the model. To this end, it might be 
worthwhile forming a collaborative group of interested parties to facilitate the capture of actual 
patient data with regard to cost and complication rates.  
3. While hundreds of thousands of patients are at risk of developing non-rheumatic AF, less than 
750 patients are treated with ablation each year. This should be highlighted to referring 
physicians and the medical aids, who are not offering their patients the best alternatives.  
4. Finally, the author would like to encourage participation of the local electrophysiology 
community, together with the Department of Health and the medical industry to initiate and 
complete a pilot study looking at the indigent population in South Africa who have rheumatic 
heart disease and AF. A number of issues should be studied: 
 The burden of AF in the South African population as result of rheumatic heart disease. 
 The efficacy of catheter ablation in these patients at one year, two years and long-term 
for maintaining sinus rhythm. 
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List of electrophysiologists interviewed 




Number of years 
in practice 
Number of PVI 
per year 
Dr. D. Milne Vincent Pallotti 
Cape Town 
8/9/2011 Telephonic 17 0 
Dr. R Gopal Panorama 
Cape Town 
18/10/2011 In person 5 75 




No response NR NR NR 
Dr. F. Lorgat  CBMH 
Cape Town 
No response NR NR NR 
Dr. P. Obel Milpark 
Johannesburg 
18/8/2011 In person 35 30 
(The late) 
Prof. A. Okreglicki  
GSH 
Cape Town 
18/8/2011 Telephonic 16 10 
Dr. A Stanley Sunninghill 
Johannesburg 
15/8/2011 In person 22 30 to 50 
Dr. A. Thornton Sunninghill 
Johannesburg 
16/8/2011 In person 16 30 to 40 
Dr. B. Vezi Ethekwini  
Durban 
18/8/2011 Telephonic 1 7 
Dr. M Alison Sunninghill 
Johannesburg 










Sample questionnaire: South African Electrophysiology Practice 
PVI for treatment of AF for patients with PAF or persistent AF 
Name of Physician  
Hospital  
Date of Interview  
Type of interview  
Practicing as EP in years  
Approximate PVI per year  
 
1.Type of Procedure 
 Yes No 
3 D mapping   
Conventional   
Cryoablation   
PVAC   
 
2. First Consultation 
 Yes No 
ECG/Stress ECG   
Echo   
24 hour Holter   
Other   
Possible codes used   
1231/1233/1235   
3620/3621/3622   
1238/1239    
 
3. Bloods 
 Yes No 
U& E   
FBC   
TSH   
Pro BNP   
INR   
Other   





4. Which AAD, ADT do you typically use? 
 Yes No 
Warfarin   
Sotalol   
Amiodarone   
Flecainide   
Propafenone   
Digoxin   
Diltizem   
Other   
Verapamil   
B Blocker   
   
Amiodarone Dose Number of weeks 
 800mg   
 600mg   
 400mg   
 200mg   
 
5. Cardioversion  
 Yes No 
TEE   
Admit CCU   




Anaesthetic/test   
Awake Sedation   
Bloods INR   
U&E   





6. PVI (between 1-4 times) 
 CCU/HC Ward 
Admission    
Days average stay   
CT Scan    
Average Theatre time   
Anaesthetist   
Awake Sedation   
TEE   
Bloods U&E   
FBC   
INR   
Other tests   
TSH, free T4   
Codes for charging Code Number of times charged 
Admission charge 0173  
TEE 3636  
TEE 3637  
EP study 1257  
Transseptal 1251   
PVI mapping 1261  
PVI ablation 1262  
Other   
 
7. Recurrent AF for Cardioversion  
 Yes No 
TEE   
Admit CCU   




Anesthetic/tist   
Awake Sedation   
Bloods U&E   
INR   
TSH free T4   





8. Recurrent PVI  (if different to initial PVI) 
 CCU/HC Ward 
Admission    
Days average stay   
CT Scan    
Average Theatre time   
Anaesthetist   
Awake Sedation   
TEE   
Bloods U&E   
INR   
TSH and free T4   
Other tests   
Codes for charging Code Number of times 
Admission charge 0173  
TEE 3636  
TEE 3637  
EP study 1257  
Transseptal 1251   
PVI mapping 1261  
PVI ablation 1262  
 
9. Follow-up after PVI 
 Yes No 
1 week/2 weeks /3 weeks   
1 month    
3 months    
6 months   
9 months   
12 months   
18 months   
24 months   





10. At Follow-up after PVI 
 Yes No 
Consultation   
Echo   
ECG   
Holter   
Bloods U&E and INR  




11. Recommended INR testing  
 X weeks/months  
1x week   
1x every two weeks   
1x month   
Other   
Other 









Results of interviews with South African electrophysiologists  
PVI for treatment of AF for patients with PAF or persistent AF 
Demographics 
     
Type of Interview P 60% T 40% 
Mean Years in Practice 17.8 Range 1-35  
Average Number of PVI’s 24 Range 7-50  
 
Type of procedure 
3D mapping  X X X X  X X NR NR 
Conventional no 3D mapping         NR NR 
Cryoablation X X X  X  X X NR NR 





XXX XXX X XXX X XXX XXX XXX NR NR 
Echo 
3620/3621/3622 
XX XXX XX XXX XXX XXX XXX XXX NR NR 
24 hour Holter 
1238/1239  
XX XX  50% 30% 50% 50% XX NR NR 
Other:         NR NR 
 
Bloods at first consultation 
U& E X X X X X X X X NR NR 
FBC X X X X X  X X NR NR 
TSH X X X X X X X X NR NR 
Pro BNP X X     50%  NR NR 
INR X X X X X X X X NR NR 
Other       XX X NR NR 







TEE OE X OE OE OE  X OE NR NR 
Admit CCU X X  X X X X X NR NR 
Admit Ward   X      NR NR 
Outpatient/casualty/non-invasive room X X  X   X X NR NR 
Anaesthetic/tist  X  X   50%  NR NR 
Awake Sedation X  X  X  50% X NR NR 
Bloods INR X X X X X X X X NR NR 
U&E X X X X X  X X NR NR 
Other bloods        X NR NR 
Other: Clexane  OE     OE  NR NR 
Note: OE – only in an emergency 
 
Drugs used 
Warfarin X X X X X X X X NR NR 
Sotalol X X  X X  X X NR NR 
Amiodarone X X X X X X X  NR NR 
Flecainide X X X X X X X  NR NR 
Propafenone  X       NR NR 
Digoxin  X  X X  X X NR NR 
Diltizem X X  X X  X  NR NR 
Other         NR NR 
Verapamil X   X X X X X NR NR 
B Blocker X  X X X X X X NR NR 
Amiodarone 1200mg weeks   2w  2w    NR NR 
800mg weeks  4 days 2w  2w    NR NR 
600mg weeks 4 w 4 days  1w    1 w NR NR 
400mg weeks  4 days 2 w 1 w Daily  10 days 1w NR NR 








Admission  CCU CCU HC CCU CCU NA CCU CCU NR NR 
Days average stay 1 2 1 2 1 NA 1 1-2 NR NR 
CT Scan  X   X  NA  X NR NR 
Average theatre time (hours) 2-3 4-5 4-5 4 4-5 NA 4-5 4 NR NR 
Anaesthetist  x 50% X  NA X X NR NR 
Awake Sedation X  50%  X NA   NR NR 
TEE x x x X X NA X X NR NR 
Bloods U&E  x x X X NA  X NR NR 
FBC  X  X X NA  X NR NR 
INR x x x X X NA X X NR NR 
Other tests ICE X     NA   NR NR 
TSH, free T4    X  NA   NR NR 
Codes for charging      NA   NR NR 
Admission charge 0173 x x x X X NA X X NR NR 
TEE 3636/3637 xx xx xx Xx Xx NA X X NR NR 
EP study 1257 x x x X X NA X X NR NR 
Transseptal 1251 xx xx xx Xx Xx NA XX XX NR NR 
PVI mapping 1261 x x xxxx X Xx NA X XX NR NR 
PVI ablation 1262 x x xxxx X Xx NA X XX NR NR 
Other rotational CT x     NA   NR NR 
Number of times redo 2 2-5 2 1-4 2 NA 2 2 NR NR 
 
Follow-up 
1 week/2 weeks/3 weeks X X    NA   NR NR 
1 month     X X NA   NR NR 
3 months  X X X X X NA X X NR NR 
6 months X X X X  NA  X NR NR 
9 months     X NA X X NR NR 
12 months X X  X  NA  X NR NR 
18 months X X X   NA   NR NR 
24 months X X  X  NA   NR NR 
Annually   X  X X NA X  NR NR 
Send back to referring Dr.   X X  NA   NR NR 







Consultation X X X X X NA X X NR NR 
Echo XXX XXX X 20%  NA 50% XXX NR NR 
ECG XX XX  X X NA X X NR NR 
Holter 1/yr. 50%  40% X NA 30% X NR NR 
Bloods U&E    X X NA   NR NR 
INR X X X X  NA X X NR NR 
LFT    X  NA   NR NR 
TSH    X  NA   NR NR 
Stop Warfarin 6mt     NA   NR NR 
 
INR testing 
         NR NR 
1x week X3 X4 1-3 X6 X3 X5 X1 X4 NR NR 
1x every two 
weeks 



















Other         NR NR 








Sample questionnaire: Anaesthetist 
PVI for treatment of AF for patients with PAF or persistent AF 
 
Name of Physician  
Hospital  
Date of Interview  
Type  
 
Anaesthetics for PVI 
Average time   
Codes   
EPS 1257  
Ablation 1261  
BP control inotropic 0039  
ICU admission 1204  
 
Other 
Modifier ASA 3 or Age 0043 
For study ASA3 used. 
 
Anaesthetic for Cardioversion 
Average time   
Codes   









Sample questionnaire: Radiographers 




Date of Interview  
Type  
 
Radiography for PVI 
Average time   
Codes   
ONCE OFF 39191  
EPS PER 30 MIN 39207  
FLURO 39167  
Attendance per 30 min 39179  
Once-off Attendance 39187  
Total   
 
Other 
References: Calkins Circ Arrhythmia Electro. 2009. 2: 340-361. 
1. Procedure time; 159 min (135 to 183 min) with mapping vs. 202 min (171 to 233 
min) with no mapping. 








Sample questionnaire: Technologists 
PVI for treatment of AF for patients with PAF or persistent AF 
 
Name of Technologist  
Hospital  
Date of Interview  
Type  
 
Technologist for PVI 
Average time   
Codes   
Prep and operation of 
monitoring 
75015  
EPS 75067  
RFA 75014  





Technologist for Holter 
Average time NA  
Codes   
Holter code for 24 to 48-hour 
monitor, set-up, hire, interpret 










Technologist for Cardioversion 
Average time   
Codes   

















Estimated age standardized incidence rates of Atrial Fibrillation with 95% uncertainty interval for men and women in North America, 
Western Europe, Central Europe and Sub Saharan Africa for 1990 and 2010. (Per 100000 person years) 
 
 














Estimated age standardized prevalence rates of Atrial Fibrillation with 95% uncertainty interval for men and women in North America, 
Western Europe, Central Europe and Sub Saharan Africa for 1990 and 2010. (Per 100 000 person years) 
 
 






Age-specific projections of the South African male population, 2000-2040  
(With-AIDS projections) (000’s) 
Year/ 
Cohort 
2000 2005 2010 2015 2020 2025 2030 2035 2040 
0-4 2 592 2 508  2 451  2 414  2 358  2 259  2 186  2 108  2 012  
5-9 2 625 2 529  2 454  2 402  2 367  2 315  2 219  2 149  2 075  
10-14 2 522  2 629  2 525  2 441  2 382  2 349  2 294  2 200  2 130  
15-19 2 371  2 536  2 636  2 528  2 435  2 378  2 342  2 289  2 193  
20-24 2 045  2 335  2 475  2 572  2 466  2 390  2 345  2 321  2 270  
25-29 1 883  1 983  2 213  2 333  2 418  2 332  2 273  2 252  2 241  
30-34 1 649 1 774  1 815  2 007  2 116  2 191  2 124  2 088  2 084  
35-39 1 522 1 544  1 606  1 619  1 799  1 890  1 953  1 903  1 882  
40-44 1 301 1 439  1 424  1 462  1 477  1 637  1 708  1 751  1 709  
45-49 1 044  1 249  1 356  1 332  1 372  1 385  1 527  1 581  1 605  
50-54 810  999  1 186  1 281  1 263  1 303  1 314  1 443  1 485  
55-59 603  759  934  1 109  1 200  1 187  1 225  1 235  1 353  
60-64 497  547  690  850 1 013  1 099  1 089  1 125  1 136  
65-69 358  428  474  601  744  890  969  964  999  
70-74 253  286  345  386  492  613  739  809  809  
75-79 147  181  208  253  286  368  463  562  619  
80+ 115  133  162  194  236  280  353  449  559  









Age-specific projections of the South African female population, 2000-2040  
(With-AIDS projections) (000s) 
 
 
Cohort 2010 2015 2020 2025 2030 2035 2040 
0-4 2,411 2,373 2,318 2,221 2,149 2,071 1,976 
5 to 9 2,419 2,362 2,327 2,276 2,182 2,113 2,039 
10 to 14 2,500 2,410 2,347 2,314 2,260 2,168 2,097 
15-19 2,633 2,512 2,412 2,350 2,314 2,262 2,167 
20-24 2,497 2,558 2,441 2,358 2,311 2,290 2,240 
25-29 2,218 2,302 2,357 2,261 2,201 2,185 2,182 
30-34 1,824 1,936 2,014 2,058 1,986 1,954 1,962 
35-39 1,630 1,559 1,665 1,725 1,756 1,704 1,689 
40-44 1,463 1,434 1,372 1,462 1,499 1,509 1,464 
45-49 1,404 1,338 1,313 1,258 1,332 1,349 1,336 
50-54 1,232 1,319 1,258 1,238 1,186 1,247 1,251 
55-59 988 1,162 1,245 1,190 1,172 1,121 1,174 
60-64 746 921 1,086 1,167 1,117 1,100 1,051 
65-69 561 679 841 995 1,072 1,029 1,014 
70-74 470 485 592 737 875 946 909 
75-79 321 375 391 482 605 723 786 
80+ 286 364 415 467 559 693 849 








Age-specific projections of AF 
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STRUCTURED ABSTRACT AND KEYWORDS  
AIMS: This overview of systematic reviews summarized findings of current systematic reviews 
on freedom from atrial fibrillation (AF) at 12 months following either radio-frequency ablation 
(RFA) or cryoablation (CB).   
METHODS: Based on pre-specified eligibility criteria, a comprehensive search was undertaken 
to identify systematic reviews comparing RFA versus CB for the treatment of patients aged 18 
to 70 years, with all patients having had paroxysmal atrial fibrillation or persistent atrial 
fibrillation and being refractory to at least one anti-arrhythmic drug. Eleven systematic reviews 
published between 2014 and 2018 were identified. These consisted of 57 unique studies with 
18,408 participants. Data were extracted and the methodological quality was assessed using 
AMSTAR.  
RESULTS: No difference was found between CB and RFA, with moderate certainty of the 
evidence (7 RCTs OR 0.98, 95%-CI [0,67 to 0,43]). Procedural time was on average shorter 
with CB than with RFA, with a high degree of heterogeneity among the studies. No difference 
was found for both fluoroscopy time and overall procedural complications. More patients 
developed phrenic nerve palsy when CB was performed compared to those who underwent 
RFA. Similarly, more patients who underwent RFA developed cardiac tamponade/pericardial 
effusion than those who underwent CB.  
CONCLUSION: This overview of systematic reviews found that there is little or no difference 
between CB and RFA in freedom from AF at 12 months.  
KEY WORDS: Pulmonary vein isolation for paroxysmal atrial fibrillation, cryoballoon and 
radio frequency ablation.  
INTRODUCTION 
Atrial fibrillation (AF) is the most commonly found and sustained cardiac arrhythmia of clinical 
significance.(1) New estimates suggest that the prevalence of AF in patients of 20 years and 





25% of all middle-aged adults in Europe and the USA will develop AF.(2) Atrial fibrillation is 
associated with debilitating symptoms and an impaired quality of life. Atrial fibrillation 
increases morbidity risk, such as through heart failure and stroke.(3) There is also an associated 
1.5-fold to two-fold increased risk of all-cause mortality in men and woman. The worldwide 
estimate for AF in 2010 was 33.5 million people. Men accounted for 62% of this statistic.(4) 
Based on the incidence rates of 2010, the estimated number of new AF cases per year is 2.7 
million for men and 2.0 million for women.(1) Higher incidence and prevalence rates are found 
in developed countries.(5)  
Atrial fibrillation is associated with cardiac disease, with coronary artery disease, valvular-heart 
disease and cardiomyopathy being the most common. Hypertension, diabetes, heart failure, 
chronic obstructive pulmonary disease and renal failure are among the most frequent co-
morbidities. Table 1 defines atrial fibrillation according to the 2016 AHA/ACC atrial 
fibrillation guidelines.(2) 
Atrial fibrillation poses a significant public health problem, accounting for 1% of the National 
Health System (NHS) budget in the UK and between $16-26 billion in the USA each 
year.(1,3,6) It is suggested that between 10 and 40% of patients who have atrial fibrillation will 
be hospitalized each year.(7) According to a study published in 2015,(8) the mean per capita 
medical spending for working adults with AF was $38,861 (95%-CI) compared to similar 
patients without AF which was $28,406 (95%-CI). This difference of $10,355 is statistically 





596,000, with an incremental cost burden of undiagnosed non-valvular AF of 3.1 billion US 
dollars.(8)  
The most recent AF guidelines recommend the use of anti-arrhythmic and anti-coagulant drugs 
for treating patients with symptomatic AF.(2) However, some large studies have shown anti-
arrhythmic drugs to be ineffective in many instances, based on the evidence that up to 85% of 
these patients are in AF again within one year.(9) This has led to the introduction of catheter-
based ablation (CB) as a Class IA level of evidence indication to maintain sinus rhythm in 
patients with symptomatic paroxysmal atrial fibrillation who are refractory or intolerant to at 
least one Vaughn-Williams Class I or III drug. It is important to assess patients for procedural 
risks, which, if present , makes ablation a Class IC level of evidence indication.(2,5,10,11)  
Both RFA and CB are used to electrically isolate the pulmonary vein (PVI) in people with PAF 
who are refractory to drug therapy. Point-by-point radiofrequency ablation is associated with 
long procedural and fluoroscopy times, as well as increased peri-procedural complications. 
RFA causes denaturing of the tissue as the tissue surrounding the catheter tip heats up, while a 
cryoablation placed in the pulmonary vein ostium electrically isolates the veins through means 
of freezing the surrounding tissue.(12-14) 
To date, a number of systematic reviews have been done to assess and compare RFA and CB 
for the treatment of PAF. This paper identifies and summarizes the most current evidence to 
allow for better decision-making processes, as well as to pinpoint gaps in research that need to 
be addressed. The aim was to provide an up-to-date overview of the effects of RFA vs CB for 





to CB regarding freedom from AF at 12 months, as well as secondary outcomes such as 
procedural time, fluoroscopy time and adverse events during the time periods reported in the 
systematic reviews.  
METHODS 
A protocol was developed according to the Cochrane guidance for overviews of systematic 
reviews(15) and registered with PROSPERO (registration number CRD42019135439). 
Criteria for Considering Reviews for Inclusion 
The overall aim was to assess the effects of CB vs RFA for PAF by summarizing the evidence 
from systematic reviews. A systematic review is characterized as having clearly stated 
objectives with pre-defined eligibility criteria for studies and a methodology that is explicit and 
reproducible, showing an attempt to identify all studies that meet the eligibility criteria. The 
risk of bias pertaining to included studies is assessed; and there is a clear and systematic 
demonstration and synthesis of the characteristics and findings of the identified studies.(15) 
Systematic reviews evaluating RFA compared to CB were identified. Both Cochrane and non-
Cochrane systematic reviews were included.(15) The participants in the studies were adults 
(aged 18 years to 70 years old) with paroxysmal and persistent atrial fibrillation, all of whom 
had already failed on at least one anti-arrhythmic drug. The primary endpoint  was reported 
freedom from AF at 12 months, while the secondary endpoints included procedural and 






Search Methods, Identification and Selection of Reviews 
A comprehensive search using Epistemonikos, PROSPERO, Embase (OVID), Medline (OVID) 
and Medline (Pubmed) was undertaken up until 18 April 2019.  
Systematic reviews from searches in Cochrane Library including DARE, HTA reviews, and 
economic assessments were also included. The literature was searched using the terms ‘atrial 
fibrillation’, ‘paroxysmal atrial fibrillation and catheter ablation’ OR ‘radiofrequency ablation’ 
OR ‘RF ablation’ OR cryoablation OR ‘catheter ablation’ OR ‘radiofrequency ablation’ OR 
‘RFA ablation’ OR ‘RFCA ablation’ OR ‘cryoablation’ OR ‘cryoballoon’. Medical Subject 
Headings (MeSH) descriptor: atrial fibrillation. Detailed information on the combinations of 
search terms used in the search strategy is available in Supplementary Table S1. We imported 
all retrieved reviews into the EndNote Web reference management software (Thomson Reuters, 
Carlsbad, CA, USA). Two reviewers (HHL and DL) independently screened and selected 
reviews. Any discrepancies were resolved by the consensus of authors of this paper. A third 
person Patricia McCarthy (PMC) was available to resolve any issues where authors HHL and 
DL did not reach consensus. Included and excluded reviews can be found on Tables 2 and 3 
respectively. 
Data Extraction 
Data of all eligible systematic reviews were extracted and examined independently by two 
reviewers (HHL and DL). Extracted data included information on the following: authors, year 





methods used in the systematic reviews, type of interventions, participants in the studies, results 
and outcomes, and the quality assessment of the original studies.  
Quality Assessment of Systematic Reviews 
Two independent reviewers (HHL and DL) used the ‘Assessing the Methodological Quality of 
Systematic Reviews’ (AMSTAR) tool to review all included studies.(16) The AMSTAR tool 
uses an 11-point system to appraise the methodological aspects of the systematic reviews where  
the  scoring system is as follows: yes = 1 point; and no, can’t answer or not applicable = 0 points. 
The total final score ranges from 0 to 11. The AMSTAR assessment can be found in Table 4.  
Data Synthesis 
The main results of the included reviews by primary and secondary outcomes were summarised 
and presented. Summary tables from the extracted data for each outcome reported the number 
and types of included studies, measure of effect, 95%-CI and tests for heterogeneity. For the 
primary outcome, freedom from AF at 12 months, a GRADE assessment was completed using 
GRADEpro version 3.6. The GRADEpro software was developed as part of a larger initiative 
led by the GRADE Working Group. GRADE offers a system for rating quality of evidence 
(ims.cochrane.org/revman/other‐resources/gradepro/about‐gradepro). In determining the 
certainty of evidence for the primary outcome, both the effects of the intervention and an 







From the databases searched, 1639 potentially relevant articles were initially retrieved. Of these 
1639 articles, 115 were retrieved from the Cochrane Library, 225 from Epistemonikos, 49 from 
PROSPERO, 365 from Medline (OVID), 428 from Embase (OVID), and 457 from Medline 
(PubMed). After the exclusion of duplicate entries, 1117 articles remained. After screening the 
titles and abstracts, 26 full text articles were identified to be read in their entirety. Of those, 
only 11 met the criteria for inclusion in this overview (Figure 1) (17-27), while 15 studies were 
excluded (28-41) (Table 3).  
Description of Systematic Reviews 
Eleven systematic reviews (Table 2) met the inclusion criteria. All of these systematic reviews 
were published between 2015 and 2018. The inclusion criteria and methods used in these 
systematic reviews varied considerably, particularly with regard to the secondary outcomes 
such as adverse events, procedural time and fluoroscopy time.  
The 11  systematic reviews addressed 187 studies with 77,486 patients. The number of unique 
primary studies was 57, involving 18,408 patients. Seventeen of the studies were randomised 
control trials (RCTs), including one RCT pilot study. The remaining studies were non-
randomised trials including cohort studies, retrospective reviews or observational studies. Many 
of the primary studies were included in more than one of the systematic reviews. Details are 





All patients included in the reviews had PAF, with a few reviews including patients with 
persistent atrial fibrillation. The patients were typically refractory to one or more anti-
arrhythmic drugs. The patient population averaged at between 55 and 60 years of age.  
The systematic reviews lacked a common approach regarding how interventions were 
categorised. In many instances, a large amount of detail was given about the cryoballoon 
technology, including manufacturer, size of balloon and whether first- or second-generation 
balloons were used. Little information about the RFA catheters was provided. In many 
instances, no mention was made about whether the RFA was done with or without a 3D 
mapping system, who the manufacturer of the catheters was, or details of the catheter and 
technology used. Some of the studies indicated the use of contact force RFA catheters but no 
further detail was provided. One of the systematic reviews (17) provided details of all the 
catheters used. In this review, it was found that in five of the 40 included studies patients 
received a contact force catheter. In a further 26 out of 40 studies it was only indicated that they 
were irrigated with ‘Thermocool™ catheters’, with no further information being provided as to 
whether a 3-D mapping system was used. The remaining nine studies included, as part of the 
RFA group, four ablations done with a high-density Mesh ablation catheter (MESH) and one 
that was done with a multi-electrode phased-RF/duty cycled (PhRF/DC) pulmonary vein 
ablation catheter (PVAC). Neither of these therapies is used frequently for RFA.(17)  
The outcomes that the systematic reviews studied were: freedom from atrial fibrillation, 
procedural time, fluoroscopy time and post-operative complications. All the primary outcomes 





atrial fibrillation (AF) for between four months and 16.5 months, with or without a blanking 
period. Primary  outcomes were also defined  as a recurrence of either AT  or AF during the 
follow-up on the original study with one review referring specifically to acute pulmonary vein 
isolation.  
For secondary outcomes, the systematic reviews made mention of phrenic nerve palsy as 
transient, persistent, permanent or unresolved. Pericardial effusion and tamponade were 
recorded. These were reported in some of the reviews as two separate incidents, while other 
reviews reported on them as a single event, regardless of whether the effusion required any 
intervention or not. The 11 reviews also measured procedural time , with two of the reviews 
defining how this measurement was made. Two reviews also defined how they arrived at the 
time for fluoroscopy and procedural time. (17,18) Three reviews reported  on major vascular 
complications, but did not qualify these. (20,21,23) Two reviews measured all-cause mortality, 
while another only mentioned death.(21,27) Four reviews reported on stroke or transient 
ischaemic attack (TIA).(20,21,23,27) Two reviews reported re-do ablation as a 
complication.(18,25) Three reviews (23,25,27) included groin site injury and major bleeding as 
complications, while the following were referred to as complications in one instance: 
pulmonary and bronchial complications, pulmonary vein stenosis, gastrointestinal 
complications, anxiety, local oedema, dyspnoea, contusion, haematuria, and post-operative 







Table 4 illustrates the AMSTAR assessment of the methodological quality of the reviews. One 
systematic review scored 10/11, with the list of excluded studies not reported on.(18) Eight 
systematic reviews (73%) scored 7 points. (17,19-21,23,25,40) These eight systematic reviews 
included confirmation of duplicate study selection and data extraction, comprehensive literature 
searches, the inclusion  of grey or unpublished literature, documented characteristics of 
included studies, methods of combining studies (for example, homogeneity tests), effect model 
used and sensitivity analysis, an assessment of publication bias demonstrated graphically or 
with a statistical test, and potential conflict of interest statement. 
The reason two (18%) of the systematic reviews scored 6 (22,26) was because neither included 
a list of excluded studies. Two of the reviews, scoring seven and ten respectively (18,25), 
provided a priori designs. Other reviews performed poorly in their methodological quality for 
failing to report on the following: a priori design (17,19,20,21,22,23,26,27), the lists of included 
and excluded studies (17,18,19,20,21.22,23,25,26,27,40), documented scientific quality 
assessment (17,19,20,21,22,23,25,26,27,40), appropriate formulation of conclusions 
(methodological rigor and scientific quality) (17,19,20,21,22,23,25,26,27,40), information on 







Effects of Intervention  
Primary Outcome 
Four of the 11 reviews reported on freedom from AF at 12 months as found in Table 6. (18,21,23,25) 
Cheng X, Hu Q. et al  (22) reported on 11 studies, three of which were RCTs and the other eight 
non-RCTs. The pooled measure of effect had a risk ratio of 1.01, 95%-CI [0.94 to 1.07]. The 
Cheng X, Hu Q. et al review did sub-group analyses on non-RCT-only studies that evaluated 
PAF and studies that compared the 28mm CB with RFA.(22) The results of these sub-group 
analyses did not change the measure of effect. Two reviews included RCTs only, with the first 
by Murray MI, Arnold A. et al including four RCTs (25) and the second, by Hachem AH, Marine 
JE. et al including seven RCTs all of which were included in the other 10 systematic reviews. 
This indicated a moderate certainty of evidence as per the GRADE assessment .(23)   
The odds ratio were 0.98, 95%-CI [0.67 to 1.43], (I2=56%)(25) and 1.13, 95%-CI [0.72 to 1.77] 
(I2=60,3%) (23) respectively. Maltoni S, Negro A. et al included 14 studies (3 RCTs and 11 non-
RCTs) that demonstrated a risk ratio of 1.04, 95%-CI [0.98 to 1.10] (I2=23%). A sub-group 
analysis of this review found a risk ratio of 1.03, 95%-CI [0.97 to 1.09] (I2=23%), when 
comparing CB with multi-polar catheters.(18)  
Two reviews reported on freedom from any atrial tachycardia including AF (see Table 7).(20,27) 
Cardoso R, Mendirichaga R. et al (20) examined 19 studies (5 RCTs and 14 non-RCTs) and 
reported the odds ratio as 1.12, 95%-CI [0.97 to 1.29] (I2=30%). The same review performed 
two sub-group analyses, the first looking at RCTs only (five studies) and found the OR to be 





contact force technology (4 reviews), found the OR to be 1.04, 95%-CI [0.71 to 1.51] (I2=0).(20) 
Garg J, Chaudhary R. et al. (27) examined nine studies (three RCTs and six non-RCTs), and 
found an odds ratio of 1.13, 95%-CI [0.96 to 1.33] (I2=26%).(27) Finally, one review including 
16 studies (four RCTs and 12 non-RCTs) examined freedom from AF/AT at 12 months, (see 
Table 8) and found a risk ratio of 1.05, 95%-CI [0.98 to 1.13] (I2 =72.5%).(21) 
Secondary Outcomes 
Procedural Time 
All of the reviews reported on procedural time as reported in Table 9. Two of the 11 systematic 
reviews defined procedural time as starting with the administration of local anaesthetic to the 
withdrawal of the catheters, (17,18) while nine reviews did not define procedural time.(19-23,25-27,42) 
Nine of the 11 reviews reported the procedural times as being less in the CB group when 
compared with the RFA group,(17-23,26,40) while two reviews (25,27) and one sub-group analysis 
comparing CB1 with multipolar catheters
(17) found the procedural time shorter in the RFA 
group. Three reviews, including one sub-group analysis with RCTs, found no statistical 
significance in the difference in procedure time between CB and RFA. In a sub-group analysis 
of three RCTs, Garg J, Chaudhary R et al. (27) found a standard mean difference (SMD) of 0.37 
min, 95%-CI [-0.52 to 1.26] (I2 =93%, 2 =29.58, p value, <0.00001).(27)  
Hachem AH, Marine JE. et al. (23) and Murray MI, Arnold A.  et al. (25) each included only RCTs 
in their reviews, being eight and four respectively. All of the studies included in the Hachem 
review (12-14, 43-47) were also found in the Murray review. (12-14,43) The Hachem review found a 





value<0.00001),(23) while Murray MI, Arnold A.  et al. in their review of four RCTs found a 
WMD of 12.91 min, 95%-CI [-5.59 to 31.31] (I2 =86.8 %, no 2 reported). 
Fluoroscopy Time 
Table 10 illustrates that only two of the 11 systematic reviews defined fluoroscopy time as 
being from start to end of the procedure.(17,18) There was very little overall difference in 
fluoroscopy time between the CB and the RFA groups, varying from a WMD of -27.66 min to 
1.17min.(19-23,25-27,42,48) Two reviews did sub-group analyses.(17,27) The first examined ten 
studies, of which two were RCTs and eight were non-RCTs, and found a SMD of 0.01min, 
95%-CI [-0.34 to 0.35] (I2 95%, 2 not reported).(27) Their second analysis looked at RCTs only, 
and reported a SMD of 0.28 min, 95%-CI[0.06 to 0.49] (I2 = 16%; 2= 1.19; p-value= 0.28).(17) 
The final sub-group analysis of two non-RCTs studies compared CB2 with RFA using contact 
force technology. In this instance, the SMD was 0.10 min, 95%-CI [-0.47 to 0.68] (I2 = 89%; 
2= 9.05; p-value= 0.003).(27) 
Liu XH, Chen CF et al. did four sub-analyses comparing CB with RFA. In 30 of the 40 included 
studies, they found the SMD for fluoroscopy time was 0.15 min, 95%-CI [0.42 to 0.13] (I2 
=97% no 2 reported).(17) The first sub-group analysis of 15 studies comparing CB1 with RFA 
found an overall SMD equal to -0.07min, 95%-CI [-0.38 to 0.24] (I2 of 96% no 2 reported).(17) 
The SMD in the second sub-group analysis, comparing CB2 with RFA in six studies, was -
0.076min, 95%-CI [-1.36 to -0.16] (I2 of 97% 2 not reported) . The third sub-group analysis 





95%-CI [-1.05 to 0.08] (I2 = 94%, 2 not reported). The final sub-group analysis comparing CB1 
with MTCA had a SMD of 0.43 min, 95%-CI [0.18 to 0.68] (I2 = 13%, 2 not reported).  
Fluoroscopy time was reported on in six (12-14,44,45,47) of the eight RCTs in Hachem et al. (23 ). 
The reported WMD was 1.17 min, 95%-CI [-4.94 to 7.2] (I2 =87%, 2= 39.74 , p value< 
0.00001). In their review of four RCTs, Murray MI, Arnold A. et al. found a WMD of -12.91 
min, 95%-CI [-31.31 to 5.59] (I2 = 65.5% no 2 reported). 
Procedure Related Complications  
Adverse events were reported as procedural related complications and these are found in Table 
11. These included groin site injuries, (23,25,27) stroke and/or thromboembolism,(20,21,23,27) major 
bleeding,(21,25,27) all-cause mortality/death, (21,27) and vascular complications. (20,21,23) These 
events were reported on as overall procedural related complications. The two most frequently 
reported adverse events were phrenic nerve palsy (18-23,25-27,40) and pericardial effusion/cardiac 
tamponade (18-21,23,25-27,40). Sub-group analyses were performed on these two adverse events.  
Nine of the 11 reviews reported on procedural related complications. (17,19,21-23,25-27,40)  One of 
two reviews that included only RCTs found an odds ratio for procedural related complications 
of 1.20, 95%-CI [0.58 to 2.52] (I2=52.2%, 2 not reported) (25), while the other RCT-focused 
review reported 1.34, 95%-CI [0.91 to 1.95] (I2=50%, 2 =12.03, p value= 0.06).(23) Over all the 
RCTs reported on in these nine reviews, (17,19,21-23,25-27,40), an overlap was found in seven of the 






Cardiac Tamponade/ Pericardial Effusion 
Eight of the eleven reviews reported on cardiac tamponade (Table 12), (18-20, 23, 40) pericardial 
effusion (Table 13) (18,20) or cardiac tamponade/effusion (Table 14).(26,27) Of the 14 RCTs listed 
on Table 12, five were reported on in only the Hachem AH, Marine JE. et al review,(13,44-47) 
while the other nine reviews included the same RCTs. (12,14,43) The results from all the reviews 
showed that the incidence of cardiac tamponade and/or pericardial effusion was statistically 
significantly lower in the patients who underwent ablation with CB, with an odds ratio of 
between 0.31-0.44 at its lowest and highest. Results were similar for the reviews that reported 
on pericardial effusion alone or with cardiac tamponade. The RCTs from the reviews that 
evaluated the incidence of pericardial effusion only, were the same as those used in detecting 
cardiac tamponade. (12-14,43-45) Only one sub-group analysis was done, this being in a single non-
RCT study and looking at CB vs multiparty catheters. In this study, the risk ratio of pericardial 
effusion was more than six times higher in RFA compared to all the other studies that reported 
on the same outcome. (49) The final two reviews, neither of which distinguished between cardiac 
tamponade and pericardial effusion (26,27), showed similar results, with CB having lower odds 
ratio OR=0.43, 95%-CI [0.26 to 0.72] (I2=0, 2=6.11, p value= 0.87) and OR 0.62 , 95%-CI 
[0.41 to 0.93] (I2 =0, 2=9.65 , p value=0.65) respectively. (12,14,26,27,43,45) 
Phrenic Nerve Palsy (PNP) 
Ten of the 11 reviews reported on phrenic nerve palsy as seen in Table 15. Overall CB was 
associated with a higher risk of PNP when compared with RFA and was the most commonly 





either transient (<12 months) or unresolved. Most of the PNP was reported as transient but at 
discharge, PNP was significantly more common in the CB group than in the RFA group (P 
<0.01); and in eight studies, three of which were RCTs, the odds ratio was 7.40, 95%-CI [2.56 
to 21.34] (I2 =0%, 2=1.89 , p-value=0.97).(20) 
Chen et al. reported that the incidence of PNP was 3.3% for CB vs 0.1% for RFA and that PNP 
accounted for 41% of all post-operative complication in the CB group, (21) while Hachem et al. 
in their review of four RCTs found that CB had a 10.3 times greater odds of PNP at 12 months 
follow-up compared to RFA with an odds ratio equal to 10.3, 95%-CI [3.09 to 34.6] (I2=0, 2 
not reported). (23) Five studies (14,43-45,47) found the PNP to be transient, while one study reported 
permanent phrenic nerve injury. (12) Murray et al. (25) in their review of four RCTs found 22 
patients with phrenic nerve palsy lasting less than 12 months (12,14,43) and one patient with 
unresolved phrenic palsy. (12) Data from a review of 18 studies, five of which were RCTs, found 
the odds ratio of 10.72, 95%-CI [2.67 to 11.04] (I2 =0%, 2=2.86, p-value=0.99). (26) 
A review of three RCT and two non-RCT studies found a risk ratio of 13.60, 95%-CI [3.87 to 
47.81] (I2 =6% 2=4.26, p-value=0.37).(19) Investigating eight non-RCTs, Jiang et al. (23) found 
the odds ratio equal to 17.35, 95%-CI [6.57 to 45.85] (I2 =7%, 2=7.56, p-value=0.37). PNP 
was only found in patients who underwent PVI with CB (5.4% vs 0%, p<0.00001) with a RR 
6.29, 95%-CI [2.44 to 16.21] (I2 =0, and 2 not reported).(22) Lastly, the review by Garg et al. 
(27) reporting on 13 studies that measured transient PNP (four of which were RCTs) found an 





RCT and four non-RCT studies that found unresolved PNP, Garg et al. found that the odds ratio 
was 4.62, 95%-CI [1.97 to 10.81] (I2 of 0, 2=1.11, p-value=0.98). (27) 
DISCUSSION  
Summary of Main Results 
This overview included 11 systematic reviews published between 2015 and 2018 comparing 
cryoablation with radiofrequency ablation for the treatment of atrial fibrillation. All of these 
studies were conducted in high income countries. All patients included in the reviews had 
paroxysmal or persistent atrial fibrillation, and were refractory to one or more anti-arrhythmic 
drugs. In general, the description of the interventions was very detailed with regard to the 
cryoballoon technology, with the name, size, 1st or 2nd generation and the manufacturer details 
included, while details relating to RFA were lacking. There was no difference in freedom from 
AF at 12 months (moderate certainty of evidence) and freedom from atrial tachycardia at 12 
months. Only two of the 11 systematic reviews did not include procedural and fluoroscopy time 
as an outcome. (17,18) There was very little difference among the reviews regarding procedural 
and fluoroscopy time. There was no difference in procedural related complications, including 
groin site injuries, (23,25,27) stroke/thromboembolism, (20,21,23,27) major bleeding, (21,25,27) all-cause 
mortality/death, (21,27) and vascular complications. (20,21,23) Of the two major adverse events that 
were documented, phrenic nerve palsy (18-23, 25-27,40) was associated with CB, while pericardial 






Overall Completeness and Applicability of Evidence 
The incidence and prevalence of atrial fibrillation is increasing, and so is the demand for 
treatment. Both CB and RFA as technologies have grown worldwide and continue to grow 
significantly. This overview included systematic reviews published between 2015 and 2018. 
Studies included in the systematic reviews were conducted in high income countries. This 
may limit the degree to which the evidence is applicable to low and middle income countries. 
However, all relevant types of participants, interventions and outcomes were investigated as 
non-valvular atrial fibrillation does not typically appear in people <18 years old. The 
comparison in all the reviews was CB vs RFA and all the relevant outcomes were addressed. 
Only four of the 11 reviews used the definition of freedom from AF at 12 months as their 
primary outcome, while the other reviews referred to a more general term of freedom from 
atrial tachycardia (AT) or freedom from atrial tachycardia and AF. All the reviews reported 
on the secondary outcomes of procedural and fluoroscopy time, with only two defining how 
this was measured. Overall post-operative procedural complications were reported in nine of 
the 11 reviews, while cardiac tamponade/pericardial effusion was reported in seven of the 
reviews and phrenic nerve palsy in eight reviews.  
An unpublished survey of South African electrophysiologists who performed AF ablation was 
undertaken by the primary author in 2010. The survey found that many of their practices were 
similar to those of electrophysiologists elsewhere, as documented in internationally published 
studies. (9) Most AF ablations are done in the private sector in South Africa, with only a limited 





overview fits well into the context of current practice in South Africa, where both RFA and 
Cryo are available and, in many instances, where both RFA and Cryo are available and used by 
the same electrophysiologist in the same hospital. Patient selection is important. Although both 
technologies can be utilized  for PVI procedures, some electrophysiologists only use RFA with 
3-D mapping, while others may choose to perform ablation with the cryoballoon for the first 
procedure, and RFA with 3D mapping when re-do ablation is required or where other complex 
arrhythmia are expected.  
Quality of the Evidence 
Among the reviews there were very few a priori designs. There was also poor attention to detail 
with regard to assessment of scientific quality and methodological rigor. However, all of these 
reviews did comprehensive literature searches, with search strategies being clearly stated. Many 
of the RCTs were included in more than one of the reviews. From the original 187 studies, there 
were only 57 that were unique. All the reviews shared the characteristics of having included 
studies and being assessed for publication bias. From the data presented, we were able to 
summarise the primary and secondary outcomes. 
Potential Biases in the Overview Process 
The protocol was registered on PROSPERO. An information specialist conducted a 
comprehensive search. The two authors independently applied pre-specified eligibility criteria 
and completed data extraction and assessment of methodological quality. The literature review 
and inclusion of systematic reviews was extensive and exhaustive. While all data relating to the 





such as, for example defining atrial fibrillation as both AF and an atrial tachycardia , the latter 
including a number of other supra-ventricular tachycardias. There was a lack of information  
regarding skill of the operators and specifics on the type  of RFA catheters used.  
Agreements and Disagreements with Other Studies or Reviews 
Phrenic nerve injury can lead to diaphragmatic paralysis or dysfunction. Phrenic nerve injury 
is common in cardiothoracic surgery (50) and cryoablation of atrial fibrillation, with up to 11.2% 
of patients developing this as an adverse event that is associated with pulmonary vein 
stenosis.(51) The data shows that most of the phrenic nerve injuries resolves within one year. 
This would not have much impact for healthy patients; however, for patients with marginal 
respiratory reserve, having phrenic nerve palsy lasting up to 12 months may have a significant 
impact on their  ventilation and oxygenation. Some of the reviews did not place much emphasis 
on this adverse event, despite the fact that it is not benign.  
Published data comparing either RFA versus drug therapy or cryoablation versus drug therapy 
showed similar results with regard to efficacy of ablation and adverse events. This indicates a 
consistency in the data with regard to the primary and secondary outcomes.  
Authors’ Conclusions 
The results of this overview of systematic reviews found that there is little or no difference 
between CB and RFA in freedom from AF at 12 months. The technology used to treat patients 
with PAF should be based on patient selection, operator choice and experience. Further research 
is likely to have an important impact on the confidence in the estimate of effect and may change 





RFA, by expanding on types of catheters used and the use of 3D mapping, including 3D 
mapping programs designed to decrease exposure to radiation.  
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Full text articles excluded: n=15 
Reasons: 
1. (n=3 registered with Prospero) 
2. (n= 2 abstracts only) 
3. (n=2 not relevant to topic included other 
therapies) 
4. (n=1 not Systematic Review) 
5. (n= 1 duplicate) 
6. (n=1 health technology assessment) 
7. (n=1 Written in Chinese) 
8. (n=2 poster presentations at congresses) 





 Systematic reviews included: n=11 







Cochrane Library including DARE, HTA 
















Table 1: Definition of atrial fibrillation (2) 
AF pattern  Definition  
First diagnosed 
AF  
AF that has not been diagnosed before, irrespective of the duration of the 
arrhythmia or the presence and severity of AF-related symptoms.  
Paroxysmal AF  Self-terminating, in most cases within 48 hours. Some AF paroxysms may 
continue for up to 7 days.a AF episodes that are cardioverted within7 days 
should be considered paroxysmal.a  
Persistent AF  AF that lasts longer than 7 days, including episodes that are terminated by 
cardioversion, either with drugs or by direct current cardioversion, after 7 days 
or more.  
Long-standing 
persistent AF  
Continuous AF lasting for ≥1 year when it is decided to adopt a rhythm control 
strategy.  
Permanent AF  AF that is accepted by the patient (and physician). Hence, rhythm control 
interventions are, by definition, not pursued in patients with permanent AF. 
Should a rhythm control strategy be adopted, the arrhythmia would be re-
classified as ‘long-standing persistent AF’.  
AF 1⁄4 atrial fibrillation; AHRE 1⁄4 atrial high rate episodes; ECG 1⁄4 electrocardiogram; ICD 1⁄4 implantable cardioverter 
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List of abbreviations 
AF = Atrial Fibrillation, CB = Cryoballoon, Cryoablation, RFA = Radiofrequency Ablation, AAD’s = Anti-arrhythmic Drug, PAF = Paroxysmal Atrial Fibrillation, PVI = Pulmonary Vein 
Isolation, RF=Radiofrequency, AT= Atrial tachycardia, EP Centre= Electrophysiology centre, RCT= Randomized Clinical Trial, NA=Not applicable, CF=contact force, RFCA, 





Table 3: List of Excluded Studies 
 
Authors’ Year Reason for exclusion 
Banga S. et al. 2018(28) Abstract/Poster at a congress 
Patel L. et al. 2018(29) Protocol registered with Prospero 
Parwani S. et al. 2017(30) Persistent Atrial Fibrillation 
Patel N. et al. 2018(31) Abstract at congress 
Chen C. et al. 2018(32) Persistent atrial fibrillation 
Desai Y. et al. 2017(33) Management of AF in the elderly 
Gasparini M. et al. 2018(34) Atrial fibrillation and cardiac resynchronisation therapy 
Junjie Z. et al. 2017(35) Catheter ablation vs Surgical ablation 
Hussain N. et al. 2017(36) Conference Abstract 
Cai Q. et al. 2017(37) Written in Chinese 
Sousa PA. et al. 2015(38) Not a Systematic review/Meta-analysis 
Cay S. et al. 2015(39) Abstract in Journal supplement 
Jiang J. et al. 2017(24) Duplicate 






Table 4: Methodological Quality Assessment of Systematic Reviews Using the AMSTAR Tool 
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al 
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al 
2017(40) 
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Liu  et al 
2016(17) 
No Yes Yes Yes No Yes No No Yes Yes Yes 7 
Ma  et al 
2017(26) 
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Table 5: Matrix of Primary Studies Included in the Systematic Reviews 
Systematic reviews 




Included study Type of study Sample 
size 
Buiatti 






































Maltoni et al 
2018 (18) 




RCT 50 (13) (13) (13) (13) (13)  (13) (13) (13) (13) (13) 
(14) Hunter 2015 RCT 237  (14) (14)  (14)   (14) (14) (14)  
(43) Luik 2015 RCT 315 (43) (43) (43)  (43)  (43) (43) (43) (43) (43) 
(44) Pokushalov 
2013 
RCT 80    (44)   (44)   (44)  
(45) Siklódy 2012 RCT 60 (45) (45)  (45)   (45) (45)  (45) (45) 
(46) Schmidt 2013 Pilot RCT 99     (46)  (46)   (46)  
(47) Malmborg 
2013 





(51) Amin 2014 Abstract -  (51)         (51) 
(52) Linhart 2009 Case Control 40    (52)   (52)     
(53) Wasserlauf 
2015 
Cohort 201 (53) (53) (53)  (53) (53) (53)    (53) 
(54) Kojodjojo 2010 Cohort study 295  (54)  (54) (54)  (54) (54)   (54) 
(55) Schmidt 2014 Cohort Study 3775 (55)    (55)  (55) (55)    
(56) Straube 2016 Cohort Study 373 (56) (56) (56)  (56) (56) (56) (56)   (56) 
(57) Schmidt 2016 Cohort study 2306  (57) (57)  (57)      (57) 
(58) Juliá 2015 Cohort Study 286  (58) (58)    (58)    (58) 
(59) AkerstrÖm 
2014 
Cohort study 630  (59)     (59)     
(60) Siklódy 2011 Cohort Study 74       (60)     
(61) Mugnai 2015 Cohort Study 1352       (61)     
(62) Sauren 2009 Cohort study 30       (62)     
(63) Wasserlauf 
2014 
Cohort study 201        (63)    
(64) Squara 2015 Cohort study, 376  (64) (64)  (64) (64) (64) (64)   (64) 
(65) Dulac 2014 Non RCT 49  (65)    (65)     (65) 
(66) Kardos 2015 Non RCT 96      (66)      





(68) Khoueiry 2016 Non- RCT 687 (68) (68) (68)  (68)   (68)   (68) 
(69) Gaita 2011 Non- RCT 108     (69)  (69)     
(70) Kühne 2010 Non-RCT 50 (70)  (70) (70)   (70) (70)   (70) 
(71) Mugnai 2014 Non-RCT 396  (71) (71) (71) (71)  (71) (71)   (71) 
(72) Jourda 2015 Non-RCT 150 (72) (72) (72)  (72)  (72) (72)   (72) 
(73) Ciconte 2015 Non-RCT 100  (73)     (73)    (73) 
(74) Aryana 2015 Non-RCT 1196  (74)    (74) (74) (74)   (74) 
(75) Mokrani 2012 Non-RCT 79  (75)         (75) 
(76) Kardos 2016 Non-RCT 98   (76)        (76) 
(77) Jourda 2014 Non-RCT 150      (77)      
(78) Defaye 2010 Non-RCT 60       (78)     
(79) Hofmann 
2010 
Non-RCT 79       (79)     
(80) Kiss 2014 Non-RCT 89       (80)     
(81) Schmidt 2012 Non-RCT 243       (81)     
(82) Chierchia 
2010 
Non-RCT 133       (82)     
(83) Neumann 
2011 





(84) Wissner 2014 Non-RCT 86       (84)     
(85) Boveda 2016 Non-RCT            (85) 
(86) Ferretto 2015 Non-RCT. 63  (86)         (86) 
(87) Knecht 2014 Prospective 327 (87) (87) (87)  (87)  (87) (87)   (87) 
(88) Herm 2013 Prospective 37       (88)     
(90) Kuck 2016 RCT 750 (90)          (90) 
(91) Providencia 
2017 
RCT 860   (91)        (91) 
(92) Koch 2012 RCT 32       (92)     
(93) Malmborg 
2013 
RCT 30       (93) (93)    
(94) Nagy-Baló 
2013 
RCT 34       (94)     
(95) Tse 2005 RCT 30       (95)     
(96) Gunawardene 
2016 
RCT 60        (96)    
(97) Bittner 2011 RCT 80        (97)    
(98) Sorgente 2010 Retrospective 
Study 





(99) Nagy 2016 Retrospective 
Study 
96      (99)  (99)    
(100) Mandell 2013 Retrospective 
Study 






Table 6: CB vs RFA Freedom from AF at 12 Months  
Review  Types of studies Study (n) Measure of effect  Statistical Heterogeneity 
Cheng X. et al. 2015.(22) 
 
3 RCTs 8 Non-RCTs 11 RR 1.01 
95%-CI [0.94 to 1.07] 
I2=5%; 2 =10.54, p value = 0.39 
Cheng X. et al. 2015.(22) 
 
Non-RCTs 8 RR 1.03 
95%-CI [0.97 to 1.09] 
I2=0%; 2=4.34, p value = 0.74 
Cheng X. et al. 2015.(22) 
 
1 RCT 7 Non-RCTs (PAF Only) 8 RR 0.99 
95%-CI [0.88 to 1.11] 
I2=20%; 2=7.48, p value = 0.28 
Cheng X. et al. 2015.(22) 
 
1 RCT 5 Non-RCTs  6 RR 1.04 
95%-CI [0.95 to 1.14] 
I2=0%; 2=4.36, p value = 0.50 
Murray MI. et al. 2018.(25) 4 RCTs 4 OR 1.13 
95%-CI [0.72 to 1.77] 
I2=60.3%  
Hachem AH. et al 2018(23) 7 RCTs 7 OR 0.98 
95%-CI [0.67 to 1.43] 
I2=56%; 2=13.7, p value = 0.03 
Maltoni S. et al. 2018(18) 3 RCTs 11 Non=RCTs 14 RR 1.03 
95%-CI [0.97 to 1.09] 
I2=23%; 2=16.99, p value = 
0.20 
Maltoni S. et al. 2018(18) 1 RCT 1 Non-RCT  2 RR 1.26 
95%-CI [0.97 to 1.63] 





Table 7: CB vs RFA Freedom from AT at 12 Months  
Review  Types of studies Study (n) Measure of effect  Statistical Heterogeneity 
Cardoso R. et al. (2016)(20) 5 RCTs and 14 Non-RCTs 19 OR 1.12  
95%-CI [0.97 to 1.29] 
I2=30%; 2=25.56, p value = 0.11 
Cardoso R. et al. (2016)(20) RCTs only 5 OR 1.00  
95%-CI [ 0.65 to 1.56] 
I2=60%; 2=10.08, p value = 0.04 
Cardoso R. et al. (2016)(20) 4 Non-RCTs (CB2 vs Contact force) 4 OR 1.04  
95%-CI [ 0.71 to 1.51] 
I2=0%; 2=1.23, p value = 0.75 
Garg J. et al. 2016(27) 3 RCTs 6 Non-RCT 9 OR 1.13  
95%-CI [0.96 to 1.33] 
I2=26%; 2=10.84, p value = 0.21 
 
Table 8: CB vs RFA Freedom from AF/AT at 12 Months  
Review  Types of studies Study (n) Measure of effect  Statistical Heterogeneity 
Chen Y. et al. 2017(21)  4 RCTs12 Non-RCTs 16 RR 1.05  
95%-CI [0.98 to 1.13] 






Table 9: CB vs RFA Procedural Time 
Review  Types of studies Study (n) Measure of effect Statistical Heterogeneity 
Buiatti, A. et al. (2016)(19) 2 RCTs 8 Non-RCTs (112-215 min vs 111-284 min) 10 WMD -14.44min 
CI – 95% [-32.91 to 4.02] 
I2=98% (no 2 reported) 
Cardoso R. et al. (2016)(20) 5 RCTs 17 Non-RCTs 22 WMD -28.9 min 
95%-CI [-49 to -8.8] 
not reported 
Chen Y. et al. 2017(21)  4 RCTs 11 Non-RCTs 15 WMD -0.37 min 
95%-CI [-2.78 to 2.04] 
I2=89%, p value =0.00 (no 2 reported) 
Cheng X. et al. 2015.(22) 
 
3 RCTs 8 Non-RCTs (149.4min vs 183.6min) 11 WMD -31.94 min 
95%-CI [ -60.43 to-3.45] 
I2=96% (no 2 reported) 
Garg J. et al. 2016(27) 3 RCTs 8 Non-RCTs 11 SMD 0.02 min 
95%-CI [-0.52 to 0.88] 
I2=93%; 2=29.58, p value< 0.00001 
Garg J. et al. 2016(27) 3 RCTs 3 SMD 0.37 min 
95%-CI [-0.52 to 1.26] 
I2 =93%; 2= 29.58; p value <0.00001  
Garg J. et al. 2016(27) 2 Non-RCTs (CB2 vs Contact force) 2 SMD 0.12 min 
95%-CI [-0.76 to 0.99] 
I2= 95%; 2= 20.71; p value <0.00001 
Jiang J. et al. 2017(40) 6 Non-RCTs 6 WMD -.39.72 min 
95%-CI [-61.36 to -18.08] 
I2 =97%; 2=197.21; p value <0.00001  





95%-CI [-1.15 to -0.18] 
Liu XH. et al. 2016(17) 3 Non-RCTs (CB1&2) 3 SMD -1.43 min 
95%-CI [-1.62 to -1.23] 
I2 =35%; 2= 3.09 p value = 0.21 
Liu XH. et al. 2016(17) 4 RCTs 4 Non-RCTs (CB1 vs MTCA) 8 SMD 0.30 min 
95%-CI [0.06 to 0.54] 
I2 =31%; 2= 10.11; p value =0.18; 
Ma H. et al. 2017(26) 5 RCTs 11 Non-RCTs 16 MD -30.38 min 
95%-CI [ -46.43 to-14.33] 
I2 =98%; 2= 626.74; p value <0.00001; 
Murray MI. et al. 2018.(25) 4 RCTs 4 WMD 12.91 min 
95%-CI [-5.59 to 31.31] 
I2 =86.8 % (no 2 reported) 
Hachem AH. et al 2018(23) 8 RCTs 8 WMD -4.08 min 
95%-CI [-19.47 to11.30] 
I2 = 89%; 2= 64.58; p value <0.00001 
Maltoni S. et al. 2018(18) 3 RCTs 18 Non-RCTs 21 WMD -23.48min 
95%-CI [-37.97 to -9.02] 







Table 10: CB vs RFA Fluoroscopy Time 
Review  Type of Study Study (n) Measure of effect Statistical Heterogeneity 
Buiatti, A. et al. (2016)(19) 2 RCTs 8 Non RCTs (17-61min vs 18-73 
min) 
10 WMD -1.05min 
95%-CI [-2.89 to -4.99] 
I2 =95% I2 = 89%; 2= 9.05, p value = 
0.003 
Cardoso R. et al. (2016)(20) 5 RCTs 17 Non-RCTs 22 WMD -2.6min 
95%-CI [-6.4 to1.3] 
I2= 95%, (no 2 reported) 
Chen Y. et al. 2017(21)  4 RCTs 11 Non-RCTs  15 WMD -27.66min 
95%-CI [ -45.24 to -10.08] 
I2 =97%, (no 2 reported) 
Cheng X. et al. 2015.(22) 
 
3 RCTs 8 Non-RCTs (35.8min vs 39.9 
min) 
11 WMD -8.6min 
95%-CI [-18.29 to 3.69] 
I2 =96%, (no 2 reported) 
Garg J. et al. 2016(27) 2 RCTs 8 Non-RCTs 10 SMD 0.01min 
95%-CI [-0.34 to 0.35] 
I2= 95%; 2= 171.70, p value <0.00001 
Garg J. et al. 2016(27) 2 RCTs 2 SMD 0.28 
95%-CI [0.06 to 0.49] 
I2 = 16%; 2= 1.19, p value = 0.28 
Garg J. et al. 2016(27) 2 Non-RCTs (CB2 vs Contact force) 2 SMD 0.10 
95%-CI [-0.47 to 0.68] 
I2 = 89%; 2= 9.05, p value = 0.003 
Jiang J. et al. 2017(40) 7 Non-RCTs  7 WMD -2.86min 
95%-CI [-7.02 to 1.30] 





Liu XH. et al. 2016(17) Not stated  15 SMD -0.07min  
95%-CI [ -0.38 to 0.24] 
I2 = 96%, (no 2 reported)  
Liu XH. et al. 2016(17) Not stated  6 SMD -0.076min 
95%-CI [ -1.36 to -0.16] 
I2 =97%, (no 2 reported) 
Liu XH. et al. 2016(17) Not stated  3 SMD -0.49min 
95%-CI [ -1.05to 0.08] 
I2= 94%, (no 2 reported) 
Liu XH. et al. 2016(17) Not stated  6 SMD 0.43min  
95%-CI [0.18 to 0.68] 
I2 =13%, (no 2 reported) 
Liu XH. et al. 2016(17) Not stated  30 SMD 0.15min  
95%-CI [0.42 to 0.13] 
I2 =97%, (no 2 reported) 
Ma H. et al. 2017(26) 5 RCTs 11 Non-RCTs  16 MD -3.18min 
95%-CI [-6.43 to 0.07] 
I2 = 95%; 2= 273.42, p value < 0.00001 
Murray MI. et al. 2018.(25) 4 RCTs  4 WMD -12.91mon 
95%-CI [-31.31 to 5.59] 
I2 = 65.5%, (no 2 reported) 
Hachem AH. et al 2018(23) 6 RCTs  6 WMD 1.17min 
95%-CI [-4.94 to 7.2] 
I2 =87%; 2= 39.74; p value < 0.00001 
Maltoni S. et al. 2018(18) 1 RCTs 17 Non-RCTs 18 WMD -1.92min 
95%-CI [-4.89 to 1.05] 






Table 11: Overall Procedural Related Complications  
Review  Type of Study Study (n) Measure of effect Statistical Heterogeneity 
Buiatti, A. et al. (2016)(19) 2 RCTs 8 Non-RCTs 10 Risk Ratio 0.92 
95%-CI [0.66 to 1.28] 
I2=22%, 2 =11.53, p value= 0.24 
Chen Y. et al. 2017(21)  4 RCTs 11 Non-RCTs 15 RR 1.08 
95%-CI [0.86 to 1.35] 
I2=26.9%, (2 not reported) 
Cheng X. et al. 2015.(22) 3 RCTs 8 Non-RCTs 11 RR 1.3 
95%-CI [0.91 to 1.85] 
I2=0%, (2 not reported) 
Garg J. et al. 2016(27) 4 RCTs 11 Non-RCTs 
 
15 OR 1.06 
95%-CI [0.84 to 1.34] 
I2=31%, 2=20.17, p value= 0.12 
Jiang J. et al. 2017(40) 7 Non-RCTs 7 OR 2.01  
95%-CI [0.91 to 4.43] 
I2=62%, 2=15.65, p value= 0.02 
Liu XH. et al. 2016(17) 7 RCTs and 21 Non-RCTs 28 RR 0.72 
95%-CI [0.58 to 0.90] 
I2=13%, 2 =30.93, p value= 0.27 
Ma H. et al. 2017(26) 4 RCTs 9 Non-RCTs 13 OR1.56 
95%-CI [1.05 to 2.31] 
I2=39%, 2=19.53, p value= 0.08 
Murray MI. et al. 2018.(25) 4 RCTs 4 OR1.20 
95%-CI [0.58 to 2.52] 





Hachem AH. et al 2018(23) 7 RCTs 7 OR 1.34 
95%-CI [0.91 to 1.95] 
I2=50%, 2=12.03, p value= 0.06 
 
Table 12: Cardiac Tamponade 
Review  Type of study Study (n) Measure of effect Statistical Heterogeneity 
Buiatti, A. et al. (2016)(19) 2 RCTs 5 Non-RCTs 7 RR 0.48 
95%-CI [0.25 to 0.89] 
 I2 =0, 2= 5.69, p value= 0.46 
Cardoso R. et al. (2016)(20) 2 RCTs 6 Non-RCTs 8 OR 0.31 
95%-CI [0.15 to 0.64] 
I2 =0, 2= 0.62, p value= 1.00 
Jiang J. et al. 2017(40) 5 Non-RCTs 5 OR 0.32 
95%-CI [0.13 to 0.78] 
I2 =0, 2= 0.38, p value=0.98 
Maltoni S. et al. 2018(18) 2 RCTs 7 Non-RCTs 9 RR 0.33 
95%-CI [0.18 to 0.62] 
I2 =0, 2= 0.75, p value= 1.00 
Hachem AH. et al 2018(23) 8 RCTs 8 OR 0.39 
95%-CI [0.11 to 1.4] 






Table 13: Pericardial Effusion 
Review  Type of study Study (n) Measure of effect Statistical Heterogeneity 
Cardoso R. et al. (2016)(20) 3 RCTs 10 Non-RCTs 13 OR 0.44 
95%-CI [0.28 to 0.69] 
I2 =0, 2= 5.06 p value= 0.96 
Cheng X. et al. 2015.(22) 3 RCTs 8 Non-RCTs 11 RR 0.58 
95%-CI [0.30 to 1.06] 
I2 =0 (2= not reported) 
Maltoni S. et al. 2018(18) 3 RCTs 6 Non-RCTs (CB vs RFA) 9 RR 0.53 
95%-CI [0.31 to 0.91] 
I2 =0, 2=4.55 p value= 0.80 
Maltoni S. et al. 2018(18) Sub-group 1 Non-RCT  1 RR 0.31 
95%-CI [0.02 to 6.24] 
N/A 
Table 14: Cardiac Tamponade/Pericardial Effusion 
Review  Type of study Study (n) Measure of effect Statistical Heterogeneity 
Garg J. et al. 2016(27) 3 RCTs 9 Non-RCTs 12 OR 0.43 
95%-CI [0.26 to 0.72] 
I2 =0, 2=6.11 p value= 0.87 
Ma H. et al. 2017(26) 4 RCTs 9 Non-RCTs 13 OR 0.62 
95%-CI [0.41 to 0.93] 





Table 15: Phrenic Nerve Palsy 
Review  Type of study Study (n) Measure of effect Statistical Heterogeneity 
Buiatti, A. et al. (2016)(19) 3 RCTs 2 Non-RCTs 5 Risk ratio 13.60 
95%-CI [3.87 to 47.81] 
I2 =6% 2=4.26, p value=0.37 
Cardoso R. et al. (2016)(20) 3 RCTs 5 Non-RCTs 8 OR 7.40 
95%-CI [2.56 to 21.34] 
I2 =0%, 2=1.89, p value=0.97 
Cheng X. et al. 2015.(22) 3 RCTs 8 Non-RCTs 11 RR 6.29 
95%-CI [2.44 to 16.21]  
I2 =0%, (2 not reported)  
Garg, J. 2016 (28) 4 RCTs 9 Non-RCTs 13 OR 14.19 
95%-CI [6.92 to 29.10] 
I2 =0%, 2=9.23, p value=0.68 
Garg, J. 2016 (28) 3 RCTs 4 Non-RCTs 7 OR 4.62 
95%-CI [1.97 to 10.81] 
I2 =0%, 2=1.11, p value=0.98 
Hachem AH. et al 2018(23) 5 RCTs 6 OR 10.3 
95%-CI [3.09 to 34.6] 
I2=0%, (2not reported) 





95%-CI [6.57 to 45.85] 
Ma, H. 2017(27) 5 RCTs 13 Non-RCTs 18 OR 10.72 
95%-CI [5.59 to 20.55] 
I2 =0%, 2=15.89, p value=0.53 
Maltoni S. et al. 2018(18) 3 RCTs 9 Non-RCTs 12 RR 5.43  
95%-CI [2.67 to 11.04] 





SUPPLEMENTARY TABLE S1: SEARCH STRATEGY 
 
Search strategy up to 18 April 2019 




Search Name:  Cochrane library issue up to 18 April 2019 
Date Run: 17 April 2019   
#12 MeSH descriptor: [Atrial Fibrillation] explode all trees 3473 
#13 "Paroxysmal atrial fibrillation ":ti,ab,kw (Word variations have been searched) 705 
#14 MeSH descriptor: [Catheter Ablation] explode all trees 1585 
#15 "catheter ablation":ti,ab,kw (Word variations have been searched) 2126 
#16 "radiofrequency ablation":ti,ab,kw (Word variations have been searched) 1212 
#17 "RF ablation":ti,ab,kw (Word variations have been searched) 184 
#18 MeSH descriptor: [Cryosurgery] explode all trees 356 
#19 "cryosurgery":ti,ab,kw (Word variations have been searched) 441 
#20 "cryoablation":ti,ab,kw (Word variations have been searched) 193 
#21 #12 or #13  3842 
Search No. Date Database searched  Hits (before duplicate removal) 
1 15/04/2019 Cochrane Library  115 
2 15/04/2019 Epistemonikos 225 
3 16/04/2019 PROSPERO 49 
4 16/04/2019 Embase (OVID) 365 
5 16/04/2019 Medline (OVID) 428 
6 16/04/2019 Medline (PubMed) 457 





#22 #14 or #15 or #16 or #17 or #18 or #19 or #20  3151 
#23 #21 and #22  847 
Epistemonikos 
(title:((title:("Atrial Fibrillation" OR "Paroxysmal atrial fibrillation ") OR abstract:("Atrial Fibrillation" OR 
"Paroxysmal atrial fibrillation ")) AND (title:("catheter ablation" OR "radiofrequency ablation" OR "RF 
ablation" OR cryoablation) OR abstract:("catheter ablation" OR "radiofrequency ablation" OR "RF 
ablation" OR cryoablation))) OR abstract:((title:("Atrial Fibrillation" OR "Paroxysmal atrial fibrillation 
") OR abstract:("Atrial Fibrillation" OR "Paroxysmal atrial fibrillation ")) AND (title:("catheter ablation" 
OR "radiofrequency ablation" OR "RF ablation" OR cryoablation) OR abstract:("catheter ablation" 
OR "radiofrequency ablation" OR "RF ablation" OR cryoablation)))) 
PROSPERO 
 
#1 MeSH DESCRIPTOR Atrial Fibrillation EXPLODE ALL TREES 121 
 
 
#2 Paroxysmal atrial fibrillation 11 
 
 
#3 #1 OR #2 122 
 
 
#4 catheter ablation 22 
 
 
#5 radiofrequency ablation 47 
 
 
#6 Cryoablation 23 
 
 
#7 MeSH DESCRIPTOR Cryosurgery EXPLODE ALL TREES 8 
 
 
#8 #4 OR #5 OR #6 OR #7 78 
 
 
#9 #8 AND #3 25 
 
 
Database: Embase 1947-Present, updated daily 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  Paroxysmal Atrial Fibrillation.mp. or paroxysmal atrial fibrillation/ or paroxysmal heart atrium fibrillation/ 
(7870) 
2  PAF.ab. or PAF.ti. (13890) 
3  1 or 2 (20149) 
4  catheter ablation/ or Catheter Ablation.mp. (30675) 





6  RF ablation.ab. or RF ablation.ti. (3833) 
7  Cryosurgery.mp. or cryosurgery/ (11440) 
8  cryoablation.mp. or cryoablation/ (6711) 
9  4 or 5 or 6 or 7 or 8 (69774) 
10  3 and 9 (2999) 
11  exp review/ (2342082) 
12  (literature adj3 review$).ab. or (literature adj3 review$).ti. (303286) 
13  exp meta-analysis/ (133186) 
14  exp "Systematic Review"/ (148437) 
15  11 or 12 or 13 or 14 (2588764) 
16  (systematic$ adj2 (review$ or overview)).ab. or (systematic$ adj2 (review$ or overview)).ti. (146423) 
17  (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanal$).ab. or (meta?anal$ or meta anal$ or meta-
anal$ or metaanal$ or metanal$).ti. (154304) 
18  (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or psychinfo or psycinfo or 
scisearch or cochrane).ab. or (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or 
psychinfo or psycinfo or scisearch or cochrane).ti. (192334) 
19  RETRACTED ARTICLE/ (8656) 
20  18 or 19 (200848) 
21  15 and 20 (150594) 
22  16 or 17 or 21 (300279) 
23  10 and 22 (76) 
24  15 or 16 or 17 (2635226) 
25  10 and 24 (265) 
 
 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1  Paroxysmal Atrial Fibrillation.mp. or paroxysmal atrial fibrillation/ or paroxysmal heart atrium fibrillation/ 
(48139) 
2  PAF.ab. or PAF.ti. (11343) 
3  1 or 2 (58528) 
4  catheter ablation/ or Catheter Ablation.mp. (31986) 
5  radiofrequency ablation.mp. or radiofrequency ablation/ (12626) 





7  Cryosurgery.mp. or cryosurgery/ (13108) 
8  cryoablation.mp. or cryoablation/ (13362) 
9  4 or 5 or 6 or 7 or 8 (48201) 
10  3 and 9 (9421) 
11  exp review/ (2364271) 
12  (literature adj3 review$).ab. or (literature adj3 review$).ti. (246024) 
13  exp meta-analysis/ (85370) 
14  exp "Systematic Review"/ (0) 
15  11 or 12 or 13 or 14 (2504058) 
16  (systematic$ adj2 (review$ or overview)).ab. or (systematic$ adj2 (review$ or overview)).ti. (120553) 
17  (meta?anal$ or meta anal$ or meta-anal$ or metaanal$ or metanal$).ab. or (meta?anal$ or meta anal$ or meta-
anal$ or metaanal$ or metanal$).ti. (122472) 
18  (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or psychinfo or psycinfo or 
scisearch or cochrane).ab. or (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or 
psychinfo or psycinfo or scisearch or cochrane).ti. (162514) 
19  RETRACTED ARTICLE/ (0) 
20  18 or 19 (162514) 
21  15 and 20 (126924) 
22  16 or 17 or 21 (252923) 
23  10 and 22 (211) 
 
Pubmed History 
Search Query Items found 
#33 Search (#32) OR #21 Field: Title/Abstract Sort by: PublicationDate 343 
#32 Search (#31) AND #20 Field: Title/Abstract Sort by: PublicationDate 195 
#21 Search (#6) AND #19 Sort by: PublicationDate Filters: Systematic 
Reviews; Field: Title/Abstract 
323 
#31 Search ((#30) OR #29) OR #28 Field: Title/Abstract Sort by: 
PublicationDate 
203260 
#20 Search (#6) AND #19 Field: Title/Abstract Sort by: PublicationDate 8915 
#28 Search meta-analysis or meta-analysis or metaanalysis Field: 






Search Query Items found 
#30 Search systematic review Field: Title/Abstract Sort by: 
PublicationDate 
119671 
#29 Search "Meta-Analysis" [Publication Type] Field: Title/Abstract Sort 
by: PublicationDate 
78730 
#23 Search systematic review Sort by: PublicationDate Filters: Systematic 
Reviews; Field: Title/Abstract 
111300 
#25 Search "Meta-Analysis" [Publication Type] Sort by: PublicationDate 
Filters: Systematic Reviews; Field: Title/Abstract 
78065 
#27 Search meta-analysis or meta-analysis or metaanalysis Sort by: 
PublicationDate Filters: Systematic Reviews; Field: Title/Abstract 
86852 
#26 Search meta analysis Sort by: PublicationDate Filters: Systematic 
Reviews; Field: Title/Abstract 
86119 
#19 Search ((((((#18) OR #16) OR #15) OR #13) OR #12) OR #9) OR #8 
Field: Title/Abstract Sort by: PublicationDate 
47323 
#6 Search (#5) OR "Atrial Fibrillation"[Mesh] Field: Title/Abstract Sort by: 
PublicationDate 
55690 
#8 Search "Catheter Ablation"[Mesh] Field: Title/Abstract Sort by: 
PublicationDate 
26823 
#18 Search cryoablation Field: Title/Abstract Sort by: PublicationDate 2913 
#16 Search "Cryosurgery" Field: Title/Abstract Sort by: PublicationDate 3359 
#15 Search "Cryosurgery"[Mesh] Field: Title/Abstract Sort by: 
PublicationDate 
11857 
#13 Search rf ablation Field: Title/Abstract Sort by: PublicationDate 3495 
#12 Search radiofrequency ablation Field: Title/Abstract Sort by: 
PublicationDate 
17513 







Search Query Items found 
#5 Search paroxysmal atrial fibrillation or PAF Field: Title/Abstract Sort 
by: PublicationDate 
17052 
#4 Search paroxysmal atrial fibrillation Field: Title/Abstract Sort by: 
PublicationDate 
6916 
#3 Search paroxysmal atrial fibrillation Sort by: PublicationDate 65878 







Appendix A: EP Europace Instructions to authors  
https://academic.oup.com/europace/pages/General_Instructions#Submission%20of%20manuscrip
ts 
EP Europace - The European Journal of Pacing, Arrhythmias and Cardiac Electrophysiology - is an 
official Journal of the European Heart Rhythm Association (EHRA), a branch of the European Society of 
Cardiology (ESC), and the ESC Working Group on Cardiac Cellular Electrophysiology. The journal aims 
to provide an international avenue of communication for top quality original scientific work and reviews 
in the fields of arrhythmias, cardiac electrophysiology, and pacing. Clinical investigations, basic science 
translational research, technical issues, short case reports, comprehensive reviews, editorial comments, 
educational articles, images in pacing and electrophysiology, book reviews and correspondence are 
included. 
Papers that do not adhere to the following instructions will be returned for revision before assessment. 
Submission of manuscripts 
EP Europace operates a web-based system for submission and peer-review, Editorial Manager. This 
system is intended to reduce manuscript processing times. The Journal does not require the first 
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This study, completed in 2011, measured the cost-effectiveness of radiofrequency ablation 
(RFA) as compared with antiarrhythmic drug therapy (ADT). A hypothetical cohort of patients 
with drug refractory paroxysmal atrial fibrillation (PAF) was treated with either RFA or one of 
three drugs, either on their own or in combination, this being projecting this over four years. 
Interviews were also conducted with South African electrophysiologists to determine costs 
associated with the two treatment options, including net treatment costs, average and 
incremental effectiveness in quality adjusted life-years (QALYs), average length of stay in 
hospital for complications, and the net monetary benefit of ADT compared with RFA for the 
isolation of the pulmonary veins. Results indicated that RFA may be a more cost-effective 
treatment for PAF patients in South African private health care than ADT. However, more 
evidence and analysis is needed before RFA can be established in routine care.  
Keywords: paroxysmal atrial fibrillation, cost-effectiveness, radiofrequency ablation 
Terminology:  
In this paper, for convenience, we use the abbreviation ‘RFA’ as a short form for 
‘radiofrequency ablation to isolate the pulmonary veins’ or ‘catheter ablation’, and ‘ADT’ for 
anti-arrhythmic drug therapy. We refer to atrial fibrillation as ‘AF’, while noting that the 
abbreviations ‘AF’ and ‘PAF’ are often used interchangeably, and that the type of AF is not 







Atrial fibrillation (AF) is the most common and sustained cardiac arrhythmia of clinical 
significance.(1) New estimates suggest that the prevalence of AF in patients of 20 years and 
older is approximately 3%. The prevalence of AF increases as patients age; and it is expected 
that 25% of all middle-aged adults in Europe and the USA will develop AF.(2) AF is associated 
with debilitating symptoms and an impaired quality of life. It increases the morbidity risk, such 
as heart failure and stroke.(3) There is also an associated 1.5-fold to two-fold increased risk of 
all-cause mortality in men and woman. In 2010, the worldwide estimate for people affected by 
AF was 33.5 million, with men accounting for 62% of this statistic.(4) Using the 2010 estimated 
incidence rates, the number of new AF cases per year is estimated at 2.7 million for men and 
2.0 million  for  women.(1)  Higher  incidence  and  prevalence  rates  are  found  in  developed 
countries than in the developing world.(5) 
AF is associated with cardiac disease, particularly coronary artery disease, valvular heart 
disease, cardiomyopathy and stroke. Hypertension, diabetes, heart failure, chronic obstructive 
pulmonary disease and renal failure are among the other most frequent co-morbidities.(2) 
AF is a significant public health problem, accounting for 1% of the National Health System 
budget in the UK, and between USD 16 billion and USD 26 billion in the US each year.(1, 3) 
It is suggested that between 10 and 40% of patients who have AF will be hospitalised each 
year. (6) According to a study published in 2015, the mean per capita medical spending for 
adults with AF was USD 38,861, CI-95% [USD 35,781 to USD 41,950] while for similar 
patients without AF, it was USD 28,506, CI-95% [USD 28,409 to USD 28,603]. This difference 
was statistically significant (p<0.001). It is further estimated that there are 596,000 undiagnosed 
non-valvular AF cases per year in the US, and that it would cost an additional USD 3.1 billion 





The cost of treating AF in South Africa is unknown. A South African survey on AF completed 
in 2014 found that the single most prevalent clinical characteristic associated with AF was 
hypertension (65.9%), and that 34.4% of patients had required hospitalisation during  the  
previous  12  months,  with  one third  of  these  patients  requiring  multiple hospitalisations.(8) 
The estimated cost of treating all South African patients who suffered from sequelae of 
diabetes, hypertension and hypercholesterolaemia - all known risk factors for developing AF - 
would be USD 34.2 billion per year, this being roughly 10% of South Africa’s 2017 GDP.(9) 
The restoration and maintenance of sinus rhythm in patients with AF is favoured as it may 
provide important hemodynamic benefits not afforded by rate control, as well as subjective 
benefits. This is therefore an important goal for AF patients.(10) 
The 2014 American College of Cardiology (ACC), American Heart Association (AHA), Heart 
Rhythm  Society  (HRS)  and  European  Society  of  Cardiology  (ECS)  2016  guidelines 
recommend anti-coagulant and anti-arrhythmic drugs for treating patients with symptomatic 
AF.(2)  Both rate- and rhythm-control strategies are recommended, based on the individual 
patients’ underlying pathologies.(2) 
RFA offers an alternative treatment option for AF. While not the first-line therapy for AF, RFA 
has become first-line therapy for many other supra-ventricular arrhythmia.(11) RFA uses energy 
that is high-frequency but low-voltage. Radiofrequency energy causes the tissue to heat up and 
small uniform lesions are created. The size of the lesions are a function of the length of the 
distal-ablation electrode, type of catheter used (irrigated or non-irrigated), uniform contact at 
the catheter-tissue interface and the power used during ablation.(12,13) 
While the success rates for RFA are highest in patients with common forms of supra-ventricular 





as technology has improved, success rates have improved for other common types of cardiac 
arrhythmia, such as AF. This includes both of the following success measures: success at the 
end of the procedure; and no incidents of AF longer than 30 seconds at 12 months.(14, 15) The 
2014 AHA guidelines recommend RFA as a strategy for maintaining sinus rhythm in patients 
with symptomatic AF who are refractory or intolerant to at least one Vaughan Williams Class 
I or III drug as a Class IA indication. Patients must, however, be assessed for procedural risks, 
which, if present, would then be recommended as a Class IC indication.(16) 
A meta-analysis undertaken by Noheria et al. in 2008 showed that 75.7% of patients treated 
with RFA were free of AF recurrence at 12 months, compared with 18.8% treated with ADT 
(RR 3.73, 95%-CI [2.47-5.63], P<0.001).(11)In this meta-analysis,(11) reported adverse events 
included hospitalisation, mild to moderate pulmonary vein stenosis in the RFA group and 
bleeding. Pappone et al.’s  2011 ablation for paroxysmal atrial fibrillation (APAF) study 
reported seven times more hospital admissions for the ADT group than the RFA group over 
the same period.(17)  Other reported adverse events in the RFA group included stroke, 
pericardial effusion and phrenic nerve palsy .(18) Of the patients treated with amiodarone, 46.7% 
reported adverse events.(19) 
ADT remains the first-line therapy when treating patients with AF. The up-front costs of RFA 
are significantly higher than the cost of drugs. However, the cost of drugs excludes the cost of 
complications, such as re-hospitalisation. 
This study is important for the South African private healthcare market as many decision- 
makers are not willing to extrapolate data from cost-effectiveness studies performed in other 





RFA has become accepted as a strategy to treat patients with PAF in patients who are refractory 
to at least one anti-arrhythmic drug that has failed to provide relief.(2) It is often the case that, 
when new technologies are introduced into healthcare, they are considered a cost driver until 
proven otherwise. Patients with AF have for many years been treated with a ‘pill in the pocket’ 
and other ADT strategies,(20) costing only a few thousand rand per year, whereas the up-front 
cost of RFA for AF may exceed R100,000 per patient. However, to understand the cost-
effectiveness of one therapy compared with another, we must measure total costs over a period 
of time. 
METHODS 
To calculate the cost-effectiveness of RFA compared with ADT, we conducted a South 
African-specific cost-effectiveness analysis using a decision tree analysis and a Markov 
simulation model for patients with AF. As a randomised control trials comparing RFA with 
ADT for outcome and success had not been done before in South Africa, this study modelled 
the analysis on an international study. The study chosen was the APAF ) study by Pappone et 
al., (19,21) as it was sufficiently applicable to the South African setting and suitable for decision 
analytic modelling. The APAF was evaluated for possible bias, with none found. The treatment 
comparators in the model are pulmonary vein isolation using RFA or ADT. 
Validation of the relevance of the APAF study in clinical practice in South Africa 
The input and output values were taken from the APAF study.(19,21) However, it was crucial 
that the treatment regimen in South African practice be comparable with that followed by the 
APAF study. To gather information on the South African treatment regimen, 10 practicing 
electrophysiologists accredited by the Cardiac Arrhythmia Society of South Africa were 
contacted. At the time of our survey in 2011, these were only 10 practicing electrophysiologists 





study was explained and the patient population was described. Of the eight 
electrophysiologists, who were interviewed either in person or over the phone, seven performed 
RFA to treat AF, while the eighth chose not to treat complex arrhythmia. Information derived 
from the interviews indicated that the treatment regimen in South Africa was sufficiently 
similar to that described by the APAF study(22) to justify the use of Pappone et al.’s input and 
output values. 
The overall finding from the responses to the questionnaire was that the strategies used by 
South African electrophysiologists to treat patients with AF compare favourably with the 
treatment regime in the Pappone et al. APAF study. 
Model structure 
The model used a decision tree analysis and a Markov simulation model to capture and simulate 
costs and outcomes at one, two, three and four-years. Four health states were created:  
 ‘AF’ (experiencing AF – all patients enter the decision tree analysis with AF, at least 
one ADT treatment having failed.) 
 ‘No AF’ (converted to sinus rhythm, or AF but no episodes of 30 seconds or longer) 
  ‘PAF’ (paroxysmal episodes of AF lasting longer than 30 seconds); and  
 ‘AF controlled’ (still experiencing AF but both doctor and patient felt control was 
adequate with regard to duration and frequency of arrhythmia recurrences).  
Each cycle ran for six months over a four-year period. If a RFA patient required a second 
RFA procedure, this was done within six months. At the end of each six-month cycle a 
patient could be in any of the four health states described above.  






Figure 1. Transition probabilities in Markov Model. 
Table 1 provides a summary of the transitions probabilities described in nine clinical studies. 
Pappone et al. investigated the probability of patients with PAF being randomised to receive 
either RFA or ADT (n=198).(22) Other clinical studies investigated the probability of AF 
recurring after one year for both RFA and ADT, as well as decrements in utilities in health 
states.(23) Other issues investigated for both RFA and ADT were death rate,(24) stroke rate and 
death rate from stroke,(25) hospitalisation rate and length of hospital stay,(26,27) one, three and 
five-year mortality,(28) cardiovascular hospitalisations, stroke and cardiovascular deaths,(3,29) 






Table 1: Transition probabilities applied to the Markov process for the ADT arm 
The probability of:                                               Probability Source 
Receiving Amiodarone 0.33 
Pappone et al, 2006 
Receiving Flecainide 0.33 
Receiving Sotalol  0.33 
Amiodarone suppressing AF 0.36 
Flecainide suppressing AF  0.21 
Sotalol suppressing AF 0.15 
Receiving Amiodarone and Flecainide   0.65 
Receiving Sotalol and Flecainide  0.35 
Crossover from drug to PVI  0.56 
AF Free on Amiodarone and Flecainide                  0.22 
AF control on Amiodarone and Flecainide   0.33 
AF control on Sotalol and Flecainide 0.23 
AF recurring after 1 year 0.29 McKenna et al, 2009 
Adverse events (ADT)   0.30 
Calkins et al, 2009 
Death (ADT)   0.03 
AF free (PVI) 0.86 
Pappone et al, 2006 
Having AT (PVI)    0.03 
Being AF controlled (PVI) 0.05 
Require second PVI  0.06 
AF free after second PVI    0.83  
AF recurring after 1 year (PVI) 0.0335 McKenna et al, 2009 
Adverse events (PVI) 0.049 
Calkins et al, 2009  
Death (PVI)  0.007  
 
Cost calculations 
Cost data were provided by Netcare head office, as more than 80% of all RFA procedures at 
the time were performed in a Netcare hospital. All RFAs were done using a 3D mapping 
system. The sample consisted of data from 51 patients, representing 20% of all RFA procedures 
in 2010. The data were anonymised, so the authors could not see the identity of either the 





The average length of hospital stay was 2.2 days, with a range of 1.5 to 5.5 days. The total 
average cost of the RFA was R134,411, with a median of R134,641. 
Outpatient costs - applicable to both the ADT and RFA groups - included all the physicians’ 
costs and diagnostic tests. The mean cost was R2,495 per patient, and the range was R2,363 to 
R2,891. 
The cost of blood tests performed included 16 international normalised ratio tests (INR) with 
dosing. Only those patients receiving amiodarone required the following additional tests: urea, 
electrolytes (U&E) and creatinine; full blood count; and thyroid and liver functions. 
The costs of drugs were derived from single exit prices on the Department of Health website. 
Calculations per drug were up to the maximum tolerable dose. For amiodarone, costs were 
calculated per day at each specific titrated and recommended dose. In instances where single 
drug therapy failed, and a combination of drugs was prescribed, the costs were calculated per 
day for combination 1 (flecainide and amiodarone, 200mg each) or combination 2 (flecainide, 
200mg, and sotalol, 240mg). 
Hospital costs included hospital stay, coronary care unit /ward fees, use of monitors, oxygen 
and medication. Theatre fees included a fee for the use of specialised equipment (for example, 
bi-plane X-ray, 3D-mapping system and ablation generator) and any drugs or disposables used 
in theatre, including catheters. Electrophysiology catheters were costed at the 2011 net 
acquisition price. All catheters were calculated as single use, as recommended by the 
manufacturer. 
Finally, the costs for re-hospitalisation included hospital, electrophysiologist fee, blood tests 





Costs associated with re-hospitalisation for AF 
The APAF study recorded 24 hospital admissions in the RFA group, nine of which were for 
repeat ablations, and 209 hospitalisations in the ADT group, of which 167 were for recurrence 
of AF and heart failure, and 42 for RFA.(23) To calculate the average cost of admissions related 
to heart failure or the recurrence of AF, we used a sample of non-patient- identifiable treatment 
costs from Netcare. The measures of interest were number of days in hospital per admission; 
and total cost, which included hospital, pathologist fee, cardioversion, daily coronary care unit 
or ward consultation with electrophysiologist fee, and one follow-up visit after discharge.  
The mean length of hospitalisation was 5.1 days, with a median cost per hospital admission of 
R8,096, and a range of between R5,819 and R9,419. All the costs are shown on Table 2. 
Table 2: Costs associated with treating PAF in South Africa 
 
Item Cost 
Outpatient costs- average R2 495.40 
Pathology costs per year R3 442. 26 
Sotalol- per month R508,29 
Flecainide- per month R662,12 
Warfarin- per month   R45,49 
Amiodarone 1st month R866,09 
Amiodarone month 2-12  R512,24 
Procedure costs  R37 877,00 
EP catheters R54 101,00 
Hospital stay R11 350,00 
Average fee for anaesthetist R9 965,00 
Average fee for radiographer R1 617,00 
Average fee for technologist R2 919,00 
Average fee for electrophysiologist  R16 582,00 
Median costs of re-hospitalisation - Total  R31 801.66 






Quality of life (QoL) calculations 
The QoL scores shown in Table 3 illustrate that patients who underwent PVI showed a significant 
long-term improvement in QoL scores. Analysis of the QoL scores of both groups on an 
intention-to-treat basis shows little difference between the PVI and ADT groups. However, it is 
noted that 90% of patients initially randomized to ADT and before crossing over to PVI showed 
significantly poorer QoL.  
Table 3: Comparisons of QoL scores for PVI and ADT at baseline,  
before crossover and at 48 months 
 
Notes: Those in italics** indicate a deterioration from baseline. 









 Baseline 48 
months 







69±18 85±12 <0.0001 68±21 **67±16 82±15 <0.0001 
Role 
physical 
63±19 82±14 <0.0001 61±17 61±14 80±15 <0.0001 
Bodily pain 68±19 80±17 <0.0001 66±24 **63±19 77±21 <0.0001 
General 
health 
65±17 79±15 <0.0001 67±17 **63±17 77±16 <0.0001 
Vitality 56±22 71±23 <0.0001 55±18 **53±16 68±21 <0.0001 
Social 
functioning 
68±22 87±14 <0.0001 66±20 **64±17 86±14 <0.0001 
Role 
emotional 
70±24 86±18 <0.0001 70±22 **66±19 84±19 <0.0001 
Mental 
health 
66±21 81±17 <0.0001 67±19 **62±15 78±17 <0.0001 
PCS 44.4±9 52.3±9 <0.0001 45.7±9 **44.1±7 52.6±8 <0.0001 








After two years, the cost of ADT was R187,000 per patient, with a QALY of 1.53, while the 
cost of RFA was R168,000 per patient, with a QALY of 1.64. Figure 3 shows that RFA (a red 
square in the top left-hand quadrant) is both more efficacious and less costly than ADT (a blue 
triangle in the bottom right quadrant). The model thus estimates that RFA generates better 
health outcomes than ADT, including at lower cost, and can thus be considered the more cost-
effective treatment option. 
 
Figure 2: Cost-effectiveness analysis of PVI vs ADT for AF  
Sensitivity analysis 
Sensitivity analysis of the duration of the study (tDuration) 
The first sensitivity analysis measured the cost-effectiveness at Years 1, 2, 3 and 4 (tDuration). 
One of the main criticisms of RFA for patients with AF is that the up-front costs are very high. 
However, the sensitivity analysis shows that PVI by means of RFA is less costly than ADT 
after Year 1 and continues to be less costly up to four years, with an incremental cost-






Table 4: Sensitivity analysis of duration (tDuration) 
 
Strategy  Variable  Cost per 
patient 
Eff. CE ICER Dominated 
PVI 1 year R158 866  0.82059  193600.1075  552059.063   
ADT 
 
R13 227  0.77243                     171247.2542 0   
PVI 2 years R168 437 1.64062 102667.0502 0   
ADT 
 
R187 357 1.52545 122821.0932  -164295.3091   (Dominated) 
PVI 3 years R180 471  2.43056  74250.84062  0   
ADT 
 
R259 999 2.19949 118208.8877   -344163.2532  (Dominated) 
PVI 4 years R194 621 3.19099  60990.94188 0   
ADT 
 




Sensitivity analysis of cost 
Figure 3 shows that up to 1.587 years, RFA costs more on average than ADT. After this, the 
cost of RFA flattens out and the cost of ADT grows exponentially. At one year, the cost of 
ADT is in the region of R130,000 compared with R160,000 for RFA. After four years, the cost 
of ADT reaches R340,000, while the cost of RFA has increased to only R190,000. This 
represents a cost increase of 19% for RFA and 162% for ADT. 
 
Figure 3: Measure of average cost at set intervals (one, two, 






Figure 4 shows that the incremental costs up to four years of RFA decline in Year 1. By Year 
2, the line on the graph has flattened out, with the incremental cost being unchanged over Years 
2 to 4. The opposite is true for ADT, which shows costs continuing to increase up to four years. 
 
Figure 4: Measure of incremental cost at set intervals  
(one, two, three and four years after initiation of treatment) 
 
Sensitivity analysis of incremental effectiveness 
Figure 5 shows that the incremental effectiveness of RFA declines marginally over the first two 
years and thereafter remains unchanged, indicating that the efficacy remains constant up to 
Year 4. On the other hand, the incremental effectiveness of ADT starts declining from the 






Figure 5: Measure of incremental effectiveness at set intervals  
(one, two, three and four years after initiation of treatment) 
Sensitivity analysis of the net monetary benefits 
The term ‘net monetary benefits’ refers to the value of an intervention in monetary terms. To 
calculate this, we need to know the willingness-to-pay threshold for a unit of benefit, in other 
words, the cost per QALY must be known. Using net monetary benefits provides a scale to 
compare the health outcomes and the use of resources to costs without using ratios like ICERs. 
To calculate the net monetary benefit, we used the formula: ([incremental benefit x threshold] 
- incremental cost).  
Figure 6 shows the net monetary benefit of the two treatment options over four years. Again, 



















   Figure 6: Measure of the net monetary benefit at set intervals  
 (one, two, three and four years after initiation of treatment) 
Sensitivity analysis of results associated with parameter change 
Finally, a series of one-way sensitivity analyses was conducted on key parameters within the 
model to test for variation in results associated with parameter change. The Tornado diagram 
in Figure 7 shows ranges of results associated with particular parameters staked according to 
descending variation.  
The one-way sensitivity analysis showed that the model was reasonably robust to the cost 
estimations of medicines and quality of life valuations for atrial fibrillation. 
 





The model was most sensitive to variations in annual admission rate for ADT patients, length 
and cost of stay in hospital for an AF-related event and the cost of the PVI procedure. However, 
at the extreme of the sensitivity analysis, the predicted ICER did not exceed R100,000/QALY 
for PVI vs ADT, providing reasonable confidence in the results of the analysis.  
A one-way sensitivity analysis is limited in that it assumes parameter variation ceteris paribus, 
when in practice certain parameters are likely to vary in correlation. For instance, if medicine 
costs are greater, cost of hospital stay is also likely to be greater. A gold standard sensitivity 
analysis would have included probabilistic sensitivity analysis where all parameters are varied 
across a given distribution. However, given the availability of data and resources available for 
analysis, the authors have provided a one-way analysis to provide an indicative understanding 
of the implications of parameter variation. 
DISCUSSION 
The Cardiac Arrhythmia Society of Southern Africa, of which many of the South African 
electrophysiologists are members, has adopted the ACC, AHA, HRS and ESC guidelines for 
the treatment of AF. At the time of writing this study (2019), the South African private sector 
reserved RFA for patients who had failed at least one ADT. 
Multiple studies have demonstrated clinical benefits of RFA for PAF, including improved 
maintenance of sinus rhythm and improved quality of life when compared with ADT. In our 
study, we used a Markov simulation model to project costs and QALY for patients with drug-
refractory PAF who were treated with either RFA or ADT. Using assumptions and transitions 
probabilities derived from medical literature, we found that, within the South African health 





RFA for AF should be considered more widely for patients with symptomatic AF as it is not 
only more efficacious but could also be more cost-effective in the South African context. 
Study limitations 
All the models used are simulations and therefore approximations of reality. The treatment of 
PAF is complex, as well as patient- and physician-dependent; and the models necessarily 
simplify treatment options and their clinical and cost impacts. However, the models do provide 
some indication of the relative cost-effectiveness of the treatment options. The clinical 
outcomes used in the models were based on a randomised controlled trial from a hospital in 
Milan, requiring an assumption that the clinical outcomes observed would be similar to 
outcomes in the South African private healthcare setting. This necessity, arising from the 
limited available data on RFA in South Africa, is somewhat mitigated by the use of the survey 
of South African clinicians who confirmed broadly similar practice in the South African private 
sector compared with the trial setting. The model only projects costs and treatment outcomes 
for a four-year period: this does not incorporate the full range of clinical and cost parameters 
experienced over the remaining life-time of the patients. However, as ADT incurs ongoing 
costs with limited relative health gain, extending the length of time incorporated within the 
model is likely to improve the relative cost-effectiveness of RFA. This would not change our 
current interpretation of our results. 
Another limitation relates to the method used. Since the data in the models were only from the 
private healthcare sector, they therefore cannot be used for recommendations for public 
healthcare in South Africa. In order to do so, we would have needed access to substantially 






Conclusion and recommendations 
The economic value of RFA has not been established in South Africa. Because of this, RFA is 
deemed to be either highly cost-effective or not cost-effective at all, depending on whose 
viewpoint is being considered (usually either the treating physician’s or the funder’s). 
Some of the biggest risk factors for heart disease and stroke are physical inactivity, smoking, 
excessive alcohol and an unhealthy diet, resulting in hypertension, diabetes, hyperlipidaemia 
and obesity.(30) These are also risk factors for AF. 
In the past, the main healthcare problems in Africa and South Africa were infectious diseases. 
However, the global prevalence of AF increased by 49% between 1990 and 2007, and again by 
31% between 2007 and 2017, including in developing nations like South Africa.(31) 
There is a paucity of data on AF in South Africa in particular and sub-Saharan Africa as a whole 
The limited data that exist suggest the prevalence of AF is currently lower in these regions than 
in developed countries but is set to increase over the next two to three decades. This is because 
major forces driving social, cultural and economic change, such as urbanisation, globalisation, 
and populations living longer, result in an increase of risk factors for cardiovascular 
disease.(30) Patients with AF constitute a significant burden of disease and associated costs. 
Despite the limitations of this study, and the fact that it was based on a small number of 
privately insured patients in South Africa, it still represents an important contribution to the 
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